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Abstract 
 
Over 7000 women are diagnosed with ovarian cancer each year in the UK. This disease is 
characterized by a particularly poor survival rate (40% at stage III, after 5 years), leading it to 
become known as a “silent killer”. This poor survival rate is due, in part, to the  biological 
mechanisms by which cancer cells become resistant to drugs used in chemotherapy. The 
enzyme autotaxin has been strongly implicated in this process. Whilst many autotaxin 
inhibitors are extremely potent in vitro, when tested in vivo they have been found to perform 
poorly. This is partly because the drugs can be rapidly absorbed from their site of action, 
through the wall of the peritoneal cavity, before undergoing hepatic metabolism. 
Herein we present a novel strategy that is designed to increase the residence time of an 
autotaxin inhibitor within the peritoneal cavity, using a novel polymer-drug conjugate 
approach for drug delivery. This was achieved through the attachment of a known autotaxin 
inhibitor to a high molecular weight polymer (Icodextrin or Inulin), known to be retained 
within the peritoneal cavity for extended periods of time. To our knowledge, Icodextrin has 
never been used as a vehicle for drug delivery outside of our research group. This thesis 
demonstrates the application of this novel drug conjugate approach, across a range of 
autotaxin inhibitors and polymers. The effect of polymer-drug loading on activity was also 
investigated, which to our knowledge has never been studied before with the supports used 
in this study. To facilitate this, a novel conjugation method was developed for the attachment 
of drug molecules to the polymer, which yielded 11 drug conjugates in total, which were then 
evaluated for their biological activity. The drug conjugates were found to be highly potent in 
separate assay types, with IC50 values as low as  300 ± 40 ng / mL-1 for Inulin-drug conjugates 
and 698 ± 294 ng / mL-1 for Icodextrin conjugates. This study also revealed the effect of drug 
loading on biological activity, which gave an unexpected result which could influence the 
design of polymer-drug conjugates in the future. The peritoneal retention of an Inulin-
autotaxin inhibitor conjugate was studied in mice for the first time. The effect of intra polymer 
cross-linking on biological activity has also been evaluated. 
Overall, the work described within this thesis could be used to provide an effective new 
therapeutic approach for the treatment of ovarian cancer; additionally the polymer 
therapeutic approach described in this work has the potential to be used in application to 
treat a variety of diseases.    
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Chapter 1: Introduction 
 
1.1 Ovarian cancer  
 
Over 7000 women are diagnosed with ovarian cancer each year in the UK and approximately 
240,000 worldwide.1,2 Though it is less prevalent than many other cancers, 4200 women die 
from ovarian cancer each year in the UK and over 100,000 worldwide.1,3 Ovarian cancer is 
typified by a poor chance of survival, often caused by a resurgence in tumour growth after 
the initial treatment.1–3 
Ovarian cancer is characterised by an uncontrolled proliferation of cells, which forms a 
tumour.  Three different cell types have been identified: germ cells, stromal cells and 
epithelial cells, though epithelial ovarian cancer is the most common.3–5 These are further 
divided into five main types: high-grade serous (70%, most prevalent), endometrioid (10%), 
clear cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%).3–5 It is reported that 
these are essentially separate diseases, which will respond differently to chemotherapy, 
therefore accurate diagnosis of the tumour type is essential for an effective treatment.3 The 
progression of ovarian cancer is defined by the FIGO system, by Stages 1-4, (Figure 1).6,7 
As may be expected, the survival rate decreases for each Stage. At stage 1, 90% of women 
will survive beyond 5 years, this decreases to 40 % at Stage 2, 20 % at Stage 3 and lastly 5 % 
at stage 4.1,8  Though the outlook is positive at Stage 1, as the cancer spreads the chance of 
survival rapidly decreases, indeed, in the UK ovarian cancer has the poorest survival rate out 
of all female only cancers.9 
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Figure 1 -Stage 1-4 ovarian cancer during the transition from one stage to the next, the 
severity of ovarian cancer increases. Stage 1 A, the tumour is localised inside one ovary; 1 B, 
the tumour is localised inside both ovaries; 1 C, the tumour is inside both ovaries and is on 
the surface of one ovary.6,7 Stage 2 A, the tumour has spread to the fallopian tubes; 2 B, the 
tumour has spread to the bladder or rectum; 2 C, cancer cells are present in the peritoneal 
cavity.6,7 Stage 3 A, cancer cells are present in samples from the peritoneum; 3 B, tumour 
growths smaller than 2 cm are found on the peritoneum; 3 C tumour growths larger than a 
diameter of 2 cm are found on the peritoneum.6,7 Stage 4 A, the cancer has caused a build-up 
of fluid in the lungs (known as a plural effusion); 4 B, the tumour has spread to the inside of 
the liver.6,7  
 
1.1.1 Ovarian cancer treatments 
 
Ovarian cancer treatments follow a similar treatment regime to many other cancer 
therapies, and typically include a combination of surgery, chemotherapy and radiotherapy. 
In the case of stage 1 A-B, the preferred route of treatment is surgery to debulk the tumour, 
known as optimal surgical staging. It is suggested that chemotherapy should not be used 
while the tumour is localised inside the ovaries.10,11 At Stage 1 C, the tumour has spread 
outside of the ovaries, making surgery suboptimal. In this situation chemotherapy is 
administered alongside surgery. In late stage ovarian cancer (Stage 2-4) it is recommended 
that complete resection of all macroscopic disease is carried out before chemotherapy is 
administered. This is referred to as neoadjuvant chemotherapy and is commonly used when 
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the tumour is too difficult to remove completely via surgery.10,11 Radiotherapy is used less 
extensively in ovarian cancer, due to its impact on fertility; it is advised to use chemotherapy 
instead.11 
The most common chemotherapeutic agents used to treat ovarian cancer are carboplatin 
(preferred over cisplatin due to it being less toxic), paclitaxel, docetaxel and doxorubicin 
(Figure 2).12,13  
 
Figure 2 - The most commonly used drugs to treat ovarian cancer 
 
Sometimes two chemotherapeutic agents of different modes of action are administered 
simultaneously, such as paclitaxel and carboplatin, drug combinations have been shown to 
be more effective than single drug regimens.14 Most chemotherapeutic agents for ovarian 
cancer are administered through an intravenous route, however it has been demonstrated 
that intraperitoneal administration can result in progression-free survival and longer survival 
periods, though it is less widely used.15 Patients are classified according to their “platinum 
sensitivity”, that is their response to platin drugs after 6 months. If they relapse they are 
defined as “platinum resistant” and their chemotherapy is adjusted so that an alternative 
agent is used, such as doxorubicin.16 The chemotherapeutic agents currently used to treat 
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ovarian cancer are undoubtedly effective therapies, however, it should be remembered that 
these drugs are cytotoxic and their use is not without detriment to the patient.14,17 There is 
a clear need for the development of new drugs tailored to ovarian cancer, with greater 
specificity for ovarian cancer cells.  
 
1.1.2 Chemoresistance  
 
As noted, ovarian cancer has a particularly poor survival rate. There are a number of factors 
that give rise to this situation. Ovarian cancer is most treatable in the early stages of disease 
progression (Stage 1 A-B, Figure 1) where it has a good rate of survival.11 Yet, because ovarian 
cancer is asymptomatic in the early stages, it is most commonly diagnosed at the later Stages 
of tumour growth (Stage 2-4, Figure 1), when it is less treatable.1 Additionally, there is a lack 
of biomarkers for ovarian cancer, which would be useful particularly to assist in early 
diagnosis of the disease.18 The most significant contributing factor to the poor survival rate 
associated with ovarian cancer is chemoresistance or multiple drug resistance (MDR). This 
phenomenon can occur 6 months or several years after the first round of chemotherapy, at 
which point tumour cells become less responsive to chemotherapeutic agents, across 
multiple classes of drugs.19,20 Chemoresistance in ovarian cancer originates via a number of 
mechanisms with ATP-Binding Cassette transporters (ABC transporters) being over-
expressed in ovarian cancer.19,20 This is thought to occur through detoxifying systems being 
activated in response to exposure to a drug.19,20 ABC transporters (such as MDR1 and MRP1) 
actively transport the drug out of the cell, causing an efflux of the drug, which reduces 
accumulation and controls apoptosis.19,20  
Ovarian cancer cells can also become resistant to paclitaxel. Paclitaxel functions by 
selectively binding to  β-tubulin, causing defects in mitotic spindle assembly, disrupting 
mitosis which leads to cell death.19,21 Ovarian cancer cells have been found to express specific 
β-tubulin isotypes, that are resistant to the effects of paclitaxel. 19,21, As stated previously, 
ovarian cancer cells quickly develop resistance to platinum-based drugs. Cisplatin / 
carboplatin cause the intercalation of platinum within DNA strands (by cross-linking with 
purine bases on DNA), causing DNA damage.22 Resistance can occur via mechanisms that 
repair the damage caused by the platin drug, through a process known as nucleotide excision 
repair (NER), which removes damaged sections of DNA.19,23–25 Ovarian cancer cells can also 
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develop chemoresistance to drugs belonging to the anthracycline class (such as doxorubicin). 
These drugs target DNA conformation-controlling nuclear enzymes: topoisomerases.19,26 
Anthracyclines function by stabilizing a reaction intermediate formed during the catalytic 
cycle of TopoII (referred to as the cleavable complex), which is involved in the transcription 
and replication of DNA, which leads to DNA damage and cell death.19,26 It is postulated that 
through mutation, resistance occurs by a reduction in cleavable complex formation, resulting 
in less DNA damage.19,26  
Of particular interest to us is the enzyme autotaxin (ATX), which has been identified to play 
a role in chemoresistance of ovarian cancer cells. ATX has also been noted to contribute to 
the proliferation, growth and survival of ovarian cancer cells.27 It is now thought of as a 
promising target for multiple drug resistance in ovarian cancer.27  
 
1.2 Autotaxin, introduction 
 
The glycoprotein autotaxin (ATX) (Figure 3), is a member of the ecto-nucleotide family 
(ENPP2) and has an important role in lipid signalling, through its function as an enzyme.27–31 
In recent years however, it has received attention regarding the part it plays in cancer and 
other diseases.27–31 
 
Figure 3 – The X-ray structure of ATX 32 
 
The physiological role of autotaxin should not go unrecognised. For example it is involved in 
the formation of vascular structure within early embryos (ATX-deficient mice were found to 
die mid-gestation due to reduced blood vessel formation).30,33 It is believed that ATX also 
contributes to the proliferation, growth and survival of ovarian cancer cells through its 
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unique action as a lysophospholipase D.27,33,34 Phospholipids, unlike other chemical 
messengers, such as neurotransmitters, cannot be stored in vesicles. This is due to their 
hydrophobic structure they diffuse through membranes. Instead they are synthesised “on-
command” from a parent molecule.32,33 Autotaxin has a high degree of specificity for the 
phospholipid lysophosphatidylcholine (LPC).31,33,35–38 ATX catalyses the hydrolysis of a 
phosphodiester bond located on LPC, removing a choline group to expose lysophosphatidic 
acid (LPA) (Figure 4).31,33,35–38 ATX has some limited activity towards 
sphingosylphosphorylcholine (SPC), hydrolysing SPC to sphingosine-1-phosphate (S1P).39–41  
 
Figure 4- ATX catalyses the hydrolysis of LPC to LPA 33 
 
Whilst other enzymatic processes lead to the production of LPA, such as the enzyme 
phospholipase A2. Phospholipase A2 catalyses the hydrolysis of LPC in the same manner, but 
despite this ATX is the major contributor of serum LPA.30 A study in which mice were 
genetically engineered to not carry the gene for autotaxin, it was found that plasma LPA 
levels had decreased by 95 %.30  
Understanding of autotaxin was greatly enhanced, when in 2011, the crystal structure for 
ATX was first reported by Perrakis and colleagues (Figure 3).42,43 This study revealed that ATX 
is comprised of four distinct domains, (Figure 5a). 
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Figure 5 - a) Distinct domains within ATX, b) expansion of  the T-shaped catalytic pocket 29,44 
 
The PDE domain (phosphodiesterase domain) primarily concerns the catalytic function of 
ATX, containing the catalytic site.32,42,44 The two SMB “like” N-terminal domains 
(somatomedin B) lie next to the PDE domain.32,42,44 They both act in a broadly similar way 
and are known to facilitate protein-protein interactions.32,42,44 There is some evidence to 
suggest that SMB 1 has a role in stimulating LPA-independent cell migration.29 The C-terminal 
nuclease “like” domain (NUC), along with the SMB domains act to encapsulate the PDE 
domain.29,44 This is achieved through two linkages: an N-linked glycan and an inter domain 
disulphide bridge, a “lasso” type loop wraps itself around the NUC domain starting from the 
PDE domain.29,44 These linkages assist in maintaining a conformationally rigid structure.29,44 
Additionally, an extensive hydrogen bond network (as a consequence of water molecules 
sitting between the catalytic and NUC domains) and several hydrophilic and hydrophobic 
interactions act to stabilise the protein.29,44 
Within the PDE domain lies the core catalytic site. Unlike other members of the ENPP family, 
this site contains a hydrophobic pocket, shown in Figure 5b. It is 15 Å deep and has a volume 
of approximately 800 Å3, is 15 Å deep. 29,32,42,44 The pocket readily accommodates 
lysophosphates but appears to have significance in determining the specificity of ATX for LPC. 
For example, LPC containing a saturated acyl (hydrophobic) chain of 14-16 carbon atoms in 
length is readily accommodated within the site, however saturated chains, longer than 18 
atoms do not fit and are therefore not substrates.29 Unsaturated (Z) acyl chains can adopt a 
“bent” conformation to fit within the pocket.29 Connected to the hydrophobic pocket is a 
tunnel, (Figure 5b) comprised of both hydrophobic and hydrophilic residues along the tunnel 
wall.29,44 It is proposed that the tunnel acts to eject LPA following its conversion from LPC. 
The tunnel forms partly within the PDE domain, but also within SMB1.29,44  
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The active site (Figure 5b) contains two Zn2+ atoms and in close proximity, a threonine residue 
(Thr209), these residues have been found to be essential for the catalytic activity of 
ATX.29,32,42,44 In a recent study by Perrakis and co-workers the hydrolysis of LPC to LPA by 
autotaxin was investigated.32 The authors suggest that the hydrolysis reaction adopts an 
associative mechanism in which the nucleophilic Thr209 (likely deprotonated by a 
neighbouring histidine reside) attacks the phosphodiester. The ligand (choline) then departs, 
analogous to a SN2 mechanism.32 The phosphodiester substrate is held in the correct position 
for nucleophilic attack by Thr209 via two zinc atoms. Following the displacement of choline, 
hydroxide then attacks the phosphoester causing Thr209 to be displaced (Scheme 1).  
 
 
Scheme 1 - Proposed catalytic cycle of the hydrolysis of LPC to LPA by autotaxin.32 
 
The study by Perrakis and co-workers involved obtaining ATX crystal structures with different 
substrates that closely match the transition state of the catalytic cycle. In the absence of 
being able to monitor it in real time, ATX-VO5 to demonstrate the transition state, prior to 
choline being expelled (Figure 6). Whilst there is little conformational change in autotaxin 
during catalysis, the enzyme does act to stabilise the reaction intermediates.32 The  O- species 
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of the phosphodiester is stabilised by an interaction with the two zinc atoms. Additionally, 
the ligand orientates itself to favour the disassociation of choline.  
 
Figure 6 - ATX crystal structure bound to VO5, and a diagram to represent the transition state 
 
1.2.1 Autotaxin and its role in ovarian cancer 
 
The significance of autotaxin with regard to ovarian cancer can be largely attributed to its 
role in the production of LPA.31,33,36,38,44,45 Indeed, ovarian cancer patients have been found 
to have LPA in concentrations of up to 80 µM in their ascites fluid (compared to 7 μM in 
healthy patients.33,45,46 Upon its formation, LPA binds to G-protein coupled receptors: LPA 1-
6. From there a cascade of different cellular responses is triggered, known to be conducive 
to the development of ovarian cancer. The extent of LPA signalling is shown in Figure 
7.31,33,36,44 
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Figure 7 - The ATX / LPA cell signalling pathway33 
 
The G-protein bound to each receptor determines the response observed. Many of these 
responses have been identified as the driving force behind the invasion and migration, 
inhibition of apoptosis, senescence, angiogenesis and chemoresistance of ovarian cancer 
cells.31,33,36,44 
 
1.2.1.1 Invasion and migration 
 
LPA causes the down-regulation of RhoA, in conjunction with G-protein: Gα 12/13 (Figure 7).47,48 
This GTPase is responsible for regulating changes in actin filament (actin filaments are 
essential for the adhesion, mobility /contraction of cells during division /replication).47,48 The 
down regulation of RhoA results in a loss of adhesion between cells, which leads to an 
increase in cell motility. This allows the infiltration of invasive cancer cells, within a healthy 
system.47,48 The loss of adhesion causes cancer cells to dislocate from a tumour, allowing the 
cancer to spread away from the primary site to a secondary site such as the peritoneal 
cavity.27,47,48 LPA also causes the activation of Src kinase, This family of enzymes is known to 
cause the breakdown of cell-cell junctions (a bridge between two cells or the extracellular 
matrix), which in a similar way to RhoA, promotes cell scattering, a process by which 
individual cells detach from cell clusters, allowing cancer cells to invade healthy tissue.27,48 
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The effect of Src kinase is potentiated by the action of urokinase Plasminogen Activator 
(uPA).27,49,50 LPA causes the secretion of uPA which binds to its specific receptors, and as a 
result of the interaction, causes the conversion of plasminogen to plasmin. Plasmin degrades 
the basement membranes of cells (containing fibrin, fibronectin, proteoglycans and 
laminin.51  
The Gi -Ras-MEKK1 pathway plays a major role in LPA mediated cell migration, through its re-
distribution of focal adhesion kinase (FAK) near the focal contacts of cells.28,45,48 The 
activation of LPA receptors coupled to the g-protein g αi / O, causes the activation of Ras, which 
in turn activates MEKK1 (Figure 7).28,33,45,48 MEKK1 facilitates the localisation of FAK near the 
focal contacts of cells (mechanism not fully understood).45,48,52 Increased turnover of focal 
adhesions (adhesions at the point of contact between a cell and the underlying substrate) 
leads to cell migration.30,45,48  
LPA induces the expression of metalloproteinases, including MMP1, MMP2, MMP7 and 
MMP9. These proteases contribute to the breakdown of the extracellular matrix, causing the 
invasion of cancer cells in the basement membrane.27 The damaging effect of MMPs are 
multiplied by a reduction in the  expression of TIMP metalloprotease inhibitors, caused by 
the presence of LPA.27,30,53  
 
1.2.1.2 Inhibition of apoptosis 
 
The action of LPA is also known to inhibit processes that lead to both intrinsic and extrinsic 
apoptosis (programmed cell death), which is essential for the survival of cancer cells. For 
example, LPA causes the translocation of the receptor Fas, from the cancer-cell surface.19,27 
Fas is a receptor that can initiate apoptosis within a cell. Once activated, Fas receptors initiate 
an intra-cellular caspase protease cascade to drive apoptosis (protease breaks down proteins 
to amino acids, resulting in cell death).19,27 This means that after its relocation, the receptor 
is less responsive to stimuli associated with apoptosis.19,27 The apoptotic response is muted 
further by LPA, by its inhibition of caspase-8, through increased expression of cFLIP, an 
inhibitor of caspase-8.27,54 LPA is also known to cause the expression of Fas ligand (FasL) on 
the surface of cancer cells.27 Fas ligand acts to promote the apoptosis of lymphocytes, 
meaning the tumour is less likely to be detected by the immune system.55  
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The protein BAD has an important part in the apoptosis of cells. It can cause the 
permeabilization of the outer mitochondrial matrix, through the activation of pore-forming 
proteins: Bak and Bax, which leads to cell death.19,27,56 LPA inhibits apoptosis by promoting 
the phosphorylation of BAD, which results in a loss of function.19,27,56 In continuation, upon 
the activation of receptor LPA2, transcriptional cofactors: NHERF2 and TRIP6 are recruited 
via a zinc finger located within the protein structure (unique to LPA2).27 NHERF2 and TRIP6 
cause the ubiquitination of pro-apoptotic, apoptosis regulatory protein, Siva-1.27,57 Thus Siva-
1 is deactivated. The significance of this is that Siva-1 is understood to inhibit Bcl-xl.57 Bcl-xl 
acts to inhibit Bak and Bax, which as stated have a significant role within the intrinsic 
apoptosis pathway.19,27 It is also worthy of note that inhibition of Bcl-xl increases the 
sensitivity of cancer cells to carboplatin.27 
RGS proteins act to regulate G-protein signalling, associated with LPA receptor 
activation.30,33,45,47 Upon the stimulation of LPA receptors, RGS proteins release GTPases, 
which hydrolyse GTP bound α-subunits.30,33,45,47 Guanosine triphosphate (GTP) is released in 
response to LPA. GTP is an important molecule in signal transduction and triggers number of 
downfield processes including those attributed to the inhibition of apoptosis.30,33,45,47 
GTPases hydrolyse GTP to guanosine diphosphate (GDP), reducing the amount of GTP 
present, moderating the signal. LPA can cause the suppression of RGS proteins, which results 
in a loss of regulation of GTP and a net increase in signalling, amplifying the 
pathophysiological effects of LPA.30,33,45,47 Interestingly, autotaxin has been shown in itself to 
confer resistance to the apoptosis of fibroblasts  by serum starvation.27,58   
 
1.2.1.3 Proliferation and senescence 
 
Senescence refers to a loss of cell growth or division as a consequence of age. This 
physiological process is an important factor in controlling the proliferation of cells / tumour 
growth.27,45,47 Replicative senescence is regulated by the tumour suppressor p53.27,45,47 In 
response to cellular stress p53, is activated, resulting in many cellular responses, including 
the senescence of cells.27,45,47  In the absence of p53, cells continue to replicate, even when 
exposed to stress, meaning that they can incur DNA damage.27,45,47 LPA is understood to 
supress p53 senescence by activation of receptor LPA2.27,45,47   
LPA is known to contribute to the angiogenesis of ovarian cancer cells. Angiogenesis is a 
process by which new blood vessels form. It follows that such a process is essential for 
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tumour growth / survival. Angiogenic growth factor, VEGF, has the ability to stimulate the 
growth of new blood vessels around the tumour and therefore has an important role in the 
proliferation of ovarian cancer cells.27,30,33,34,38 LPA can trigger the production of VEGF, but 
can also cause increased VEGF receptor expression on endothelial cells.27,30,33,38 VEGF can 
cause the expression of autotaxin by ovarian cancer cells, which leads to increased turnover 
of extracellular LPA.27,30,33,38 Intriguingly, a study by Hu et al,  found that LPA was able to act 
as a growth factor by increasing the level of checkpoint regulator, cyclin D1 in ovarian cancer 
cells, resulting in an increased rate of proliferation.38  
LPA has been found to stimulate growth-regulated oncogene α (GROα), a chemokine 
commonly associated with angiogenesis.19,27,59 In a study by Lee et al, it was found that when 
ovarian cancer cells were starved in serum-free medium they ceased to secrete GROα.59 
However, when exposed to LPA, GROα was once more expressed.59 Additionally, LPA has 
been observed to further aid angiogenesis in cancer cells by causing the expression of IL-8, a 
pro-angiogenic factor.30  
 
1.2.1.4 Chemoresistance  
 
Ovarian cancer is typically treated with paclitaxel or carboplatin, which in many cases prove 
to be an effective therapy.27 Paclitaxel (taxol) functions by targeting tubulin, a protein that is 
a large component of the eukaryotic cytoskeleton. Cells exposed to taxol are found to have 
defects in their mitotic spindle formation.60 These defects result in cancer cells losing their 
ability to undergo mitosis and eventually leads to cell death.27,60 However, over time patients 
can become less responsive to these chemotherapeutic agents, which accounts for the poor 
survival rate attributed to ovarian cancer patients over a five-year period.19,27,30,57 LPA is 
known to activate the phosphoinositide 3-kinase (PI3K) pathway, which then triggers several 
responses down-field. Of particular note is the AKT pathway, known to mediate cell survival 
signals which act to protect cells from apoptosis. 19,27,30,45,57 Concerningly, it has been 
observed that the PI3K pathway has the ability to restore spindle function in cancer cells 
damaged by paclitaxel.30 
 In a study by Testa and co-workers, ovarian cancer cells were treated with a PI3K inhibitor 
(LY294002). Inhibition of PI3K augmented cisplatin-induced apoptosis. Similarly LY294002 
has been shown to enhance the effect of taxol on tumour cell growth.61–63 Therefore, 
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targeting extracellular LPA through the inhibition of ATX may prove to be a beneficial 
approach to combating chemoresistance in ovarian cancer cells.19,27,30,45,57,61–63 
Drug resistance is also conferred by LPA through its role in the deactivation of the pro-
apoptosis protein Siva-1, as stated earlier. The inhibition of LPA results in cancer cells 
becoming resistant to cis-platin.27,41 
  
1.2.1.5 Self-potentiation 
 
Along with its part in the migration and invasion, proliferation and senescence, inhibition of 
apoptosis  and chemoresistance of ovarian cancer cells, the ATX / LPA signalling pathway has 
what can be described as a ”self-potentiating action”.27,33 That is, mechanisms exist by which 
LPA signalling is increased, meaning that the processes linked to the development of ovarian 
cancer cells will be intensified. For example, LPA has been identified as a growth factor in its 
own right and has been shown to stimulate the growth of ovarian cancer cells. 27,33 Ovarian 
cancer cells have been observed to increase ATX levels, leading to elevated levels of LPA.27 
Moreover, cancer cells are known to increase the expression of LPA receptors on their 
surface, compared to healthy cells.33 Lastly, LPA under physiological conditions has a short 
half-life of around 5 minutes.29,30 This is due to the action of lipid phosphate phosphatases 
(LPP) which break down LPA, attenuating its interaction with LPA receptors.57,64 Cancer cells 
are known to down-regulate the expression of LPPs, compared to normal cells, leading to 
increased LPA.33 The self-potentiating properties of ATX / LPA, in combination with the down-
field response following LPA receptor activation has been described by some as a “perfect 
storm” for the development of ovarian cancer.33 
 
1.2.2 Autotaxin and its role in other diseases 
 
Although the role of autotaxin (ATX) in ovarian cancer is the primary focus of this work, it 
should be stated that ATX has been identified as having a major role within the pathogenesis 
of a number of other diseases. As the pathways become clearer, it is anticipated that 
autotaxin will receive greater attention as a target for the treatment of these diseases.33  
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In particular, ATX has been linked with Idiopathic Pulmonary Fibrosis (IPF). IPP is a lung 
disease characterised by a progressive and permanent decline of lung function caused by a 
thickening and scarring of connective lung tissue (fibrosis).33,58,65–68 Treatment options are 
very limited.58,66 A connection between autotaxin and IPF has been established through its 
role in the synthesis of LPA, and subsequent activation of LPA receptors (LPAr’s), in a similar 
manner to ovarian cancer.33,58,65,67,68 Elevated levels of ATX have been found in the synovial 
fluid of patients with rheumatoid arthritis (RA). The ATX / LPA signalling pathway has been 
implicated in the progression of RA, through events downfield of LPAr activation. LPAr 1-3 
have been identified to trigger responses deemed to potentiate RA.33,69,70 Aidinis and co-
workers showed that when ATX expression was conditionally ablated in mice, inflammation 
slowed, demonstrating the significance of ATX in rheumatoid arthritis.33  Autotaxin has also 
been linked to obesity. Obesity occurs in reaction to excess nutrients and energy via the 
chronic inflammation of metabolic tissue, such as adipose, muscle and liver, through the 
induction of cytokines. In mice engineered to overexpress ATX, it was discovered that when 
fed with a high fat feedstock, they took on more fat in comparison to wild type mice.33,71  
 
1.2.3 Inhibition of ATX 
 
Autotaxin has a significant role in the development of ovarian cancer, through the part it 
plays in the migration and invasion, proliferation and senescence, inhibition of apoptosis  and 
chemoresistance of ovarian cancer cells. It follows that by inhibiting autotaxin, extracellular 
LPA should be significantly reduced and tumour growth slowed. There is little evidence to 
suggest ATX inhibition can actually cause cell death to occur. The inhibition of ATX may 
restore cell sensitivity to existing chemotherapeutic agents such as taxol.33,72,73 Therefore, 
autotaxin inhibitors are likely to be most effective when used in combination with a cytotoxic 
agent, as evidenced by the work of Banerjee and Samadi et al.72,73 
One may question whether LPA receptors could make a suitable target for inhibition 
considering that many of the aforementioned processes occur as a direct consequence of 
LPA, down-field of autotaxin. However, it is our belief that autotaxin is a much more suitable 
target for inhibition for two main reasons. 
Rather than having a single defined structure, LPA has a number of variants, with regard to 
its acyl chain, such as chain length and degree of saturation.30,74 These differences result in 
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LPA receptors (LPAr) having a strong affinity for only certain sub-types of LPA, which varies 
throughout LPAr 1-6.30,74 For example, LPA4 has a greater affinity for longer acyl chain lengths 
on LPA, of around 16-20 carbon atoms, whereas LPA2 has greater specificity for shorter 
chains: 12-14 carbon atoms.74 For the processes attributed to the development of ovarian 
cancer to be effectively modulated, every LPA receptor subtype should be inhibited. Owing 
to their differing substrate specificity there may be considerable challenge in designing an 
effective antagonist that has wide-reaching LPAr activity. Allosteric modulation may provide 
a more effective mode of inhibition but designing a drug for this purpose brings with it other 
challenges. Secondly LPA signalling has an important physiological role, such as cerebral 
cortex formation, neuronal cell proliferation and causes the apoptosis of cells.75,76 In 
consideration of this, deactivation of LPA receptors may disrupt important physiological 
processes within the body and could potentially cause damage. Reducing extracellular LPA 
levels via ATX inhibition will control LPAr activation and the down-field effects associated 
with cancer, whilst maintaining physiological function. This is evidenced in a study by Ninou 
et al in which it was suggested that up to 80 % of ATX / LPA signalling could be dispensed 
with in adult mice whilst still maintaining physiological function.58,77 
 
1.2.3.1 Known ATX inhibitors 
 
Unsurprisingly, over the last 12 years many autotaxin inhibitors have appeared in the 
literature, and have evolved in structural complexity, from early LPA mimetic type drugs to 
complex heterocyclic systems that have activity in the low nanomolar range.44,78  
The current range of autotaxin inhibitors can be divided into two groups according to their  
structure: lipid like inhibitors and small-molecule inhibitors (non-lipid-like).44,78 With little 
exception, both classes act as competitive inhibitors.44,78  From a historical perspective, lipid 
inhibitors were the first to be developed, from 2006 onwards, using LPA as a starting point, 
which in its own right is known to have a weak inhibitory action on ATX.78,79 The lipid-like ATX 
inhibitors developed to date are listed in Table 1. 
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Table 
entry 
 
Compound structure / 
Name (if available) 
 
Activity 
/ 
IC50  
 
Mr / 
g / mol 
 
Log P 
 
Publication 
date 
 
 
1 
 
 
 
252 nM 
 
474.68 
 
7.42 
 
2006 79 
 
2 
 
 
 
140 nM 
 
404.54 
 
5.65 
 
2006 80 
 
3 
 
 
FTY720-P 
 
350 nM 
 
387.5 
 
4.73 
 
2008 81 
 
4 
 
 
BrP-LPA 
 
22 nM 
 
487.41 
 
5.58 
 
2008 78,82 
 
5 
 
 
S32826 
 
 
5.6 nM 
 
 
397.5 
 
 
5.5 
 
 
2008 83 
 
6 
 
 
 
 
 
170 nM 
 
368.5 
 
7.3 
 
2010 33,84,85 
19 
 
 
7 
 
 
 
1.93 
nM 
 
494.3 
 
3.9 
 
 
2015 86 
 
Table 1 - A summary of lipid like ATX inhibitors published to date 
 
A recurring motif within this class of inhibitor is a phosphate “spearhead,” sometimes 
substituted for phosphorothioate, that interacts with the active site of ATX, in a similar 
manner to LPA (discussed in 1.2.1).44,78 Additionally, these inhibitors incorporate a long alkyl 
/ alkenyl tail that sits in the hydrophobic pocket, not unlike LPA.44,78 Many of these inhibitors 
have very acceptable potencies. It is speculated that compounds with low nanomolar activity 
are caused by a covalent bond between the Thr209 residue on ATX and the substrate.44,78 
The majority of lipid-like compounds in the literature were published from 2006-2010. After 
that point in time, inhibitors based around “unnatural substrates” were published much 
more frequently.44,78 This was in part due to the X-ray crystal structure of autotaxin being 
solved in 2011, which was a significant step forward in terms of rational drug-design. With 
the aid of docking studies and virtual screening many different small molecule inhibitors 
were quickly developed. The other and perhaps more definitive reason lipid-like inhibitors 
are less prevalent today is because of their strong structural similarity to LPA. Lipid-like 
inhibitors can act down-field of autotaxin, meaning the inhibitor has the potential to activate 
LPA receptors which would negate any therapeutic benefit of ATX inhibition.44,78 It has also 
been found that many of the lipid-like inhibitors, such as S32826 have poor bioavailability 
and stability in vivo.83 
A summary of the small molecule ATX inhibitors are listed in Table 2: 
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Table 
entry 
 
Compound structure / name (if available) 
 
Activity / 
IC50  
 
Mr / 
(g/ 
mol) 
 
Log 
P 
 
Publication 
date 
 
 
 
1 
 
 
 
 
 
<1 μM 
 
 
534.3 
 
 
2.6 
 
 
2009 87 
 
 
2 
 
PF-8380 
 
 
2.8 nM 
 
 
476.3 
 
 
3.0 
 
 
2010 
44,78,87 
 
 
3 
 
HA155 
 
5.7 nM 
 
463.2 
 
2.7 
 
2011 43 
 
 
4 
 
 
 
 
 
4 nM 
 
 
 
364.4 
 
 
 
 
3.6 
 
 
 
2012 
35,44  
 
 
5 
 
3BoA 
 
 
 
13 nM 
 
 
476.1 
 
 
4.9 
 
 
2013 88 
21 
 
 
 
6 
 
 
 
 
1.7 nM 
 
 
438.5 
 
 
3.7 
 
 
2013 
44,89 
 
 
7 
 
 
 
 
2 nM 
 
 
440.3 
 
 
2.6 
 
 
2014 
44,90  
 
8 
 
 
 
1 nM 
 
 
561.5 
 
 
3.5 
 
 
2014 91 
 
9 
 
GLPG 1690 
 
 
 
131 nM 
 
 
 
588.7 
 
 
 
4.9 
 
 
 
2017 67 
 
Table 2 – A summary of small molecule ATX inhibitors 
 
Although each inhibitor shown in Table 2 incorporates different functionality and structural 
motifs, they do share a common trait regarding their shape. Using PF-8380 as an example. 
These inhibitors typically contain a lipophilic tail, an acidic head and a spacer group set in the 
middle, which is in many ways analogous to LPA (Figure 8).44 
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Figure 8 - The common structural features of small-molecule ATX inhibitors. 44 
 
These features can be observed throughout the small-molecule inhibitor series, although 
more recently there appears to be a trend in compounds moving away from using an acidic 
head group, such as GLPG 1690 (Table 2, entry 9).67 It is common for this class of inhibitor to 
have a high degree of flexibility, particularly in the centre of the structure. This enables the 
molecule to correctly orientate itself within the hydrophobic pocket of ATX to assist drug 
binding.44,78 Many small molecule ATX inhibitors have a high molecular weight, typically 
higher than  400 g/mol and a log P value over 4. Whilst these values may be considered 
unacceptably high under normal circumstances, one must consider the active site of ATX and 
its natural substrate: LPA. LPA has a high molecular weight of 436.52 g/mol (18:1 carbon 
chain) and is highly lipophilic, with a log P value of approximately 6.12. Under these 
circumstances a high molecular weight should be considered acceptable because of the need 
shown for LPA to fill the hydrophobic pocket of ATX as well as bind to its active site for an 
effective interaction to occur. To fulfil these two requirements, the drug molecule has to be 
reasonably long due to the size of the cavity. This will inevitably lead to an increase in 
molecular weight. Lipophilicity can be controlled by careful drug design and indeed has been 
brought down to acceptable levels. 
For some of the compounds in Table 2 the crystal structure was obtained of the drugs bound 
to ATX. The X-ray structures revealed information about their binding mode (Figure 9).  
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Figure 9 - ATX bound to 4 different inhibitors: a) 3BoA, b) HA155, c) PF-8380 (Table 2, entry 
5, 3, 2, respectively)  d) LPA 43,87,88 
 
Figure 9 shows three different drug molecules bound to ATX. Despite having different 
structures, each compound adopts a similar binding pose. The acidic head group interacts 
with two zinc atoms (shown in blue). Figure 9d shows LPA bound to ATX, in a near identical 
fashion to a-c, suggesting that these inhibitors interact with ATX in a similar way to LPA. It 
has been suggested that, like LPA, the acidic headgroup is susceptible to nucleophilic attack 
from the Thr209 residue on ATX, forming a covalent bond.44,78 The covalent bond accounts 
for the high potency observed for all three compounds (low nanomolar). Not all autotaxin 
inhibitors adopt this binding pose, including the recently published GLPG 1690.67 
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Figure 10 – a) GLPG 1690 bound to ATX, b) the binding mode of GLPG, c) 1690. 67  
 
The X-ray structure of GLPG 1690 bound to ATX (Figure 10a) shows the drug adopting an 
alternative binding mode. The fluorobenzyl half sits in the hydrophobic pocket and the 
hydroxyazetidine portion lies in the tunnel.67 Notice that the drug does not appear to interact 
with zinc atoms (shown in blue) within the active site (i.e. it is not a “zinc binder”). The 
authors speculate that the reason for the compound being highly potent is that it occupies 
part of the tunnel.67 The tunnel is thought to have a significant role in the removal of LPA 
(post hydrolysis of LPC). In blocking access to the tunnel, the catalytic cycle is disrupted, 
leading to inhibition of ATX.67   
 
1.2.3.2 Autotaxin inhibitors in the clinic 
 
The past 10 years have seen considerable advancement in the development of autotaxin 
inhibitors from both industry and academia. The compounds featured in Table and Table 2 
are the result of extensive screening and library synthesis over a period of many years, but 
despite this, as of 2018, there is only one autotaxin inhibitor in clinical trials.44,65,67 The 
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compound in question, GLPG 1690 developed by Galapagos NV, is being investigated as a 
potential therapy for Idiopathic Pulmonary Fibrosis (IPF).67 The drug is orally active, taken 
once daily and has so far performed very well in clinical trials, advancing to stage III in recent 
months.92  
Despite the apparent success of Galapagos and their flagship compound in this area. ATX 
inhibitors as treatments for ovarian cancer have unfortunately not progressed past pre-
clinical studies.44 We speculate that the reason for this is the unique challenge of targeting 
organs within the peritoneal cavity (discussed in chapter 1.4. The further development of 
ATX inhibitors for ovarian cancer therapy may be hindered until this problem is overcome. 
The focus of our research, over the last several years, has been to investigate new methods 
by which the pharmacokinetic properties of autotaxin inhibitors can be improved, without 
compromising activity inherent to the drug molecule. This has led us to investigate the use 
of polymeric drug–delivery strategies as a method to increase peritoneal retention of ATX 
inhibitors.93,94 
 
1.3 Drug delivery and polymer therapeutics 
 
Novel strategies for drug delivery, in particular polymer-based therapeutics have been of 
interest since the mid 1970 s.95 In principle, these systems have the potential to enhance the 
physicochemical and pharmacokinetic properties of a drug, which may otherwise have been 
considered unacceptable within a biological system.95,96 Previously, drug delivery systems 
have been used to change the solubility, toxicity and improve the half-life of drug 
molecules.95,96 Additionally, they can be designed to target a specific area of the body or even 
particular organs. This ensures that the drug is distributed to where it is needed, which can 
reduce dosing.95,96 Drug delivery should not be confused with formulation approaches in 
which a drug’s properties are modified by an external “technology”. This may include using 
an enteric coating on a pill to prevent the degradation of an acid-labile drug in the stomach.97 
The difference between this application and a drug delivery approach is that such a 
modification does not involve any chemical bonding, though we would extend this definition 
to non-covalent interactions as well.96 The majority of drug delivery systems featured in the 
current literature can be divided into two classifications: reactive and passive.98,99 
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1.3.1 Reactive drug delivery systems  
 
Reactive drug delivery systems are designed to transport drug molecules to a target area. 
Then the drug is released through a specific response to the environment (such as a change 
in pH). Such systems have the potential advantage of being highly specific in the areas that 
they target but they can be very difficult to design and to get to work effectively. Two 
common examples of this type of drug delivery approach are encapsulation and targeted 
drug release.96,100,101 Encapsulation is an attractive approach to extend the half-life of a drug 
and is commonly achieved by functionalising a polymer.100,102,103 Under specific conditions 
the polysaccharide may form a micelle. During the formation of a micelle a drug is introduced 
into solution it can become entrapped within the structure  (Figure 11a).99,102,104  
 
Figure 11 - a) Encapsulated drug delivery system, b) targeted drug release system 
 
The encapsulated drug in response to an external factor, such as temperature, will be slowly 
released as the micelle deforms, as demonstrated by Zhang and co-workers.104 Drug 
molecules can also be encapsulated using supramolecular arrays. However, these have 
limited use outside of academia due to their poor biocompatibility.105 One criticism of the 
use of encapsulation as a drug delivery device is that the drug can be released only very 
slowly or not at all. This is due to the material being held too tightly within the micelle or 
liposome, which reduces its therapeutic benefit.106  
Targeted drug release systems are similar to a passive polymer therapeutic approach. 
However, they differ in that they are designed to transport the drug and then release their 
payload through a cleavable linker unit (Figure 11b).98  
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These systems often have a targeting molecule attached to the polymer to assist in the site 
specificity of the drug delivery device. For example, Ojima and co-workers conjugated 
vitamin B7 to their Taxane vehicle.107 Tumour cells are known to over express vitamin 
receptors on the cell surface, meaning that the device was able to selectively target tumours 
and release a taxol derivative via a “self-immolating” disulfide linker.107,108   
 
1.3.2 Passive drug delivery systems  
 
Passive drug delivery systems concern the covalent attachment of a drug molecule to a 
polymer (known as polymer therapeutics). Through this modification the drug molecule can 
take on some of the properties of the polymer which may enhance its pharmacokinetic 
profile. The polymer chosen for this purpose is usually inert and does not interact with the 
biological target by itself. These materials are polydisperse by nature and therefore their use 
from a therapeutic viewpoint would appear to counter the efforts of the pharmaceutical 
industry during the last century. Which has pursued monodisperse molecules, rather than a 
polymer drug conjugate made of many different molecular weight fractions and irregular 
drug loading. However, provided the polymer is known to be inert and biocompatible, the 
greatest safety concern in any polymer-based drug delivery system should rest with that of 
the drug. This is evidenced by polymer therapeutics now routinely being used in the clinic 
during the last 20 years.96  
Polymer therapeutics are further divided into two categories: natural and synthetic 
polymers.  Examples of natural polymers include dextrans, chitosans and alginates. These 
polymers are typically water-soluble materials that contain functionality which can be used 
to covalently attach (conjugate) drug molecules to their structure.95,96 Examples of synthetic 
polymers include dendrimers, polyethylene glycol (PEG), N-(2-hydroxypropyl) 
methacrylamide (HPMA) and linear polyamidoamines. Synthetic polymers have an 
advantage over natural polymers in that their polydispersity and physical properties can be 
controlled, which is desirable from a design viewpoint. Dendrimers can be “grown” by the 
sequential addition of reagents creating branching. As each layer of branching is added the 
dendrimer goes through a change in generation, which defines its physical characteristics.109 
It follows that synthetic polymers can be tailored to meet a particular requirement of a drug 
delivery application.109,110 Synthetic polymers have sometimes been found to be cytotoxic 
28 
 
leading them to be withdrawn from clinical trials.111 A number of different polymer 
therapeutic approaches have been applied to a variety of drug types (Figure 12).  
 
Figure 12 - a) polymer-protein conjugate, b) polymer DNA-complex, and c) polymer drug 
conjugate  
 
Recombinant DNA and monoclonal antibody technologies have produced a vast reservoir of 
peptide and protein-based drugs, which have the potential to be effective therapies. 
However, these can suffer from a short plasma half-life, solubility and stability issues, which 
have slowed their development. Polymer-protein conjugates (Figure 12a) are a useful way 
to improve the shortcomings of protein drugs. Abuchowski and co-workers first 
demonstrated the PEGylation approach in 1977, in which PEG was conjugated to a protein.112 
This had a positive effect on the solubility and stability of the protein, starting a whole new 
field of research and a multi-billion dollar industry.96,113  
DNA or oligonucleotides have large therapeutic potential as they have the ability to 
selectively bind to DNA / RNA sequences and inhibit gene expression and therefore have 
value in viral and cancer therapy.114 Disappointingly, the clinical progression of this 
technology has been slow which is most likely due to their low resistance to nucleases.114 
DNA polymer conjugates (polyplex) (Figure 12b) have been shown by Liao et al and 
Frederiksen et al to be effective gene delivery devices for cancer and viral treatments.115,116 
The drug polymer conjugate approach (Figure 12c) is of most relevance to this thesis. Natural 
and synthetic polymers have been conjugated to a variety of drugs. A drug conjugate 
approach may attenuate unwanted attributes such as high toxicity, low aqueous solubility, 
low stability, high acid lability, low plasma half-life and high lipophilicity.96 The main principle 
behind this approach is that because the bulk of the conjugate is a polymer, the drug 
(covalently bonded) will take on some of the properties of the polymer.117 For example, if 
the polymer were particularly hydrophilic (such as a polysaccharide) then the drug bound to 
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the polymer would overall become more hydrophilic. Conversely, because the polymer is not 
biologically active and has no role in the interaction of the drug with its target, the drug 
should retain its potency. The drug polymer conjugate approach has been investigated for 
use in cancer therapy. A study by Peppas and co-workers featured the preparation of a 
doxorubicin-Inulin conjugate.118  Interestingly, CTI Biopharma have developed a paclitaxel-
polyglutamate conjugate (Paclitaxel Poliglumex). This has been shown to increase the 
solubility of taxol (within the overall drug-conjugate) and decrease administration 
times.96,119,120 Further to this, the material can be administered in higher dosages than taxol 
alone, Paclitaxel Poliglumex has entered phase III clinical trials in women with ovarian cancer. 
As part of our own research endeavours in this area, a potent lipid-like ATX inhibitor (S32826) 
was attached to a 3rd generation PAMAM dendrimer (Figure 13).93 It was envisaged that, 
after the attachment of the dendrimer to S32826, the drug’s bioavailability would be 
improved along with an increase in the site specificity of the drug, which is a common 
problem associated with this class of inhibitor.78,93 It was found that the drug retained its 
activity following attachment to the dendrimer (IC50 = 160 nM). This drug delivery system 
was not developed further due to toxicity concerns associated with dendrimers. However, 
the concept explored within the study formed the basis of our future investigations.94,121  
 
 
Figure 13 - PAMAM-S32826 dendrimer conjugate 
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1.3.3 Polymer therapeutics in the clinic 
 
As of 2018, over 10 polymer-drug conjugates are at various stages of clinical development, 
with many drug conjugates having cleared phase III trials over the last 20 years leading to 
their widespread adoption in the clinic.122 As alluded to earlier, PEGylated proteins dominate 
the list (Table 3) although taking into account the drug conjugates currently in development, 
this trend may change over the next decade.96,122 
 
Type Trade name Drug Polymer Disease 
Polymeric drug Copaxone Glatiramer 
acetate 
Glu Ala Tryp co 
polymer 
Multiple 
Sclerosis122 
Polymeric drug Synvisc Hyaluronic 
acid 
Hyaluronic 
acid 
Arthritis 122 
Polymer 
protein 
conjugate 
Zinostatin 
stimalamer 
Zinostatin Lipiodol  Liver cancer123 
PEGylated 
protein  
Cimzia Anti-TNF Fab PEG Chron's disease124 
PEGylated 
protein 
Mircera Epoetin-β PEG Anaemia 
associated with 
chronic kidney 
disease125  
PEGylated 
protein 
Pegasys Interferon α 2b PEG Hepatitis c126 
PEGylated 
protein 
Neulasta hrGCSF PEG Neutropenia 
caused  by   
chemotherapy96,122 
PEGylated 
protein 
Uricase-PEG20 Uricase PEG Gout127 
Drug polymer 
conjugate  
Abraxane Paclitaxel Albumin Breast, lung and 
pancreatic 
cancer128 
 
Table 3 - Clinically approved polymer-conjugate treatments 
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It is worth noting that two of the drugs featured in Table 3, Copaxone and Neulasta, have 
each amassed sales of several billion dollars, and at one stage (2011) featured in the top 10 
selling pharmaceutical products in the world.96,129,130 This shows that drug-polymer 
conjugates have progressed significantly from academic curiosities, and are now a widely 
accepted therapeutic approach by the pharmaceutical industry.  
 
1.4 The peritoneal cavity  
 
As stated in Chapter 1.2.3 it is postulated that one of the reasons that autotaxin inhibitors 
perform poorly in vivo is that they are rapidly eliminated from the peritoneal cavity and 
therefore away from the location of the tumour. We hypothesised that the properties of an 
autotaxin inhibitor can be enhanced by the use of a drug delivery strategy, specifically a drug 
polymer conjugate approach (Figure 12c). We postulated that this modification will 
significantly increase the residence time of an autotaxin inhibitor within the peritoneal 
cavity.  
The peritoneal cavity (Figure 14)  is located in the abdominal area of the body. and exists as 
potential space, separated by a thin membrane between the abdominal wall and major 
organs including the small intestine, liver, pancreas and for women, ovaries. 131,132  
 
Figure 14- The Peritoneal Cavity (enlarged, for the purposes of the diagram) 133 
 
Chemotherapeutic agents may be administered intraperitoneally, meaning the drug is 
injected directly into the peritoneal cavity.15,134 This technique appears to garner superior 
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results (in terms of drug response) compared to intravenous injection or oral intake.15 It can 
be speculated that this is due to establishing a localised concentration of the material near 
the cancerous area.15,134 Additionally, the peritoneal membrane, which acts as barrier 
between the peritoneal cavity and the rest of the body, contains many capillaries that are 
ideal site for absorption.132,135,136  
The peritoneal membrane (peritoneum) is commonly used medically, in a process known as 
Peritoneal Dialysis or Ultrafiltration.132 Ultrafiltration is the process by which solutes are 
transported through the peritoneal cavity via the peritoneum (a layer of tissue comprised of 
many blood vessels).131,132 The peritoneum itself is semi-permeable to molecules, depending 
on their physical properties and clinically this is exploited for peritoneal dialysis.15,132,137 
Toxins (e.g. methanol) that would otherwise not be metabolised though complications 
associated with renal failure, are removed from blood.132 A typical procedure (Figure 15) 
involves the introduction of dialysis fluid (typically comprising a high molecular weight 
dextran polysaccharide dissolved in water) into the peritoneal cavity through a permanent 
catheter.132 Solutes are filtered through the peritoneum and after several hours an 
equilibrium is established, the fluid is then drained off from the peritoneal cavity, removing 
many unwanted / toxic solutes.132 The entire process can be then repeated. Peritoneal 
dialysis is often a very effective treatment for those with reduced renal capacity.132 
 
 
Figure 15- Typical peritoneal dialysis procedure 138 
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With reference to ovarian cancer, when the cancer metastasises it can cause irritation of the 
peritoneum, which triggers the build-up of ascites fluid.46 The accumulating fluid puts 
pressure on the abdomen which can be very painful. Patients suffering with ovarian cancer 
regularly need to have the ascites fluid drained to alleviate the pressure.46 
 
1.5 The development of a novel drug delivery strategy for the peritoneal cavity 
 
Transport of material through the peritoneum, and by extension the intraperitoneal cavity, 
is a complex process, but to be able to design an effective drug-polymer conjugate it must 
be understood. There are two ways for a solute to be transported through the peritoneum 
(away from the peritoneal cavity) namely: diffusive transport and convective transport.132  
Diffusive transport is driven by the concentration of a given solute in the capillaries (of the 
peritoneum) and the peritoneal cavity.132 A difference in concentration results in a 
concentration gradient, which acts to distribute solute molecules within a defined space.132 
Diffusive transport is an entropically driven process which is directly proportional to 
temperature.132 Molecular weight is a significant factor which affects diffusion; the rate of 
diffusion for a solute is inversely proportional its molecular weight.132,136,139,140 A solute of 
high molecular weight diffuses at a slower rate than those of a low molecular weight (Figure 
16).132 
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Figure 16 - The effect of increasing molecular weight on the rate diffusion of molecules 
through the peritoneal membrane 132 
  
This effect is observed regardless of capillary pore size, as increasing pore size acts to reduce 
the total surface area available for diffusion, and therefore a reduction in transport will be 
observed.132 
Conversely connective transport is largely independent of the molecular weight of the solute. 
When a solute of high molecular weight accumulates within the peritoneal cavity it would 
be expected that a concentration gradient would be established, i.e. a high concentration of 
solute in the peritoneal cavity compared to a low concentration on the outside.132,136,139,140 
As the osmotic pressure increases against the peritoneal membrane to around 25 mm/Hg it 
is significant enough to force high molecular weight solutes through the capillary pores 
(hydrostatic pressure of blood flow = 15 mm/Hg at capillary end).132 Inward diffusion of high 
molecular weight solutes acts to equilibrate the pressure gradient. By establishing a 
concentration gradient within the peritoneal cavity the rate of ultrafiltration is significantly 
increased, which explains why dextran solutions are routinely used as an osmotic agent in 
peritoneal dialysis procedures.132,140 The rate of ultrafiltration can be increased further by 
increasing the concentration of osmotic agent.132  
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Pappenheimer’s theory of restricted diffusion, states that three factors can influence the 
passage of molecules across capillaries: 132,141 
1. Steric hindrance at the entrance to a capillary pore141 
 
2. Friction between molecules moving within a pore, which relates directly to the 
molecular weight of the solute141 
 
3. Molecular friction within the stationary walls of a pore141 
 
Other factors that affect diffusion across the peritoneal membrane depend on whether the 
solute carries a charge. This is because the capillary pores are lined with basic amino acid 
groups as well as phosphate and choline groups. It has been observed that the rate of 
diffusion for acids / bases decreases across the peritoneum.132 Additionally the use of 
vasodilating drugs significantly increases the rate of diffusion for larger molecular weight 
solutes.132  
By understanding the principles which underlie the transport of molecules through the 
peritoneal membrane, it should be apparent that the peritoneal cavity presents an 
inhospitable environment for drug molecules to be able to function correctly. Because of 
their relatively low molecular weight they are rapidly expelled through the peritoneal 
membrane and are subsequently metabolised. As a consequence a small-molecule would 
not be expected to inhibit autotaxin present within the intraperitoneal cavity to any 
measurable extent.132,136  
 
A suitable polymeric drug carrier would therefore be expected to possess the following 
characteristics: 
• Highly biocompatible, meaning that it is completely inert within the body 
(containing no toxicophores) and ideally already be approved for use / 
precedent for its use within the peritoneal cavity. 
• Possess a high molecular weight, over 5000 Da 
• Have no affinity for autotaxin in its own right  
• Contain suitable functionality for the covalent conjugation of drugs 
• Not carry any charged species 
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1.5.1 Suitable polymer supports - Icodextrin  
 
Icodextrin (IDX) (Figure 17) is a polysaccharide with an average molecular weight of 
approximately 13-19 kDa.139,140,142,143 It is comprised entirely of glucose subunits, which are 
linked at the α (1,4) position and branched by α (1, 6) glycosidic bonds, to a lesser extent.140  
 
Figure 17 - The structure of Icodextrin 
 
Icodextrin is used commercially, in solution, as an osmotic agent for peritoneal dialysis and 
as a post-surgery adhesion reductant, under the trade names Extraneal™ and Adept™ 
respectively, produced by Baxter healthcare.139,140,144  
From a synthetic standpoint IDX is potentially very suitable as a polymeric drug support. This 
is because it can be easily isolated in large quantities as a solid from solution via dialysis. 
Additionally, it contains many free OH groups to which drug molecules can be covalently 
attached. From a materials viewpoint IDX is also ideally suited as a polymer drug carrier. IDX 
has been approved in 31 countries for use in the peritoneal cavity and is widely considered 
to be completely safe / inert.145 It has also been shown in numerous studies that Icodextrin 
has a significantly longer retention time in the peritoneal cavity compared to the equivalent 
monosaccharide glucose (Figure 18).139,140,142,145,146  
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Figure 18 - A graph to show the retention of IDX and glucose in the peritoneal cavity.139 
 
Typically, less than 40% of IDX in solution will be absorbed in a 12-hour period and has a 
median plasma half-life of 14.73 hours.139,144  This means that IDX is retained in the peritoneal 
cavity for up to several days, making it an ideal polymer support to maximise peritoneal 
retention of a drug molecule.  In a study previously conducted by us, an Icodextrin-drug 
conjugate was shown to be retained within the peritoneal cavity up to 30% of its original 
concentration, after 24 hours.147 This significantly increased the residence time of the drug 
in the peritoneal cavity. In comparison < 0.1 % of the free-drug equivalent was observed after 
24 hours.147 Outside of the research efforts of our group, to our knowledge Icodextrin has 
never been used as a polymer-drug support.  
IDX is not metabolised in the human peritoneal cavity to any extent. Instead it must diffuse 
though the peritoneal membrane and into the bloodstream. Icodextrin is metabolised by the 
enzyme α-amylase, of which many subtypes exist, that break down specific glycosidic 
linkages.144,148–150 Icodextrin is metabolised into smaller oligosaccharides (approximately ten 
units) and then to smaller, soluble carbohydrates that can easily be digested.150  
While in many ways Icodextrin is ideally suited as a polymer drug support, this study will 
utilise two separate polymers. This decision was taken for two reasons, the first being that it 
would be beneficial to contrast the performance of Icodextrin to another polymer, as a drug 
delivery device. It may be observed that there is a difference in peritoneal retention for 
different polymer drug-conjugates. Additionally, it may be found that using a different 
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polymer results in a reduction or increase in potency. It could be envisaged that this effect 
would result from the space occupied by the polymer, causing the drug (pharmacophore) to 
interact less favourably with the active site of ATX through steric hindrance.  Another 
polymer may cause a less pronounced reduction in potency because of it having a different 
structure and may not hinder the interaction of ATX and the pharmacophore as significantly. 
Secondly, as mentioned previously, IDX is metabolised by the enzyme α-amylase.148,149,151 In 
humans this fact is of little significance because it is produced in comparatively low 
concentrations, contributing to its high residency time in the peritoneal cavity.149,151 
However, rodents have a much higher concentration of amylase, meaning that certain 
polysaccharides are metabolised faster, compared to humans. Humans have approximately 
7 U/L amylase present in their peritoneal cavity, conversely Rats are known to have 1252 U/L 
(U = the amount of enzyme that catalyses 1 μM of substrate per minute). 151,152 The 
significance of this is that ultimately animal models will need to be used to demonstrate that 
the polymer-drug conjugates produced in this project have improved peritoneal retention 
compared to their free-drug counterparts. If the polymer support is metabolised before the 
drug can significantly inhibit ATX, there is concern that a false-negative result may be 
obtained. Paradoxically, because of the increased α-amylase present in rodents, IDX 
peritoneal retention may be significantly reduced, whereas in human studies this would not 
be the case.151,152    
 
1.5.2 Suitable polymer supports – Inulin 
 
This reflection points to the need to investigate a second polymer. It should be similar to IDX, 
such as being a polysaccharide in order for a meaningful comparison between the two to be 
made. However, the material also needs to be resistant to amylases, so some structural 
differences would be anticipated. By using two polymers in tandem, the chance of producing 
effective drug-conjugates would be increased. 
Through an extensive examination of the literature it was found that the most suitable 
alternative polysaccharide was Inulin, a furanose sugar of an average molecular weight of 5 
kDa, derived from Jerusalem Artichokes.153,154 It can be purchased cheaply from commercial 
sources and has been tested in the peritoneal cavity, and FDA approved, indeed it is 
commonly taken as a dietary supplement, highlighting its high biocompatibility.153,154 Inulin 
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(INU) has a similar structure to IDX (Figure 19), the main difference being that IDX is made of 
pyranose where as INU is made of fructose, save a terminal glucose unit.153,155 The difference 
is that amylases are only capable of metabolising glycosidic bonds on glucopyranosides, 
meaning that Inulin is not a substrate of amylase.148  Further to this Inulin is known to pass 
through the human body undigested, showing complete stability to a variety of other 
enzymes.154  
 
Figure 19 - Shows the structure of Inulin 
 
There is also some evidence to suggest that INU has superior peritoneal retention compared 
to IDX, which would be beneficial.136,156 However it is worth stating that peritoneal retention 
of IDX and INU have never been evaluated in the same study so the results are not directly 
comparable.  
 
1.5.2.1 Inulin-drug conjugates in the literature 
 
An added advantage of Inulin is that unlike IDX, there are a wealth of studies that attempt to 
utilise INU as a polymer support in various capacities.  Yang and co-workers conjugated 
Ibuprofen to inulin through attachment at its carboxylic acid group.104 The resulting 
Ibuprofen-Inulin conjugate underwent self-assembly in water, due to the hydrophobic region 
on Ibuprofen contrasting with the hydrophilic Inulin.104 This action formed a micelle, allowing 
the steroid (methylprednisolone) to be encapsulated for the purposes of drug delivery.104 
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Peppas and co-workers developed a doxorubicin-Inulin conjugate to reduce the 
cardiotoxicity effects associated with the chemotherapeutic agent.118 Disappointingly, while 
an increase in potency was observed (compared to the free drug) the toxicity also increased. 
The authors suggested this was due to increased cell uptake of the conjugate, causing the 
drug to accumulate.118 Further to this, Giammona and co-workers attempted to encapsulate 
doxorubicin through the formation of a micelle, via ceramide units conjugated to Inulin.106 
The authors were able to show that doxorubicin could be released in a controlled manner in 
a variety of aqueous media and that cell uptake was increased compared to the unprotected 
drug.106 Caron and co-workers demonstrated an Inulin-Triton X-100 conjugate, in an effort 
to increase the hydrophilic nature of the surfactant.157 The purpose of this work was to create 
a surfactant suitable for solubilisation of a biological structure157 Based on the preposition 
that the large polymer support would prevent the hydrophobic component of the surfactant 
from penetrating the hydrophobic region of the protein and not causing activity to be 
reduced.157 This led to limited success in reducing the toxicity of Triton X-100, but not 
significant enough to constitute further development.157 Inulin has also been used as a siRNA 
delivery system, by conjugating diethylenetriamine units to the polymer.158 In acidic 
conditions the terminal amine groups are protonated, which allows for an electrostatic 
interaction between the negatively charged nucleic acid residues of siRNA and ammonium 
groups of the modified INU.158 The resulting siRNA conjugates showed improved cell-wall 
penetration. However, the overall effectiveness of the drug conjugate was questionable 
because siRNA was unable to detach from the polymer.158 Inulin hydrogels have been used 
to deliver the chemotherapeutic agent 2-methoxyestradiol.159 The drug was entrapped in 
INU via an internal cross-linking reaction between divinyl sulfone (covalently attached to 
Inulin) and the thiol groups of tris(3-mercaptopropionate), with the cross-linked strands of 
Inulin acting as a “cage”.159  
 
1.5.3 Drug attachment methodologies in the literature 
 
As noted, many Inulin drug conjugates feature in the literature. Consequently, a variety of 
methodologies exist for covalently attaching molecules to Inulin. This is also the case for 
other polysaccharides such as Dextrans, of which methods should be broadly applicable to 
both Icodextrin and Inulin.160  The challenges posed in attaching a drug molecule to a polymer 
(to prepare a drug-polymer conjugate) are three-fold: the reaction conditions must be 
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suitably mild so that no degradation occurs within the drug structure, to retain its biological 
activity. The functionality at the point of attachment should be relatively inert and not be 
susceptible to acidic hydrolysis. This is  to ensure free drug is not deposited in the peritoneal 
cavity, which would reduce the benefit of polymeric enhancement. Further to this, it would 
be prudent for the linkage point to have no interaction with ATX, so as not to interfere with 
the intended pharmacophore. Therefore, only certain methods will be applicable for the 
attachment of drug-like molecules. 
As previously mentioned, in a study by Yang and co-workers, Ibuprofen was conjugated to 
inulin, first, by reacting carbonyldiimidazole with the carboxylic acid group on Ibuprofen, 
then Inulin was added to the reaction mixture (Scheme 2).104 Ibuprofen displaces the 
imidazole group, which results in the formation of an Ibuprofen-INU conjugate.104  
                          
Scheme 2 – Synthesis of an Ibuprofen-Inulin conjugate 104 
 
Similarly, Rodríguez-López and co-workers cinnamoylated Inulin by reacting INU with 
cinnamic acid chloride (Scheme 3).103 
       
Scheme 3 – Synthesis of Cinnamoylated-Inulin 
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While this method is facile in its inception and is clearly suited to conjugating drug molecules, 
an ester linkage was felt to be too labile and would be susceptible to hydrolysis within the 
peritoneal cavity in our proposed study.161  
Another attractive method is to pre-functionalize inulin by reacting it with chloroacetic acid. 
As demonstrated by Peppas and co-workers this can be conjugated to an amino acid unit of 
a drug (such as doxorubicin) using standard peptide coupling conditions (Scheme 4). 118 
         
Scheme 4 - Synthesis of doxorubicin-Inulin Conjugate 118 
 
While being suitable for many applications, the amide moiety would be susceptible to 
hydrolysis and be unsuitable for our own work.161 Alternatively, some polysaccharides are 
known to undergo oxidation to an aldehyde (1° alcohol position), in the presence of 
galactose-6-oxidase or oxidative cleavage of cis 1,2-diols using sodium periodate (Scheme 
5).160,162 
       
Scheme 5 - Periodate oxidation of a polysaccharide 160 
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The newly formed aldehyde provides a useful synthetic handle from which reductive 
amination with an amine can be used to attach drug molecules.160,163 The downside is that, 
in the case of oxidative cleavage, the polysaccharide undergoes significant derivatisation.160 
Epoxides are a particularly useful functionality for conjugating molecules to 
polysaccharides.160 One approach is to modify the intended substrate by attaching an 
epoxide group, often using epichlorohydrin such as in the work by Caron and co-workers.157 
The epoxide intermediate can then be reacted with Inulin in basic media (Scheme 6).157 
 
Scheme 6 - Conjugation of Triton X-100 to Inulin 157 
 
The advantage of this method  is that it employs an ether linkage for attachment, which is 
comparatively inert and provides a stable backbone for conjugation. The ether-alcohol unit 
also closely mimics the polysaccharide structure, so is unlikely to interfere with the 
pharmacodynamics of the drug-conjugate. The stability of the epoxide-drug molecule would 
be of concern though, due to the highly reactive nature of epoxides.161 
This method has also been used in “reverse” by Moltini who first activated Inulin by reacting 
it with epichlorohydrin. Then, in a basic environment, a second epoxide forms by an 
intramolecular displacement of chloride via the neighbouring hydroxyl group (Scheme 
7).164,165 
 
Scheme 7 - Formation of epichlorohydrin activated Inulin 164,165 
 
The resulting epoxide unit is susceptible to nucleophilic attack by amines, allowing for a 
structure to be conjugated to the polysaccharide. Another advantage of this method is that 
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it has been employed successfully on multiple polysaccharides, such as dextrans and would 
therefore have potential to be used with IDX.164 Ideally, this procedure would be applicable 
to alcohols as well, however there remains a paucity of evidence in the literature to suggest 
that this is possible.165   
An alternative method to form ether linkages with polysaccharides is to install a suitable 
leaving group in place of the primary hydroxyl.160 This can then be displaced by nucleophilic 
attack from a drug molecule to attach the substrate. For example, Inulin has been tosylated 
by Ren and co-workers, in the presence of LiCl, to disrupt hydrogen bonding within the sugar 
(Scheme 8).166  
                       
Scheme 8 - Synthesis of tosylated Inulin 166 
 
Hienze and co-workers have also applied this method to cellulose under similar conditions 
and more interestingly efforts by our own group have shown coupling to Icodextrin.94,167 This 
strategy proved to be a relatively effective approach in our previous work for attaching an 
autotaxin inhibitor by a simple SN2  displacement of the tosylate, by the modified drug 
molecule (Scheme 9).94  
               
 
Scheme 9 - The addition of an ATX inhibitor to Icodextrin 94 
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This method can also be applied in reverse synthesising a drug molecule modified with a 
suitable leaving group. The polysaccharide can then be treated with a strong base (typically 
sodium hydride) to generate an alkoxide which then displaces the tosylate.94,160,168  This 
method has been applied to Icodextrin in our previous research endeavours, by employing a 
specially modified drug molecule (Scheme 10).94 
 
Scheme 10 - Shows the "reverse" tosylation approach 94 
 
Out of the two “tosylation” approaches utilised by us, tosylating the drug prior to conjugation 
was preferred.94 This was because of the greater amount of control available in terms of the 
stoichiometry of drug-to-polymer, which is harder to control by pre-functionalizing IDX with 
tosyl chloride, due to  it being reliant on every tosyl group reacting with a drug molecule. 
Otherwise some tosyl residues may be left on the polymer, which is of concern, considering 
the toxicity generally associated with alkylating agents.169  
 
1.5.4 Analysis of drug-polymer conjugates 
 
The preferred mode of analysis for the conjugate described in Scheme 10 was 1H NMR 
spectroscopy; typical methods of analysis associated with synthetic chemistry are less useful 
when analysing polymers, this is because of the lack of uniformity / regulation associated 
with a polymeric system, compared to a small molecule.147 Mass spectrometry has recently 
found some use in the analysis of polymers, using “soft” ionisation techniques (such as 
Matrix Assisted Laser Desorption/Ionization, MALDI), however methods remain in their 
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infancy for the analysis of polymer drug conjugates.170 Elemental analysis, FTIR spectroscopy 
and TGA have also used in the analysis of the materials. Because of the restricted rotation of 
the IDX polymeric system, 1H NMR spectra often lack definition and are unresolved, 
regardless of temperature. For this reason 13C NMR spectroscopy has limited use, with peaks 
noticeably broad. Nonetheless 1H NMR spectroscopy offers a convenient means by which to 
demonstrate the formation of a drug-polymer conjugate, as shown in Figure 20.171 
 
Figure 20 - The 1H NMR spectra of: a) Icodextrin and b) Drug-IDX conjugate (400 MHz) 
 
The amount of drug molecule attached to the polymer (drug-loading) can be quantified by 
either fluorescence spectroscopy or elemental analysis. The results can then be expressed as 
the degree of substitution (DS), which refers to the number of drug molecules attached to 
the hydroxyl groups of a monomeric unit of the polysaccharide, averaged over the whole 
polymer.160 For instance, IDX has a maximum DS value of 3.   
 
It is also worthy to note the selectivity observed in almost all the polymer-conjugation 
reactions for the primary hydroxyl groups of the sugars. This can be explained in part due to 
the hydroxyl groups adjacent to the electrophile being electron withdrawing, which 
disfavours SN2 displacement.160,172 This effect is less prominent for primary electrophiles due 
to being located further from the alcohol groups. Conversely when the polysaccharide takes 
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the role of the nucleophile the primary alcohol reacts in preference to the secondary.160,172,173 
This effect is caused by increased nucleophilicity of the primary hydroxyl group. Although the 
reaction is not entirely regioselective, with some alkylation occurring with the secondary 
alcohols, as evidenced by DS (degree of substitution) values of up to 2 reported for some 
polysaccharides.173  
 
1.5.5 Approaches to the synthesis of novel drug-conjugates 
 
Overall, of the different methods available for the covalent attachment of drug molecules to 
polymers, there are two differing approaches. Firstly, via modification of the polymer to 
increase its reactivity.166,167  Or through modification of the substrate so that it reacts with 
the polymer.157,166,167 The latter approach can be divided into two further subtypes: taking an 
active drug molecule and preforming minimal synthetic changes needed for conjugation, or 
alternatively, a ground-up approach in which an analogue of the intended drug molecule is 
made. A new synthetic handle is installed on the molecule from which the drug can be 
attached, at a position that is not likely to disrupt key pharmacophoric interactions with the 
target. The main problem with the former method is that while it is less synthetically 
challenging,  it relies on pre-existing functionality of the drug molecule. If those functional 
groups are modified for attachment, then a decrease in potency may be expected. The 
“ground-up” approach is seen rarely in the literature, likely due to the synthetic challenges 
posed. Our own previous work utilised this method for the advantages outlined previously.94 
 
1.5.6 The use of linker / spacer units in drug polymer conjugates 
 
On the topic of drug modification for attachment, one additional modification to a drug 
compound may be to include a spacer / linker unit (Figure 21). 174,175 
 
Figure 21 – Use of a linker to separate a polymer from a drug 
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Spacer groups are used to alleviate unfavourable steric interactions that may occur as a 
consequence of attaching a drug to a polymer. When one considers the highly branched and 
bulky nature of a polysaccharide, it can be envisaged that this may disrupt the interaction of 
a drug molecule and the active site of the target. The effect may lead to a loss in potency of 
the drug-conjugate (compared to the free drug) and therefore the dosage would need to be 
increased. Using a spacing unit between the drug molecule and a polysaccharide should 
reduce the effect of unfavourable steric interactions with the polymer, by introducing a 
suitable distance between each entity. This principle has been utilised by Caron and co-
workers who synthesised dextran-alprenolol conjugates incorporating an alkyl spacing 
unit.174 Additionally, Infante and co-workers have also using alkyl linkers in the preparation 
of Inulin conjugates.175 Our work has also previously employed a spacer unit comprised of 
diethylene glycol, chosen to closely mimic the environment of Icodextrin, rather than an alkyl 
linker which may act to reduce aqueous solubility of the conjugate.94 
 
1.6 Relevance to previous work 
 
The work described within this thesis builds upon an investigation previously described by 
us, J. Med. Chem., 2018, 61, 7942–7951.147 In those studies, we presented a novel drug 
delivery strategy for use within the peritoneal cavity. Many autotaxin inhibitors have been 
found to be highly potent in vitro, but when they have been tested within a living organism, 
they often perform poorly. One reason suggested for this reduced activity was the drug is 
rapidly eliminated from the peritoneal cavity and then metabolised. To increase the 
residence time of an ATX inhibitor within the peritoneal cavity, a polymer therapeutic 
approach was taken. An analogue of the potent autotaxin inhibitor, HA155 (Table 2) was 
attached to Icodextrin using the “tosylated-drug method” (Chapter 1.5.3). Icodextrin was 
viewed as an ideal polymer support, based upon its desirable pharmacokinetic properties, in 
which it has been shown to be retained within the peritoneal cavity for up to several days by 
virtue of its high molecular weight. Following the attachment of the ATX inhibitor to IDX, we 
postulated that the resulting drug-conjugate (Figure 22) would demonstrate significantly 
improved peritoneal retention whilst maintaining is inherent biological activity.  
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Figure 22 - Icodextrin-drug conjugate 
 
The resulting conjugate was then evaluated for biological activity in vitro using two artificial 
substrate enzyme assays (bis p-NPP and FS-3). The drug residue was found to retain much of 
its original potency following conjugation to the polymer: 0.86 ± 0.13 µg mL−1 (FS-3) and 0.94 
± 0.12 µg mL−1 (bis-pNPP) compared to the free inhibitor, 0.297 ± 0.08 µg mL−1.147 A wound 
closure assay was then performed on OVCAR-3 cells, in the presence of the free-inhibitor, 
the icodextrin-drug conjugate, parent-Icodextrin and a control (DMSO). The results are 
shown in Figure 23.147 Both the icodextrin-drug conjugate and the free autotaxin inhibitor 
reduced wound closure by approximately 50% compared with cells exposed to DMSO.147  
 
Figure 23 - Effect of percentage wound closure by  IDX, IDX-drug conjugate and free-inhibitor 
Most significantly the peritoneal retention of the drug conjugate was tested within mice and 
was found to be retained up to 30% of its original concentration after 24 hours.147 This 
significantly increased the residence time of the drug in the peritoneal cavity, in comparison 
<0.1 % of the free-drug equivalent was observed after 24 hours.147  
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1.7 Project outline 
 
The work described above, functioned as proof of concept for our novel drug delivery 
strategy, designed specifically for use within the peritoneal cavity, as a treatment for ovarian 
cancer. In this thesis we describe a new application of the carbohydrate-based polymer 
Icodextrin in drug-conjugate synthesis, and our approach to the synthesis of conjugated 
analogues of recently published autotaxin inhibitors (Figure 24).88 
 
Figure 24 - Three potent ATX inhibitors from a study by Nagano and co-workers and the 
HA155-carboxylic acid analogue previously investigated by us. 88 
 
These inhibitors contain a boronic acid moiety instead of a carboxylic acid group employed 
in our previous efforts.94 Carboxylic acids are less synthetically challenging to install 
compared to boronic acids. Indeed, even as of 2018, there remains few reliable synthetic 
methods to install boronic acids.176–179 Boronic acid ATX inhibitors are known to be 
significantly more potent than their carboxylic acid counterpart, such as HA155, described 
by Albers and co-workers, with an IC50 value of 5.7 nM.43 This is due to the covalent bond 
between the boronic acid group and the Thr209 residue on ATX, with two zinc atoms holding 
the substrate in place, in a similar manner to the interaction between LPC and ATX (Figure 
25a).42,43,88  
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a)    b)    
Figure 25 – a) 4-BoA bound to the active site of ATX, b) the boronic acid group coordinating 
to zinc and covalently bonded to Thr209.88 
 
As denoted by the arrow in Figure 25a, one hydroxyl group from the boronic acid sits 
between two zinc atoms (grey spheres) and coordinates to these ions.88 The nucleophilic 
hydroxyl group of Thr209 forms reversibly a covalent bond with the boronic acid, which 
accounts for the high level of activity attributed to 4-BoA.43,88 
Novel Inulin (INU) drug conjugates will also be produced, and explored as an alternative to 
Icodextrin, given Icodextrin’s susceptibility to hydrolysis by amylase in rodents.149 It is 
envisaged that the complementary Inulin conjugates could be synthesised in a similar 
manner to the Icodextrin conjugates.94 The importance of this is that for an IDX conjugate to 
be compared to an INU equivalent, the linker chemistry used to attach the drug to the 
polymer must be equivalent, in order to determine which polymer is the more suitable for 
use in the peritoneal cavity. 
As in our previous work, the ATX inhibitor will be modified to incorporate a linker unit, with 
a suitable point of attachment having been identified (Figure 26).147 The site was chosen so 
that it would not interfere with those key groups that are involved in binding to the active 
site, based on the X-ray crystal structure (Figure 26) of 4-BoA bound to autotaxin.88 
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Figure 26 - The proposed point of attachment 
 
It was anticipated that the necessary functionality could be installed by adapting the 
synthetic route published by Nagano, by directly substituting the starting materials to 
incorporate the desired synthetic handle.88  
The initial work for this project will involve the synthesis of three different drug-linker, based 
around the three most potent inhibitors from Nagano’s original publication, 2-BoA, 3-BoA, 
4-BoA (Figure 27).88 These ATX inhibitor analogues will then be used to produce drug-
conjugates with Icodextrin and Inulin, yielding six conjugates in total for the initial study. 
 
Figure 27 - Three drug-linker compounds that will be produced for this project 
 
These 1st generation conjugates will be evaluated for biological activity using in vitro enzyme 
assays, such as a bis pNPP artificial substrate assay and a FS-3 florescence assay, to quantify 
the inhibition of ATX. A peritoneal-retention study will also be conducted to measure the 
residence time of a drug-conjugate within the peritoneal cavity.94 These results will be used 
to guide the approach taken for the subsequent studies. As alluded to earlier, conjugating a 
drug to a polymer is likely to result in a loss of potency (compared to the free drug). 
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Therefore, efforts should be made to increase potency of the drug conjugate so that it is 
similar to that of the parent drug. There are several ways this can potentially be achieved. 
For example, linker length is very likely to be an important factor in determining activity. As 
suggested by Caron and co-workers, increasing the degree of separation between the drug 
pharmacophore and the polymeric backbone can potentially reduce any unfavourable steric 
interactions caused by the polymer. By using a longer linker one could expect a rise in 
potency to be observed.174 Another possible modification may be to change the position of 
the linker on the drug. Due to the significance of the interaction between B(OH)2 and ATX, 
the close proximity of the linker may result in the conjugate losing activity (compared to the 
free drug). A more suitable point of attachment may be the piperazine moiety of the 
inhibitor, which in itself does not interact with ATX. The chemistry used to establish this 
functionality could be based upon the work of Berkheij et al, involving direct α-lithiation of 
N-Boc piperazine.180 Another less well-studied modification is the effect on activity of the 
drug loading on the polymer. Whilst one might expect that the highest drug loading possible 
may lead to a highly potent conjugate, somewhat counterintuitively this may not be the case. 
This is because a high degree of substitution may actually reduce the total available 
pharmacophore because the neighbouring drug molecules could prevent the drug from 
interacting with ATX, through steric hindrance.   It would therefore be beneficial to produce 
a series of drug conjugates with differing quantities of drug bound to the polymer, to 
determine the optimum drug loading.  
Additional investigations will include the conjugation of other autotaxin inhibitors to 
Icodextrin and Inulin. A search of the literature highlighted three potential drug molecules 
that appeared suitable for modification to allow conjugation (Figure 28). These were chosen 
in part due to their high potency, but were also those felt to be the least challenging, 
synthetically, to produce drug-linker analogues. 43,67,87 
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Figure 28 – Other potential ATX inhibitors that could be conjugated to a polymer  43,67,87 
 
GLPG 1690 (Figure 28) would contrast particularly well to the other ATX inhibitors featured, 
as it employs an alternative binding mode, interacting with the hydrophobic pocket and 
tunnel of ATX rather than its active site.67  
 
1.8 Significance of drug-conjugation for potential treatment in the clinic 
 
As stated earlier, it is common for patients with ovarian cancer to have elevated levels of 
ascites fluid in their peritoneal cavity, aggravated by tumour growth. The fluid is typically 
drained as a matter of course in their treatment regime.46 Icodextrin is commonly used to 
achieve peritoneal dialysis, under the tradename “Extraneal”.181 This is a major advantage 
for our study as this polymer is known to be safe and is regularly used in the clinic and so 
forms an ideal base for potential drug conjugation.142,181 It should be noted that there have 
been no previous reports of Icodextrin being used as a basis for a drug polymer-conjugate.147 
We propose that an Icodextrin / Inulin drug conjugate could be administered during or after 
this ascites drainage procedure.182 This is likely to cause minimal inconvenience to the 
patient and potentially require fewer repeat dosages, by virtue of the improved 
pharmacokinetic properties offered by this drug-delivery system. We envisage that the ATX 
inhibitor conjugate would be taken in combination with a commonly used chemotherapeutic 
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agent such as taxol, to augment the properties of the conjugate and hopefully lead to a 
reduction in tumour size.73,183 
1.9 Aims of this work 
 
The overall aim of this study is to investigate the use of two polysaccharides Inulin and 
icodextrin as novel drug delivery systems, in order to improve the pharmacokinetic 
properties of a number of autotaxin inhibitors as a potential new treatment for ovarian 
cancer. To date, ATX inhibitors typically perform poorly in vivo as ovarian cancer therapies, 
because they rapidly diffuse through the peritoneal cavity into the systemic circulation 
where they are metabolised readily. Through the use of a drug-polymer conjugate, a 
localised concentration of the drug should be established within the peritoneal cavity from 
where it can then act. Autotaxin is an enzyme known to be an autocrine motility factor; 
through its inhibition, the mechanisms by which ovarian cancer cells survive, proliferate and 
become resistant to chemotherapy will be disrupted.93,94,147 
 
The aims of this project can thus be summarised as follows: 
• To synthesise new analogues of autotaxin inhibitors based on BoA 2, 3 and 4, to 
incorporate a suitable linker unit.88  
• To produce novel drug-polymer conjugates using those modified ATX inhibitors, 
based on the use of both Icodextrin and Inulin. 
• To evaluate the biological activity of the novel drug conjugates in vitro and assess 
the extent to which the drug conjugates retain potency compared to their free-drug 
equivalents.  
• Through animal studies, to compare the peritoneal retention of IDX-conjugates and 
INU-conjugates to determine which polymer offers the longer residence time in the 
peritoneal cavity.  
• To produce a series of 2nd generation drug-conjugates, to increase their potency, in 
anticipation of a loss of activity (compared to the free drug) associated with the drug 
being attached to a polymer. Areas identified for investigation include: length of 
spacing group, the position of attachment for the linker, the degree of drug loading 
and alternative autotaxin inhibitors. 
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Chapter 2: Synthesis of Icodextrin drug-polymer conjugates 
 
2.1 Synthesis of 3-BoA linker analogue, initial route 
 
The starting point for this investigation was to synthesise analogues of a series of boronic 
acid-containing ATX inhibitors, incorporating a linker unit (Figure 29).88  
 
Figure 29 - A representation of the target drug-linker analogues 
 
It was decided that 3BoA-linker would be synthesised first because it was likely to be the 
most potent (with reference to Nagano’s study, free-drug inhibition =  13 nM).88 Once a 
synthetic route had been established, it was anticipated that the two additional analogues 
(4BoA-linker and 2BoA-linker, Figure 29) could be prepared by similarly using the appropriate 
starting material. It was our original intention to base the synthetic route for 3BoA-linker on 
the route published by Nagano for the parent drug (Scheme 11).88 
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Scheme 11- Nagano’s synthesis of 3BoA 88 
 
The synthetic route shown in Scheme 11 has an overall yield of 11 %, over four steps.88 Whilst 
Nagano’s route was a useful starting point, there were some challenges that would need to 
be addressed. For instance, 3BoA was synthesised as part of a compound library. In total 31 
mg was made as part of the study and the compound was purified by HPLC.88 For our 
purposes, 3BoA-linker is required in multigram quantities so the chemistry used to synthesise 
it should be robust and relatively facile. Additionally, the synthetic route chosen must 
account for the difficulties posed in working with boronic acid groups, namely; they react 
with silica gel so cannot be purified by column chromatography; they are generally insoluble 
in common organic solvents; there are comparatively few reliable methods by which they 
can be synthesised; they are sometimes unstable and are susceptible to dimerization or 
trimerization. Therefore, a sensible approach would be to install the boronic acid group as 
the last synthetic step, post conjugation. Our initial synthetic route for the 3BoA-Icodextrin 
drug conjugate is shown in Scheme 12. 
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Scheme 12 - Proposed synthesis route for 3BoA- IDX drug conjugate 
 
The route shown in Scheme 12 employs a convergent approach, using three separate 
fragments: Nagano’s heterocycle, an aryl boronic ester and the diethylene glycol linker. Ten 
synthetic steps are involved, with seven as the longest linear sequence. The route has been 
designed so that the final step is the hydrolysis of the boronate ester group of the drug, 
several methods exist for this transformation. Boronate esters, in particular the BPin moiety, 
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offer a convenient approach to install what are essentially, “boronic acid protection groups” 
on to aromatic systems, through the Miyaura borylation reaction or CH Borylation developed 
by Hartwig and co-workers.184,185 In order to attach the drug-linker compound to IDX our 
previously developed “tosylated icodextrin” method will be used in preference to the reverse 
approach (tosylated drug). This is because the “tosylated IDX” method uses a much milder 
base (Et3N, compared to NaH), which is unlikely to compromise the integrity of the BPin 
moiety, of which are known to degrade in the presence of a strong base.  
 
2.1.1 Preparation of Nagano’s heterocycle  
Synthesis began with the construction of Nagano’s heterocyclic compound according to the  
literature procedure, starting with the Boc protection of 1,4 piperazine using Boc anhydride, 
N-Boc piperazine 1 was then reacted with rhodanine and 3,4-dichlorobenzaldehyde in a 
multicomponent “Knoevenagel reaction, to give 2 (Scheme 13). Finally, the N-Boc protecting 
group was removed from the heterocycle 2, in the presence of TFA (Scheme 13).88 
       
Scheme 13 - Synthesis the heterocycle 3, over three steps  
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During the formation of heterocycle 2, N-Boc piperazine acts as both a base and a 
nucleophile. Hydrogen sulfide gas and water is given off as a by-product, the suggested 
mechanism for the formation of 2 is shown in Mechanism 1. 
 
Mechanism 1 – Suggested mechanism of the formation of 2 
 
Heterocycle 3, resulting from the N-Boc deprotection of 2 formed a salt with trifluoracetic 
acid (N-TFA). Nagano suggested that this could be released in situ during the SN2 
displacement reaction with the phenyl boronic acid compound (Step 4, Scheme 11), in the 
presence of Cs2CO3.88 
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2.1.2 Synthesis of the boronic ester fragment  
 
With Nagano’s heterocycle in hand, the boronate ester fragment could now be synthesised,                     
(Scheme 14). 
                 
                                                                                       4 
Scheme 14 -The first step in the synthesis of the boronate ester fragment, 4 186 
 
The Miyaura borylation reaction proceeded smoothly and in excellent yield, on a multigram 
scale. The next step was to install a suitable leaving group at the methyl position. It was felt 
the most convenient way this could be achieved was through radical bromination. Phenol 4 
was subjected to standard radical bromination conditions in CCl4 (Scheme 15).187 
 
        
 
 
                  4                                                                               5                                   6 
Scheme 15 - Attempted radical bromination of 4 
 
The intended bromo species 5 was not isolated, instead it appeared that an electrophilic 
aromatic bromination reaction had occurred 6. Typically, for an electrophilic aromatic 
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bromination to occur, the reaction must be performed in the presence of a catalyst. However 
it is known that when a substituent has a strong activating effect, for example an alcohol, a 
catalyst may not be required.188 Indeed, this appears to be the case with the phenol 4. The 
OH group is strongly electron donating and it causes aromatic bromination to be favoured 
over radical bromination of the methyl group. Bromination would have also very likely 
occurred at the para position in addition to the ortho, had the para position not been 
occupied by the BPin group.188  The reaction was repeated under the same reaction 
conditions, but the same result was replicated. No reaction was observed at room 
temperature, highlighting the importance of temperature in the electrophilic aromatic 
bromination reaction.  
An alternative method to synthesise phenol 5 was investigated, using a different boronate 
ester substrate 7 (Scheme 16).  
 
                                                                                          7   
Scheme 16 - The synthesis of 7 
 
This approach used a boronate ester with a benzylic alcohol as a useful synthetic handle from 
which a leaving group could be installed. As can be seen in Scheme 16, the yield was very low 
and the majority of starting material was recovered. Repeat reactions saw little 
improvement. Additionally, the starting material was expensive. Consequently, a much more 
efficient method was developed using a considerably cheaper substrate (Scheme 17). 
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                                                                             8                                                       7 
Scheme 17 - Alternative synthesis of phenol 7 
The route delivered 7 in an overall yield of 48% over the two steps in multigram quantities. 
With the desired boronate ester, various methods were attempted to generate the desired 
bromide, as summarised in Table 4. 
 
        7                                                                  5 
Scheme 18 - General reaction scheme for Table 4 
 
Reagent (s) 
 
Solvent / Conditions Yield 
HBr 48% aq.  Toluene, reflux 0% 
PBr3 CHCl3, r.t. 0% 
Xtalfluor-E, 2,6 Lutidine, Tetrabutyl 
ammonium bromide 189 
 
DCM (anhydrous) 
Ar, r.t 
0% 
 
Table 4 - The attempted bromination reactions with 7 
 
Disappointingly, the desired compound could not be synthesised, in all cases only unreacted 
starting material was collected. Alternative methods were then investigated. A synthetically 
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attractive reductive amination reaction between aldehyde 8 and Nagano’s heterocycle 3 was 
attempted (Scheme 19) which had the potential to reduce the overall number of synthetic 
steps.  
 
       8                                            3                                                                             9 
Scheme 19 - The attempted reductive amination between heterocycle 3 and aldehyde 8 190 
 
This reaction was unsuccessful, possibly due to the low solubility of Nagano’s heterocycle in 
DCM. Attention was then turned back to the radical bromination reaction. A diethylene 
glycol linker version of phenol 4 was synthesised. Compound 10 was then exposed to radical 
bromination conditions (Scheme 20). The rationale behind this was two-fold: by converting 
the alcohol to an ether it may cause the substituent to become subtlety less electron 
donating, encouraging desired radical bromination to occur. Secondly using the same linker 
that would otherwise be installed at a later stage in preference to another protecting group, 
such as a methoxy group, would reduce the total number of synthetic steps required. 
                                                                             
 
       10                                                                                              11 
Scheme 20 - Attempted radical bromination of 10 
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Inspection of the crude material by 1H NMR spectroscopy showed some indication of the 
formation of the desired product, indicated by the appearance of a methylene peak at 4.52 
ppm. However, the material soon appeared to degrade (by 1H NMR). Encouraged by these 
results, a TIPS-protected version of Compound 4 was synthesised, to give compound 12, 
radical bromination was then attempted with this compound (Scheme 21).  
 
        4                                              12                                                                             13 
Scheme 21 - Attempted radical bromination reaction with Compound 12 
 
Analysis of the crude reaction mixture by 1H NMR spectroscopy strongly suggested the 
formation of the desired compound by the appearance of a new methylene singlet at 4.61 
ppm. Despite a reaction time of two days, only 50 % of the material had been converted to 
the halogenated species. Unfortunately, the mixture could not be purified by column 
chromatography.  It can be speculated that the bulky TIPS group adjacent to the methyl 
group hinders the approach of the bromine radical, accounting for the poor conversion. One 
could easily envisage complete conversion to the brominated compound if a TMS protection 
group was used. However, this was not necessary, taking into account the change in 
reactivity observed by converting the phenol to an ether. Compound 12 was converted to an 
ester following treatment with acetic anhydride (Scheme 22).191 Esters are less electron 
donating than alcohol or ether groups so it was anticipated that radical bromination of 
acetate 14 would proceed in preference to aromatic bromination.161  
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       4                                                         14                                                                          15       
Scheme 22 - Acetyl protection of 4 and the subsequent radical bromination reaction 
 
Acylation of 4 afforded acetate 14 in consistently excellent yield.  Radical bromination of 
acetate 14 gave the desired compound 15, also in excellent yield, with no indication of the 
aromatic brominated species. Both materials required minimal purification and had an 
overall yield of 86%, over the three steps. 
 
2.1.3 SN2 coupling between both fragments 
 
It was decided at this point to diverge from the originally planned synthetic route (Scheme 
12) and attempt to react heterocycle 3 with compound 15. This was because it was felt it 
may be beneficial to keep the acetyl protection until after the SN2 coupling reaction, so as to 
lower the chance of a side reaction occurring. Heterocycle 3 was reacted with compound 15 
in the same manner as described in Nagano’s original publication (Scheme 23).88 
 
       15                                               3                                                                            16 
Scheme 23 - SN2 coupling reaction between compound 15 and heterocycle 3 
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The reaction conditions used resulted in a mixture of materials being returned, with little 
indication of the desired product. The likely cause of this was using 4 eq. of Cs2CO3, as 
described in Nagano’s paper, to remove the TFA salt in situ from the heterocycle, exposing 
the amine so that it could displace bromide in the substitution reaction.88 Under these 
conditions the BPin group of compound 15 appeared to degrade, giving rise to a complex 
mixture. It was decided that the N-TFA salt of heterocycle 3 should be removed prior to the 
substitution reaction. Therefore only one equivalent of carbonate base would be required, 
conditions for which BPin groups are known to be tolerant.192 Several methods were found 
to generate the free amine, such as treatment of the heterocycle with a basic ion exchange 
resin (Amberlyst® A21) in DCM.193 The most suitable method, applicable on multigram scales, 
was to make a basic aqueous solution of heterocycle 3 basic with sodium carbonate and then 
use continuous liquid-liquid extraction in CHCl3 to isolate the desired heterocycle 17. The 
difficulty in isolating the free amine was compounded by its poor solubility in low-boiling 
point organic solvents. An X-ray crystal structure was obtained for the free-amine 
heterocycle 17, confirming the Z-geometry about the double bond (Figure 30). 
 
                                                                                                                17 
Figure 30  - X-ray crystal structure of  free amine 17 
 
Bromide 15 was then reacted with piperazine 17, using slightly modified reaction conditions 
to those used previously (Scheme 24). 
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Scheme 24 –SN2 coupling reaction between piperazine 17 and bromide 15 192 
 
The reaction resulted in an overall conversion of approx. 60% (as measured by 1H NMR 
spectroscopy on the crude material). Under the conditions described, the acetate group also 
underwent hydrolysis to expose the phenol. Whilst this was not undesirable in principle, 
considering that acetate hydrolysis would be the next synthetic step, both compounds 
closely eluted with one another. This made them difficult to purify by column 
chromatography. Additionally, this method did not favour the transition to a larger scale, 
with a decrease in yield being observed. Attempts were made to completely deacetylate 
acetate 16 after the substitution reaction in situ, however this was unsuccessful. 
A suitable method was found for acetyl deprotection that was sufficiently mild to maintain 
the integrity of the BPin ring, as summarised in Table 5. 
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Conditions: Comment:  
NaOAc 
H2O / EtOH, reflux 194 
Partial hydrolysis resulting in a complex mixture 
NaHCO3 
H2O / MeOH, N2, r.t 194 
No reaction 
 
2M NaOH aq.  
EtOH, r.t 194 
Caused the hydrolysis of the boronate ester, with  
no deacetylation observed 
K2CO3 
DMF / H2O, 50 °C 
Compound degraded, no deacetylation observed 
K2CO3 (0.1 eq.) 
MeOH, 40 °C 
Quantitative deacetylation 
 
Table 5  - Different reaction conditions explored in the deacetylation of acetate 16 
 
Deacetylation of acetate 16 was effected in the presence of K2CO3 (0.1 eq.) and MeOH, 
without any hydrolysis of the BPin group. With deacetylation conditions in hand, attention 
turned back to the SN2 coupling reaction. The solvent was changed to acetone from DMF / 
H2O, which resulted in formation of mostly the acetate 16, with only around 5-10 % of the 
deprotected form (9) being produced. The mixture was then exposed to the deacetylation 
conditions previously established (Scheme 25). 
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Scheme 25 - Final version of the SN2 coupling reaction and subsequent deacetylation 
 
The method shown in Scheme 25 was used to produce phenol 9  in multi gram quantities, 
our attention then turned to the attachment of the diethylene glycol linker.  
 
2.1.4 Attachment of the linker to phenol 9 
Ether 18 was synthesised by the treatment of diethylene glycol with hydrobromic acid (aq.) 
in toluene, under Dean-Stark conditions (Scheme 26). 
                           
                                                                                                                                 18 
Scheme 26 – Synthesis of  ether 18 
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It was found that, due to stability issues, it was essential to synthesise ether 18 and use it 
directly in subsequent reactions. Substituting ether 18 for the commercially available (and 
shelf stable) chloro-analogue led to negligible yields in the linker addition reaction; 
interestingly with other drug compounds (Chapter 2.4) the chloro ether gave yields of up to 
95 %.  
Using a method described by Maccarrone and co-workers phenol 9 was reacted with ether 
18 through an in situ Finkelstein reaction with KI (Conditions 1), these were then modified to 
facilitate the synthesis of ether 19 (Conditions 2) (Scheme 27).195 
 
                       9                                                                                                             19 
Scheme 27 – Attempted  linker addition reaction between phenol 9 and ether 18 (Conditions 
1: KOH, KI, MeCN, 60 °C, 0 %) 
 
Conditions 1 were found to be too harsh (KOH) and heterocycle 9 had low solubility in 
acetonitrile, resulting in the need to use conditions 2. Conditions 2 (Scheme 27) resulted in 
the successful synthesis of ether 19, in reasonable yield. 
 
2.1.5 The conversion of  ether 19 to a boronic acid 
 
As per the synthetic route originally proposed, at this stage ether 19 would be attached to 
icodextrin (using the “tosylated-icodextrin” approach), then as the final step, the boronate 
ester would be converted to a boronic acid.  However, to ensure that this proposition was 
feasible, ether 19 would be converted to a boronic acid in a test reaction and to obtain a 
complete data set, confirming the presence of a boronic acid functional group. Once ether 
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19 was attached to IDX there would be few analytical techniques for analysing the resulting 
conjugate; following deprotection of the boronate ester the key piece of evidence would be 
the loss of the distinctive (BPin) 12 H singlet in the 1H NMR spectrum. The data from the 
boronic acid version of 19, the 1H NMR spectrum of the final conjugate (showing the loss of 
the distinctive BPin singlet) and high potency in vitro of the conjugate would serve as 
evidence that the boronate ester had been successfully converted to a boronic acid.  
Using a method devised by Sun and co-workers, a test reaction was attempted with aldehyde 
8 to convert the BPin group to a sp3-hybridized boron · DEA adduct, which can then by 
hydrolysed to a boronic acid in the presence of dilute HCl aq. (Scheme 28).176 
                              
                                     8                                                                                           20 
Scheme 28 - Attempted synthesis of a sp3-hybridized boron · DEA adduct of aldehyde 8 
 
The test reaction was unsuccessful. An alternative method was then explored in which the 
boronate ester was first converted to the corresponding trifluoroborate salt, which was then 
successfully hydrolysed to the boronic acid.178,196,197 These conditions were then applied to 
ether 19.  
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Scheme 29  - The conversion of  ether 19 to BF3K salt 21 and the subsequent hydrolysis to 
boronic acid 22 
Trifluoroborate 21 was produced in a quantitative yield, with minimal purification being 
necessary (Scheme 29). The reaction is reversable although favouring the BF3K salt 
(Mechanism 2). Methodology developed by Aggarwal and co-workers was applied to the 
isolation of trifluoroborate 21; thus the pinacol by-product was removed by azeotropic 
distillation using MeOH / H2O as an evaporation partner, to drive the reaction to    
completion.197  
 
Mechanism 2 – Suggested mechanism for the conversion of ester 19 into BF3K salt 21 
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Trifluoroborate 21 was then hydrolysed in MeCN in the in the presence of trimethylsilyl 
chloride and H2O to give the corresponding boronic acid 22 (Scheme 29). The resulting 
boronic acid 22 was produced in acceptable yield, with minimal purification being necessary. 
This study demonstrated that ether 19 could be converted to boronic acid 22 and indicating, 
in principle, that such a transformation would be possible with the polymer conjugate.  
 
2.1.6 Synthesis of 3-BoA linker, summary  
 
The complete synthetic route for boronic acid 22 has an overall percentage yield of 16.1 % 
and employed 12 synthetic steps, with the longest linear sequence being 8 steps.  Our 
attention then turned to the preparation of 4BoA linker analogue. 
With a viable synthetic route to synthesise drug-linker analogues now established, the same 
methodology was applied to the 4BoA linker compound. Boronate ester fragment 25 was 
first synthesised, then reacted with heterocycle 3 (Scheme 30). Acetate 26 was then 
converted to phenol 27 and then reacted with 2-(2-chloroethoxy) ethanol in the presence of 
KI, to give the corresponding ether 28. 
76 
 
 
Scheme 30 - The synthesis of 4 BoA linker 28 
   
The yield of ether 28 was disappointingly low, but based on experience from the synthesis 
of ether 19, it can be speculated that had 2-(2-bromoethoxy)ethanol (ether 18) been used, 
the yield would have been much higher. Consequently, the overall yield for ether 28 was 6 
%, employing nine synthetic steps, with the longest linear sequence being six steps. 
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2.2 The attempted preparation of a 3-BoA-Icodextrin conjugate using the “tosylated IDX 
method” 
 
With the boronate ester derivative of 4BoA-linker now complete, work could begin on the 
attachment of drug-linker compounds to Icodextrin. Using a stock of tosylated IDX (Figure 
31) small-scale drug-IDX couplings were then attempted. 
 
Figure 31 - Representation of tosylated Icodextrin 
 
The boronate ester version of 3BoA-linker 19 was reacted with tosylated Icodextrin    
(Scheme 31).  
 
                           19                                                                                                         Conjugate 1 
Scheme 31 - The coupling of ether 19 with IDX to give Conjugate 1 
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After the reaction mixture was heated at 100 °C for two days, the crude mixture was purified 
by dialysis. In a relatively simple procedure, the material was transferred to a dialysis 
membrane and then submerged in a volume of water / methanol of around 100 times 
greater than the membrane contents. Molecules smaller than the molecular weight cut off 
value (MWCO) of the membrane (typically 8 kDa), will move through the membrane and into 
the solvent by diffusion. The dialysis fluid is then changed regularly (> 10 times) to ensure 
that only the polymeric material is retained, by virtue of its high molecular weight. 
The results of this first conjugation reaction were disappointing, although there was some 
evidence (by 1H NMR spectroscopy) to suggest that the reaction was successful. This was 
indicated by the incorporation of material relating to ether 19 within the 1H NMR spectrum 
of Conjugate 1 (Figure 32). Despite this, the aromatic region was noticeably different, 
suggesting a loss of structural integrity of the molecule. 
 
 
Figure 32 – 1H NMR spectra comparison (400 MHz, DMSO-d6) a) the aromatic region of 19 
and b) the aromatic region of Conjugate 1 
 
Due to the high level of derivatisation observed for Conjugate 1, an alternative approach was 
investigated. An attempt was made to directly conjugate boronic acid 22 to IDX (Scheme 32). 
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                          22                                                                                                         Conjugate 2       
Scheme 32 -  Attempted synthesis of Conjugate 2 
 
After dialysis, the reaction returned tosylated IDX without any drug attachment being 
observed. The reaction conditions were then modified, increasing the number of equivalents 
of boronic acid 22 from 1.3 eq. to 1.7 eq. (relative to 1 eq. of the polysaccharide, determined 
by the equivalent molecular weight of the monosaccharide) although this was found to have 
no improvement. 
 
2.2.1 Tosylated icodextrin approach, model study 
 
Due to the discouraging results seen with Conjugate 1 and 2 a “model study” was then 
conducted, using a model of the drug molecule, ether 10. Which could be synthesised quickly 
and on a larger scale (Scheme 33). This was done in order to evaluate the feasibility of 
attachment by this method and potentially optimise the reaction conditions. 
                                     
 
                  4                                                                                              10                                                                                                        
Scheme 33 - Synthesis of 10 
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Alcohol 10 was then reacted with tosylated IDX in the same manner as Conjugate 1 and 2  
(Scheme 34). 
 
      10                                                               Conjugate 3  
Scheme 34 - Attempted synthesis of Conjugate 3  
 
Inspection of the 1H NMR spectrum of the material, after dialysis indicated that the model 
drug 10 had not been attached. The reaction was repeated at a lower temperature (75 °C), 
known not to cause the molecule to degrade and separately, over a longer reaction time 
(three days). Both modifications had no effect on the stated outcome.  
The effect of changing the BPin group of the alcohol 10 for either a trifluoroborate salt or a 
boronic acid group was also investigated. Alcohol 10 was converted to BF3K salt 29, a portion 
of which was hydrolysed to the corresponding boronic acid 30 (Scheme 35). 
   
 
             10                                                           29                                                         30 
Scheme 35 - Synthesis of BF3K salt  29 and boronic acid 30 
 
The two compounds were then reacted (separately) with tosylated IDX, in the same manner 
as previously stated (Scheme 36). 
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            29 / 30                                                   R= BF3K = Conjugate 4     R= B(OH2) = Conjugate 5                        
                                                                         
Scheme 36 - Attempted synthesis of Conjugate 4 and 5 
 
After dialysis the isolated product compounds were analysed using 1H NMR spectroscopy. 
Both reactions were unsuccessful, so at this stage it was decided that the tosylated IDX 
conjugation method would not be explored further. Instead, the “tosylated drug” approach 
would be used from hereon in.  
 
2.2.2 The attempted preparation of a 3-BoA-Icodextrin conjugate, using the “tosylated drug 
method” 
In our previous work the “tosylated drug method” was extensively used, but as explained, 
the “tosylated IDX method” was initially preferred for this work due to it using milder 
reaction conditions. A tosylated version of ether 19 was therefore synthesised, by reacting 
ether 19 with tosyl chloride in the presence of triethylamine (Scheme 37). 
  
                        19                                                                                       31 
Scheme 37 - Synthesis of  tosylate 31 
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Using the same conjugation methodology applied in our previous work, an attempt was 
made to attach  tosylate 31 to IDX (Scheme 38). Icodextrin was first solubilised in (anhydrous) 
dimethylacetamide (DMAc) / LiCl co-solvent system at 160 °C. LiCl is used to disrupt the 
extensive hydrogen bonding network that is established within IDX, increasing its solubility 
and accessibility towards reactants. Solubilised IDX was then treated with NaH (60% mineral 
oil dispersion), to generate an alkoxide on IDX, which then displaces the tosyl group on the 
drug-linker compound, yielding a drug-IDX conjugate.   
 
                                                                                                                                Conjugate 6 
Scheme 38 - Attempted conjugation reaction between IDX and  tosylate 31 
After stirring the reaction mixture for 16 hours at room temperature, the mixture was 
dialysed and then analysed by 1H NMR spectroscopy. Unfortunately, no conjugation product 
was observed. The reaction time was increased to 10 days, which led to a small amount of 
material being incorporated onto the polymer, as indicated by the 1H NMR spectrum shown 
(Figure 33). 
 
Figure 33 - The 1H NMR spectra of Conjugate 6 (400 MHz, DMSO-d6) 
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As can be seen in Figure 33, only a very small amount of material was added to IDX, estimated 
(by the relative integration of drug and IDX peaks) to be 1 in 30 monomeric units that 
incorporated drug material. This was felt to be an unacceptably low level of drug loading to 
have therapeutic benefit, especially considering the length of time needed to synthesise the 
conjugate. Instead, an alternative route was evaluated, whereby boronate ester 31 was 
converted to BF3K salt 32, then reacted with IDX (Scheme 39). 
 
Scheme 39 - Conversion of boronate 31 to BF3K salt 32, and subsequent reaction with IDX 
 
Unfortunately, no attachment of trifluoroborate salt 32 to IDX was observed by 1H NMR 
spectroscopy, and so the synthesis of a boronic acid version of BF3K salt 32 was attempted 
(Scheme 40). 
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                      32                                                                                                  33 
Scheme 40 - Conversion of  BF3K salt 32 to boronic acid 33 
 
Despite the stability of the parent BF3K salt 32, boronic acid 33 was extremely unstable, and 
it was not possible to analyse the material without it degrading. This was observed on all 
three occasions that it was synthesised, regardless of storage conditions (-18 °C / N2). The 
synthesis of boronic acid 33 was taken no further.  
 
2.2.3 Alternative approaches using the “tosylated-drug method” 
 
A  different approach was investigated. It was postulated that the degree of separation 
between the drug and the tosyl group may be too small. Consequently, the approach of the 
anion may be hindered by the drug, especially considering the steric bulk of the polymer and 
this may account for the low drug loading observed in Conjugate 6. Therefore, if the degree 
of separation is extended by using a longer linker group, then it may be expected that drug 
loading can be increased. A version of ether 9 was synthesised with a longer glycol linker, 
which was then tosylated and then reacted with IDX (Scheme 41). 
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Scheme 41 – Attempted synthesis of Conjugate 8 
 
After reacting for two days, the material was dialysed and analysed by 1H NMR spectroscopy. 
Unfortunately no conjugation was observed. It was then decided to investigate the effect of 
the leaving group size /ability on the degree of conjugation observed. Mesylate 36 was 
synthesised by reacting ether 19 with methanesulfonyl chloride and triethylamine and then 
reacted with icodextrin (Scheme 42). 
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Scheme 42 - The mesylation of ether 19 and its subsequent reaction with IDX 
 
Unfortunately, no conjugation was observed, despite a reaction time of 5 days, which in 
consideration of Conjugate 6, one would have expected to see at least an equal amount of 
drug incorporation, as it is said that the leaving group ability of mesylates and tosylates are 
similar.161 
The reaction conditions for the “tosylated drug” method were then changed to include one 
equivalent of NaI. It was hoped that the tosylate 31 would give an iodide species in situ, 
which would then be displaced by IDX. The new method was trialled and allowed to react for 
5 days, however there was no improvement compared to Conjugate 6.  
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2.2.4 Tosylated drug approach, model drug study 
 
At this stage a number of “model drug” studies were conducted, to attempt to find a method 
suitable for the attachment of boronate esters to IDX, by varying the base, leaving group and 
reaction conditions. To facilitate this, two “model drugs were prepared (Scheme 43).  
 
       10                                                                         37= OTs, 38 = OCO(CH2Cl) 
Scheme 43 – General scheme for the synthesis of tosylate 37, in the presence of TsCl and 
chloroacetate 38, in the presence of chloroacetyl chloride 
 
The “model drugs” were then used in various test reactions, based on the generic reaction 
(Scheme 44), the results of which are listed in Table 6. 
 
                         
Scheme 44 - Generic reaction scheme for the test reactions 
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Name 
(Conjugate) 
Leaving  
group 
Reagents Comment Result 
10 OTs 
 
(37) 
 
NaH  No 
conjugation 
observed 
11 OTs 
 
(37) 
NaH, 15-Crown 5  15-Crown 5 coordinates 
to the Na counter ion, 
preventing ion-pairing to 
give a “naked” IDX anion 
(better nucleophile)  
No 
conjugation 
observed 
12 OTs 
 
(37) 
 
KH KH is a stronger base than 
NaH, more likely to 
generate the anion 
No 
conjugation 
observed 
13 OTs 
 
(37) 
KH, 18-Crown 6 18-Crown 6 coordinates 
to K counter ion, prev- 
enting ion-pairing to give 
a “naked” IDX anion 
(better nucleophile) 
No 
conjugation 
observed 
14 OTs 
 
(37) 
BTPP  
(P1-t-Bu-
tris(tetramethylene) 
 
Uses a phosphazene 
“super base”,   PKBH+ = 
28.4, containing no 
counterion, therefore IDX 
anion will be a better 
nucleophile198,199 
No 
conjugation 
observed 
15 Cl 
 
(38) 
DMAP, Pyridine Mild reaction conditions, 
literature precedent for 
coupling to occur with 
non-polymeric systems 
No 
conjugation 
observed 
 
Table 6 – A table to summarise the results of the test reactions attempted  
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Despite a number of different approaches being taken, conjugation did not occur in any of 
the test reactions and considering the number of attempts made up to this point, this was of 
concern.  
Working on the hypothesis that, compared to the carboxylic acid drug used in our previous 
work, the presence of the boronate ester and related functionality was causing an inherent 
loss in reactivity within the conjugation reaction. A simple test substrate was used in place 
of tosylate 37. IDX was reacted with benzyl bromide using the exact same procedure as 
before (Scheme 45). The benzylation of sugars is widely known, so it would be almost 
certainly expected for IDX to be successfully benzylated. This was also an effective way to 
remove any doubt in the experimental rigour of the previous conjugation reactions, 
regarding our air sensitive-techniques.  
 
                                                                                       Conjugate 16 
Scheme 45 - The benzylation of Icodextrin 
 
After leaving the reaction for two days, the mixture was dialysed, then precipitated in 
acetone. The resulting solid was collected by vacuum filtration and analysed by 1H NMR 
spectroscopy. The spectrum for Conjugate 16 strongly suggested the successful benzylation 
of Icodextrin had been achieved, as shown in Figure 34. 
 
Figure 34 - The 1H NMR spectrum of Conjugate 16 (400 MHz, DMSO-d6) 
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The successful benzylation of IDX should be taken as a proof-in-principle of the efficacy of 
the conjugation methodology. Additionally, the positive result does suggest that boron 
functionality has some retarding effect on the attachment of the substrates previously 
investigated (Conjugates 1-15). To that end, no further attempts were made to attach 
analogues of Nagano’s BoA series to IDX. This decision was taken because of the significant 
amount of time already devoted to their synthesis with little progress. It was felt that the 
remaining time would be better spent working on a different drug series, to complement the 
study and to increase the chance of producing drug-IDX conjugates for biological evaluation.   
 
2.3 Re-synthesis of HA155 analogue 45 
 
Despite the successful benzylation of IDX Conjugate 16, there was some concern with work 
undertaken by a previous student regarding the attachment of an ATX inhibitor containing a 
carboxylic acid group to IDX, as featured in Chapter 1. On review, it became apparent that 
several key pieces of data were incomplete or missing, which considering the significance 
that it had on the foundation of this current work, was worthy of re-investigation. Work 
therefore began with the resynthesis of the drug-linker compound. 
The first part of the synthetic route was to prepare the linker fragment, and this was achieved 
in three steps. Firstly 3,4-dihydroxybenzaldehyde was regioselectively alkylated with methyl-
4-(bromomethyl)-benzoate at the para hydroxy position via an SN2 displacement, using a 
method described by Plourde and co-workers (Scheme 46).200 Ester 39 was then reacted with 
2-(2-chloroethoxy) ethanol and the corresponding ether 40 was hydrolysed in the presence 
of sodium hydroxide to a carboxylic acid. 
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Scheme 46- Synthesis of carboxylic acid 41 
 
The regioselectivity observed in this reaction can be rationalized since the aldehyde group, 
being electron withdrawing, causes the proton of the hydroxyl group para to the aldehyde 
to be more acidic, since the resulting conjugate base is stabilised by resonance through to 
the aldehyde group. Deprotonation of the alternative OH group cannot lead to this 
resonance stabilisation.  
With carboxylic acid 41 in hand, heterocycle 42 was synthesised in one step by reacting 4-
flourobenzyl bromide with thiazolidine-2,4-dione, in the presence of sodium hydride 
(Scheme 47). Heterocycle 42 was then reacted carboxylic acid 41, via a Knoevenagel 
condensation. Carboxylic acid 43 was then protected using triisopropylsilyl chloride and 
silane 44 reacted with tosyl chloride.  
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Scheme 47 - The synthesis of heterocycle 45 
 
Carboxylic acid 43 was protected with TIPS Cl to ensure the  carboxylic acid group did not 
react with IDX in the conjugation reaction (step 8).  
 
2.3.1 Conjugation of 45 to IDX (Conjugate 17) 
 
Compound 45 was synthesised in 7 steps, with the longest linear sequence being 6 steps, 
with an overall yield of 8 %. Using the resulting drug-linker compound 45, a conjugation 
reaction with IDX was attempted, with the same reaction conditions utilised previously in 
this study (Scheme 48). 
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                                                                                                         Conjugate 17 
Scheme 48 – Conjugation of  heterocycle 45 to IDX 
 
After dialysis, the product was analysed by 1H NMR spectroscopy (Figure 35), the resulting 
spectra showed the incorporation of drug material on to IDX, which was comparable to that 
obtained by the previous student. Additionally, in agreement with our previous findings, the 
TIPS protection group had been removed during the course of the reaction. This was 
evidenced by the disappearance of peaks corresponding to the TIPS group in the 1H NMR 
spectrum, so the conjugate required no further modification.  
 
Figure 35 - The 1H NMR spectrum of Conjugate 17 (400 MHz, DMSO-d6) 
 
Repeating the synthesis of Conjugate 17 showed that carboxylic acid-based ATX inhibitors 
could be attached to IDX. The data set obtained for each compound was used as part of the 
experimental section in our recent publication in the Journal of Medicinal Chemistry (J. Med. 
Chem., 2018, 61, 7942–7951).147 
By demonstrating the successful conjugation of tosylate 45 to IDX, one may question as to 
why the many attempts to attach the BoA series to IDX failed? As mentioned previously, the 
presence of boron-containing functionality was a prime suspect in the difficulties 
encountered.   
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The carboxylic acid drug used in our previous investigation was modelled on a boronic acid 
inhibitor (HA155) reported by Albers and co-workers (Figure 36).42 
 
Figure 36 - HA155 and the carboxylic acid derivative 43,147 
 
 
2.4 The attempted synthesis of a HA155-IDX conjugate, using the “tosylated drug method” 
 
The carboxylic acid analogue of HA155 was chosen in our original study due to its relative 
ease of synthesis in comparison to the corresponding boronic acids. Biologically, the 
carboxylic acid group was expected to behave in the same way as a boronic acid at the active 
site of ATX, so would serve as an appropriate mimic. Therefore because of its structural 
similarity, a linker analogue of HA155 would be expected to react with IDX, based on the 
precedent set by its carboxylic acid equivalent, giving the best chance of producing a novel 
IDX drug conjugate. A HA155-IDX conjugate would be expected to be superior to its 
carboxylic acid counterpart, as indicated by HA155 being much more potent that the 
carboxylic acid analogue. On the other hand, if the conjugation reaction between HA155-
linker and IDX was unsuccessful, it can be concluded that the presence of boron functionality 
leads to an inherent decrease in reactivity under the reaction conditions.  
 
2.4.1 The preparation of a boronic acid, HA155 linker analogue 
 
To that effect, a boronate ester linker analogue of HA155 was synthesised. As with the work 
on the BoA series it was intended for the BPin unit to serve as a boronic acid protecting 
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group, which could be removed, post conjugation, to expose the boronic acid. In the first 
step 3,4–dihydroxybenzaldehyde was reacted with 4-bromobenzyl bromide in a 
regioselective manner, using methodology published by Plourde and co-workers (Scheme 
49). 200 Bromide 46 was then converted to boronate ester 47, via the Miyaura borylation 
reaction, the diethylene glycol linker was then installed to give ether 48. Ether 48 was then 
reacted with heterocycle 42 in a Knoevenagel condensation, alcohol 49 was tosylated to 
afford the target compound, tosylate 50. 
                
 
Scheme 49 - Synthesis of tosylate 50 
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2.5 The attempted conjugation of a linker analogue of HA155 to IDX 
 
The six-step synthesis of tosylate 50 was achieved with an overall yield of 7 %, in five linear 
steps. The material was then reacted with Icodextrin using our standard conjugation 
conditions (Scheme 50).  
   
                                                                                                             Conjugate 18 
Scheme 50 - The attempted conjugation of tosylate 50 to IDX 
 
Disappointingly, the conjugation reaction was unsuccessful, with only unreacted IDX being 
observed (by 1H NMR spectroscopy) after dialysis. To attempt to effect conjugation an 
alternative approach was taken in which the boronic acid version of tosylate 50 was 
synthesised (Scheme 51), boronic acid 51 was then reacted with IDX. 
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Scheme 51 - The conversion of tosylate 50 to boronic acid 51 and its reaction with IDX 
 
2.6 Discussion of the difficulties encountered with attaching drug-linker analogues to IDX 
 
Again, no conjugation was observed after dialysis. Though the results were discouraging, an 
important conclusion can be made. The only difference between tosylate 45 and tosylate 50 
is the presence of boron functionality in place of a carboxylic acid group, they are otherwise 
identical. It has been shown that tosylate 45 can be attached to IDX, whereas the conjugation 
of boronate ester 50 and boronic acid 51 were unsuccessful. This result strongly suggests 
that the presence of a boronate ester / boronic acid functional group has a strong 
attenuating effect on the conjugation reaction. To explain why this effect is observed is 
extremely difficult, especially considering the possible contribution by the polymeric system 
to the reduction in reactivity observed. Boronate esters and even boronic acids are widely 
known to participate in nucleophilic substitution reactions, without any indication of causing 
a retarding effect on reacrivity.42,88,192 There are however, some factors which are likely to 
contribute to the reduction in reactivity observed in the conjugation reactions.   
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On the occasions where limited attachment of boronate ester compounds to IDX was 
observed, such as Conjugate 6 there was an interesting observation regarding the 1H NMR 
spectra of the conjugates. The region at approximately 1.15-1.35 ppm was noticeably 
derivatised, BPin groups have a characteristic 12 H singlet at 1.20 ppm (DMSO-d6), whereas 
in those spectra there was two singlets in its place (Figure 37).  
 
Figure 37 - The 1H NMR spectrum of Conjugate 6 in the region 1.00 - 1.75 ppm (400 MHz, 
DMSO-d6) 
 
It is felt that the appearance of the two singlets could indicate the partial hydrolysis or 
transesterification of the BPin group in the presence of sodium hydride (Figure 38). 
 
Figure 38 - The proposed partial hydrolysis / transesterification  product 
 
Further to this, boronic acids are known to react with sugars in a reversible manner, through 
boronic acid-diol interactions. This effect is widely known and has been exploited in materials 
chemistry applications in which boronic acid compounds / bound polymers act as glucose 
sensors, by measuring the fluorescence of the resulting sugar-boronic acid complex (Scheme 
52).177,201,202 
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Scheme 52 – Proposed IDX-boronic acid complex formation 
 
It can be suggested that the anhydrous conditions used in the conjugation reaction could 
actively promote this reaction to occur. In the absence of water, the equilibrium will be 
driven to the right (boronic acid-IDX complex). However, the liberation of a water molecule 
will either immediately quench the IDX anion or react with NaH and be consumed. Either 
consequence will disfavour the conjugation reaction. With the drug bound to the polymer 
(via its boronic acid group) it will have restricted movement, which is necessary for the 
correct orientation in the displacement of the tosyl group. Once the material is dialysed, 
water present in the dialysis fluid will push the equilibrium to the left, to give the parent 
boronic acid and polymer. It may also be possible for IDX to interact with the hydrolysed 
material (Figure 38) and form a complex. 
 
Figure 39 – Proposed structure of the partially hydrolysed boronate ester reacting with IDX 
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There is also the possibility that the IDX may directly attack the boronate ester, causing the 
partial hydrolysis of BPin observed in a similar manner to bis-benzoboroxole oligosaccharide 
detectors developed by Hall and co-workers.203  
In a similar vein, boronic acids are also known to react with themselves, forming dimers and 
even cyclic trimers (Figure 40).204–206 This, like the reaction with oligosaccharides is reversible, 
however because of the anhydrous conditions used in the coupling reaction it will push the 
equilibrium towards the dimer / trimer.204–206 
 
Figure 40 – The suggested boronic anhydride formation of the drug linker compound 
When dialysed, the equilibrium will be pushed back to the left and the anhydride will be  
“broken-up”. The formation of a boronic anhydride is anticipated to have a negative effect 
on the conjugation of the drug-linker compound to IDX, making it less accessible to 
nucleophilic attack.  
 
2.7 Alternative approaches to the preparation of boronic acid ATX inhibitor-IDX conjugates 
 
Considering the ideas presented above, a conclusion could be drawn regarding how best to 
proceed with the conjugation reactions. Although the BPin moiety is a synthetically useful 
method to introduce a boron functionality into a system, it is potentially susceptible to 
hydrolysis and is therefore not suited to the reaction conditions used in the conjugation 
reactions in this study. Secondly if a boronic acid drug-linker compound is used in the 
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conjugation reaction, then water should be used as an additive to frustrate the formation of 
boronic anhydrides.  
To that effect, three additional conjugation reactions were planned: 
• The conjugation of boronic acid 51 to IDX in an aqueous environment, using 
potassium carbonate as a base. 
• The attachment of a MIDA-protected boronic acid version of HA155 to IDX, using the 
“tosylated drug approach”. 
• A “late-stage borylation” approach, involving the attachment of an aryl bromide 
version of HA155, with a view to borylate the drug post-conjugation.  
 
2.7.1 MIDA protected boronic acid approach 
 
MIDA boronates (Figure 41) are widely used as boronic acid protecting groups.207 Unlike BPin, 
they can be considered  “true” boronic acid protecting groups. This is because for their 
deprotection they do not need to be converted to an intermediate and can be “put on and 
taken off”.207,208 Another reason for the MIDA group being used is that it is known to be 
tolerant of NaH, albeit for short reaction times (approx. 30 minutes), so it was felt to be 
suitable for application in our proposed conjugation reactions.207  
 
Figure 41 - MIDA boronate 
 
A MIDA boronate version of boronic acid 51 was synthesised as follows: boronate ester 49 
was converted to boronic acid 52, in a two-step process (Scheme 53). Boronic acid 52 was 
then reacted with N-methyliminodiacetic acid under Dean-Stark conditions, followed by 
tosylation of MIDA boronate 53, to give tosylate 54. 
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Scheme 53 - Shows the conversion of heterocycle 49 to a tosylate 54 
 
Tosylate 54 was synthesised in nine steps, the longest linear sequence was eight steps, and 
the overall yield was 0.3 %. The low overall yield was likely the result of boronic acid 52 and 
MIDA boronate’s 53  low solubility in most organic solvents, which resulted in long reaction 
times.  
Tosylate 54 was then reacted with IDX using the standard conjugation reaction conditions 
(Scheme 48).  
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                                                                                                           Conjugate 20 
Scheme 54 - Attempted synthesis of Conjugate 20 
 
Disappointingly, no conjugation was observed in the 1H NMR spectra of the material, after it 
had been dialysed. It can be speculated that although MIDA groups are known to be tolerant 
of NaH over short reaction times. The long reaction time employed (5 days)  in the synthesis 
of Conjugate 20 may have caused the MIDA group to convert to a boronic acid, which as 
previously stated is unlikely to result in conjugation.207 
 
2.7.2 Conjugation of 51 to IDX in the presence of water 
 
Using the boronic acid 51, an alternative conjugation reaction was attempted. With a view 
to disrupting the possible boronic anhydride formation (suggested in Chapter 2.7), the 
attachment conditions were modified: a 1:1 H2O / DMF solvent system was used alongside 
potassium carbonate as the base (Scheme 55). 
       
                                                                                                                                                                                                                                                     
Scheme 55 - Attempted synthesis of Conjugate 21 
It was observed that the boronic acid 51 was almost completely insoluble (at the 
concentration used in the reaction). It was necessary to heat the reaction mixture to 75 °C. 
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This was not originally planned, as it was intended to mimic the conditions previously used 
in the conjugation reaction, i.e. reaction at room temperature. Despite heating, the material 
was still only slightly soluble. It is also worth noting that boronate anhydrides are reported 
to form more readily at elevated temperatures (above room temperature).206 Another factor 
is the nucleophilicity of the primary alcohol group of IDX, because of the electron 
withdrawing effects of the neighbouring hydroxyl groups, the 1° alcohol may not be 
sufficiently nucleophilic to displace the tosylate on boronic acid 51. If the reaction had been 
repeated, then a water-soluble base such as NaOH could have been more suitable. The 
solvent ratio would have also been changed to favour the organic solvent (perhaps 10:1 DMF 
/ H2O) to improve solubility, removing the need to heat the mixture. Because of the 
subsequent success enjoyed by us with the “epichlorohydrin method”(described in chapter 
3), this approach was not investigated further. 
 
2.7.3 “Late-stage” borylation approach 
 
With the difficulties encountered in attaching drugs with boron functionality to IDX in mind, 
this approach was intended to circumvent this issue. It was postulated that if a version of 
tosylate 50 with an aryl bromide in place of the BPin group was attached to IDX, then the 
necessary synthetic handle would be in place to install a BPin group post conjugation. The 
boronate ester could be subsequently converted to a boronic acid. 
The target compound was synthesised over 5 steps by adapting the previously established 
synthetic route, in an overall yield of 25%. Bromide 57 was then reacted with IDX (Scheme 
56). 
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Scheme 56 – Synthesis of bromide 57 and its conjugation to IDX  
 
After reacting for 5 days, the material was dialysed and then analysed by 1H NMR 
spectroscopy. As anticipated, by using this new approach, the spectrum strongly suggested 
that drug material had been incorporated within IDX. This was evidenced by the appearance 
of new peaks in the aromatic region of the spectrum (Figure 42). 
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Figure 42 – The 1H NMR spectrum of Conjugate 22 (400 MHz, DMSO-d6) 
 
While this attempt at conjugation to IDX can be considered successful, in parallel to these 
studies, work on an “epichlorohydrin activation method” was being undertaken (Chapter 3) 
and was showing very promising results. Since these conjugation studies appeared to require 
significant additional optimisation in order to improve drug-loading and three additional 
synthetic steps to install a boronic acid group, it was decided not to pursue this route 
development any further. Ultimately this decision proved to be well founded, taking into 
account the success enjoyed with the alternative epichlorohydrin method.  
The work presented in this chapter demonstrated the preparation of a number of novel ATX 
inhibitor analogues. Attempts were made to attach these compounds to the polymer: 
Icodextrin. This was done through two methods that were previously developed by us, “the 
tosylated IDX method” and the “tosylated drug method”. In both cases only a limited success 
was observed.  Modifications were then made to attempt to effect conjugation, however this 
was not wholly successful.  
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Synthesis of Inulin drug conjugates 
and the development of the 
“epichlorohydrin activation 
method” for both Inulin and IDX 
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Chapter 3: Synthesis of Inulin drug conjugates and the development of the 
“epichlorohydrin activation method” for both Inulin and IDX 
 
3.1 Attempted preparation of Inulin drug conjugates, using the “tosylated drug method” 
 
In parallel with the investigation described in Chapter 2, regarding Icodextrin, attempts were 
also made to attach drug-linker analogues of ATX inhibitors to Inulin.  
As an initial investigation into the feasibility of attaching a drug linker compound to Inulin via 
the “tosylated-drug” method, a “model study” was attempted (Scheme 57) using tosylate 37 
as a representation of 3BoA-drug linker 22.  
 
 
Scheme 57 - Model study of the attempted conjugation of tosylate 37 to Inulin 
 
Despite there being strong literature precedent to suggest that the 1° alcohols in Inulin would 
displace a suitable leaving group in the presence of a strong base, this reaction was 
unsuccessful.157,160  Not discouraged by this, the methodology was applied separately with 
the drug linker compounds tosylate 31 and tosylate 32 (boronic acid “protected” versions of 
3BoA-linker) (Scheme 58). 
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Scheme 58 - The attempted attachment of 31 and 32 Inulin to give Conjugate 24 and 25 
 
Unfortunately, no conjugation was observed (by 1H NMR spectroscopy). Mirroring the 
decision taken in Chapter 2, work concerning the attachment of analogues of Nagano’s BoA 
series was discontinued. To complement the synthesis of Conjugate 17 an attempt was made 
to produce an Inulin version of Conjugate 17. This would allow for the two polymers to be 
evaluated against one another for retention within the peritoneal cavity. 
To that end, in the same manner as Conjugate 17 tosylate 45 was reacted with Inulin (Scheme 
59). 
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Scheme 59 - Attachment of tosylate 44 to Inulin to give Conjugate 26 
 
The material was then purified by dialysis, and the polymer product analysed by 1H NMR 
spectroscopy. Pleasingly, a small amount of material appeared to have been conjugated to 
inulin (Figure 43). 
 
Figure 43 - The 1H NMR spectrum of Conjugate 26, (400 MHz DMSO-d6) 
 
Despite the drug loading appearing to be significantly lower than its IDX counterpart 
Conjugate 17 (by comparing the relative integration of the “drug” peaks to the polymer), the 
reaction was very promising. It was anticipated that with a small optimisation study, the drug 
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loading could be increased. However, despite this apparent success of this “tosylated-drug” 
approach in application with Inulin, the method was not investigated any further, due to the 
progress being made with an “epichlorohydrin activation method”. Had the epichlorohydrin 
method not shown such encouraging results, it is likely the “tosylated-drug approach” would 
have proven to be a useful method from which to conjugate ATX inhibitors to Inulin. 
 
3.2 The development of the “epichlorohydrin activation method” for Inulin, introduction 
 
Because of the many challenges experienced throughout this project, in the attempted 
synthesis of drug-polymer conjugates, an alternative conjugation method was sought. Ideally 
this alternate method would address the shortcomings noted in the “tosylated IDX” method 
and the “tosylated drug” method. Fortunately, several methods have been previously 
reported for the attachment of various substrates to Inulin, as detailed in Chapter 1.  Of most 
interest to us was a method developed by Molteni, in which Inulin was treated with 
epichlorohydrin in basic aqueous media.165 The highly reactive epoxide group on 
epichlorohydrin was found to be susceptible to nucleophilic attack by the hydroxyl groups 
present on Inulin. This caused a ring-opening reaction to occur that exposed a hydroxyl 
group, at the alpha position relative to the chloro group (Mechanism 3).  
 
 
Mechanism 3 - The epichlorohydrin activation of Inulin 
 
In the presence of dilute base, the alkoxide group will displace the chloro group 
intramolecularly to form a second epoxide, this is termed the “activation step”.165,209 
Epichlorohydrin-activated Inulin (EPI-INU) reportedly can be isolated as a powder and stored 
for many months without it degrading, or more conveniently generated in situ.165 The 
epoxide residues contained within EPI-INU are able to react with nucleophiles, facilitating 
the attachment of a drug molecule to Inulin. In a study by Remon and co-workers the 
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antiarrhythmic drug procainamide was attached to EPI-INU in this manner via the aniline 
group present within its structure (Scheme 60). 
 
 
Scheme 60 - The addition of procainamide to EPI-INU 
 
A consequence of the epoxide ring opening by procainamide is the formation of a secondary 
hydroxyl group. Whilst introducing additional functionality into the polymer was less than 
ideal for our purposes. It was postulated that the alcohol group would unlikely affect the 
binding of any drug to ATX, considering the structure of Inulin / IDX. Intrigued by the potential 
application of this method for our own work, the possibility of attaching a drug-linker 
analogue to Inulin using this method was investigated. It was decided, that despite there 
being a literature precedent for the attachment of aniline groups to EPI-INU, the drug-linker 
compounds developed for this project would not be modified further. The primary alcohol 
of the drug linker compounds would act as the nucleophile.209 This was reasoned due to a 
desire not to introduce additional functionality into the linker that may potentially interfere 
or compete with the interaction of key functional groups on the drug. However, there was 
concern that a primary alcohol group would not be sufficiently nucleophilic to be able to 
attack an epoxide residue on EPI-INU. In one book Chapter from the mid-seventies, it is 
suggested (by Molteni) that alcohols can act as suitable nucleophiles for EPI-INU although 
this is never substantiated with experimental details or references to similar studies.165 A 
thorough examination of the literature revealed a similar approach had been taken by 
Infante and co-workers. In their method, the epichlorohydrin activation method had been 
applied in “reverse”, in which a phenyl epoxide compound was reacted with Inulin (Scheme 
61).175  
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Scheme 61 - Addition of a phenyl-epoxy compound to Inulin, as described by Infante and co-
workers. 175 
 
3.2.1 Trial reactions 
 
Whilst not identical to the suggested nucleophilic attack by the alcohol group of the drug 
linker compound, the literature precedent was encouraging. The feasibility of using a 
“reversal” of the epichlorohydrin method for our purposes was investigated by reacting a 
“model” drug-linker compound (ether 10) with epichlorohydrin. However, in both attempts 
the compound could not be isolated, likely due to the highly reactive epoxide group 
degrading.  
A trial conjugation reaction was attempted: EPI-INU was prepared by reacting Inulin with 
epichlorohydrin in the presence of dilute NaOH aq. for 16 hours. The material was then 
neutralised with dilute hydrochloric acid. In the presence of triethylamine, ether 10 was 
added as a solution in acetone and reacted for 5 days (Scheme 62). 
The reaction conditions are worthy of comment, for example the reason the EPI-INU is 
neutralised and then triethylamine is added afterwards is due to the desire to avoid the use 
of a  NaOH in the presence of a boronic ester, as explained previously. Triethylamine was 
chosen as it is miscible in water and from our own investigations, does not act to degrade 
boronate esters. EPI-INU and ether 10 were reacted in an acetone / H2O co-solvent system, 
due to the low solubility of Inulin in common organic solvents and the very low solubility of 
ether 10 in water. By using a mixture of two solvents that are miscible in one another, Inulin 
and ether 10 became homogeneous at an elevated temperature (50 °C), which proved 
essential for the etherification reaction to occur. Using a co-solvent system avoided the need 
to use a phase-transfer catalyst such as tetra-N-butylammonium bromide, as has been 
applied in other studies.175 When this method has been applied to other drug-linker 
compounds it has often been found to be necessary to change the solvent ratio to achieve 
complete dissolution of both components at 50 °C. If this method were to be applied to drug 
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molecules outside the remit of this thesis, the minimum amount of organic solvent should 
be used to solubilise the drug compound at an elevated temperature, so as not to precipitate 
the polysaccharide. If acetone was found to be unsuitable, other water miscible organic 
solvents  such as IPA, DMF, MeCN, DMAc or DMSO could be used.  
 
                                                            
Scheme 62 - Attachment of  ether 10 to EPI-INU to give Conjugate 27 
 
The reaction was left for 5 days, then the material was precipitated in acetone and dialysed 
and analysed by 1H NMR spectroscopy. To our delight, the model drug  (ether 10) appeared 
to have attached to EPI-INU with an acceptable drug loading (Figure 44). 
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Figure 44 - Shows a comparison between the 1H NMR spectra of: a) Conjugate 27 and b) 
Inulin, (400 MHz, D2O) 210 
 
With the knowledge that a boronate ester “model drug” could be attached to Inulin, we 
wondered if BF3K salt 29 could be attached to inulin via this method. The resulting conjugate 
would be advantageous over Conjugate 27, as it would require minimal “post-conjugation” 
modification to hydrolyse the BF3K group to a boronic acid (Scheme 63).  
 
Scheme 63 - Attempted synthesis of Conjugate 28 
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Interestingly, after dialysis, the only material to be recovered was epichlorohydrin activated 
Inulin, suggesting that the BF3K group had a direct effect on the conjugation reaction 
inhibiting the reaction. We then decided to investigate if a boronic acid “model drug” 
(boronic acid 30) could be directly conjugated to EPI-INU (Scheme 64). 
                                                                                                
Scheme 64 - Coupling of boronic acid 30 to EPI-INU to give Conjugate 29 
 
Pleasingly, inspection of the 1H NMR spectrum of the dialysed product indicated the 
successful attachment of boronic acid 30 to INU (Figure 45). 
 
Figure 45 - The 1H NMR spectrum of Conjugate 29 (400 MHz, D2O) 
 
With the knowledge that the boronic acid “model drug” could be directly conjugated to EPI-
INU, logically the next step of this investigation was to attempt to attach the drug linker 
analogue of 3BoA (ether 22) to Inulin. But before this was attempted there was one concern 
that needed to be resolved. In the 1H NMR spectra of Conjugates 27 and 29 (Figure 44 and 
Figure 45) there is a broad singlet at approx. 1.12 ppm. This peak could be assigned as a BPin 
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12 H singlet for Conjugate 27. However, the peak is also visible in the spectra of Conjugate 
29 which contained no boronate ester. A clue to the peaks origin was provided in the 1H NMR 
spectrum of Conjugate 28, despite no material coupling to Inulin, the singlet was still visible. 
This strongly suggesting that the new peak was a consequence of the conditions / reagents 
used in the conjugation reaction. To test this hypothesis a test reaction was conducted, 
mimicking the method used for Conjugate 27 except for the addition of ether 10. The 
resulting product was dialysed and analysed via 1H NMR spectroscopy, as predicted the 
resonance at 1.12 ppm was visible. A sample of EPI-INU was also prepared and analysed in 
the same manner; in this case, there was no such peak observed. It can therefore be 
concluded that the resonance 1.12 ppm forms when the model drug is added to the reaction 
mixture, but occurs independently of the drug itself, for example as a result of heating. Whilst 
the identity of the peak was not yet confirmed (discussed in Chapter 3.5) it was felt that the 
conditions could be modified at a later stage in this study to attenuate its appearance.  
 
3.2.2 Attempted preparation of a 3-BoA-Inulin conjugate using the “epichlorohydrin 
activation method” 
 
Having demonstrated that a boronic acid “model drug” could be directly attached to Inulin,  
an attempt was made to attach the drug-linker analogue (ether 22) to EPI-INU,  in the same 
manner as conjugates 27 and 29 (Scheme 65). 
                                                                                                        
Scheme 65 - Attempted synthesis of Conjugate 30 
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Disappointingly, the conjugation reaction was not successful. A likely cause of this lack of 
success may be the thermal stability of the drug-linker analogue, considering compound 22 
was typically stored at -18 °C. However, this could not be confirmed as the material was 
dialysed over several litres of solvent, making its recovery impractical. At this point in time 
our focus moved away from the BoA series and towards inhibitors based around the HA155 
scaffold. 
 
3.2.3 Preparation of carboxylic acid-ATX inhibitor Inulin conjugates, early method 
 
As was stated earlier, it was desirable to prepare an Inulin equivalent of Conjugate 17 for the 
peritoneal retention of IDX and Inulin to be effectively evaluated. With limited success using 
our “tosylated-drug” approach, it was decided that ether 44 would be attached to Inulin 
using the “epichlorohydrin activation method” (Scheme 66). 
 
Scheme 66 – The preparation of Conjugate 31 
 
In this first study, the TIPS-protected version of the drug-linker analogue (ether 44) was used 
in the conjugation reaction rather than the unprotected carboxylic acid equivalent, in order 
to prevent side reactions from occurring with the carboxylic acid. Additionally, ether 44 was 
more soluble in a variety of organic solvents compared to the carboxylic acid version, which 
rom a practical viewpoint made it considerably easier to manipulate. When the same 
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conjugation reaction was attempted with carboxylic acid 43, it did not dissolve in an acetone 
/ H2O co-solvent system and required the addition of DMF for complete dissolution. 
Gratifyingly, the conjugation reaction (Scheme 66) proceeded smoothly and the drug-linker 
compound (ether 44) was successfully reacted with EPI-INU, as evidenced by the 1H NMR 
spectrum of Conjugate 31 (Figure 46).  
 
Figure 46 - The 1H NMR spectrum of Conjugate 31 (D2O, 400 MHz) 
In agreement with findings in our previous studies, the TIPS ester group had undergone 
hydrolysis under the reaction conditions, which meant the conjugate required no further 
chemical modification, post conjugation.  
 
3.3 The development of the “epichlorohydrin activation method” for IDX 
 
In comparison to Conjugate 17 (attached to IDX via the “tosylated drug” method), the drug 
conjugates synthesised with Inulin using the “epichlorohydrin activation” method are almost 
structurally identical (except for the polymer). However, the drug is attached to Inulin 
through a secondary alcohol bridged-ether chain, whereas Conjugate 17 is linked by a 
straight alkyl ether chain. The difference in linkage to each polymer is not anticipated to have 
any significant change on activity (the linker unit is believed to be completely inert). But for 
Inulin and IDX drug conjugates to be directly comparable, it was felt the drug should be 
attached to each polymer using the same conjugation chemistry. As detailed earlier (Chapter 
3.1), the “tosylated drug method” was used to limited effect on Inulin, so to complement 
those studies a series of IDX drug conjugates using the “epichlorohydrin method” would be 
made.  
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To that end, the feasibility of producing EPI-IDX drug conjugates was investigated by reacting 
Icodextrin with epichlorohydrin in the same manner as with Inulin, under the standard 
reaction time of 16 hours. The material was then neutralised, evaporated and triturated in 
acetone to give a white powder. This was then analysed by 1H NMR spectroscopy, the results 
are shown in Figure 47. 
 
Figure 47 -  1H NMR spectra of a) IDX and b) epichlorohydrin-activated IDX (D2O, 400 MHz) 
 
As can be seen in Figure 47b the spectrum is noticeably different to that of IDX (Figure 47a), 
with the multiplet at 3.40-3.55 ppm (Figure 47b) appearing to have incorporated new 
material, in comparison to pure IDX. This suggested that epichlorohydrin may have reacted 
with IDX. This may also indicate that intra polymer cross-linking has occurred with the 
attached epoxide groups and the hydroxyl groups on neighbouring sugars.211  
It is thought that, in keeping with our previous assertion, the primary hydroxyl group of IDX 
will react preferentially with epichlorohydrin due to it being more nucleophilic than the  
secondary alcohol groups also present. This is substantiated by other studies on epoxide 
addition to glucose-containing polysaccharides.211,212 However, the epoxide may also react 
with secondary alcohol groups contained within the sugar, considering the precedent set in 
the epoxidation of Inulin, with DS values of up to 2 being reported.165  
Having evidence that IDX will react with epichlorohydrin, a conjugation reaction was 
attempted. Epichlorohydrin-activated IDX (EPI-IDX) was prepared by reacting IDX with 
epichlorohydrin for 16 hours. The pH was then adjusted to neutral (using dilute HCl aq.).  In 
the same manner as Conjugate 31, EPI-IDX was reacted with triethylamine and ether 44  for 
2 days at 50 °C (Scheme 67). 
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                                                                                                                Conjugate 32 
Scheme 67 - The attempted synthesis of Conjugate 32 
 
The product was analysed by 1H NMR spectroscopy. To our disappointment, no drug material 
appeared to have been attached to IDX. In attempting to discern why the reaction failed, 
attention was drawn to the 1H NMR spectrum in Figure 47b, regarding the change in 
appearance within the spectrum. If it was the case that IDX had crosslinked with itself (as 
represented in Figure 48) then it could have a negative effect on the conjugation reaction.  
 
Figure 48 - Intra IDX crosslinking, (cross-linking highlighted in blue) 
 
Intra molecular and (possibly) inter molecular cross-linking will have two main consequences 
with regard to the conjugation reaction: there will be fewer epoxide units with which the 
drug can react, reducing the total amount of drug that can be theoretically attached. 
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Secondly, cross-linking may hinder the approach of the drug molecule, making conjugation 
less likely. Cross-linking may also cause the polymer to fold in on itself, in the same manner 
as a tertiary protein structure. Potentially, this agglomeration may mean that any un-reacted 
epoxide units are inaccessible to the drug molecule.  
 
3.3.1 1H NMR Study of the reaction between epichlorohydrin and IDX over time 
 
Working on the hypothesis that the cross-linking effect was occurring over time, a study was 
undertaken to evaluate the reaction between epichlorohydrin and IDX over time. Icodextrin 
was reacted with epichlorohydrin for set time periods, then worked-up as previously 
described. The isolated material was then analysed by 1H NMR spectroscopy (Figure 49).  
The study gave a valuable insight into the reaction of epichlorohydrin with IDX. As can be 
seen from the spectra in Figure 49, IDX loses much of its structural definition after 4 hours, 
with reference to the 1H NMR spectra of pure IDX. It is suggested that the gradual change in 
shape of the peaks at 3.20 - 4.00 ppm is the result of cross-linking enveloping IDX. After 16 
hours IDX is likely to be highly crosslinked. It can be concluded that when the conjugation 
reaction was attempted using EPI-IDX with a 16-hour reaction time (Scheme 67), the 
approach of tosylate 44 was likely to be extremely hindered. This study highlights the 
importance of time on the activation step. It is indicated that the intra IDX cross-linking 
process occurs over several hours, so if the activation time was reduced, there is likely to be 
less internal cross-linking within IDX, but potentially still be sufficient epoxide residues with 
which drug-linker molecules can react with. The study also revealed the gradual loss of the 
anomeric proton within the structure of IDX. The broad singlet at 5.25 ppm diminished in 
intensity and eventually (after 12 hours) disappeared. This was taken to show the 
degradation of the polymer over time.  
The study also revealed a second process, which we also feel is important to the attachment 
of drug molecules to IDX. After 10 minutes, the NMR spectrum reveals two small multiplets 
at 2.58 – 2.61 ppm and 2.74 – 2.79 ppm (Figure 50). At 30 minutes their intensity (by relative 
integration) has increased, which was mirrored at 1 hour and by 4 hours these were at their 
most intense. After 4 hours, these multiplets slowly decreased in size, and by 16 hours they 
have disappeared.  
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It is believed that these peaks indicate the formation of the epoxide group on IDX (following 
the attachment epichlorohydrin to IDX). The evidence for this is that if it were the hydroxy-
chloro version of IDX  it would be expected to have a different splitting pattern and be shifted 
downfield to approx. 3.50 ppm (using the 1H NMR spectrum of epichlorohydrin as a guide). 
The formation of the epoxide group is probably essential for the successful addition of a drug 
molecule to IDX and additionally is a process that intra IDX cross-linking is reliant upon for it 
to occur. This is evidenced by the gradual reduction and eventual disappearance of the 
epoxide peak over time. Implying that the epoxide has been consumed in the cross-linking 
process, to expose the hydroxyl group, which is obscured by the main bulk of IDX in the 
spectrum, though the epoxide could be ring-opened by H2O. The epoxide ring opening will 
most probably take preference in the drug addition / cross-linking reaction, over direct 
displacement of the chloro group of hydroxy chloro IDX  although the same result will be 
obtained regardless.  
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Figure 49 - The 1H NMR spectra of epichlorohydrin activated IDX with differing reaction times 
(D2O, 400 MHz) 
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Figure 50 - The formation of an epoxide on IDX and the spectral assignment of the new peaks 
 
3.3.2 Refinement of the epichlorohydrin method for IDX 
 
Using the insight afforded by the 1H NMR study, the conjugation reaction between IDX and 
ether 44 was re-attempted, using a 1-hour activation time. Because although after 4 hours 
(Figure 49) the epoxide peaks were at their most intense, suggesting that there are the most 
epoxide residues available to react with IDX, after this time the spectrum began to lose its 
resolution, indicating cross-linking was occurring. At 1 hour, the epoxide peaks are still  
intense, but the resonances remain well resolved. After one hour, the reaction mixture was 
neutralised and the product isolated as a solid and used immediately in the drug coupling 
step.  
To our delight, the conjugation reaction appeared to be successful, with ether 44 appearing 
to be incorporated into IDX, as shown in the 1H NMR spectrum of Conjugate 33 (Figure 51). 
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Figure 51 - 1H NMR spectrum of Conjugate 33 after dialysis (DMSO-d6, 400 MHz)   
 
 
3.4 Further refinement of the “epichlorohydrin activation method” for Inulin and IDX 
 
When the conjugation reaction was repeated using EPI-IDX with activation times of 4 and 8 
hours, interestingly no conjugation was observed despite there being epoxide residues 
present on the polymer as suggested by 1H NMR spectroscopy (Figure 49). This observation 
highlights the significance that cross-linking has on the reactivity of EPI-IDX, presumably by 
hindering the approach of the drug-linker compound. It can therefore be said that intra 
polymer cross-linking and epoxide formation both have a significant effect on the ability to 
attach a drug molecule to a polymer using this method. These factors must be taken into 
account if the epichlorohydrin activation method is applied to other polysaccharides such as 
dextran.  
As previously stated, the Inulin drug-conjugate Conjugate 31 was prepared with an activation 
time of 16 hours, whereas IDX required an activation time no longer than 1 hour.  One may 
question as to why the two polymers behaved so differently. To answer this, a study similar 
to that shown in Figure 49 was conducted. Inulin was reacted with epichlorohydrin for set 
periods of time, then isolated as a solid by precipitation in acetone and analysed by 1H NMR 
spectroscopy (Figure 52). 
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Figure 52 - The 1H NMR spectra of the reaction between Inulin and epichlorohydrin at 
different periods of time (D2O, 400 MHz) 
 
The rate at which resolution of the spectrum is lost is significantly slower than that of IDX 
(Figure 49), suggesting that intra Inulin cross-linking occurs at a reduced rate. Additionally, 
at 16 hours, epoxide peaks are still visible. Indicating that only partial cross-linking has 
occurred, which explains why the conjugation reaction still proceeded at 16 hours. When the 
structure of IDX and Inulin are compared (Figure 53) the reason for the difference in the rate 
of cross-linking is clear. The main difference between IDX and Inulin, aside from the number 
of carbon atoms in their rings, is that IDX is a branched polymer whereas Inulin is more akin 
to a linear polymer. We suggest that the structure of IDX, through its α (1,6) branching 
increases its propensity to cross-link with itself because of neighbouring sugar units being 
held in close proximity.  
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Figure 53 - The structure of IDX and Inulin 
 
3.5 Final reaction optimisation 
 
A further modification was made to the procedure used to make the Inulin Conjugate 31: 
instead of leaving Inulin to react with epichlorohydrin for 16 hours, the time would be 
reduced to 80 minutes (the conditions would otherwise be kept the same). This resulted in 
the successful conjugation of ether 44 to Inulin, however the loss of resolution observed (by 
1H NMR) in conjugate 31 (using a 16-hour activation time) was reduced. It was felt that this 
would make conjugates produced with Icodextrin and Inulin more comparable, as they 
should have similar levels of crosslinking, which would be beneficial for their biological 
evaluation.   
Before the conjugation methodology for IDX and Inulin could be finalised, there was one 
additional factor to be resolved. As mentioned earlier in this Chapter, for every conjugation 
reaction attempted with both IDX and Inulin, a multiplet at approx. 1.05-1.20 ppm was visible 
(Figure 51, for example). In the case of Conjugate 31, this was initially explained by the TIPS 
protection group being retained post conjugation. Elemental analysis showed a much higher 
percentage of nitrogen than could arise from the drug, a likely culprit for the increase in 
nitrogen was felt to be triethylamine: used in the conjugation reaction (though it did not 
match its associated reference data).213 A solution to this problem was found by using a 
different base. On a small scale, potassium carbonate was substituted for triethylamine (the 
conjugation reaction conditions were otherwise kept the same). The resulting conjugate 
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showed no indication of the aforementioned peak, and also demonstrated the removal of 
the TIPS group, exposing the carboxylic acid. This modification was also applied to IDX, which 
satisfyingly, saw the disappearance of the multiplet.  
 
3.6 Synthesis of IDX and Inulin drug conjugates, optimised conditions 
 
With the optimised conjugation condition conditions in hand, work began on the synthesis 
of IDX and Inulin drug conjugates for biological evaluation. Using the optimised conditions, 
1.2 eq. of ether 44 was reacted with EPI-INU in the presence of K2CO3. 
An equivalent is defined as being relative to the number of moles of polysaccharide used in 
the reaction, determined by the molecular weight of the equivalent monosaccharide (IDX = 
161 g / mol, INU = 162 g / mol). 
After the material had been dialysed, it was analysed by 1H NMR spectroscopy (Figure 54). 
 
Figure 54 - The 1H NMR spectrum of Conjugate 34 (DMSO-d6, 400 MHz) 
 
As can be seen in Figure 54, a significant amount of compound 44 was incorporated within 
IDX. The same methodology was then applied to Inulin, the material was then analysed by 
1H NMR spectroscopy (Figure 55). 
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Figure 55  -The 1H NMR spectrum of Conjugate 35 (D2O, 400 MHz) 
 
The spectrum in Figure 55 showed the incorporation of drug onto Inulin. An additional 
purification step was used from Conjugate 34 onwards. It was found that the polymer 
conjugates precipitated in a 1:1 mixture of DMF / acetone whilst the drug material stayed in 
solution. The liquid was decanted, the procedure was then repeated 10 times. The advantage 
to this method is the free-drug is completely removed from the mixture before it is dialysed, 
ensuring that no free-drug material is present in the final product.  
 
3.7 Drug loading study 
 
Now that the versatility of the epichlorohydrin activation method had been proven for both 
Inulin and IDX, it was decided that to complement this study conjugates with different drug 
loadings would be investigated. Conjugates of different drug loadings are of interest because 
differing drug concentrations may result in a change in biological activity.  The results of this 
study can be exploited to enhance the design of polymer-drug conjugates.  
Starting with Inulin, the number of equivalents of ether 44 used in the conjugation reaction 
were varied. Using the original 1.2 eq. as a starting point, the following equivalents of drug 
were investigated: 1.7, 0.8, 0.5 and 0.3 eq., otherwise the conditions were kept the same. It 
was hoped that by varying the amount of the drug available to react with EPI-INU the degree 
of substitution of the drug bound to the polymer could be manipulated. Each polymer 
conjugate was purified as previously described and then analysed by 1H NMR spectroscopy 
(Figure 56). 
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Figure 56 - The 1H NMR spectra of Conjugates 36, 37 and 38 (D2O, 400 MHz) 
 
The drug loading of Inulin was successfully manipulated by changing the number of 
equivalents of drug used in the conjugation reaction. However, when the number of 
equivalents were increased to 1.7 (Conjugate 39) from 1.2 eq., there was no change in the 
amount of drug attached (by comparing the relative integration of the drug peaks to Inulin 
peaks for each conjugate). Therefore, using between 0.8 - 1.2 eq. of ether 44 in the 
conjugation reaction gave the maximum amount of drug that can be attached to Inulin, using 
the epichlorohydrin activation method.  
A series of conjugates with decreasing drug loadings were then made with IDX, using: 0.8, 
0.5 and 0.3 equivalents of ether 44. The results of this study are shown in Figure 57. 
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Figure 57 - The 1H NMR spectra of Conjugates 40, 41 and 42 (DMSO-d6 400 MHz) 
 
3.7.1 Quantification of drug loading: determining the degree of substitution (DS) 
 
The quantity of drug present in the polymer conjugates and degree of substitution was then 
calculated for each material. A convenient method for quantification of the drug was found 
in microanalysis. Ether 44 possesses one nitrogen, EPI-IDX or EPI-INU have no nitrogen 
content. Therefore, the amount of nitrogen, determined by elemental analysis, will relate 
directly to the amount of drug material present within the polymer conjugate. Each drug-
conjugate was analysed by elemental analysis, then using an equation adapted from a 
publication by Domb and co-workers (Equation 1) the degree of substitution was 
calculated.214 
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Equation 1 - Equation to calculate the degree of substitution (DS), MSU = Molecular weight of 
saccharide monomeric unit, MN = molecular weight of nitrogen, MDRUG = molecular weight of 
drug 
 
The results of this study are shown in Table 7 and Table 8. 
Conjugate 
 
Number of 
eq. of drug 
(44) 
% N 
(By elemental 
analysis) 
DS (degree of 
substitution) 
% of drug in 
conjugate 
35 1.2 1.74 0.68 70% 
36 0.8 1.35 0.35 55% 
37 0.5 1.30 0.32 52% 
38 0.3 1.16 0.25 47% 
EPI-INU - <0.1 - 0% 
Table 7 - Table to show the degree of substitution for Inulin drug conjugates 
 
Conjugate 
 
Number of 
eq. of drug 
(44) 
% N 
(By elemental 
analysis) 
DS (degree of 
substitution) 
% of drug in 
conjugate 
34 1.2 1.80 0.76 73% 
40 0.8 1.50 0.44 61% 
41 0.5 1.38 0.36 56% 
42 0.3 1.13 0.24 46% 
EPI-IDX - <0.1 - 0% 
Table 8 - Table to show the degree of substitution for IDX drug conjugates 
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3.8 Synthesis of a highly crosslinked Icodextrin drug-conjugate 
 
While it has previously been stated that intra polymer cross-linking would likely have a 
negative effect on activity, this may not be the case from a pharmacokinetics standpoint. IDX 
crosslinked “bridges” may provide a non-hydrolysable barrier to attack from α-amylase, 
increasing its residence time in the peritoneal cavity. Additionally, if inter IDX cross-linking 
occurs between different IDX polymer chains, then one could anticipate a large increase in 
molecular weight from the standard weight of 13-19 kDa. This attribute has been shown to 
be beneficial to the retention of a material in the peritoneal cavity.132  
By purposely designing an IDX drug conjugate with increased crosslinking, it will allow the 
effect of cross-linking on biological activity to be studied and the influence that it has on 
peritoneal retention to be evaluated.  
To synthesise a highly crosslinked drug-conjugate, the conjugation procedure was modified. 
1 eq. of epichlorohydrin was reacted with IDX for two hours. EPI-IDX was isolated by 
precipitation then immediately reacted with ether 44 for two days. The drug conjugate was 
isolated by precipitation in 1:1 acetone / DMF, reacted with 3 eq. of epichlorohydrin for 18 
hours and then isolated by dialysis. The results of this study are shown in Figure 58. 
 
Figure 58 1H NMR spectra comparison of a) Conjugate 43 b) Conjugate 43 after treatment 
with 3 eq. of epichlorohydrin (DMSO-d6, 400 MHz) 
Conjugate 43 DS = 0.2 
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There is a clear difference in structure between Figure 58 a) and b). Following the addition 
of epichlorohydrin (3 eq.) the spectrum of Conjugate 43 loses much of its structural 
definition, becoming considerably less resolved than any conjugate previously synthesised. 
This was interpreted that the polymer was highly cross-linked.  
 
3.9 Boronic acid ATX inhibitor IDX / Inulin conjugates, using the epichlorohydrin method 
 
In Chapter 2 a number of different methods were attempted with the aim of attaching an 
ATX inhibitor containing a boronic acid moiety to IDX and to Inulin (Chapter 3). It was 
postulated that these boronic acid ATX inhibitors would be significantly more potent than 
the carboxylic-acid containing drug used in our previous investigation.42 Despite these 
efforts, a suitable method for the conjugation of boron-containing drug-linker analogues was 
not found. However, as stated in Chapter 2, it was hypothesised that one of the possible 
reasons for the lack of success was because the boronic acid group may interact with itself 
and form a boroxine anhydride and/or react with the polysaccharide support itself. It was 
felt that these side reactions would be detrimental to the conjugation reaction. This effect 
may have been potentiated by the conjugation reaction being performed under anhydrous 
conditions, which in the absence of water would push the equilibrium towards forming 
anhydrides, and reactions with the polysaccharide.  
It was decided that the epichlorohydrin activation method would be used to attempt to 
attach boronic acid 52 (a drug-linker analogue of the potent ATX inhibitor HA155) to IDX and 
Inulin. It was thought that the reaction conditions used for the epichlorohydrin activation 
method may overcome the obstacles previously encountered in the attempted conjugation 
reactions. This is because the epichlorohydrin method uses an acetone / H2O co-solvent 
system. The presence of water in the reaction mixture may help to push the equilibrium back 
to the boronic acid, so the drug linker can react with the epoxide residues present on each 
polymer.  
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EPI-INU was reacted with 1.2 eq. of boronic acid 52 for two days (Scheme 68). 
 
Scheme 68 - The synthesis of Conjugate 44 
 
The material was worked-up and dialysed, as previously described, then analysed by 1H NMR 
spectroscopy, the results of which are shown in Figure 59. 
 
Figure 59 -  The 1H NMR spectrum of Conjugate 44 (D2O, 400 MHz) 
DS (Conjugate 44) = 0.2 
Pleasingly the reaction proceeded smoothly, with boronic acid 52 reacting with EPI-INU, 
albeit at a lower degree of substitution than the equivalent carboxylic acid drug conjugate 
(Conjugate 35).  
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The method was then applied to Icodextrin, using the same conditions and number of 
equivalents of boronic acid 52. The material was worked-up and dialysed as previously 
described, then analysed by 1H NMR spectroscopy (Figure 60). 
 
 
Figure 60 - 1H NMR spectrum of Conjugate 45 (DMSO-d6, 400 MHz) 
DS (Conjugate 45) = 0.07 
 
As can be seen in Figure 60, the reaction appears to have been successful, indicating that 
boronic acid 52 had been conjugated to IDX. The DS value for Conjugate 45 is quite low. 
However, when the many unsuccessful attempts to attach boronic acid compounds to IDX 
are considered, it is still a notable achievement. Additionally, with a DS value of 0.07, 22% of 
the conjugate (by mass) corresponds to the drug, which is not insignificant considering the 
low nanomolar potency of the parent drug.  
 
3.9.1 Synthesis of boronic acid “free-drug” 
 
The 11 drug conjugates synthesised via the epichlorohydrin method were then evaluated for 
biological activity (Chapter 4). As per our previous work, the conjugates would be tested 
against a non-polymeric equivalent of the parent drug (Figure 61).  
138 
 
 
Figure 61 - The "free-drug" target 
 
A hydroxyl group was included at the position usually occupied by the linker unit, this was 
seen as an effective way to mimic the drug-linker compound in its “free-form”. 
The free-drug was synthesised to provide a comparison between the free drug and the drug-
conjugate. In the case of observed activity, this will indicate any loss in potency which results 
from the attachment of the drug to a polymer. From a pharmacokinetics standpoint it will 
provide a reference for the residence time of the free-drug within the peritoneal cavity, to 
demonstrate the effect of conjugation on peritoneal retention. 
The boronic acid “free-drug” was synthesised in six synthetic steps, boronate ester 47 was 
reacted with heterocycle 42 in a Knoevenagel condensation, to give boronate 58. Boronate 
58 was converted to its BF3K salt 59, then hydrolysed to the corresponding boronic acid to 
give the target compound (Scheme 69). 
 
Scheme 69 – Synthesis of boronic acid 60 
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The free drug was synthesised with a respectable overall yield of 8 %, and was tested 
alongside the drug conjugates, when they were evaluated for biological activity (Chapter 4).   
 
3.10 Attempted conjugation of GLPG 1690 to IDX and Inulin 
 
3.10.1 Introduction 
With the epichlorohydrin activation method now proven to be an effective and versatile 
approach to the formation of drug-polymer conjugates, in the final stage of this project our 
attention was drawn to a recently published autotaxin inhibitor: GLPG 1690 (Figure 62). As 
mentioned in Chapter 1, this drug is of interest for two reasons: it is the only autotaxin 
inhibitor to enter clinical trials (to date) and second, it displays an alternative binding mode 
compared to the ATX inhibitors previously studied (3BoA and HA155) which would 
complement our investigation.65,67 
By examining the X-ray crystal structure of GLPG 1690 bound to ATX, a suitable position for 
attachment was determined (Figure 62).67 The hydroxyazetidine terminus is not reported to 
have a significant role in the binding of GLPG 1690 to ATX, so is an ideal location for the 
diethylene glycol linker unit to be attached.67 
 
Figure 62 - The crystal structure of GLPG 1690 bound to ATX and the position determined for 
the attachment of a linker unit. 67 
 
From a synthetic perspective, GLPG 1690 is an attractive substrate from which a drug-linker 
analogue can be made, this is because the drug can be synthetized as per its literature 
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preparation and then as the final synthetic step the linker unit can be installed. This means 
that the drug-linker analogue of GLPG 1690 (Figure 63) should be synthesised with relative 
ease.   
 
Figure 63 - Target compound:  GLPG 1690 linker-analogue 
 
3.10.2 Synthesis of GLPG 1690 
 
3.10.2.1 Fragment 1 
 
GLPG 1690 was synthesised according to the procedure outlined in the original publication 
by Heckman and co-workers, although it is worthy of note that some of the procedures 
required modification for the stated reaction to be reproducible in our hands.  The synthetic 
route employed a divergent strategy using three fragments. The first fragment was 
synthesised in two synthetic steps (Scheme 70). The formation of the thiazole component 
proceeded via the cyclisation of thiourea and the aromatic ketone in the presence of iodine. 
Amine 60 was then converted to a chloride, through the Sandmeyer reaction, following 
treatment with tert-butyl nitrite and CuCl2 and dilute HCl aq.215,216 
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Scheme 70 – The synthesis of chloride 62 
 
3.10.3 Synthesis of fragment 2 
 
With chloride 62 in hand, work then proceeded towards the synthesis of the second 
fragment with the first synthetic step involving a multi-component Groebke-Blackburn-
Bienayme reaction (Scheme 71).217,218 Amine 63 was then stirred in neat formic acid to give 
the corresponding amide 64, which was then methylated, using methyl iodide and potassium 
carbonate. Amide 65 was then converted to its corresponding amine.  
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Scheme 71 - The synthesis of amine 66 
 
3.10.4 Coupling reaction between amine 66 and chloride 62 and proceeding transformations 
 
Fragments 62 and 66 were then coupled together by an SNAr displacement, in the presence 
of sodium hydride, heterocycle 67 then underwent a Buchwald-Hartwig coupling with N-Boc 
piperazine. The Boc protecting group was then removed from N-Boc piperazine 68 using 
ethereal HCl (Scheme 72).  
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Scheme 72 - Synthesis of heterocycle 70 (material carried through to the next step without 
isolation) 
 
3.10.5 The preparation of fragment 3 and synthesis of GLPG 1690 
 
GLPG 1690 (Compound 71) was prepared by reacting azetidine hydrochloride with 2-
chloroacetyl chloride, in the presence of potassium carbonate. Azetidine 70 was then reacted 
with piperazine 69 in a SN2 reaction to give GLPG 1690 (Scheme 73). 
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Scheme 73 - The synthesis of GLPG 1690 (Compound 71) 
 
GLPG 1960 (Compound 71) was synthesised over 12 synthetic steps, with the longest linear 
sequence using 8 steps. The overall yield was very low at 0.14 %, however this was caused 
by the low return in material following the Buchwald Hartwig coupling. This significantly 
affected the subsequent synthetic steps. Had the reaction been repeated the conversion 
could possibly have been improved. Notwithstanding this, a small amount of GLPG 1690  was 
available to evaluate if a linker group can be directly attached to its hydroxyazetidine 
terminus. 
 
3.11 Attempted attachment of a diethylene glycol linker to GLPG 1690 
 
In line with our previous work, 2-(2-chloroethoxy)ethanol was reacted with GLPG 1690 
(Compound 71) in the presence of K2CO3 and KI (Scheme 74). 
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Scheme 74 - Shows the attempted linker addition to GLPG 1690 (Compound 71) 
 
Disappointingly, there was little evidence to show that the reaction had been successful. The 
crude material was very polar, making column chromatography with normal phase silica gel 
difficult. Had the reaction been repeated, a more suitable approach may be to attach the 
linker to fragment 3 (azetidine 70) prior to the coupling reaction in Scheme 73. Time 
constraints towards the end of this research project prevented the further development of 
a GLPG 1690-linker analogue and so the study was not pursued any further.  
 
3.12 Summary of Chapter 2 and 3 
 
The attachment of drug-linker analogues of ATX inhibitors containing  boronic acid groups to 
Icodextrin and Inulin is an extremely challenging undertaking, and reasons for the difficulties 
encountered have been suggested. Despite this, a novel conjugation method developed 
during this project has allowed the synthesis of boronic acid ATX inhibitor polymer 
conjugates. From the work described in Chapters 2 and 3, eleven testable drug polymer 
conjugates have been prepared using two alternative polymer supports (IDX and Inulin) and 
using two separate drug-linker series. These novel polymer conjugates and their free-drug 
counterparts were then evaluated for biological activity, using enzyme assays and for 
peritoneal retention studies, animal models. This work is described in Chapter 4. 
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Chapter 4: 
 
The biological evaluation of novel 
ATX inhibitor-IDX and ATX inhibitor-
Inulin drug conjugates 
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Chapter 4: The biological evaluation of novel ATX inhibitor-IDX and ATX inhibitor-Inulin 
drug conjugates 
 
4.1 Introduction 
 
Resulting from the work described within Chapters 2 and 3, eleven drug conjugates were 
prepared for biological evaluation. This study involved both in vitro and in vivo investigations 
and provided significant information regarding the efficacy of the drug conjugate approach 
explored throughout this thesis. Of particular interest to us was the biological activity of the 
drug conjugates, as one might anticipate a loss in activity of the drug following polymeric 
attachment. Additionally, there was some concern that the intra-polymer cross linking that 
occurs as a consequence of the conjugation reaction may lead to a further reduction in 
activity. An effective method from which to assess the activity of the conjugates was 
therefore required. It was decided that two separate enzyme assays would be used to 
evaluate conjugate activity, the key reason for this is that the assays will use two sources of 
ATX, one commercial and the other obtained in-house. These assays have been used to 
evaluate the activity of drug conjugates in our previous work in this area and additionally 
have been widely used in the literature.73,78,147,219–222  
The second part of our biological investigation was an animal study in which the peritoneal 
retention of an Inulin-drug conjugate would be measured in mice. This was the first time that 
the residence time of Inulin in the peritoneal cavity had been compared to IDX and would 
allow us to determine which polymer offers superior peritoneal retention. The study also 
had the potential to provide a valuable insight into how a drug-polymer conjugate may 
perform in the human body.  
 
4.2 Autotaxin inhibition assays 
 
The enzyme assays used in this investigation are known as “artificial substrate assays” in 
which a substrate mimicking LPC, containing a phosphodiester bond, is used in place of LPC. 
It is then assumed that ATX will hydrolyse the material in the same manner as LPC because 
of the substrate’s structural similarity.219 The concentration of the hydrolysed substrate can 
then be measured by fluorescence or absorbance spectroscopy. It follows that the amount 
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of hydrolysed material produced is a measure of the enzyme’s activity and in the presence 
of an inhibitor will be reduced. Over the last decade there have been many artificial substrate 
assays developed, such as a fluorescence probe developed by Nagano and co-workers. 
However, for this study we chose the two most widely used, which will assist in comparing 
the results to other studies.88,219 
 
4.2.1 Bis(para-nitrophenyl) phosphate (Bis-pNPP) artificial substrate assay 
 
Bis-pNPP is understood to be hydrolysed in the same manner as LPC (Chapter 1). A  product 
of this reaction is the chromophore: p-nitrophenol the concentration of which can be 
measured at 405 nm by absorbance spectroscopy (Figure 64). Therefore, the concentration 
of the hydrolysis product (p-nitrophenol) provides a useful indication as to the activity of ATX 
and in the presence of an inhibitor. This was done by measuring the absorbance of p-
nitrophenol in the presence of a drug conjugate, which was used to determine the IC50 value 
for each material.  
 
Figure 64 - The hydrolysis of bis-pNPP by ATX 
 
Recombinant ATX , obtained from 3E3 cells that were genetically engineered to overexpress 
ATX, was purified by passing the material through a Sepharose column, and then dialysed. 
The drug conjugates were diluted to a concentration appropriate to their predicted activity 
in distilled water. A 3-fold dilution series was then prepared (final concentration = 0 μg / mL, 
well H = distilled water). A solution of autotaxin, reaction buffer, bis-pNPP and conjugate at 
its respective concentration were mixed in a 96-well plate and incubated for 4 hours at 37 
°C. The absorbance of the plate was measured at a wavelength of 405 nm, and the resulting 
data were analysed using Graph Pad Prism software. Non-linear regression was used to fit a 
4 parameter (Hill equation) dose-response curve to determine the IC50 value for each 
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conjugate. The free drug equivalents of each inhibitor were also analysed in this manner, as 
well as samples of  the “parent” Icodextrin and Inulin (150 μg / mL) polymers and it was 
found that they no inhibitory action on ATX. Each experiment was repeated a minimum of 3 
times for each conjugate / free-drug, on separate days, using different batches of purified 
ATX.  
 
4.2.1.1 Dose response curves for Bis-pNPP 
 
The dose response curves obtained for each sample tested are featured in Figure 65 and 
Figure 66. 
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Figure 65 - Shows the dose response curves for Conjugates 34-40 
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Figure 66 - Shows the dose response curves for Conjugates 41-45 and Compound 60 
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4.2.1.2 Bis-pNPP assay results 
 
The IC50 values determined for the Icodextrin-drug conjugates (Figure 67) are shown in Table 
9.  
 
Sample IC50 / μg mL-1 
(n=3) 
Degree of substitution 
/ DS 
Conjugate 34 3.22 ± 0.15 0.76 
Conjugate 40 4.41 ± 1.21 0.44 
Conjugate 41 12.41 ± 1.33 0.36 
Conjugate 42 4.45 ± 1.43 0.24 
Conjugate 43 (High cross-linking) 0.70 ± 0.29 0.20 
Conjugate 45 16.92 ± 1.79 0.07 
Icodextrin 0 n / a 
 
Table 9 -Shows the results of the bis-pNPP assay for IDX-drug conjugates 
 
Figure 67  - Diagram to show the structure of each conjugate that was tested 
 
The IC50 value of compound 60 “free-drug” (Figure 68) was 0.019 ± 0.008 μg / mL or 39.67 ± 
16.70 nM  
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Figure 68 – Boronic acid 60 
 
The IC50 values for the Inulin-drug conjugates (Figure 69) were then calculated (Table 10)   
 
Sample IC50 / μg mL-1 
(n=3) 
Degree of substitution / DS 
Conjugate 35 0.30 ± 0.04 0.68 
Conjugate 36 22.35 ± 1.51 0.35 
Conjugate 37 23.88 ± 2.45 0.32 
Conjugate 38 3.14 ± 0.45 0.25 
Conjugate 44 21.88 ± 1.28 0.20 
Inulin 0 n / a 
 
Table 10 - Shows the results of the bis-pNPP assay for Inulin conjugates 
 
154 
 
 
Figure 69 - Diagram to show the structure of each Inulin conjugate that was tested 
 
Additionally, both Icodextrin and Inulin were found to have no measurable inhibitory action 
on ATX, at 150 μg / mL. 
 
4.2.2 Fluorogenic substrate-3 (FS-3) artificial substrate assay 
 
FS-3 artificial substrate assays are a widely used and convenient method for screening 
potential autotaxin inhibitors. They are commercially available as an enzyme assay kit from 
Echelon biosciences Inc.40,220,221,223 In a similar manner to bis-pNPP, FS-3 closely mimics the 
structure of LPC. Following the hydrolysis of its phosphodiester bond a fluorophore “tag” is 
released which can then be detected at 485 nm excitation / 528 nm emission, as shown in 
Figure 70. Additionally, the FS3-3 substrate has a quenching tag at the “choline terminus”. 
The FS-3 assay has a number of advantages over bis-pNPP; for example, the substrate is 
designed to mimic the structure of LPC. As can be seen in Figure 71, the substrate is of a 
similar length to LPC and contains linear alkyl chains, it is therefore anticipated to adopt a 
similar binding mode to LPC in the active site of ATX. Rather than simply measuring the rate 
of hydrolysis of a phosphodiester bond (in the case of the bis-pNPP assay), the FS-3 substrate 
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should realistically depict the rate of hydrolysis of LPC and provide a more representative 
value for the inhibitory potential of each conjugate.  
 
Figure 70 - The hydrolysis of FS-3 by ATX 
 
Figure 71 - The structure of FS-3 223 
 
The drug conjugates were diluted to a concentration appropriate to their predicted activity 
in distilled water and a 3-fold dilution series was prepared. The assay was then performed as 
follows:  ATX (supplied by Echelon) as a solution in reaction buffer was mixed with the drug-
conjugate (at each concentration of the dilution series), in a 96-well plate. A solution of FS-3 
substrate was then added to each well. The fluorescence was then read immediately (λ Ex = 
485 nm, λ Em = 528 nm) and every two minutes thereafter, for 30 minutes in total (at room 
temperature). Fluorescence for each concentration was plotted as a function against time. A 
linear regression was then fitted to the graph. Non-linear regression was then used to fit a 4 
parameter (Hill equation) dose-response curve to the rate of reaction for each concentration 
in order to determine the IC50 value for each conjugate. An internal replicate was used for 
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each drug-conjugate analysed. Each experiment was repeated a minimum of three times 
(n=3) over multiple days.  A secondary screen was performed with each conjugate to ensure 
the fluorescence reading was not a false positive due to interference with the fluorescence 
of hydrolysed FS-3. The results of this study are shown in Figure 72 and Figure 73. 
Owing to restrictions on the number of compounds that could be assayed, using the results 
obtained from the bis-pNPP assay only the 8 most promising candidates were carried 
forward to this assay; thus Conjugates 36, 37, 40 and 41 were omitted from this study.  
 
4.2.2.1 FS-3 Dose response curves 
 
Figure 72 - The dose response curves for Conjugates 34-35, 38 and 42, obtained via the FS-3 
artificial substrate assay 
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Figure 73 - The dose response curves for Conjugates 43-45 and compound 60, obtained via 
the FS-3 artificial substrate assay 
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4.2.2.2 FS-3 assay results 
 
The mean IC50 values (n=3), and standard deviation for this assay are shown in Table 11. 
 
Sample IC50 / μg mL-1 
Degree of 
substitution / DS 
  (n=3) 
 
Conjugate 34 2.00 ± 0.78 0.76 
Conjugate 42 6.89 ± 0.92 0.24 
Conjugate 43 4.18 ± 0.56 0.20 
Conjugate 45 53.60 ± 8.02 0.07 
Conjugate 35 0.24 ± 0.18 0.68 
Conjugate 38 30.51 ± 6.35 0.25 
Conjugate 44 2.42 ± 1.15 0.20 
Compound 60 0.014 ± 8.02 (29.33 ± 14.61 nM) n/a 
 
Table 11 - Shows the IC50 values for samples assayed using the FS-3 substrate (pink = IDX, blue 
= Inulin) 
 
The structure of each conjugate / drug is shown in Figure 67, Figure 68 and Figure 69. 
 
4.3 Discussion of results 
 
Pleasingly, as can be seen from the IC50 values featured in Table 9, Table 10 and Table 11, the 
drug-linker analogues retained a significant level of potency when attached to Inulin and IDX. 
The data obtained from the bis-pNPP assay (Table 9 and Table 10) appears to be in 
agreement with those from the FS-3 assay (Table 11), with the same trends observed within 
the data replicated in each Table. There is of course, some slight difference in the activity for 
each compound across each assay, however this is negligible considering the difference in 
substrate specificity, therefore the two assays provide a useful assessment of the ATX 
inhibitory potential of each conjugate.  
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The most active Icodextrin conjugate (prepared using the standard epichlorohydrin 
activation method), was Conjugate 34 (Figure 74) which had an IC50 value of 3.22 ± 0.15 μg 
mL-1 (Bis-pNPP).  
 
Figure 74 - Conjugate 34 
 
The most potent drug conjugate produced in this study was one prepared from Inulin, 
Conjugate 35 (Figure 75), which had an activity of 0.30 ± 0.04 μg mL-1 and is the most potent 
drug conjugate synthesised by us to date.  
 
Figure 75 - Conjugate 35 
 
With regards to the carboxylic acid-functionalised inhibitor used in this study, the activity 
obtained by the corresponding Conjugate 35 (Figure 75), is at the upper-limit of what could 
be expected, considering that the activity of the “model” free drug (Figure 76) is stated to be 
0.14 ± 0.08 μg mL-1.147  
 
Figure 76 - Carboxylic acid "free-drug" 
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To achieve even greater potencies in the future, alternative ATX inhibitors should be 
investigated. The likely reason for the differences in potency between Conjugate 34 (IDX) 
and Conjugate 35 (Inulin) (Figure 74 and Figure 75 respectively) is that despite having 
comparable degree of substitution (DS) values, there is a difference in structure between the 
two polymers. As explained previously, IDX is highly branched whereas Inulin is more 
“linear”. This could make the drug molecules bound to Inulin more accessible to the active 
site of ATX.   
The HA155-polymer conjugates (Conjugates 44 and 45, Figure 77) incorporated a boronic 
acid group, when compared to a corresponding carboxylic acid moiety, also performed 
satisfactorily in both assays.  
 
Figure 77 - Conjugate 44 and 45 
 
Of the two conjugates, Conjugate 44 (Figure 77) appeared to be the more potent, with an 
IC50 value of 2.42 ± 1.15 μg mL-1 (FS-3). Though if the potency of the model “free drug” 
(compound 60, Figure 68) is considered (0.014 ± 0.007 μg mL-1, FS-3) then the drug has lost 
a significant amount of activity, post conjugation. This could be explained by the low drug 
loading of the two conjugates; however, as explained in the next paragraph, a low DS value 
may not necessarily lead to a reduction in potency.  A more subtle reason may be (as stated 
in Chapter 2) that the boronic acid group of the drug is able to react with the hydroxyl groups 
present on each polymer, in the same manner as “glucose sensing biomaterials” featured in 
the literature.201 This reversible interaction may compete with that of ATX and the inhibitor, 
giving rise to the reduced potency  observed in Conjugate 44 (Figure 77), compared to the 
free drug (Figure 68). In the future, if drug loading cannot be improved by reaction 
optimisation, potentially a more potent HA155-polymer conjugate could be prepared by 
synthesising a highly-crosslinked version as per Conjugate 43 (Figure 81), which would, in 
effect “cap-off” any free hydroxyl groups present on the polymer.  
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4.3.1 The effect of drug loading on activity 
4.3.1.1 Introduction 
 
The most intriguing part of the biological activity study is revealed when the effect of drug 
loading on activity is examined; for clarity, the results have been re-tabulated in Table 12 and 
Table 13, the structure of each conjugate is shown in Figure 78 . 
Icodextrin 
  
Sample Degree of substitution IC50  / µg mL
-1 
  (DS) (n=3) 
Conjugate 34 0.76 2.00 ± 0.78 
Conjugate 40 0.44 4.41 ± 1.21 
Conjugate 41 0.36 12.41 ± 1.33 
Conjugate 42 0.24 4.45 ± 1.43 
 
Table 12 - Icodextrin drug-loading study results 
Inulin 
  
Sample Degree of substitution IC50  / µg mL
-1 
  (DS) (n=3) 
Conjugate 35 0.68 0.30 ± 0.04 
Conjugate 36 0.35 22.35 ± 1.51 
Conjugate 37 0.32 23.88 ± 2.45 
Conjugate 38 0.25 3.14 ± 0.45 
 
Table 13 - Inulin drug-loading study results 
 
 
Figure 78 - The structure of each IDX and Inulin conjugate prepared for this study 
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Inspection of Table 12 and Table 13, showed an interesting and unexpected trend: as the 
degree of substitution decreases then activity decreases, as would be anticipated. However, 
as the DS further decreases the activity increases again - this trend is demonstrated across 
both polymer series, as shown in Figure 79. 
 
 
Figure 79 - The effect of drug loading on activity 
Further to this, the trend observed with IDX is continued in Conjugate 43 (Figure 81, highly 
cross-linked drug conjugate). As a consequence of the conditions used in its preparation, the 
material had a low DS value of 0.20, but was had an activity of  0.70 ± 0.29 μg mL-1. Which 
makes Conjugate 43 the most potent IDX-drug conjugate produced by us, to date.  
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4.3.1.2 Discussion of results for the drug loading study 
 
Despite this effect of drug loading on activity being unexpected, the fact that it was observed 
in both IDX and Inulin suggests that it has significance and is not merely an anomaly - to our 
knowledge this is the first time that such a trend has been observed. It can possibly be 
explained by considering the environment that is created by changing the degree of 
substitution of the drug (Figure 80), although it should be noted that we have not carried out 
any investigations on the structural and conformational properties of these polymeric 
conjugates at this stage. 
With the lowest loaded polymer conjugates (Conjugates 38 and 42, Figure 78), each drug 
molecule is effectively in isolation from its neighbour and is therefore not affected by steric 
or electronic effects due to the other drug molecules on the polymer, as shown in Figure 80c, 
and the polymer may remain relatively linear in structure. Therefore, in this environment the 
pharmacophore is able to interact relatively unimpeded with the ATX active site, with the 
polymer displaying levels of activity which are dependent upon the properties of the drug.   
As the loading is increased to produce conjugates with “medium” levels of drug loading (such 
as Conjugates 37 and 41, Figure 78) one might then expect an increase in steric and electronic 
effects to occur between the more closely situated drug molecules, leading to a possible 
change in conformation of the polymer backbone. Further to this, medium-loaded drug 
molecules will likely have a distinct hydrophobic region (the drug) and a hydrophilic region 
(the polymer). In an aqueous environment  (such as that which the conjugates were tested 
in), an Inulin-ibuprofen conjugate was observed to form a micelle, which would in effect 
encapsulate the drug, with the polymer backbone on the outside.104 This change in 
conformation may therefore manifest itself in the reduced accessibility of  pharmacophores 
to allow successful binding to the active site of ATX (Figure 80b). 
For highly loaded conjugates (such as Conjugates 34 and 35, Figure 78) nearly every sugar 
unit has a drug molecule attached to it (according to the DS calculation). The “swamping” of 
the polymer with drug molecules in this manner,  causing maximum steric and electronic 
effects between closely situated drug moieties, this may have the effect of forcing the drug 
units to repel one another to such a degree that may prevent the formation of a micelle. This 
effect would act to restrict the conformational change which affects the positioning of the 
drug molecules on the medium-loaded conjugate and now ensures that there is more likely 
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to be an available drug molecule on the surface of the polymer for binding to ATX. Hence, 
the activity of the conjugate is seen to increase, compared to medium-loaded conjugates. 
It is suggested by us that the effect of drug loading on activity is a dynamic process and will 
change subtly across different polymers and different drugs. The influence of linker length 
may also play a part in the overall result. The results of this study strongly indicate that to 
assume the amount of drug attached to a polymer will directly correlate to the activity 
observed, is a misnomer. A linear rise in potency may be observed in conjugates of a low 
loading (such as those with a DS value lower than 0.25), but at higher loadings, steric 
hindrance caused by neighbouring drug molecules will have a stronger influence on binding 
to ATX – which in that instance means that although every drug residue is capable of 
interacting with ATX, they are not all able to interact at the same time.  
 
Figure 80 - A diagram to explain the effect of drug loading on activity 
 
The effect of drug loading on activity could be exploited in the design of future drug 
conjugates. Rather than concentrating efforts on preparing materials with the highest drug 
loading, a more constructive approach may be to focus on conjugates of a lower loading. By 
tailoring a series of low DS drug conjugates, with small changes in loading, a potency equal 
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or greater than an equivalent conjugate with a high loading could be achieved. This conjugate 
would have a number of advantages to its high DS counterpart. For example the preparation 
of a low DS conjugate requires significantly less drug-linker compound, which means that it 
is far more economical to produce. Additionally, low drug loadings have improved aqueous 
solubility; Conjugates 34 and 35 had low solubility in water (1-2 mg / mL) whereas Conjugates 
38 and 42 were much more soluble (>10 mg / mL). 
 
4.3.2 The effect of intra-polymer cross-linking on biological activity 
 
As alluded to earlier, Conjugate 43 (Figure 81) was found to be extremely potent (0.70 ± 0.29 
μg mL-1, Bis-pNPP).  It can therefore be reasonably concluded that intra-polymer cross-linking 
has no effect on activity. 
 
Figure 81 - Conjugate 43 
 
Its high potency should be attributed to the drug loading effect described previously. Future 
studies could include analysis by size exclusion chromatography to determine whether the 
materials average molecular weight has changed following the cross-linking step during its 
preparation. A peritoneal retention study could also be performed on the conjugate to 
evaluate whether it offers an improvement on the residence time of the material in the 
peritoneal cavity, compared to our previous endeavour.  
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4.4 Peritoneal retention study 
 
4.4.1 Introduction  
In our previous work, a peritoneal retention study was used to demonstrate that the 
residence time of a drug was significantly improved following attachment to IDX.147 30 % of 
the drug-conjugate was found to be retained within the peritoneal cavity of mice after 24 
hours.147 The limitations with this study were detailed in Chapter 1: rodents are known to 
have higher levels of the enzyme amylase, which means that they metabolise IDX faster than 
humans do.151 Based on information published on the peritoneal retention of Icodextrin, it 
would be expected that the IDX-inhibitor conjugate previously prepared by us would be 
retained at a quantity greater than 30 % after 24 hours if it were tested in a human.139 The 
limitations of this study were the driving force behind our interest in Inulin as a polymer 
support for our current work because, the polysaccharide Inulin is resistant to amylase, 
although has a molecular weight similar to IDX. Inulin drug conjugates may therefore display 
superior peritoneal retention in comparison to IDX conjugates, in rodent models.   
 
4.4.2 Method 
 
The peritoneal retention of Conjugate 35 was evaluated using a method similar to that used 
in our previous investigation. A 0.2 mg / mL solution of Conjugate 35 in PBS was made up, 
and this was then filtered through a syringe filter in order to sterilise the solution. In addition, 
a 0.2 mg / mL solution of Inulin was prepared and sterilised in the same manner as described 
above. 7-Week old nude mice were allowed to acclimatize for one week before the 
experiment began. Mice were injected with a solution of Conjugate 35 (0.4 mL) in their lower 
left quadrant at pre-determined timepoints (0 min, 30 min, 1 hour, 3 , 6 and 24 hours). The 
mice were then dispatched by cervical dislocation, this entire process was performed in 
triplicate. The peritoneal cavity was washed with PBS solution (0.4 mL), and the washings 
were collected, centrifuged, and the supernatant was then collected. As a control, three mice 
were injected with a solution of Inulin and then immediately dispatched and processed, as 
described previously. The peritoneal washings were analysed using fluorescence 
spectroscopy (λEx = 360 nm, λEM = 485 nm), alongside a calibration curve prepared with 
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conjugate 35, (2-fold dilution, 0.2 μg / mL, top conc.) in order to determine the concentration 
of the conjugate present in each sample.  
 
4.4.3 Discussion of results 
 
To our disappointment, the data obtained initially suggested that there was no drug 
conjugate present in the peritoneal cavity of the mice, even for those dispatched at 0 
minutes. However, it became apparent that drug conjugate may never have actually been 
injected into the mice, the original solution of Conjugate 35 was analysed by fluorescence 
spectroscopy and found to contain no drug. It was concluded that the test drug must have 
been removed from solution during the filtration step and therefore only PBS solution was 
injected into the mice, giving rise to the results observed.  
Due to time and financial constraints the experiment could not be immediately repeated, 
but if it were an alternative method of sterilisation should be used for the conjugate / Inulin.  
 
4.5 Conclusion 
 
Though the failed peritoneal retention study was disappointing, it should not have any 
negative bearing on similar studies conducted in the future, which should demonstrate that 
the drug-conjugate approach taken in this thesis will significantly enhance the residence time 
of a drug in the peritoneal cavity. Based on our previous findings concerning the peritoneal 
retention of Icodextrin drug conjugates, we would anticipate that the IDX drug conjugates 
produced in this study to show a similar level of peritoneal retention (30% removed after 24 
hours). Notwithstanding this, the two enzyme assays performed in this study (bis-pNPP and 
FS-3) have shown that the drug-linker analogues retain their potency, following conjugation 
to a polymer. Many of the conjugates produced by us have been shown to be very potent, 
such as Conjugate 35 and 43. Additionally, the effect of changing the degree of substitution 
on activity has been revealed, which has the potential to influence the design of drug 
conjugates in the future.  
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Chapter 5: Novel approaches to the asymmetric synthesis of 3-substituted isoindolin-1-
ones  
 
The work described within this chapter was completed alongside my work on the synthesis 
and biological evaluation of ATX inhibitor polymer conjugates. It is entirely separate from 
that work and is included for the sake of completeness.  
 
5.1 Introduction 
 
Isoindolinones are a family of compounds that have numerous medicinal properties that are 
of therapeutic benefit. For instance isoindolinones act as anti-inflammatory, 
antihypertensive, antipsychotic and anaesthetic agents, as well as many other biological 
activities such as vasodilatory, antiulcer, antiviral,  and antileukemic properties.224–230 Indeed, 
our own research endeavours have seen them evaluated as novel NMDA receptor 
antagonists as a treatment for Alzheimer’s disease and as antimicrobial agents.231 As shown 
in Figure 82, the isoindolinone framework is incorporated into a variety of biologically active 
drugs.227 
 
Figure 82 - A selection of therapeutic agents that incorporate the isoindolinone motif (shown 
in red) 
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Based on the numerus biological systems that isoindolinones are known to target, the 
indolinone framework could be described as a privileged structure and is therefore of 
significant interest to the pharmaceutical industry. A complication in the synthesis of 
isoindolinones is that they commonly contain a stereogenic centre at the C-3 position (as 
denoted in Figure 82).232 Functionality at the C-3 position is often essential to the biological 
activity of isoindolinone drugs.227,232 In recent times it has become less acceptable to 
administer a drug as a racemate, and it is preferred that the active component is synthesised 
as a single enantiomer.233 Unsurprisingly, considering their therapeutic potential, there have 
been a number of efforts towards the enantioselective synthesis of 3-substituted 
isoindolinones.230,234,235 
 
5.1.1 Approaches of to the stereoselective synthesis of isoindolinones in the literature 
 
Deniau and co-workers pioneered a chiral auxiliary-hemiaminal approach, in which an 
intermediate was constructed by condensing phthalic anhydride with (S)-1-amino-2-
methoxymethylpyrrolidine. Groups could then be introduced to the C-3 position via a 
Grignard reagent and later, as featured in the work of Couture and co-workers, using an 
alkenoyl alkylation strategy (Scheme 75).232,236,237 Upon the treatment of triethylsilane, the 
approach of the nucleophile is hindered by the chiral auxiliary, which gives rise to a preferred 
diastereomer. The chiral auxiliary was then easily removed by oxidative cleavage.236,237   
 
 
Scheme 75 - The chiral auxiliary approach used by Deniau and co-workers. 
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Clayden and co-workers were able to exert stereocontrol at the C-3 position of 
isoindolinones through cyclization and re-aromatisation of lithiated benzamides, which were 
formed using a chiral nucleophile.238 For the reaction to proceed in an enantioselective 
manner, the method required the presence of an N-tert-butyl group on the indolinone 
framework, which was synthetically difficult to remove, thus limiting the scope of the 
procedure. (Scheme 76).238 
                     
Scheme 76 - The enantioselective isoindolinone synthesis strategy used by Clayden and 
colleagues. 
 
Royer and co-workers demonstrated a diastereoselective metalation /α-amino alkylation 
reaction (Scheme 77). The approach of the electrophile was guided by conformational 
control of the chiral auxiliary. The auxiliary could then was then removed using a method 
previously developed by our own group, though the authors elected that this be a formal 
synthesis only (Scheme 82).234,239  
                  
Scheme 77 - The diastereoselective alkylation strategy used by Royer and co-workers. 
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Despite the elegance of their methodology and the potential scope of the substituents that 
could be introduced to the C-3 position, the procedure suffered from inconsistent 
diasteroselectivities and issues with purification that may prevent wider application.239  
Comins and co-workers used a chiral auxiliary mediated approach towards the asymmetric 
synthesis of isoindolinones, the versatility of this method was demonstrated when it was 
employed to construct the biologically active alkaloid: (+)-Lennoxamine in high enantiomeric 
excess (Scheme 78).235  
 
Scheme 78 - The diastereoselective synthesis strategy used to prepare (+)-Lennoxamine by 
Comins and co-workers 
 
5.1.2 Our previous work 
 
Our own efforts in this area have been concerned with the development of a stereoselective 
route towards the synthesis of tricyclic γ-lactams, from readily available keto-acids and 
enantiomerically pure amino-alcohols (which themselves can be derived easily from amino 
acids or can be purchased) (Scheme 79).234,240–242  
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Scheme 79 - The cyclo-condensation reaction to give a tricyclic γ-lactam, under Dean-Stark 
conditions 
 
The induced stereochemistry at the stereocentre formed at the C-3 position of the isoindolin-
1-one ring (denoted by *) is determined by the stereochemistry of the amino alcohol used in 
the cyclo-condensation reaction.240 This reaction is highly diastereoselective and was used 
to prepare tricyclic lactams on multigram quantities, with minimal purification.234 In our 
previous work the tricyclic lactam scaffold served as a template from which two methods 
were developed to access chiral 3-substiuted isoindolin-1-one’s (Scheme 80). 234,240–242 
 
Scheme 80 - The two methods applied by our group for the synthesis of 3-subsitituted 
isoindolin-1-ones 
 
In Method 1 (Scheme 80), the tricyclic lactam template was reacted with a Lewis acid (TiCl4) 
and a hydride source (triethylsilane) to give the ring-opened product. This reaction was found 
to be highly diastereoselective, effectively only giving one diastereomer as the product.234 
The stereochemical outcome can be rationalised by considering the mechanism of the ring-
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opening reaction and the preferred conformation of the reactive intermediate, as shown in 
Figure 83.234 
 
Figure 83 - The mechanism for the ring-opening reaction and the conformational 
rationalisation of the stereochemical outcome 234 
 
The Lewis acid is expected to coordinate to the ether oxygen of the lactam substrate, this 
assists in the generation of the crucial N-acyliminium ion, through the ring-opening reaction 
promoted by the N-lone pair.234,241,242 Triethylsilane then attacks the N-acyliminium species 
to yield the N-substituted isoindolinone intermediate, following an acidic work-up. 234,241,242  
The high diastereoselectivity observed with this method is attributed to the chelation control 
(Figure 83) and the presence of the angular R group which gives one preferred conformer. 
234,241,242  Consequently, triethylsilane will approach from the less hindered face of the planar 
acyliminium species. 234,241,242  When a non-coordinating Lewis acid was used in place of TiCl4, 
the diastereoselectivity was reduced to 4 : 1, which highlights the significance of chelation in 
the stereochemical outcome of the reaction.234 The obvious benefit to this method is the 
high diastereoselectivity observed, however its synthetic utility is limited, due to there being 
few commercially available ketoacids that have different substitutions at the R position (R = 
Ph, Me in our study). While it is possible to synthesise ketoacids with the appropriate 
substitution, the chemistry used to achieve this is not trivial. 
Based on the limited substitution patterns that could be accessed from Method 1, Method 2 
(Scheme 80) served as a complementary approach.234 In this approach a carbon nucleophile 
was used in place of hydride, with the aim of increasing the variety of substitution patterns 
available at the C-3 position. However, the C-3 Hydrogen lacks the steric bulk of the methyl 
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or phenyl groups in method 1 to differentiate between the different conformations, as 
shown in Figure 84. The leads to a considerable drop in diastereoselectivity. 
 
Figure 84 - The mechanism for method 2, with regard to the stereochemical outcome 
 
With this method there is a clear advantage over Method 1 in the wider variety of 
compounds that can be prepared, however it does result in much poorer levels of product 
diastereoselectivity, especially in comparison to Method 1.234 
Two methods that did not lead to racemisation of the product were developed to remove 
the chiral auxiliary and yield the desired 3-subsitituted isoindolin-1-one targets.234 
Methodology developed by Vernon and co-workers was applied, in which the auxiliary was 
removed through a three-step (one-pot method) by converting the alcohol group to a 
mesylate, which was then converted to the N-H isoindolinone, following a base-induced 
elimination to give an enamide, followed by acidic hydrolysis (Scheme 81).234,243  
 
Scheme 81 - Methodology by Vernon and co-workers, for the removal of a chiral auxiliary 
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The chiral auxiliary could also be removed from the N-substituted isoindolinone 
intermediates by reaction with concentrated sulfuric acid to form the enamine intermediate, 
as per Vernon’s methodology (Scheme 82).234 
               
Scheme 82 - The removal of the chiral auxiliary, using concentrated sulfuric acid. 
 
The product formed was found to have a very high level of enantiomeric excess (e.e.), as 
determined by chiral HPLC.234 
In later studies carried out alongside the work in this thesis, we were interested in producing 
a series of C-3 substituted tricyclic γ-lactams as potential NMDA receptor antagonists.231 We 
were inspired by the work of Couture and co-workers in which the stereoselective alkylation 
of an isoindolinone-like compound was demonstrated. This approach is in itself, an extension 
of “Meyers”, polycyclic lactam methodology.237,244,245 Based upon the literature precedent, 
we hoped that the phenyl group contained within the lactam structure would help guide the 
approach of an incoming electrophile and result in a high level of diastereoselectivity, as 
indicated in Scheme 83.231,237 Lactam template was treated with KHMDS at -78 °C, then an 
alkyl halide was added and the mixture warmed to room temperature.  
            
Scheme 83 – Attempted stereoselective alkylation of a tricyclic lactam template  
 
The alkylation reaction (Mechanism 4) was attempted with a small number of alkyl, allyl and 
benzyl halides and was found to be successful, but to our disappointment was not 
particularly diastereoselective, despite the literature precedent to the contrary on similar 
substrates.231,237 
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Mechanism 4 - Mechanism for the alkylation of a tricyclic lactam template 237 
 
Attempts were then made to influence the diastereoselectivity by altering the counterion 
present on the base, as per the work of Royer and co-workers. The results of this study are 
shown in Table 14.239 
Base Alkyl halide Diastereoselectivity % Conversion 
LiHMDS Me-I 1:1 50 
LiHMDS Benzyl-Br 3:1 94 
LiHMDS Allyl-Br 4:1 96 
NaHMDS Allyl-Br 9:1 50 
KHMDS Allyl-Br 6:1 57 
 
Table 14 – Alkylation of tricyclic lactam templates using alternative base, and electrophiles 
(% conversion determined by 1H NMR spectroscopy, of the crude material) 231 
 
The study revealed that NaHMDS gives a sharp rise in diastereoselectivity compared to 
LiHMDS, however this was at the expense of conversion.231 Diastereoselectivity was also 
influenced by the relative “size” of the electrophile, as evidenced with LiHMDS: methyl iodide 
gave a d.e. of 1:1, which increased to 3:1 for benzyl bromide and to 4:1 for allyl bromide.231 
Despite these modifications there was little real benefit, because the two product 
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diastereomers could not be separated using column chromatography, and also co-eluted 
with unreacted starting material.231 
While this was disappointing, the study also revealed that if LiHMDS was used as the base, a 
high level of conversion could be achieved, which suggested that the reaction could be used 
in an alternative approach.231 We decided to attempt to use this approach in combination 
with Method 1 (Scheme 80), as a novel method to access 3-subsitituted isoindolin-1-ones. 
As stated above, when the N-acyliminium ion is generated in the ring-opening reaction 
(Figure 83), any stereochemistry present at the C-3 position is lost, meaning that the 
diastereoselectivity of the intermediate alkylation step is of no significance.234 The 
stereocentre can be re-established with high levels of stereoselectivity when the 
intermediate N-acyliminium ion  is reduced with triethylsilane with chelation control. Only a 
single diastereomer should be observed, resulting in a convenient method from which to 
synthesise a wide range of N-substituted isoindolinone targets.234  
In the an initial experiment the tricyclic lactam template 73 was alkylated using allyl bromide, 
to give the intermediate compound (Scheme 84).231 This 4:1 mixture of diastereomers was 
carried through to the next reaction along with unreacted starting material, following an 
aqueous workup.231 This mixture was treated with TiCl4 and triethylsilane to give the ring-
opened product with an excellent level of diastereoselectivity (92:8), and the target could be 
isolated as a crystalline solid via flash column chromatography (Scheme 84). 
 
Scheme 84 - The diastereoselective ring-opening of the allyl intermediate 
 
The approach shown in Scheme 84 overcomes the shortcomings of both Methods 1 and 2 
(Scheme 80) because it can be used to introduce a wide variety of substituents at the C-3 
position and is highly diastereoselective.  
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5.2 Application to the synthesis of a range of 3-subsitituted isoindolin-1-one targets  
 
The tricyclic lactam template 73 was deprotonated with LiHMDS and the anion reacted with 
an alkyl, allyl or benzyl halide. The crude alkylation product was then carried through to the 
ring-opening reaction (Scheme 85). 
 
           73                                                                                                                                           74 a-g 
Scheme 85 - The 2-step synthetic route to prepare N-substituted isoindolinone targets from a 
common template 73 
 
Seven compounds were prepared using this method, with diasteroselectivities >92:8 
(determined by 1H NMR spectroscopy of crude material) and in acceptable to good yields 
(when the percentage conversion in Step 1 is considered). The results of the study are shown 
in Table 15. 
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Alkyl halide ds 
(Step 1) 
 
Product 
(74) 
Ds 
(Step 2) 
yield 
(%) 
Methyl iodide 1.3:1 a ≥93:7 32 
Ethyl iodide 1:1 b ≥94:6 47 
Propyl iodide 2:1 c ≥94:6 32 
Allyl bromide 4:1 d ≥92:8 49 
Benzyl bromide 1.5:1 e ≥93:7 35 
2-Fluorobenzyl bromide 5:1 f ≥93:7 65 
3-Methoxybenzyl bromide 4:1 g ≥94:6 61 
 
Table 15 - The results of the two-step alkylation and ring-opening procedure  
 
A consistently high level of diastereoselectivity was observed for every substrate in Step 2. 
To confirm the structure of the major diastereomer of the  reductive ring-opening reaction, 
X-ray crystal structures were obtained for the major diastereomers of compounds 74b, d and 
e (74e shown in Figure 85). 
 
Figure 85 - The X-ray crystal structure of compound 74e and the structure showing the 
observed (R, R) stereochemistry 
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The (R, R)-stereochemistry shown in Figure 85 for compound 74e was also observed for 
compounds 74b and 74d. This confirmed our previous assertion that the reductive ring-
opening reaction followed the proposed conformational model (Figure 83).234 
 
5.2.1 Removal of the chiral auxiliary  
 
With a range of N-substituted isoindolinone intermediates in hand (Table 15), we decided to 
completed the synthesis of a 3-substituted NH-isoindolin-1-one, by applying our previously 
established strategy for removal of the chiral auxiliary (Scheme 86).234 Compound 74a was 
dissolved in concentrated sulfuric acid, then heated over a steam bath for precisely 2 minutes 
(longer reaction times led to racemisation of the C-3 stereocentre centre), then worked-up 
and purified by preparative chromatography. 
 
                                      74a                                                               75 
Scheme 86 - The chiral auxiliary removal of compound 74a 
 
The  purified material was then analysed independently by Reach Separations (BioCity, 
Nottingham) using chiral HPLC, by comparing the enantio-enriched compound to the racemic 
version of (75) that was also prepared by us. To our delight, the enantiomeric excess was 
determined to be 98%, meaning that no loss of stereochemical integrity had occurred during 
the acid-mediated cleavage of the auxiliary group. 
 
5.3 Attempted enantioselective synthesis of an isoindolinone drug molecule  
 
With an effective synthetic route towards the synthesis of 3-substituted isoindolin-1-ones 
having been established, our attention turned towards applying it to the enantioselective 
synthesis of an isoindolinone drug molecule. A particular target of interest was (S)-PD 
172938, a potent dopamine D4 ligand (Figure 86). 
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Figure 86 - The structure of (S)-PD 172938  
 
In the original publication in which (S)-PD 172938 first featured, Belliotti and co-workers 
prepared the compound as a racemate and the two enantiomers were then separated via 
chiral resolution as the final step (using chiral HPLC).246 The obvious problem with the 
approach used by Belliotti was that of waste, since the (R)-enantiomer of PD 172938 is 
inactive at the dopamine receptor.246 There is a clear need for an asymmetric approach for 
the preparation of these compounds in the spirit of atom economy and for a cost-effective 
synthesis. Singh and co-workers presented their domino enantioselective alkynylation / 
lactamization method to construct an indolinone template with a suitable synthetic handle, 
which was then transformed in five additional synthetic steps to give (S)-PD 172938, in 
reasonable overall yield and e.e. of 91 % (Scheme 87).227 
 
Scheme 87 - The approach taken by Singh and co-workers, to synthesise (S)-PD 172938 227 
 
The catalytic asymmetric approach taken by Singh (Scheme 87), could be considered superior 
to our own method to construct isoindolinones, due to it being necessary in our method to 
remove the chiral auxiliary as the final step, which is inherently wasteful.227,234 However, the 
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organo-copper catalyst employed in their approach has to be prepared, adding an additional 
synthetic step. Additionally, to install the piperazine moiety requires the installation of aryl 
and mesyl groups, that are removed in subsequent steps.227 The chiral auxiliary used in our 
approach is derived from inexpensive amino acids meaning that a synthetic route employing 
our methodology is likely to be much more cost effective.  
We designed a synthetic route using our alkylation / ring-opening methodology employing 
2-bromomethyl-1,3-dioxolane as the electrophile in order to install a synthetic handle from 
which the piperazine moiety (commercially available) could be introduced.  It was intended 
for reductive amination to be used to couple the two fragments, the chiral auxiliary would 
then be removed as the final step (Scheme 88).  
 
Scheme 88 - The proposed synthetic route for the preparation of (S)-PD 172938 
 
It is worth noting that a number of other electrophiles were considered, such as 
bromomethyl acetate, however when this reaction was attempted, it was found to be 
unsuccessful (on multiple occasions) so the route was not pursued further. The aldehyde 
intermediate (Scheme 88) was of particular synthetic utility, as this handle could be used to 
synthesise multiple classes of isoindolinone drugs, pazinaclone and (R)-JM 1232 contain a 
common methyl amide linkage at the C-3 position (Figure 82).227 The synthetic route could 
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be easily adapted to prepare targets of this type, by oxidising the aldehyde to a carboxylic 
acid, followed by amide bond formation. 
 
In a similar manner to our previous investigation, the (S)-tricyclic lactam template was 
alkylated with bromomethyl-1,3-dioxolane, using LiHMDS as a base (Scheme 89). 
    
                                                                                                76 
Scheme 89  -The synthesis of dioxolane 76 
 
The crude material was then analysed via 1H NMR spectroscopy, which strongly indicated 
that the desired product had formed (by the appearance of resonances thought to belong to 
the dioxolane group), with a conversion of around 50 % and a d.s. of 1:1. As per usual, the 
material was carried through to the next step without further purification (Scheme 90). 
  
                        76                                                                   77 
Scheme 90 - The synthesis of 77 
 
To our disappointment, the reaction gave an inseparable mixture of components which could 
not be purified by column chromatography. This result was unexpected as the reaction 
usually proceeded smoothly and the product was relatively easy to purify. The reason for this 
was identified in the published synthesis of Tamiflu® by Hoffmann-La Roche. In their 
synthetic route, a dioxolane moiety was treated TiCl4 and triethylsilane in near identical 
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conditions to that of the reductive ring-opening reaction attempted  by us.247,248 They 
demonstrated that under those conditions, a dioxolane is susceptible to ring-opening. 
Therefore, when 76 was treated with TiCl4 and triethylsilane, at least 2 competing reactions 
occurred, the alternative reaction product is shown in Scheme 91a.247,248 
 
Scheme 91 - The alternative reaction products 
 
Though it is quite possible that both competing ring-opening reactions could occur on the 
same substrate (Scheme 91b), there was evidence to suggest that this may be observed in 
the 1H NMR spectra of the crude product mixture. Despite it being inconvenient that this side 
reaction occurred, it was felt that the order in which each synthetic manipulation was 
performed could be an important factor in successfully preparing (S)-PD 172938. For 
instance, taking our previous findings into account, it may be prudent to convert the 
dioxolane intermediate 76 into an aldehyde, prior to the ring opening reaction, if the 
conversion is sufficiently mild, this could be done as part of the work-up, by washing in dilute 
HCl. This work on the preparation of (S)-PD 172938 was passed over to a project student and 
is still under investigation by our group.  
 
5.4 Conclusion 
In summary, the work described within this Chapter demonstrates a significant advance on 
previously developed strategies for the synthesis of 3-substituted isoindolinones. The 
alkylation / reductive ring-opening methodology developed by us expands the scope of 
substitution patterns accessible at the C-3 position, limited only be the availability of 
alkylating agents. Our previously established strategy for the removal of the auxiliary group 
was applied to a ring-opened template 74a, to obtain an N-H isoindolinone with an high level 
of enantiomeric excess of 98 %. An attempt was then made to apply our alkylation / reductive 
ring-opening methodology towards the synthesis of an enantio-enriched drug target.  
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Chapter 6: Conclusion, future work and final comments 
 
6.1 Conclusion 
 
The work described within this thesis concerns the synthesis and biological evaluation of 
novel autotaxin inhibitor-polymer conjugates as a potential treatment for ovarian cancer.  
In Chapter 1 the case for ATX as a target for ovarian cancer was made. ATX has been linked 
to ovarian cancer cells developing resistance to a number of chemotherapeutic agents. It is 
thought that reduced sensitivity towards anti-cancer drugs is a major factor in the poor 
survival rate observed in patients with ovarian cancer.27 Further to this, ATX has been found 
to instigate many of the processes which are conducive to the proliferation metastasis and 
survival of ovarian cancer cells. It is suggested that by inhibiting autotaxin, using a small drug 
molecule, the mechanisms by which ovarian cancer cells rely on for multi-drug resistance will 
be disrupted. However, it has been noted that many ATX inhibitors perform poorly in vivo, 
most likely due to the drug being rapidly eliminated from the peritoneal cavity and away 
from the tumour. We have proposed a novel polymer drug delivery strategy to increase the 
residence time of an ATX inhibitor within the peritoneal cavity, building upon our previous 
work in this field.147 Two separate polymers were identified for this study, to maximise 
peritoneal retention, and several autotaxin inhibitors were also chosen for this investigation.  
In Chapter 2 the 12-step preparation of an analogue of the potent ATX inhibitor, 3-BoA, was 
presented. The same methodology was applied to the 4-BoA isomer.88 Chapter 2 
documented the attempted attachment of the 3BoA-linker intermediate to IDX. However, 
this was largely unsuccessful. The re-synthesis of an HA155 analogue (Compound 45) was 
described and as explained, the data-set obtained for this compound and its intermediates 
were published in the Journal of Medicinal Chemistry.147  
Chapter 3 described the attempted preparation of Inulin drug conjugates using similar 
conjugation chemistries used in Chapter 3 and this was also found to be mostly unsuccessful. 
A new method for the covalent attachment of ATX inhibitors to IDX and Inulin was therefore 
developed by studying the reaction between IDX and epichlorohydrin over time. This new 
“epichlorohydrin activation” method was used to great effect to prepare a range of drug 
conjugates from both Inulin and Icodextrin and has the potential to be applied to many other 
polysaccharides. The effect of changing the drug loading on activity was investigated by 
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preparing a series of drug conjugates with different degrees of substitution. A highly cross-
linked IDX drug conjugate was also prepared in order to investigate the effect of cross-linking 
on biological activity. The epichlorohydrin method was also used to synthesise drug 
conjugates containing a boronic acid moiety (an analogue of the potent ATX inhibitor 
HA155), which would not have been possible using previous conjugation chemistry.43 
Chapter 4 described the biological evaluation of the conjugates prepared in Chapter 3. To 
our delight the drugs used in this investigation retained their potency following attachment 
to Icodextrin and Inulin, using both Bis-pNPP and FS-3 as the substrate. A number of 
conjugates tested were found to be highly potent. Conjugate 43 had an IC50 value of 0.70 ± 
0.29 μg mL-1, which is the most potent IDX-drug conjugate prepared by us to date. 
Additionally, the Inulin drug conjugate, Conjugate 35, was found to be  extremely potent, 
with an IC50 value of 0.30 ± 0.04 μg mL-1. To our surprise, intra polymer cross-linking appeared 
to have no effect on the conjugate’s in vitro activity. We postulate that cross-linking improves 
resistance to amylase and increases peritoneal retention. If this is the case, such a feature 
can then be incorporated into the design of future drug conjugates. A non-linear relationship 
between polymer drug loading and activity was established. This study suggests that a 
polymer conjugate with a low DS could have a comparable or higher activity than a conjugate 
with a high DS value. This discovery will  influence the design of drug conjugates in the future 
and could result in conjugates displaying improved solubility and high activity, which are 
cheaper and to prepare. 
Chapter 5 demonstrated a significant advantage to previously developed strategies for the 
synthesis of 3-substituted isoindolinones. The alkylation / reductive ring-opening 
methodology developed by us, expands the scope of substitution patterns accessible at the 
C-3 position, limited only be the availability of alkylating agents. This was achieved while 
maintaining a high level of diastereoselectivity. Our previously established chiral auxiliary 
removal strategy was applied to a ring-opened template to obtain the product with an 
exceptional enantiomeric excess of 98 %. An attempt was then made to apply our alkylation 
/ reductive ring-opening methodology towards the synthesis of an enantioenriched drug 
targets. 
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6.2 Future work 
 
While undertaking the work described within this thesis, it became apparent that additional 
avenues of investigation could be explored. Most evident, was an extension of the biological 
evaluation of the drug conjugates, described in Chapter 4. In particular, the peritoneal 
retention study of Conjugate 35 should be repeated. It was postulated that the most likely 
reason the peritoneal retention study was not successful was due to the sterilisation method 
chosen. The experiment should therefore be repeated using a freeze-drying sterilization 
method. The peritoneal retention study will also give an early indication of any issues with 
toxicity surrounding the conjugates. The results of the peritoneal retention study should 
indicate which polymer (IDX or Inulin) has the longest residence time in the peritoneal cavity 
(in mice) and is therefore most suited as a polymeric support for use in a drug conjugate.  
Moving forward, the next biological investigation should be to examine the inhibition of ATX 
in vivo, within the peritoneal cavity of mice, by directly monitoring the LPA concentration at 
set time periods after administration of the drug conjugate.  
As stated in Chapter 4, based on the findings from the drug loading study, a more extensive 
investigation should be conducted. The study should involve the preparation of around 10 
drug conjugates of DS values increasing in 0.05 increments, using the epichlorohydrin 
activation method. This should provide a greater understanding of the effect of drug loading 
on activity, the predicted trend that could be observed is shown in Figure 87. 
 
Figure 87 – The predicted response to increased drug loading, from zero. 
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The trend predicted in Figure 87 shows how the effect of drug loading may influence activity, 
based upon the experimental observations featured in Chapter 4. As drug loading is 
increased from zero, activity should increase in a linear fashion. At low levels of drug loading, 
neighbouring drug molecules attached to the polymer should have little to no influence on 
the interaction of ATX. As the degree of loading increases, neighbouring drug molecules may 
begin to influence the interaction between the binding drug and ATX and may encourage the 
formation of a micelle, further restricting access of ATX to the pharmacophore. At this stage 
a linear response to increased drug loading will end (Figure 87). The graph should then follow 
a similar “bowl shaped” curve, as observed in the data collected in Chapter 4. There was 
some experimental evidence that a lower drug loading may result in a conjugate with a 
higher potency, in comparison to a conjugate with the maximum loading that is available via 
the epichlorohydrin activation method. This is indicated in curve B (Figure 87). This study will 
better inform the design of polymer therapeutics in the future and help to understand the 
effect of drug loading on activity, which to our knowledge has not been studied before.  
When the drug polymer conjugate approach described within this thesis and our earlier work 
is considered, it should be clear that its application should not be limited to autotaxin 
inhibitors and ovarian cancer. One can imagine a whole host of drugs that could benefit from 
enhancement in this manner as novel treatments for a variety of diseases. For example, it 
could be envisaged that a linker analogue of 18-hydroxycorticosterone could be synthesised 
and attached to Icodextrin. This polymer conjugate could be used as a new arthritis therapy. 
It is believed that attachment to IDX will improve the pharmacokinetics properties of 
corticosterone.249,250 When the material is injected into the joints, a localised concentration 
of the drug may be established, which could increase the half-life of the drug and reduce the 
time between repeated injections.249,250  
As stated in Chapter 1, there is little evidence to suggest that ATX inhibitors have any 
inherent cytotoxic properties and will therefore not act to reduce the size of a tumour. For 
the effective treatment of ovarian cancer, an ATX inhibitor should be used in combination 
with a conventional chemotherapeutic agent. For the reasons outlined previously, it would 
be beneficial to extend the residence time of paclitaxel within the peritoneal cavity. 
Additionally, by attaching taxol to IDX, its aqueous solubility would likely be significantly 
improved. We propose that if the number of equivalents of epichlorohydrin are carefully 
controlled in the preparation of an ATX inhibitor polymer conjugate, then there may be 
sufficient hydroxyl residues left, from which to attach a linker analogue of paclitaxel. The 
resulting conjugate (Figure 88) would therefore have a dual-action: the inhibition of ATX, 
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disrupting the mechanisms that govern chemoresistance, proliferation and metastasis in 
ovarian cancer cells and the inhibition of mitosis (by paclitaxel), leading to cell death. While 
to synthesise an analogue of paclitaxel is far from trivial, there are many examples of the 
structural modification of paclitaxel in the literature to assist in this endeavour. For instance, 
it is known that the alcohol group at the C’2 position of paclitaxel (Figure 88) can be 
selectively alkylated with a carboxylic acid, to give the corresponding ester (which retains 
activity). This chemistry appears to be robust and does not result in racemisation of any 
stereocentres.251–253 This method could be used to install the diethylene glycol linker, 
previously employed in our investigations, to give a paclitaxel-linker analogue. 
 
Figure 88 - The proposed IDX-paclitaxel conjugate, 44 = red, paclitaxel = pink, linker = green, 
succinate ether chain = blue and EPI-IDX = black. 
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6.3 Concluding remarks 
 
Ovarian cancer is responsible for over 4200 deaths each year in the UK. There is clearly a  
need for new drugs to be developed and strategies found to combat chemoresistance, which 
is linked to the poor survival rate associated with ovarian cancer.1   
The work described within this thesis has produced 11 drug conjugates, using both IDX and 
Inulin as a polymer support, all of which were found to be highly potent. The effect of intra 
polymer cross-linking and drug loading on activity has been investigated and has the 
potential to impact on the design of drug conjugates in the future. The results of these 
investigations will be published in due course. Overall the new ATX inhibitor polymer 
conjugate approach described within this thesis could provide the basis for an effective new 
therapeutic strategy for the treatment of ovarian cancer and could help overcome the 
problems associated with multi-drug resistance in chemotherapy.  
.  
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Chapter 7: Experimental methodology  
Solvents were removed under reduced pressure with a Büchi rotary evaporator. Any remaining 
solvent was removed under high vacuum. The progress of the reactions was monitored by 
TLC analysis, using glass pre-coated silica gel plates (Merck) visualised by UV irradiation at 
a wavelength of 254 nm or using a potassium permanganate stain. Flash column 
chromatography was carried out on silica gel 60 (43-60 mesh); columns were slurry packed 
in the appropriate eluent mixture and samples were added as a concentrated solution or pre-
absorbed onto silica. Dialysis was carried out using 20 kDa, 8 kDa, 3.5 kDa MWCO 
(Biodesign) and 1 kDa MWCO (Spectrum) dialysis membrane tubing, where stated. H2O was 
of distilled grade or higher. 
1H- and 13C-nuclear magnetic resonance (NMR) spectra were measured on a Jeol eclipse 400 
MHz Fourier transform spectrometer using D6-DMSO, CDCl3, D2O, D6-acetone, D4-methanol 
and D3-acetonitrile solvents. Chemical shifts are quoted in ppm downfield from TMS; 
coupling constants (J) are quoted in Hertz (Hz). TMS was defined as 0 ppm in 1H NMR spectra 
and the residual chloroform triplet as 77.10 ppm in 13C NMR spectra. The following 
abbreviations were used in analysis: broad (br), singlet (s), doublet (d), triplet (t), quartet (q), 
double doublet (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt) and multiplet 
(m). 
Infra-red (IR) spectra were recorded in their natural state on a Perkin Elmer spectrum 100 FT-
IR spectrometer and the vibrational frequencies were recorded in the range 4000-600 cm-1. 
Mass spectra were obtained from the EPSRC UK National Mass Spectrometry Facility at 
Swansea University, using electron spray ionization (ESI) or atmospheric pressure chemical 
ionization (APCI) in positive or negative mode. Optical rotation measurements were obtained 
from a Bellingham and Stanley ADP440+ Polarimeter, at 23.9 °C, at a concentration of 0.5 
g/100 ml, with a cell length of 5 cm. Melting points were measured on a Stuart SMP10 melting 
point apparatus. Elemental analysis was performed by the elemental analysis service at 
London Metropolitan University. Enantiomeric excess (e.e.) was determined independently 
by Reach Separations Ltd. Analysis was carried out using a chiral stationary phase, Chiralpak 
IC column, 4.6 mm x 250 mm, 5 µm, (Daicel Chemical Industries). The isocratic mobile phase 
comprised of 20:80 MeOH:CO2 (0.2% v/v NH3). The flow rate of the mobile phase was 4.0 
mL min-1. A detector wavelength of 210-400 nm was utilised. The column temperature was 
maintained at 40 oC and the injection volume was 1.0 µL. The sample was compared to a 
racemic compound in order to determine the enantiomeric excess, (e.e.) 
Reagents and solvents were purchased from Sigma-Aldrich, Acros Organics, Fluorochem, 
Fisher Scientific Alfa Aesar, and were used without further purification. Anhydrous solvents 
(used where specified) were purchased and used without further drying. Reactions were 
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carried out under a flow of nitrogen gas, where specified. Dry ice/acetone baths were used to 
cool reactions to -78 °C. Solvents were degassed by injection of a flow of nitrogen gas, 
connected to a suitable outlet.  
 
Note: the relaxation time between a C-B bond is too long for the respective 13C NMR 
resonance to be observed (caused by broadening of the peak) in 13C NMR spectroscopy and 
hence is reported as missing / not visible.  
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7.1 Synthetic chemistry  
 
7.1.1 2-(Hydroxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, (7) 
Method 1 
 
 
B2Pin2 (1.04 g, 4.10 mmol, 1.2 eq.), dppf (83 mg, 0.15 mmol, 0.05 eq.) and KOAc (1.08 g, 
11.00 mmol, 3.5 eq.) were added to 5-bromo-2-hydroxy benzyl alcohol (0.80 g, 3.10 mmol, 
1.0 eq.) dissolved in anhydrous dioxane (20 mL), under N2. The resulting mixture was 
degassed under N2, for 5 min, PdCl2dppf (0.12 g, 0.15 mmol, 0.05 eq.) was then added and 
the resulting mixture heated at 80 ℃ and stirred overnight. The mixture was then heated under 
reflux with activated charcoal (8 mg) for 10 min and then cooled to room temperature. The 
crude mixture was filtered through celite (prepared with EtOAc), then the filtrate was 
evaporated under reduced pressure to obtain a brown oil. The material was purified by flash 
column chromatography, 50 % EtOAc / 50 % hexanes, to afford boronate ester 7 as an off-
white solid (192 mg, 23 %). 
 
1H NMR (400 MHz, CDCl3) δ = 7.67 (dd, J = 8.1, 1.4 Hz, 2H), 7.49 (s, 1H), 6.89 (d, J = 8.1 
Hz, 1H), 4.88 (br s, 2H), 1.33 (s, 12H) 
(1H NMR spectrum identical to that reported by Xiao-Ling and co-workers)254 
 
Method 2 
To a solution of 2-hydroxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde  
(0.55 g, 2.22 mmol, 1.0 eq.), in ethanol (35 mL) cooled to 0 ℃, NaBH4 (42 mg, 1.11 mmol, 
0.5 eq.) was added, and the resulting mixture was stirred for 2 h. The solvent was then 
evaporated under reduced pressure to yield a white solid. The material was dissolved in HCl 
aq. (1 M, 60 mL) and extracted with EtOAc (3 x 60 mL). The organic extracts were combined, 
dried over anhydrous MgSO4, filtered and evaporated to obtain boronate ester 7 as an off-
white solid, that was used without further purification (0.44 g, 80 %). 
 
The sample was analysed by 1H NMR spectroscopy (CDCl3) and found to be in agreement the 
compound generated according to method 1 and literature values.  
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7.1.2 2-Hydroxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde, (8) 
 
 
 
B2Pin2 (2.08 g, 8.2 mmol, 1.1 eq.), KOAc (2.20 g, 22.3 mmol, 3.0 eq.) and PdCl2dppf (0.31 g, 
0.37 mmol, 0.05 eq.) were added to 5-bromo-2-hydroxybenzaldehyde (1.50 g, 7.46 mmol, 1.0 
eq.) dissolved in anhydrous dioxane (20 mL), under N2. The resulting mixture was degassed 
under N2, for 10 min, then heated to 110 ℃ and stirred overnight. The cooled reaction mixture 
was filtered through celite (DCM), concentrated under reduced pressure and purified by flash 
column chromatography, to afford aldehyde 8 as a white crystalline solid, (1.09 g, 59 %).  
 
1H NMR (400 MHz, CDCl3) δ = 11.23 (s, 1H), 9.92 (s, 1H), 8.05 (d, J = 1.6 Hz, 1H), 7.95 
(dd, J = 8.4, 1.7 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 1.35 (s, 12H) 
 
 
1H NMR spectrum identical to that reported by Lee and co-workers.255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
7.1.3 2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, (4) 
 
 
 
4-Bromo-2-methyl phenol (1.80 g, 9.6 mmol, 1 eq.), B2Pin2 (2.70 g, 10.6 mmol, 1.1 equiv.) 
and KOAc (2.84 g, 28.8 mmol, 3 eq.) were degassed under nitrogen in anhydrous dioxane (35 
mL) for 10 min. PdCl2dppf (0.39 g, 0.48 mmol, 0.05 eq.) was added. The mixture was then 
heated to 80 °C and stirred for 16 h. The mixture was cooled to room temperature, then filtered 
through a plug of silica (DCM), the filtrate was then filtered through a second plug of silica 
and evaporated under reduced pressure to give a golden-brown oil. 
The crude product was purified via flash column chromatography, (30% EtOAc / 70 % light 
petroleum ether), to afford phenol 4 as a white crystalline solid (2.17 g, 97 %). 
 
1H NMR (400 MHz ,CDCl3) δ = 7.59 (s, 1 H), 7.54 (dd, J = 8.1, 1.3 Hz, 1 H), 6.75 (d, J = 8.0 
Hz, 1 H), 5.10 (s, 1 H), 2.24 (s, 3 H), 1.33 (s, 12 H). 
 
 
1H NMR Data identical to that reported by Hanson and co-workers186  
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7.1.4 2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (14) 
 
 
 
Triethylamine (1.88 mL, 13.5 mmol, 1.5 eq.) was added to a solution of 2-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (2.11 g, 9.0 mmol, 1 eq.)  in DCM (30 mL). 
Acetic anhydride (1.7 mL, 18.0 mmol, 2 eq.) was then added dropwise over 2 minutes and the 
resulting mixture stirred for 16 h at room temperature. The volatiles were then removed under 
reduced pressure to obtain a rose-pink solid. The material was diluted in H2O (30 mL) and 
extracted with DCM (3 x 30 mL). The organic extracts were combined, washed with brine (30 
mL), dried over anhydrous MgSO4, filtered and evaporated to obtain acetyl 14 as an off-white 
crystalline solid (2.43g, 98%).  
 
1H NMR (400 MHz ,CDCl3) δ = 7.69 (s, 1 H, C(BPin)CHC(CH3)), 7.65 (dd, J = 8.1, 1.6 Hz, 
1 H, C(BPin)CHCH), 7.01 (d, J = 8.0 Hz, 1 H, C(BPin)CHCH), 2.31 (s, 3 H, ArOCOCH3), 
2.18 (s, 3 H, ArCH3), 1.33 (s,12 H, BO2C2(CH3)4); 13C NMR (100 MHz,  CDCl3) δ = 168.98, 
151.84, 137.75, 133.60, 129.37, 121.31, 83.76, 24.76, 20.77, 15.86, C-BPin not visible; IR 
(neat) 2978, 2929, 1764, 1606, 1559, 1354, 1280, 1168, 1118 cm-1; HRMS (ESI) [M + H]+ 
calcd for C15H21 11BO4, 277.1606 found 277.1606.  
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7.1.5 2-(Bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (15) 
 
 
 
N-Bromo succinimide (1.51 g, 8.5 mmol, 1.1 eq.) and benzoyl peroxide (75 % in H2O, 99 mg, 
0.3 mmol, 0.04 eq.), under a flow of argon, were added to a solution of  2-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate (2.12 g, 7.7 mmol, 1 eq.) in CCl4 (20 mL). 
The resulting mixture was heated to 84 °C and stirred for 20 h. The mixture was then cooled 
to 0 °C and the resulting precipitate removed by filtration. The filtrate was then evaporated to 
a  yellow oil, dissolved in DCM (10 mL) and diluted with H2O (20 mL). The organic phase 
was extracted with DCM (3 x 30 mL), combined,  dried over anhydrous MgSO4, filtered and 
evaporated under reduced pressure to obtain bromide 15 as an off-white crystalline solid, (2.46 
g, 90 %).  
The material was used without further purification in subsequent reactions* 
 
1H NMR (400 MHz ,CDCl3) δ = 7.85 (d, J = 1.4 Hz, 1 H, C(CH2Br)CHC(BPin)), 7.79 (dd, J 
= 8.1, 1.5 Hz, 1 H, CHCHC(BPin)), 7.14 (d, J = 8.0 Hz, 1 H, CHCHC(BPin)), 4.43 (s, 2 H, 
CH2Br), 2.37 (s, 3 H, ArCO2CH3), 1.34 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz ,CDCl3) 
δ = 137.63, 136.64, 129.01, 122.72, 84.23, 27.82, 24.97, 21.15, C-B not visible; IR (neat) 
2978, 2929, 1721, 1618, 1411, 1311, 1233, 1198, 1122, 990, 856, 799, 655 cm-1; HRMS (ESI) 
[M - H]+ calcd for C15H19 11B 79BrO4, 354.0562 found 353.0558; Mp = 81 - 83 °C. 
 
 
*After approx. three weeks the material tended to strongly discolour (red/purple), regardless 
of storage conditions (-18°C / N2), however inspection by 1H NMR spectroscopy showed 
retention of the titular compound without any degradation of the structure.  
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7.1.6 tert-Butyl piperazine-1-carboxylate, (1)  
 
 
 
To a stirring solution of 1,4 piperazine (6.90 g, 80.0 mmol, 1 eq.) in DCM (200 mL) a solution 
of di-tert-butyl dicarbonate (9.60 g, 44.0 mmol, 0.55 eq.) in DCM (100 mL) was added 
dropwise over a period of 1 h, at room temperature, then stirred for 16 h. The volatiles were 
removed under reduced pressure to expose a white oily residue, H2O (200 mL) was then added, 
causing the precipitation of a white solid which was filtered under gravity. The filtrate was 
extracted in DCM (3 x 200 mL), combined, dried over anhydrous MgSO4, filtered and 
evaporated to obtain N-Boc piperazine 1 as a white crystalline solid (5.34 g, 65%). 
 
1H NMR (400 MHz ,CDCl3) δ = 3.40 - 3.35 (m, 4 H), 2.82 - 2.76 (m, 4 H), 1.45 (s, 9 H) 
 
The 1H NMR data was found to be in agreement with that of Nagano and co-workers.88  
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7.1.7 tert-Butyl-(Z)-4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)piperazine-1-carboxylate, (2) 
 
 
 
A solution of tert-butyl piperazine-1-carboxylate (4.50 g, 24.0 mmol, 2.4 eq.) and 3,4 dichloro 
benzaldehyde (2.10 g, 12.0 mmol, 1.3 eq.) in anhydrous ethanol (10 mL) was added dropwise 
to a solution of rhodanine (1.30 g, 10.0 mmol, 1 eq.), in anhydrous ethanol (20 mL), under 
nitrogen. The resulting mixture was then heated to 70 °C and stirred for 16 h. The mixture was 
evaporated under reduced pressure and under high vacuum give to a viscous red / orange oil. 
The oil was triturated in cold ethanol (10 mL) which precipitated a yellow solid, that was 
collected via vacuum filtration to give heterocycle 2 (2.17 g, 49 %).  
 
1H NMR (400 MHz ,DMSO-d6) δ = 7.86 (d, J = 2.2 Hz, 1 H), 7.76 (d, J = 8.5 Hz, 1 H), 7.62 
(s, 1 H), 7.57 (dd, J = 8.4, 2.1 Hz, 1 H), 3.91 - 3.86 (m, 2 H), 3.67 - 3.61 (m, 2 H), 3.52 - 
3.43 (m, 4 H), 1.39 (s, 9 H) 
 
The 1H NMR spectroscopy data was found to be in agreement with that of Nagano and co-
workers.88  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
203 
 
7.1.8  (Z)-5-(3,4-Dichlorobenzylidene)-2-(piperazin-1-yl)thiazol-4(5H)-one, (17) 
 
 
 
A solution of trifluoracetic acid (8.44 mL, 27.5 mmol, 25 eq.), in DCM (50 mL) was added 
dropwise over 1 h to a solution of tert-butyl (Z)-4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-
dihydrothiazol-2-yl)piperazine-1-carboxylate (2.00 g, 1.1 mmol, 1 eq.) in DCM (100 mL). 
The mixture was stirred for 1 h at room temperature. The mixture was evaporated under 
reduced pressure to a golden oil. The crude material was the re-dissolved in DCM (approx. 30 
mL) and evaporated under reduced pressure. This process was repeated five times to 
completely remove excess TFA from the material, whereupon it transformed to a yellow solid, 
N-TFA salt form 3 (quantitative).  
 
1H NMR (400 MHz ,DMSO-d6) δ = 7.87 (d, J = 2.1 Hz, 1 H), 7.78 (d, J = 8.9 Hz, 1 H), 7.66 
(s, 1 H), 7.58 (dd, J = 8.5, 2.2 Hz, 1 H), 4.12 - 4.04 (m, 2 H), 3.91 - 3.81 (m, 2 H), 3.27 (br. s., 
4 H)    (The 1H NMR data were in agreement with that of Nagano and co-workers.88) 
 
The N-TFA salt was ground to a fine powder and dissolved in the minimum amount of water 
to make a thick syrup. Sodium carbonate was then added portion wise to basify the mixture to 
pH 12, to expose the titular compound in its free base form. 
The product was then isolated by continuous liquid-liquid extraction in chloroform over a 
period of two days, to give piperazine 17 as a yellow powder (3.01 g, 80 %).  
 
1H NMR (400 MHz, CDCl3) δ = 7.66 (s, 1 H, C=CH), 7.58 (d, J = 2.1 Hz, 1 H, 
C(Cl)CHC(HC=C)), 7.49 (d, J = 8.3 Hz, 1 H, C(C=C)CHCH), 7.33 (dd, J = 8.2, 2.1 Hz, 1 H, 
C(C=C)CHCH), 4.06 (d, J = 5.0 Hz, 2 H, NCH2CH2NH), 3.68 - 3.57 (m, 2 H, NCH2CH2NH), 
3.08 - 2.93 (m, 4 H, (NCH2CH2NH) x2); 13C NMR (100 MHz ,CDCl3) δ = 180.4, 174.6, 134.4, 
133.7, 133.4, 131.0, 130.9, 130.0, 128.9, 128.8, 50.4, 50.1, 46.1, 45.7; IR (neat) 2998, 2735, 
1664, 1541, 1448, 1356, 1284, 1194, 1123, 1028 cm-1; HRMS (ESI) [M + H]+ calcd for C14H13 
35Cl2N3OS, 342.0229 found 342.0234; Mp = 223 – 225 ℃. 
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A single crystal was grown by slow evaporation in chloroform, and submitted for analysis by 
single crystal X-Ray diffraction, confirming the Z geometry of the double bond. 
 
A suitable crystal was obtained by slow evaporation in chloroform. Diffraction data (7683 
total reflections with Rint = 0.0331) were collected on a Rigaku Oxford Diffraction Excalibur 
diffractometer at T = 150 K using graphite-monochromated Mo-Kα radiation. The structure 
was solved and refined using the SHELXS-2016 and SHELXL-2016 programs.256 Crystal 
data: C14H12N3O1S1Cl2 , M = 341.24, orange plate, 0.378  0.359  0.290 mm3, monoclinic, 
space group P21/C, V = 1455.74(14) Å3, Z = 4, Dc = 1.5568 g/cm3, F000 = 700, Xcalibur, 
Sapphire3, Gemini, Mo K radiation,  = 0.71073 Å, T = 150.00(10)K, 2max = 58.6º, 7683 
reflections collected, 3362 unique (Rint = 0.0331). Final GooF = 1.062, R1 = 0.0588, wR2 = 
0.1566, R indices based on 2661 reflections with I I > 2(I) (refinement on F2), 190 parameters, 
0 restraints. Lp and absorption corrections applied,  = 0.082 mm-1. 
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7.1.9 (Z)-2-((4-(5-(3,4-Dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)piperazin-1-
yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (16) 
 
 
 
2-(Bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate (2.50 g, 7.0  
mmol, 1.2 eq.) and K2CO3 (0.81 g, 5.9 mmol, 1.0 eq.) were added to a solution of (Z)-5-(3,4-
dichlorobenzylidene)-2-(piperazin-1-yl)thiazol-4(5H)-one, (2.01 g, 5.9 mmol, 1.0 eq.) in 
acetone (160 mL), the resulting mixture was heated to 50°C and stirred for two days. The 
mixture was then evaporated under reduced pressure to obtain a light tan powder, which was 
dissolved in EtOAc (100 mL) and diluted with water (100 mL). The organic portion was 
extracted with EtOAc (5 x 50 mL), combined, washed with brine (200 mL), dried over 
anhydrous MgSO4, filtered and evaporated to a yellow solid, as the crude product 16. 
 
The crude material: containing a mixture of starting materials and product as well as a small 
amount (10% approx.) of the Ar-OH deprotected form This was used directly in the next step 
without further purification  
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7.1.10 (Z)-5-(3,4-Dichlorobenzylidene)-2-(4-(2-hydroxy-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one, (9) 
 
 
 
A flask was charged with, (Z)-2-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-
2-yl)piperazin-1-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate  
(crude) (2.00 g, 3.30 mmol, 1.0 eq.) and dissolved in methanol (120 mL). K2CO3 (46 mg, 0.03 
mmol, 0.10 eq.) was added. The mixture was heated to 40 °C and stirred over two days and 
then evaporated under reduced pressure to give a light-yellow solid, which was purified via 
flash column chromatography (100% EtOAc), to afford phenol 9 as a light-yellow powder, 
(1.54 g, 51%, over two steps).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.90 (d, J = 2.2 Hz, 1H, C(HC=C)CHC(Cl)), 7.78 (d, J = 
8.5 Hz, 1H, C(Cl)CHCH), 7.64 (s, C=CH, 1H), 7.59 (dd, J = 8.8, 2.2 Hz, 1H, C(Cl)CHCH), 
7.49 (d, J = 1.5 Hz, 1H, C(BPin)CHC(HC=C)), 7.44 (dd, J = 8.0, 1.6 Hz, 1H, C(BPin)CHCH), 
6.80 (d, J = 8.0 Hz, 1H, C(BPin)CHCH), 3.91 (br. s., 2 H, CH2NCH2CH2), 3.66 (br. s., 2 H, 
CH2NCH2CH2), 3.59 (s, 2 H, CH2NCH2CH2), 2.63 - 2.49 (m, 4 H, (CH2NCH2CH2) x2), 1.24 
(s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz ,DMSO-d6) δ = 179.47, 174.05, 159.96, 137.75, 
135.87, 135.26, 132.55, 132.51, 131.86, 131.72, 131.32, 129.41, 127.83, 122.52, 115.64, 
83.87, 57.16, 52.35, 51.9, 49.00, 48.62, 25.23; IR (neat) 2975, 1681, 1612, 1558, 1470, 1351, 
1294, 1243, 1141cm-1 ; HRMS (ESI) [M + H]+ calcd for C27H30 11B 35Cl2N3O4S, 574.1505 
found 574.1502; Mp = 226 – 229 ℃. 
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7.1.11 2-(2-Bromoethoxy)ethan-1-ol, (18) 
 
 
 
Freshly procured / distilled diethylene glycol (4.46 mL, 47.1 mmol, 1.0 eq.), was mixed in 
toluene (150 mL) with HBr (48% in H2O, 5.32 mL, 47.1 mmol, 1.0 eq.). The mixture was then 
heated under dean-stark conditions for 4 h, upon which it was cooled to 0 °C and quenched 
with NaOH aq. (1 M, 50 mL). The mixture was diluted with H2O (200 mL) and extracted with 
EtOAc (2 x 200 mL), combines, washed with brine (200 mL), dried over anhydrous MgSO4, 
filtered and evaporated under reduced pressure to a pale-yellow oil. The crude material was 
purified by flash column chromatography (40% EtOAc / 60% hexanes), to afford ether 18 as 
a pale-yellow oil, (3.13 g, 40 %).* 
 
1H NMR (400 MHz, CDCl3) δ = 3.83 (t, J = 6.0 Hz, 2H), 3.79 - 3.73 (m, 2H), 3.63 (d, J = 4.3 
Hz, 2H), 3.51 (t, J = 6.0 Hz, 2H), 2.12 - 2.01 (m, 1H). 
 
*It was found that for best results, 2-(2-bromoethoxy)ethan-1-ol should be used immediately 
after purification in the next reaction, dues to issues with shelf stability. 
 
Data in agreement with that stated by Koley and co-workers.257 
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7.1.12 (Z)-5-(3,4-Dichlorobenzylidene)-2-(4-(2-(2-(2-hydroxyethoxy)ethoxy)-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one, (19) 
 
 
 
K2CO3 (0.32 g, 2.3 mmol, 1.5 eq.) was added to a solution of (Z)-5-(3,4-dichlorobenzylidene)-
2-(4-(2-hydroxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-
yl)thiazol-4(5H)-one (0.89 g, 1.6 mmol, 1 eq.) in DMF (25 mL). This was followed by a 
solution of 2-(2-bromoethoxy)ethan-1-ol (0.76 g, 4.5 mmol, 2.9 eq.) dissolved in DMF, added 
dropwise and lastly KI (0.26 g, 1.6 mmol, 1.0 eq.). The mixture was heated to 80 °C and stirred 
for 20 h, then cooled to room temperature, diluted with H2O (50 mL). The organic portion was 
extracted with EtOAc (3 x 75 mL), washed with a solution of 5 % LiCl aq. (3 x 100 ml), dried 
over anhydrous magnesium sulfate, filtered and evaporated to brown oil. The crude material 
was then purified by flash column chromatography (90% EtOAc / 10% acetone → 100% 
acetone) to obtain alcohol 19 as a golden-brown oil (0.48 g, 61 %).  
 
1H NMR (400 MHz ,CDCl3) δ = 7.71 (dd, J = 8.2, 1.8 Hz, 1 H, CHCHC(BPin)), 7.66 (d, J = 
1.8 Hz, 1 H, C(CH2)CHC(BPin)), 7.62 (s, 1 H, C=CH), 7.55 (d, J = 2.3 Hz, 1 H, 
CHCHC(Cl)C(Cl)CH), 7.47 (d, J = 8.7 Hz, 1 H, CHCHC(Cl)C(Cl)CH), 7.31 (dd,  J = 8.5, 
2.1, 1 H, CHCHC(Cl)C(Cl)CH), 6.86 (d,  J = 8.2 Hz, 1 H, CHCHC(BPin)), 4.19 - 4.13 (m, 2 
H, ArOCH2CH2), 4.09 - 4.02 (m, 2 H, CH2NCH2CH2), 3.92-3.88 (m, 2 H, ArOCH2CH2), 3.76 
- 3.69 (m, 2 H, OHCH2CH2), 3.67 - 3.58 (m, 6 H, ArCH2, OHCH2CH2, CH2NCH2CH2), 2.71 
- 2.57 (m, 5 H, (CH2NCH2CH2) x2, OH), 1.32 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz 
,CDCl3) δ = 180.55, 174.32, 159.87, 138.41, 136.4, 134.59, 133.66, 133.48, 131.11, 130.96, 
130.24, 128.92, 128.72, 124.12, 111.06, 83.88, 72.56, 69.58, 67.38, 61.76, 56.29, 52.54, 52.29, 
49.01, 48.88, 25.08, C-BPin not visible; IR (neat) 3350, 2931, 2868, 1673, 1604, 1556, 1386, 
1272, 1252, 1131, 993 cm-1; HRMS (ESI) [M + H]+ calcd for C31H38 11B 35Cl2N3O6S, 662.2030 
found 662.2017. 
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7.1.13 Potassium (Z)-(3-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl) 
piperazin-1-yl)methyl)-4-(2-(2-hydroxyethoxy)ethoxy)phenyl)trifluoroborate, (21) 
 
 
 
To a solution of (Z)-5-(3,4-dichlorobenzylidene)-2-(4-(2-(2-(2-hydroxyethoxy)ethoxy)-5-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one           
(57 mg, 0.1 mmol, 1.0 eq.) in methanol (2 mL), a solution of KHF2 aq. (4.5 M, 0.11 mL, 0.5 
mmol, 5.65 eq.) was added in one portion. The mixture was stirred for 1 h at room temperature 
and then acetone (10 mL) was added. The solution filtered, and the filtrate evaporated under 
reduced pressure to give a tacky white residue. The residue was then co-evaporated with a 1:1 
mixture of H2O / methanol 4 times (procedure described below). The reaction was then 
repeated again using the crude material, then purified in the same manner, to obtain 
trifluoroborate 21 as a white crystalline solid (quantitative). This was used immediately in the 
next reaction. 
 
1H NMR data included for reference: 
1H NMR (400 MHz, MeOH-D3) δ = 7.74 (d, J = 2.1 Hz, 1H), 7.70 - 7.59 (m, 2H), 7.52 (dd, J 
= 8.2, 1.9 Hz, 1H), 7.45 - 7.38 (m, 2H), 6.84 (d, J = 8.3 Hz, 1H), 4.25 - 4.09 (m, 2H), 4.06 - 
3.94 (m, 2H), 3.85 (dd, J = 5.3, 3.8 Hz, 2H), 3.78 - 3.58 (m, 8H), 2.81 - 2.60 (m, 4H) 
 
The material was then used immediately as an intermediate for the next reaction 
 
Evaporation procedure: 
The material was dissolved in 1:1 H2O / methanol, using a volume approx. ¼ that of the round 
bottom flask, and evaporated under reduced pressure, starting at 200 mbar (50 °C water bath, 
approx. 180 rpm) then the vacuum was increased in 10 mbar increments to 50 mbar over a 
period of 3-4 min, taking care not to “bump” the material. Once 50 mbar was attained the 
material could be held under continuous vacuum. 
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7.1.14 (Z)-(3-((4-(5-(3,4-Dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)piperazin-1-
yl)methyl)-4-(2-(2-hydroxyethoxy)ethoxy)phenyl)boronic acid, (22) 
 
 
Trimethylsilyl chloride (0.03 mL, 0.26 mmol, 3.0 eq.) and H2O (5 µL, 0.26 mmol, 3.0 eq.) 
were added to a solution of potassium (Z)-(3-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-
dihydrothiazol-2-yl)piperazin-1-yl)methyl)-4-(2-(2-hydroxyethoxy)ethoxy)phenyl) tri 
fluoroborate (55 mg, 0.09 mmol, 1.0 eq.) in MeCN (2 mL). The mixture was stirred for 1 h at 
room temperature. A solution of sodium bicarbonate sat. aq. (0.2 mL) was added to the 
mixture, which was then dried using anhydrous sodium sulfate, filtered and evaporated under 
reduced pressure to obtain boronic acid 22 as a crystalline cream solid (29 mg, 59%).  
 
1H NMR (400 MHz, MeOH-D3) δ = 7.73 - 7.61 (m, 1H, C(HC=C)CHC(Cl)), 7.61 - 7.51 (m, 
3H, C=CH, C(Cl)CHCH, C(B(OH)2)CHC(CH2)), 7.43 (dd, J = 8.5, 2.1 Hz, 1H, C(Cl)CHCH), 
7.07 - 6.89 (m, 1H, C(B(OH)2)CHCH), 4.24 - 4.12 (m, 2H, ArOCH2CH2), 4.07 - 3.97 (m, 2H, 
NCH2CH2NCH2Ar), 3.91 - 3.82 (m, 2H, ArOCH2CH2), 3.77 - 3.62 (m, 8H, 
NCH2CH2NCH2Ar, CH2CH2OH, NCH2Ar), 2.84 - 2.63 (m, 4H, (NCH2CH2NCH2Ar) x 2), 
CHCHC(OCH2CH2) not visible; 13C NMR (100 MHz, MeOH-D3) δ = 180.85, 174.80, 137.30, 
135.17, 134.43, 133.29, 132.87, 131.05, 130.96, 130.02, 128.76, 128.51, 123.25, 120.41, 
110.73, 72.47, 69.43, 67.43, 60.96, 55.43, 51.83, 51.60, 48.77, 44.03, C-B(OH)2 not visible; 
IR (neat); 3234, 2921, 1675, 1605, 1555, 1470, 1444, 1341, 1288, 1181 cm-1; HRMS (ESI) 
(Sample + ethylene glycol) [M + H]+ calcd for C27H32 11B 35Cl2N3O6S, 606.1409 found 
606.1400*; Mp = 85 – 88 ℃. 
 
*Molecular ion peak was not detected by the EPSRC national mass spectrometry facility, a 
problem found to not be uncommon with boronic acid compounds. Instead the sample was 
reacted with a small amount of ethylene glycol, to give the corresponding boronic ester, 
allowing the acquisition of the molecular ion for the devitalised compound.258  
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7.1.15 (Z)-2-(2-(2-((4-(5-(3,4-Dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2yl)piperazin-
1-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl4-
methylbenzenesulfonate, (31) 
 
 
 
Tosyl chloride (0.14 g, 0.7 mmol, 1.3 eq.) and triethylamine (0.15 mL, 1.1 mmol, 2.0 eq.) 
were added to a solution of (Z)-5-(3,4-dichlorobenzylidene)-2-(4-(2-(2-(2-
hydroxyethoxy)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl) 
piperazin-1-yl)thiazol-4(5H)-one, (0.37 g, 0.6 mmol, 1.0 eq.) in DCM (20 mL). The resulting 
mixture was stirred at room temperature for two days. The volatiles were then removed under 
reduced pressure to obtain a yellow residue which was purified via flash column 
chromatography (100% EtOAc) to afford a tosylate 31 as a yellow oil (0.20 g, 45%). 
 
 
1H NMR (400 MHz, CDCl3) δ = 7.78 (d,  J = 8.2 Hz, 2H, (SO3)CCH), 7.75 - 7.70 (m, 2H, 
C(BPin)CHC(CH2), C(BPin)CHCH), 7.65 (s, 1H, C=CH), 7.58 (d, J = 2.3 Hz ,1H, 
C(HC=C)CHC(Cl)), 7.49 (d, J = 8.2 Hz, 1H, CHCHC(Cl)), 7.34 (dd, J = 8.2, 2.3 Hz, 1H, 
CHCHC(Cl)), 7.30 (d, J = 8.2 Hz, 2H, C(CH3)CH), 6.85 (d, J = 8.2 Hz, 1H, C(BPin)CHCH), 
4.20 - 4.15 (m, 2H, ArOCH2CH2), 4.10 (dd, J = 5.3, 3.9 Hz, 2H, CH2CH2OTs), 4.08 - 4.03 
(m, 2H, NCH2CH2NCH2), 3.82 (dd, J = 5.3, 3.9 Hz, 2H, CH2CH2OTs), 3.78 - 3.74 (m, 2H, 
PhOCH2CH2), 3.69 - 3.61 (m, 4H, NCH2CH2NCH2, ArCH2,), 2.69 - 2.59 (m, 4H, 
(NCH2CH2NCH2) x2), 2.41 (s, 3H, ArCH3), 1.35 (s, 12H, BO2C2(CH3)4); 13C NMR (100 MHz 
,CDCl3) δ = 180.5, 174.4, 159.7, 145.0, 138.1, 136.2, 134.5, 133.6, 133.4, 132.9, 131.0, 131.0, 
130.3, 130.0, 128.8, 128.6, 128.0, 124.4, 111.1, 83.8, 69.9, 69.4, 69.0, 67.5, 55.7, 52.2, 51.9, 
49.2, 48.9, 25.0, 21.8, C-BPin not visible; IR (neat) 2978, 2926, 2245, 1686, 1604, 1558, 1353, 
1284, 1254, 1174, 1133cm-1; HRMS (ESI) [M + H]+ calcd for C38H44 11B 35Cl2N3O8S2, 
816.2225 found 816.2211.  
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7.1.16  Potassium (Z)-(3-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)piperazin-1-yl)methyl)-4-(2-(2-(tosyloxy)ethoxy)ethoxy)phenyl)trifluoroborate, (32) 
 
 
 
KHF2 aq. (4.5 M, 0.44 mL, 2.0 mmol, 10.0 eq.) was added in one portion to a solution of (Z)-
2-(2-(2-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)piperazin-1-
yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)phenoxy)ethoxy)ethyl -4-methyl 
benzenesulfonate (0.16 g, 0.2 mmol, 1.0 eq.) in MeOH (5 mL). The mixture was stirred for 1 
h at room temperature. Acetone (7 mL) was added, the solution was then filtered and 
evaporated under reduced pressure to give a golden brown solid. The solid was then co-
evaporated with a 1:1 mixture of H2O / MeOH 3 times. The entire reaction / purification 
procedure was then repeated with the product, to obtain trifluoroborate 32 as an orange 
crystalline solid (quantitative).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.86 (d, J = 1.8 Hz, 1H, C(HC=C)CHC(Cl)), 7.77 - 7.70 
(m, 3H, C(SO3)CH, C(Cl)CHCH), 7.60 (s, 1H, HC=C), 7.58 (dd, J = 8.2, 1.8 Hz, 1H, 
C(Cl)CHCH), 7.38 (br d, J = 7.8 Hz, 2H, C(CH3)CH), 7.21 (d, J = 0.9 Hz, 1H, 
C(BF3K)CHC(CH2)), 7.14 (d, J = 8.2 Hz, 1H, C(BF3K)CHCH), 6.66 (d, J = 8.2 Hz, 1H, 
C(BF3K)CHCH), 4.19 - 4.07 (m, 2H, ArOCH2CH2), 3.97 - 3.80 (m, 2H, CH2CH2OTs), 3.70 - 
3.56 (m, 6H, NCH2CH2NCH2Ar, ArOCH2CH2, CH2CH2OTs), 3.51 - 3.40 (m, 2H, NCH2Ar), 
2.40 - 2.32 (m, 3H, ArCH3)*; 13C NMR (100 MHz, DMSO-d6) δ = 179.47, 173.86, 155.44, 
145.42, 135.33, 135.16, 135.14, 132.97, 132.55, 132.01, 131.93, 131.82, 131.41, 130.66, 
129.38, 128.11, 127.64, 123.0, 111.17, 70.67, 69.73, 68.62, 68.04, 56.27, 52.35, 52.22, 49.31, 
48.96, 21.61, (C-BF3K not visible); IR (neat) 3673, 2986, 2900, 1679, 1600, 1555, 1447, 1348, 
1130 cm-1; HRMS (ESI) [M - K]- calcd for C32H32 11B 35Cl2F3N3O8S2, 756.1166 found 
756.1173. 
 
*(NCH2CH2NCH2Ar) x2 obscured by DMSO residual solvent  
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7.1.17 (Z)-5-(3,4-Dichlorobenzylidene)-2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-5-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one, (34) 
 
 
To a solution of (Z)-5-(3,4-dichlorobenzylidene)-2-(4-(2-hydroxy-5-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one (0.29 g, 0.5 mmol, 1.0 eq.) 
in DMF (5 mL) K2CO3 (0.11 g, 0.8 mmol, 1.5 eq.), a solution of 2-[2-(2-chloroethoxy)ethoxy] 
ethanol (0.22 ml, 1.5 mmol, 3.0 eq.) dissolved in DMF (1 mL) (dropwise, over 1 min) and KI 
(81 mg, 0.5 mmol, 1.0 eq.) were added. The resulting mixture was heated to 75°C and stirred 
for 16 h, cooled and then concentrated under reduced pressure to give a brown oil. The material 
was diluted with H2O (30 mL), extracted with EtOAc (3 x 50 mL), combined, dried over 
anhydrous MgSO4 and evaporated to obtain a light brown oil. The crude product was purified 
via flash column chromatography (80% EtOAc / 20% acetone →100% acetone), to afford 
alcohol 34 as a yellow oil which overnight crystallised to a golden solid  (195 mg, 55 %).  
 
1H NMR (400 MHz, CDCl3) δ = 7.69 (dd, J = 8.2, 1.8 Hz, 1H, C(BPin)CHCH), 7.65 (d, J = 
1.6 Hz, 1H, C(BPin)CHC(CH2)), 7.60 (s, 1H, HC=C), 7.53 (d, J = 2.3 Hz, 1H, 
C(HC=C)CHC(Cl)), 7.45 (d, J = 8.2 Hz, 1H, C(Cl)CHCH), 7.29 (dd, J = 8.2, 2.3 Hz, 1H, 
C(Cl)CHCH), 6.85 (d, J = 8.2 Hz, 1H, C(BPin)CHCH), 4.19 - 4.10 (m, 2H, ArOCH2CH2), 
4.08 - 3.93 (m, 2H, NCH2CH2NCH2), 3.88 - 3.78 (m, 2H, ArOCH2CH2), 3.75 - 3.56 (m, 12H, 
NCH2CH2NCH2, ArCH2, CH2OCH2CH2OCH2, CH2CH2OH), 2.72 - 2.59 (m, 4H, 
(NCH2CH2NCH2) x2), 1.31 (s, 12H, BO2C2(CH3)4); 13C NMR (100 MHz, CDCl3) δ = 180.27, 
174.08, 159.64, 138.10, 136.13, 134.25, 133.38, 133.19, 130.83, 130.67, 129.99, 128.66, 
128.40, 123.83, 110.97, 83.58, 72.60, 70.69, 70.26, 69.54, 67.29, 61.59, 55.49, 51.85, 51.59, 
48.92, 48.66, 24.78; IR (neat) 3402, 2974, 2926, 2870, 1690, 1604, 1557, 1470, 1446, 1387, 
1353, 1133 cm-1 ; HRMS (ESI) [M + H]+ calcd for C33H42 11B 35Cl2N3O7S, 706.2292 found 
706.2281; Mp = 65-67 °C.  
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7.1.18 (Z)-2-(2-(2-(2-((4-(5-(3,4-Dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl) 
piperazin-1-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy) 
ethoxy)ethyl 4-methylbenzenesulfonate, (35) 
 
 
 
 
Triethylamine (0.08 mL, 0.5 mmol, 2.0 eq.) and tosyl chloride (103 mg, 0.5 mmol, 2.0 eq.) 
was added to a solution of (Z)-5-(3,4-dichlorobenzylidene)-2-(4-(2-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one (0.19 g, 0.3 mmol, 1.0 eq.) in DCM (5 mL). The 
resulting mixture was stirred at room temperature for 4 days, and then evaporated to an orange 
residue. The residue was re-dissolved in DCM (30 mL), washed in brine (20 mL), dried over 
anhydrous MgSO4 and evaporated to obtain an orange oil. The crude material was purified via 
flash column chromatography (95% EtOAc / 5% acetone) to afford tosylate 35 as a yellow oil 
(114 mg, 49 %). 
1H NMR (400 MHz, CDCl3) δ = 7.75 (d, J = 8.2 Hz, 2 H, (SO3)CCH), 7.72 - 7.68 (m, 2 H, 
C(HC=C)CHC(Cl), C(BPin)CHCH), 7.61 (s, 1 H, C=CH), 7.54 (d, J = 1.8 Hz, 1 H, 
C(BPin)CHC(CH2)), 7.46 (d, J = 8.7 Hz, 1 H, C(Cl)CHCH), 7.34 - 7.26 (m, 3 H, C(CH3)CH, 
C(Cl)CHCH), 6.85 (d, J = 8.2 Hz, 1 H, C(BPin)CHCH), 4.15 - 4.10 (m, 4 H, ArOCH2CH2, 
CH2CH2OTs), 4.06 - 4.00 (m, 2 H, NCH2CH2NCH2), 3.85 - 3.79 (m, 2 H, ArOCH2CH2), 3.69 
- 3.56 (m, 10 H, ArCH2, CH2OCH2CH2OCH2, CH2CH2OTs, NCH2CH2NCH2), 2.67-2.58 (m,  
4 H, (NCH2CH2NCH2) x2), 1.32 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz ,CDCl3) δ = 
180.42, 174.31, 159.84, 144.97, 138.05, 136.27, 134.59, 133.53, 133.44, 133.02, 131.01, 
130.97, 130.33, 129.95, 128.87, 128.53, 128.05, 111.16, 83.85, 76.43, 70.92, 70.72, 69.88, 
69.38, 68.83, 67.66, 55.77, 52.32, 52.02, 49.25, 48.98, 25.02, 21.72, C-BPin missing; IR (neat) 
cm-1 ; HRMS (ESI) [M + H]+ calcd for C40H48 11B 35Cl2N3O9S2, 860.2382 found 860.2373. 
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7.1.19 (Z)-2-(2-(2-((4-(5-(3,4-Dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-
yl)piperazin-1-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy) 
ethoxy)ethylmethanesulfonate, (36) 
 
 
Triethylamine (0.05 mL, 0.4 mmol, 2.0 eq.) was added to a stirring solution of (Z)-5-(3,4-
dichlorobenzylidene)-2-(4-(2-(2-(2-hydroxyethoxy)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one (125 mg, 0.2 mmol, 1.0 eq.) in 
DCM (10 mL) cooled to 0 °C. Methanesulfonyl chloride (0.03 mL, 0.4 mmol, 2.0 eq.) was 
added dropwise over 2 min. The reaction mixture was then warmed to room temperature and 
stirred for 18 h. The mixture was diluted with H2O (10 mL), the organic portion extracted with 
DCM (3 x 30 mL), combined, dried over anhydrous MgSO4 and evaporated under reduced 
pressure. The crude material was purified by column chromatography (85% EtOAc / 15% 
acetone → 100% acetone) to afford mesylate 36 as a yellow oil (0.11 g, 76 %).  
 
1H NMR (400 MHz, MeOH-D3) δ = 7.75 (br s, 1H, C=CH), 7.73 - 7.69 (m, 2H, 
C(HC=C)CHC(Cl), CHCHC(BPin)), 7.64 - 7.59 (m, 2H, C(HC=C)CHCH, 
C(CH2)CHC(BPin)), 7.49 (dd, J = 8.6, 1.9 Hz, 1H, C(HC=C)CHCH), 7.02 (d, J = 8.2 Hz, 1H, 
CHCHC(BPin)), 4.43 - 4.35 (m, 2H, ArOCH2CH2), 4.25 - 4.18 (m, 2H, CH2CH2OMs), 4.05 
(br s, 2H, NCH2CH2NCH2Ar), 3.96 - 3.74 (m, 8H, CH2CH2OMs,  NCH2CH2NCH2Ar, 
ArOCH2CH2, NCH2Ar), 3.06 (s, 3H, SO3CH3), 2.94 - 2.79 (m, 4H, (NCH2CH2NCH2Ar) x2), 
1.32 (s, 12H, (CH3)4); 13C NMR (100 MHz, MeOH-D3) δ = 182.23, 176.47, 161.39, 139.57, 
137.82, 137.85, 135.86, 134.67, 134.24, 132.46, 132.31, 131.47, 130.07, 129.99, 112.34, 
85.02, 70.96, 70.72, 70.28, 68.77, 56.52, 52.97, 52.79, 37.37, 25.21, C-BPin not visible, 
NCH2CH2NCH2Ar obscured by residual solvent peak; IR (neat) 2976, 2927, 2243, 1686, 
1604, 1559, 1470, 1353, 1284, 1174, 1133 cm-1; HRMS (ESI) [M + H3O]+ calcd for 759.1989 
C32H44 11B 35Cl2N3O9S2, found 759.1980.  
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7.1.20 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, (23) 
 
 
 
 
B2Pin2 ( 2.09 g, 8.3 mmol, 1.10 eq.) and KOAc (2.42 g, 24.7 mmol, 3.00 eq.) were  added to 
a solution 5-Bromo-2-methyl phenol (1.40 g, 7.50 mmol, 1.0 eq.) in anhydrous dioxane (25 
mL), then the resulting mixture was degassed under N2 for 10 min. PdCl2dppf (0.31 g, 0.4 
mmol, 0.05 eq.) was added and then the mixture was stirred at 80 °C for 16 h. The reaction 
mixture was cooled to room temperature, upon which it was filtered through a plug of silica, 
eluting with DCM, the filtrate was then filtered through a second plug of silica and then 
evaporated to a golden-brown oil. The crude product was purified via flash column 
chromatography (30% EtOAc / 70% light petroleum ether) to afford boronate ester 23 as a 
cream crystalline solid (1.68g, 96%).  
 
1H NMR (400 MHz, CDCl3) δ = 7.29 (dd, J = 7.3, 0.8 Hz, 1H, C(BPin)CHCH), 7.19 (s, 1H, 
C(BPin)CHC(OH)), 7.13 (d, J = 7.3 Hz, 1H, C(BPin)CHCH), 5.12 (s, 1H, OH), 2.26 (s, 3H, 
ArCH3), 1.31 (s, 12H, BO2C2(CH3)4); 13C NMR (100 MHz, CDCl3) δ = 153.36, 130.67, 
127.77, 127.12, 120.57, 83.76, 24.76, 16.04, C-BPin not visible. 
 
Data in agreement to that reported by Hoheisel and co-workers.259 
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7.1.21 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (24) 
 
 
 
Triethylamine (0.9 mL, 6.4 mmol, 1.5 eq.) was added to a solution of 2-methyl-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.00 g, 4.2 mmol, 1.0 eq.) in DCM (25 mL). 
Acetic anhydride (0.81 mL, 8.5 mmol, 2.0 eq.) was added dropwise to the mixture, and stirred 
for 16 h at room temperature. The volatiles were then removed under reduced pressure to yield 
a yellow oil as the crude product, the oil was then partitioned between EtOAc (30 mL) and 
H2O (40 mL) and extracted with EtOAc (3 x 30 mL), combined, dried over anhydrous MgSO4 
and evaporated to obtain acetyl 24 as a cream crystalline solid (1.17g, 94 %). 
 
1H NMR (400 MHz, CDCl3) δ = 7.57 (dd, J = 7.5, 0.9 Hz, 1 H, C(BPin)CHCH), 7.42 (s, 1 H, 
C(BPin)CHC(OAc)), 7.23 (d, J = 7.4 Hz, 1 H, C(BPin)CHCH), 2.29 (s, 3 H, ArCH3), 2.19 (s, 
3 H, ArOC(O)CH3), 1.31 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz, CDCl3) δ = 169.41, 
149.19, 133.76, 132.64, 130.88, 128.03, 83.96, 24.96, 20.94, 16.58, C-BPin not visible; IR 
(neat) 2978, 2929, 1764, 1608, 1559, 1356, 1207, 1170, 1120  cm-1; HRMS (ESI) [M + NH4]+ 
calcd for C15H25 11BO4N, 294.1871 found 294.1871, Mp = 127-130 °C. 
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7.1.22 2-(Bromomethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (25) 
 
 
 
Freshly recrystallized N-bromo succinimide (0.71 g, 3.9 mmol, 1.10 eq.) and benzoyl peroxide 
(75 % in H2O, 47 mg, 0.1 mmol, 0.04 eq.) was added to a solution of 2-methyl-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate (1.00 g, 3.6 mmol, 1.0 eq.) in anhydrous 
CCl4 (20 mL), under a flow of argon. The resulting mixture was heated to 85 °C and stirred 
for two days. The reaction mixture was then cooled to 0 °C and the solids removed by gravity 
filtration, the filtrate was evaporated under reduced pressure to a yellow oil. The crude 
material was diluted with H2O (20 mL) and extracted with DCM (4 x 25 mL). The combined 
organic extracts were then dried over anhydrous MgSO4, filtered and evaporated under 
reduced pressure to afford bromide 25 as a pale-yellow oil (1.02 g, 80%).  
 
The material was used in the next reaction without any further purification.  
 
1H NMR (400 MHz ,CDCl3) δ = 7.64 (dd, J = 7.4, 0.9 Hz, 1 H, C(BPin)CHCH), 7.51 (s, 1 H, 
C(BPin)CHC(OAc)), 7.41 (d, J = 7.5 Hz, 1 H, C(BPin)CHCH), 4.41 (s, 2 H, CH2Br), 2.36 (s, 
3 H, ArOC(O)CH3), 1.32 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz ,CDCl3) δ = 169.24, 
148.65, 132.73, 132.62, 130.45, 129.27, 84.28, 27.53, 25.05, 21.03, C-BPin not visible; IR 
(neat) 2969, 2262, 2104, 1686, 1604, 1436, 1192, 924 cm-1; HRMS (ESI) [M + H]+ calcd for 
C15H20 11B 35BrO4, 355.0544  found 355.0597.  
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7.1.23 (Z)-2-((4-(5-(3,4-dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)piperazin-1-
yl)methyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, (26) 
 
 
 
(Z)-5-(3,4-Dichlorobenzylidene)-2-(piperazin-1-yl)thiazol-4(5H)-one (0.40 g, 1.2 mmol, 1.0 
eq.) was added to a solution of 2-(bromomethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl acetate (0.50 g, 1.5 mmol, 1.2 equiv.) in DMF / H2O 10:1 (22 mL). K2CO3 (0.16 
g, 1.2 mmol, 1.0 eq.) was added, the solution was heated to 50°C and stirred for two days.  
The reaction mixture was then evaporated under reduced pressure to dryness obtain an orange 
residue. The residue was dissolved in EtOAc (10 mL) and the insoluble material filtered and 
discarded, the filtrate was then evaporated to yield a yellow solid as the crude product.  
Flash column chromatography (100% EtOAc) was used to isolate acetyl and phenol (de-
protected) derivatives as a mixture. The isolated mixture (acetyl 26 and phenol 27) were used 
directly without further purification. 
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7.1.24 (Z)-5-(3,4-Dichlorobenzylidene)-2-(4-(2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one, (27) 
 
 
 
K2CO3 (8 mg, 0.1 mmol, 0.12 eq.) was added to a solution of (Z)-2-((4-(5-(3,4-
dichlorobenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)piperazin-1-yl)methyl)-5-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate, as a mixture, (0.28 g, 0.5 mmol, 1.0 eq., 
MAX) in MeOH (12 mL). The resulting mixture was heated to 40 °C and stirred for 2 days. 
At which point the reaction was quenched following the addition of a solution of 0.1 M aq. 
HCl to pH 7. The volatiles were removed under reduced pressure to obtain a white solid, this 
was then partitioned between DCM (25 mL) and H2O (30 mL). The organic portion was 
extracted using DCM (4 x 25 ml), combined, dried over anhydrous MgSO4, and evaporated 
under reduced pressure to obtain phenol 27 as a white solid (0.37 g, 55 %, over two steps). 
 
1H NMR (400 MHz, CDCl3) δ = 7.68 (s, 1 H, C=CH), 7.57 (d, J = 2.3 Hz, 1 H, C(Cl)CHCH), 
7.50 (d, J = 8.2 Hz, 1 H, C(Cl)CHC(HC=C)), 7.33 (dd, J = 8.4, 2.1 Hz, 1 H, C(Cl)CHCH), 
7.31 (s, 1 H, C(BPin)CHC(OH)), 7.27 (d,  J = 7.3 Hz, 1 H, C(BPin)CHCH), 7.01 (d, J = 7.3 
Hz, 1 H, C(BPin)CHCH), 4.18 - 4.07 (m, 2 H, NCH2CH2NCH2), 3.79 (s, 2 H, ArCH2), 3.71 – 
3.67 (m, 2 H, NCH2CH2NCH2), 2.77 - 2.66 (m, 4 H, (NCH2CH2NCH2) x2), 1.33 (s, 12 H, 
BO2C2(CH3)4); 13C NMR (100 MHz ,CDCl3) δ = 180.38, 174.94, 156.66, 134.33, 133.95, 
133.53, 131.16, 130.98, 129.86, 129.54, 128.96, 128.73, 126.22, 123.21, 122.43, 84.02, 61.38, 
52.16, 51.94, 48.53, 48.37, 24.94, C-BPin not visible; IR (neat): 3691, 2978, 1677, 1606, 1559, 
1351, 1293, 1246, 1172, 1120, 993 cm-1; HRMS (ESI) [M + H]+ calcd for C27H30 11B 
35Cl2N3O4S, 574.1505 found 574.1497; Mp = 193-195 °C. 
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7.1.25 (Z)-5-(3,4-Dichlorobenzylidene)-2-(4-(2-(2-(2-hydroxyethoxy)ethoxy)-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-4(5H)-one, (28) 
 
 
 
 
2-(2-Chloroethoxy)ethanol (57 mg, 0.5 mmol, 3.0 eq.), K2CO3 (65 mg, 0.5 mmol, 3.0 eq.) and 
KI (26 mg, 0.2 mmol, 1.0 eq.) were added to a solution of (Z)-5-(3,4-dichlorobenzylidene)-2-
(4-(2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-1-yl)thiazol-
4(5H)-one (90 mg, 0.2 mmol, 1.0 eq.) in DMF (10 mL). The resulting mixture was stirred at 
75 °C for 24 h. The reaction mixture was cooled to room temperature, then evaporated under 
reduced pressure to obtain an orange residue which was dissolved in EtOAc (30 mL) and 
diluted with H2O (30 mL). The organic portion was extracted using EtOAc (3 x 20 mL), then 
DCM (1 x 20 mL), combined, dried over anhydrous MgSO4, filtered and evaporated to give a 
yellow oil. This was then purified using flash column chromatography (90 % EtOAc / 10 % 
acetone → 100 % acetone) to afford alcohol 28 as a yellow oil, (15 mg, 15 %).  
 
1H NMR (400 MHz, CDCl3) δ = 7.66 (s, 1H, C=CH), 7.58 (d, J = 2.3 Hz, 1H, 
C(Cl)CHC(HC=C)), 7.50 (d, J = 8.2 Hz, 1H, C(Cl)CHCH), 7.43 (d, J = 7.3 Hz, 1H, 
C(BPin)CHCH), 7.37 - 7.30 (m, 3H, C(BPin)CHCH, C(BPin)CHC(OCH2), C(Cl)CHCH), 
4.26 - 4.19 (m, 2H, ArOCH2CH2), 4.13 - 4.04 (m, 2H, NCH2CH2NCH2), 3.92 - 3.84 (m, 2H, 
ArOCH2CH2), 3.78 - 3.63 (m, 8H, CH2CH2OH, NCH2CH2NCH2, NCH2CH2NCH2), 2.79 - 
2.63 (m, 4H, (NCH2CH2NCH2) x2), 1.35 (s, 12H, BO2C2(CH3)4); 13C NMR (100 MHz, CDCl3) 
δ = 180.33, 179.34, 174.34, 156.59, 134.28, 133.57, 133.33, 130.92, 130.82, 130.72, 129.94, 
128.76, 128.72, 127.39, 117.54, 83.95, 72.36, 69.72, 67.58, 61.65, 56.02, 52.35, 51.94, 48.71, 
48.46, 24.81, C-BPin not visible; IR (neat) cm-1; 3363, 2931, 2868, 1682, 1604, 1559, 1470, 
1354, 1285, 1135; HRMS (ESI) [M + H]+ calcd for C31H39BCl2N3O6S 662.2030, found 
662.2021.  
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7.1.26 2-(2-(2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy) 
ethan-1-ol, (10)  
 
 
A solution of 2-(2-bromoethoxy)ethan-1-ol, (0.96 g, 5.7 mmol, 2.9 eq.) dissolved in DMF (2 
mL) was added dropwise (over 1 min) to a solution of 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenol, (0.45 g, 1.9 mmol, 1.0 eq.) in DMF (15 mL). K2CO3 (0.53 g, 3.8 
mmol, 2.0 eq.) was then added, followed by KI (0.32 g, 1.9 mmol, 1.0 eq.), the resulting 
mixture was heated to 80 °C and stirred for 16 h. The mixture was evaporated under reduced 
pressure, diluted in H2O (50 mL) and extracted using EtOAc (4 x 40 mL). The combined 
organic extracts were dried over anhydrous MgSO4 and evaporated under reduced pressure to 
a brown oil. The crude product was purified via flash column chromatography (50% EtOAc / 
50% light petroleum ether) to afford alcohol 10 as a pale-yellow oil (0.35 g, 58%).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.46 (dd, J = 8.1, 1.3 Hz, 1H, CHCHC(BPin)), 7.42 (s, 
1H, C(CH3)CHC(BPin)), 6.91 (d, J = 8.2 Hz, 1H, CHCHC(BPin)), 4.73 - 4.51 (m, 1H, OH), 
4.17 - 3.98 (m, 2H, ArOCH2CH2), 3.81 - 3.66 (m, 2H, ArOCH2CH2), 3.54 - 3.43 (m, 4H, 
CH2CH2OH), 2.12 (s, 3H, ArCH3), 1.22 (s, 12H, B(O2C2(CH3)4)); 13C NMR (100 MHz, 
DMSO-d6) δ = 159.31, 136.79, 134.10, 125.19, 110.72, 83.27, 72.58, 68.91, 67.10, 60.26, 
24.69, 15.83, C-BPin Not visible; IR (neat) 3436, 2980, 1604, 1405, 1351, 1321, 1285, 1254, 
1131, 1069 cm-1; m/z (ESI) [M + Na]+ 345.34 
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7.1.27 Potassium trifluoro(4-(2-(2-hydroxyethoxy)ethoxy)-3-methylphenyl)borate, (29) 
 
 
 
KHF2 aq. (4.5 M, 1.37 mL, 6.2 mmol, 5.65 eq.) was added to 2-(2-(2-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethan-1-ol (0.35 g, 1.1 mmol, 1.0 eq.) 
in MeOH (7 mL) and stirred for 1 h at room temperature.  The reaction mixture was diluted 
with acetone (10 mL) and filtered. The filtrate was evaporated under reduced pressure to give 
a white residue. The residue was then subjected to three evaporation cycles in MeOH / H2O 
1:1 (15 mL), as described previously. 
The procedure above was repeated entirely using the crude reaction mixture, to ensure the 
material fully reacted, to give trifluoroborate 29 as a white solid (quantitative).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.09 - 6.95 (m, 2 H, C(BF3K)CHCH, 
C(BF3K)CHC(CH3)), 6.60 (d, J = 8.3 Hz, 1 H, C(BF3K)CHCH), 4.61 (br. s., 1 H, OH), 4.04 - 
3.88 (m, 2 H, ArOCH2CH2), 3.72 - 3.62 (m, 2 H, ArOCH2CH2), 3.47 (s, 4 H, CH2CH2OH), 
2.04 (s, 3 H, ArCH3); 13C NMR (100 MHz ,DMSO-d6) δ = 155.06, 134.67, 130.25, 123.56, 
110.58, 73.14, 69.84, 67.83, 60.82, 16.74, C-BF3K (not visible); IR (neat) 2923, 2881, 1603, 
1501, 1451, 1405, 1367, 1249, 1123, 1056 cm-1; m/z (ESI) [M - K]+ 263.22; Mp = 215 – 218 
℃ (decomposed) 
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7.1.28 (4-(2-(2-Hydroxyethoxy)ethoxy)-3-methylphenyl)boronic acid, (30) 
 
 
 
 
 
Trimethylsilyl chloride (0.56 mL, 4.5 mmol, 6.0 eq.) and H2O (0.08 mL, 4.5 mmol, 6.0 eq.) 
was added to potassium trifluoro(4-(2-(2-hydroxyethoxy)ethoxy)-3-methylphenyl)borate 
(0.225 g, 0.80 mmol, 1.0 eq.) dissolved in MeCN (9 ml) and stirred for 1 h at room 
temperature. Sat. aq. sodium bicarbonate solution (0.8 mL) was added. The mixture was dried 
over anhydrous Na2SO4, filtered and evaporated to give a boronic acid 30 as a white solid 
(0.10 g, 56%).    
 
 
1H NMR (400 MHz, MeOH-D3,) δ = 7.49 - 7.23 (m, 2H, Ar-H), 7.10 - 6.88 (m, 1H, Ar-H), 
6.83 - 6.55 (m, 1H, Ar-H), 4.08 - 3.91 (m, 2H, ArOCH2CH2O), 3.80 - 3.65 (m, 2H, 
ArCH2CH2O), 3.63 - 3.45 (m, 4H, CH2CH2), 2.08 (s, 3H, CH3)* 
 
* 1H NMR indicated the formation of dimers / trimers within the structure, after 1 day the 
material was found to have degraded (by 1H NMR), which prevented further analysis. 
Compound synthesised just prior to use in subsequent reactions.  
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7.1.29 2-(2-(2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)ethoxy)ethyl4-methylbenzenesulfonate, (37) 
 
 
 
Triethylamine (0.22 mL, 1.5 mmol, 2.0 eq.) and tosyl chloride (0.29 g, 1.5 mmol, 2.0 eq.) 
were added to a stirring solution of 2-(2-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenoxy)ethoxy)ethan-1-ol (0.25 g, 0.8 mmol, 1.0 eq.) in DCM (10 ml). The resulting 
mixture was left stir at room temperature for 24 h. It was then diluted with H2O (40 mL), 
extracted in DCM (4 x 30 mL. The combined organic extracts were dried over anhydrous 
MgSO4, filtered and evaporated. The crude product was purified via flash column 
chromatography (30% EtOAc / 70% light petroleum ether), to yield tosylate 37 as a pale-
yellow oil (0.37 g, 74%).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.75 (d, J = 8.2 Hz, 2H, CHCHC(SO3)), 7.46 (d, J = 8.1 
Hz, 1H, CHCHC(BPin)), 7.43 (s, 1H, C(CH3)CHC(BPin)), 7.40 (d, J = 8.5 Hz, 2H, 
CHCHC(SO3)), 6.88 (d, J = 8.1 Hz, 1H, CHCHC(BPin)), 4.18 - 4.08 (m, 2H, ArOCH2CH2), 
4.06 - 3.96 (m, 2H, CH2CH2OTs), 3.74 - 3.62 (m, 4H, CH2CH2OTs, ArOCH2CH2), 2.36 (s, 
3H, CH3TsO), 2.10 (s, 3H, ArCH3), 1.26 (s, 12H, B(O2C2(CH3)4)); 13C NMR (100 MHz, 
CDCl3) δ = 159.35, 144.73, 137.14, 134.07, 132.77, 129.71, 127.84, 125.97, 110.12, 83.43, 
69.75, 69.24, 68.84, 67.34, 24.76, 21.53, 15.96, C-BPin Not visible; m/z (ESI) [M + Na]+ 
499.41 
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7.1.30 2-(2-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethoxy)ethyl 
2-chloroacetate, (38) 
 
 
 
To a solution of 2-(2-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)ethoxy)ethan-1-ol, (0.16 g, 0.5 mmol, 1.0 eq.) dissolved in DCM (3 mL), under a 
flow of N2. Pyridine (0.04 mL, 0.5 mmol, 1.0 eq.) was added. Chloroacetyl chloride (0.08 mL, 
1.0 mmol, 2.0 eq.) was then added dropwise, and stirred at room temperature for 2 h. The 
reaction was quenched following the addition of H2O (10 mL) and diluted with DCM (30 mL), 
then washed with H2O (2 x 10 mL), NaOH aq. 0.1 M  (1 x 20 mL) and 1 x 0.1M HCl aq. The 
organic component was dried over anhydrous MgSO4, the volatiles were then removed under 
reduced pressure to give a golden-brown oil. The crude material was purified via flash column 
chromatography eluting with 40% EtOAc / 60 % light petroleum ether, to afford chloride 38 
as a yellow oil (0.16 g, 81%). 
 
1H NMR (400 MHz, CDCl3) δ = 7.62 (d, J = 8.1 Hz, 1H, CHCHC(BPin)), 7.60 (s, 1H, 
C(CH3)CHC(BPin)), 6.81 (d, J = 8.1 Hz, 1H, CHCHC(BPin)), 4.39 - 4.34 (m, 2H, 
ArOCH2CH2), 4.18 - 4.14 (m, 2H, CH2CH2CO2Cl), 4.07 (s, 2H, CH2Cl), 3.91 - 3.86 (m, 2H, 
CH2CH2CO2Cl), 3.85 - 3.80 (m, 2H, ArOCH2CH2), 2.22 (s, 3H, ArCH3), 1.33 (s, 12H, (CH3)4); 
13C NMR (100 MHz, CDCl3) δ = 167.46, 159.56, 137.35, 134.25, 126.20, 110.38, 83.62, 
69.88, 69.15, 67.58, 65.37, 40.92, 24.94, 16.15, C-BPin not visible; IR (neat) 2976, 2342, 
1759, 1604, 1407, 1354, 1287, 1135, 965 cm-1; HRMS (ESI) [M + H]+ calcd for C19H28 11B 
35ClO6, 398.1662 found 398.1659 
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7.1.31 4-((4-Bromobenzyl)oxy)-3-hydroxybenzaldehyde, (46) 
 
 
 
3,4–Dihydroxybenzaldehyde (0.55 g, 4.0 mmol, 1 eq.) was added to a stirring solution of 4-
bromo benzyl bromide (2.00 g, 8.0 mmol, 2 eq.) in DMF (20 mL), followed by the addition 
of NaHCO3 (0.50 g, 6.0 mmol, 1.5 eq.) and NaI (0.18 g, 1.2 mmol, 0.3 eq.). The resulting 
mixture was heated at 40 °C for 24 h. The reaction was quenched by the addition of a solution 
of 1 M HCl aq. (10 mL) and then diluted with 5% LiCl aq. solution (50 mL). The organic 
portion was extracted using EtOAc (1 x 50 mL) and washed with 5 % LiCl solution (2 x 50 
ml). The organic extract was dried over anhydrous MgSO4, filtered and evaporated to give a 
light brown solid. The crude mixture was purified by flash column chromatography using 40 
% EtOAc / 60 % light petroleum ether as the eluent to give aldehyde 46 as an off-white 
crystalline solid (0.68 g, 55 %).  An analytical sample was obtained by recrystallization using 
DCM and hexanes, to afford a white crystalline solid.  
 
1H NMR (400 MHz, CDCl3) δ = 9.83 (s, 1 H, C(O)H), 7.55 (d, J = 8.2 Hz, 2 H, CHCBr), 7.45 
(d, J = 2.3 Hz, 1 H, C(CHO)CHC(OH)), 7.40 (dd, J = 8.7, 2.1 Hz, 1 H, C(CHO)CHCH), 7.29 
(d, J = 8.2 Hz, 2 H, C(CH2)CH), 6.99 (d, J = 8.7 Hz, 1 H, CHCHC(OCH2ArBr)), 5.79 (br. s., 
1 H, C(OH)), 5.15 (s, 2 H, CH2);  13C NMR (100 MHz ,CDCl3) δ = 191.15, 150.79, 146.39, 
134.36, 132.27, 131.16, 129.68, 124.44, 123.03, 114.76, 111.62, 70.66;  IR (neat) 3210.33, 
2807.11, 1660.83, 1601.18, 1503.99, 1412.22, 1274.37, 1127.60, 1007.14, 798.73 cm-1; 
HRMS (ESI) [M + H]+ calcd for C14H11 11BrO3, 306.9964 found 306.9968; Mp = 131 - 134 ℃ 
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7.1.32 3-Hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)benzaldehyde, (47) 
 
 
 
B2Pin2 (0.38 g, 1.5 mmol, 1.1 eq.) and KOAc (0.40 g, 4.1 mmol, 3.0 eq.) were added to a 
solution of 4-((4-bromobenzyl)oxy)-3-hydroxybenzaldehyde (0.42 g, 1.4 mmol, 1 eq.) in 
anhydrous dioxane (15 mL), the resulting mixture was degassed under nitrogen for 5 min. The 
flask was then charged with PdCl2dppf (56 mg, 0.7 mmol, 0.05 eq.) and heated to 80 °C, under 
a flow of nitrogen for 48 h. The reaction mixture was then cooled to room temperature, filtered 
through a pad of silica (prepared with DCM) and flushed through with additional DCM (100 
mL). This process was repeated once more using the filtrate. The volatiles were then removed 
under reduced pressure to obtain a golden-brown oil. The crude mixture was the purified using 
column chromatography, 50% EtOAc / 50% light petroleum ether eluent. Evaporation of 
desired fractions afforded boronate ester 47 as a pale-yellow solid (0.39 g, 77%). An analytical 
sample was obtained by recrystallization using DCM and hexanes, to afford a white crystalline 
solid.  
 
1H NMR (400 MHz ,CDCl3) δ = 9.82 (s, 1 H, C(O)H), 7.85 (d, J = 7.9 Hz, 2 H, CHC(Br)), 
7.45 (d, J = 2.0 Hz, 1 H, C(CHO)CHC(OH)), 7.41 (d, J = 7.9 Hz, 2 H, C(CH2)CH), 7.38 (dd,  
J = 8.2, 2.0 Hz, 1 H, C(CHO)CHCH), 6.99 (d,  J = 8.2 Hz, 1 H, CHCHC(OCH2ArBPin), 5.81 
(s, 1 H, ArOH), 5.22 (s, 2 H, , CH2), 1.34 (s, 12 H, (CH3) x4); 13C NMR (100 MHz ,CDCl3) δ 
= 191.12, 150.98, 146.49, 138.27, 135.49, 131.07, 127.08, 124.49, 114.55, 111.69, 84.19, 
71.34, 24.98, C-BPin missing; IR (neat) 3546, 3226, 2982, 2871, 1655, 1603, 1583, 1456, 
1323, 1283, 1087, 1020, 963 cm-1; HRMS (ESI) [M + H]+ calcd for C20H23 11BO5, 355.1711 
found 355.1705; Mp = 120 – 122 ℃. 
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7.1.33 3-(4-Fluorobenzyl)thiazolidine-2,4-dione, (42) 
 
 
 
2,4-Thiazolindindione (2.94 g, 25.0 mmol, 1.5 eq.) was added to anhydrous DMF (50 mL) 
and the stirred solution was cooled to 0 °C, under N2. NaH was then added as a 60 % mineral 
oil dispersion (0.92 g, 23.0 mmol, 1.35 eq.),  followed by 4-flouro benzyl bromide (2.1 mL, 
17 mmol, 1 eq.) as a solution in  anhydrous DMF (10 mL). The resulting solution was left to 
warm to room temperature over a period 90 min and then stirred for a further 5 h.  
The reaction mixture was poured over crushed ice / water (100 mL), hexanes (50 mL) were  
then added to give a loose cream precipitate. The mixture was refrigerated at 4 °C for a period 
of 12 h. On decanting the liquid portion in to a separate flask, a white solid was spontaneously 
formed.  This left an oily residue on the base of the original flask, which precipitated a white 
solid upon the addition of hexanes (100 mL). The precipitates from both flasks were collected 
by vacuum filtration, washed with cold hexanes and combined to give an off-white solid. The 
solid was then dissolved in DCM (250 mL) and washed with 5% aq. LiCl solution (1 x 200 
mL, then 2 x 100 mL). The organic layer was then dried over anhydrous MgSO4, filtered and 
evaporated to yield heterocycle 42 as an off-white crystalline solid, 3.26 g 80%.  
 
 
1H NMR (400 MHz, CDCl3) δ = 7.46 - 7.35 (m, 2H), 7.08 - 6.94 (m, 2H), 4.73 (s, 2H), 3.95 
(s, 2H) 
 
1H NMR data was in agreement with that published by Albers and co-workers.43 
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7.1.34 3-(2-(2-hydroxyethoxy)ethoxy)-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)benzaldehyde, (48) 
 
 
 
To a stirring solution of 3-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)benzaldehyde  (0.27 g, 0.7 mmol, 1 eq.) in DMF (5 mL), potassium carbonate 
(0.15 g, 1.1 mmol, 1.5 eq.) was added. 2-chloro-2-ethoxy ethanol (0.23 mL, 2.2 mmol, 3 eq.) 
dissolved in DMF (1 mL) was then added dropwise (over 1 minute) to the mixture, followed 
by the addition of KI (0.18 g, 0.7 mmol, 1 eq.). The resulting mixture was heated to 75 °C and 
stirred for 36 h. The solvent was then evaporated under reduced pressure to obtain a brown 
oil, which was dissolved in H2O (30 mL). The organic portion extracted with EtOAc (3 x 30 
mL). The combined organic extracts were then dried over anhydrous MgSO4, filtered and 
evaporated to obtain brown oil. The crude material was purified by flash column 
chromatography (50 % EtOAc / 50 % light petroleum ether) to afford alcohol 48 as a pale-
yellow oil (0.26 g, 70 %). 
 
1H NMR (400 MHz, CDCl3) δ = 9.79 (s, 1 H, CHO), 7.80 (d,  J = 8.2 Hz, 2 H, C(BPin)CH), 
7.45 (d, J = 2.3 Hz, 1 H, C(CHO)CHC(OCH2)), 7.37 (dd, J = 8.2, 2.1 Hz, 1 H, 
C(CHO)CHCH), 6.94 (d, J = 8.2 Hz, 1 H, C(CHO)CHCH), 5.23 (s, 2 H, CH2ArBPin), 4.26 - 
4.21 (m, 2 H, ArOCH2CH2), 3.95 - 3.86 (m, 2 H, ArOCH2CH2), 3.78 - 3.59 (m, 5 H, 
OHCH2CH2, OHCH2CH2, OHCH2CH2), 1.32 (s, 12 H, BO2(CH3)4); 13C NMR (100 MHz, 
CDCl3) δ = 191.08, 154.08, 149.37, 139.24, 135.23, 130.38, 127.03, 126.43, 112.93, 111.58, 
84.06, 72.81, 70.83, 69.57, 68.93, 61.98, 25.02, C-BPin not visible; IR (neat) 3423, 3978, 
3931, 2871, 1583, 1655, 1584, 1508, 1268 cm-1; HRMS (ESI) [M + H]+  calcd for C24H31 
11BO7, 443.2236 found 443.2228 
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7.1.35  (Z)-3-(4-Fluorobenzyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)-4-((4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)benzylidene)thiazolidine-2,4-dione, (49) 
 
 
 
3-(4-Fluorobenzyl)thiazolidine-2,4-dione (0.1 g, 0.4 mmol, 1 eq.) was added to a solution of 
3-(2-(2-hydroxyethoxy)ethoxy)-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzyl) 
oxy)benzaldehyde (0.2 g, 0.4 mmol, 1 eq.) in ethanol (5 mL),  followed by piperadine (45 µl, 
0.4 mmol, 1 eq.). The resulting mixture was heated to 78 °C and stirred for 24 h. The solution 
was cooled to room temperature and evaporated to an orange residue. This was then purified 
by flash column chromatography (50 % EtOAc / 50 % light petroleum ether) to afford alcohol 
49 as a yellow oil (0.16 g, 55 %). 
 
1H NMR (400 MHz ,CDCl3) δ = 7.83 - 7.77 (m, 3 H, C=CH, C(BPin)CH), 7.44 - 7.38 (m, 4 
H, C(CH2O)CH, C(CH2N)CH), 7.07 - 6.96 (m, 4 H, C(HC=C)CHCH, C(HC=C)CHC(OCH2), 
C(F)CH), 6.91 (d, J = 9.1 Hz, 1 H, (C(HC=C)CHCH), 5.20 (s, 2 H, CH2ArBPin), 4.84 (s, 2 
H, CH2ArF), 4.24 - 4.18 (m, 2 H, ArOCH2CH2), 3.95 - 3.89 (m, 2 H, ArOCH2CH2), 3.75 - 
3.65 (m, 4 H, OHCH2CH2, OHCH2CH2), 1.33 (s, 12 H, BO2(CH3)4); 13C NMR (100 MHz, 
CDCl3) δ =167.91, 166.25, 162.69 (d, 1JC-F =247.28 Hz), 150.95, 149.11, 139.41, 135.17, 
134.25, 131.17 (d, 4JC-F =2.88 Hz), 130.97 (d, 3JC-F =7.67 Hz), 126.47, 126.38, 125.31, 118.81, 
115.71 (d, 2JC-F =21.09 Hz), 115.32, 114.10, 83.97, 72.78, 70.84, 69.54, 69.12, 61.92, 44.53, 
24.95, C-BPin not visible; IR (neat): 3672, 2974, 2902, 2298, 2108, 1734, 1676, 1590, 1508, 
1311 cm-1; HRMS (ESI+) (m/z) calcd for C34H37 11BFNO7S+ [M + H]+ 650.2396, found 
650.2396.  
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7.1.36 (Z)-2-(2-(5-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-((4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenoxy)ethoxy)ethyl 4-methyl 
benzenesulfonate, (50) 
 
 
Method 1: 
Triethylamine (0.04 mL, 0.3 mmol 2 eq.) was added slowly (over 1 min) to a solution of (Z)-
3-(4-fluorobenzyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)-4-((4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2yl)benzyl)oxy)benzylidene)thiazolidine-2,4-dione (84 mg, 0.1 mmol, 1 eq.) in 
DCM (5 mL), followed by tosyl chloride (49 mg, 0.3 mmol, 2 eq.). This was then stirred at 
room temperature for 36 h. The reaction mixture was diluted with H2O (50 mL) and the 
organic layer extracted with DCM (3 x 25 mL). The combined organic extracts were then 
dried over anhydrous MgSO4, filtered and evaporated to obtain a yellow oil. 
The crude mixture was purified via flash column chromatography (35 % EtOAc / 65 % 
petroleum ether to afford tosylate 50 as a yellow oil (44 mg, 44 %). 
 
1H NMR (400 MHz, CDCl3) δ = 7.81 - 7.75 (m, 5 H, CHC(SO3), CHC(BPin), C=CH), 7.44 - 
7.37 (m, 4 H, C(CH2O)CH, C(CH2N)CH), 7.27 (d, J = 8.1 Hz, 2 H, C(CH3)CH), 7.06 - 6.96 
(m, 4 H, C(HC=C)CHCH, C(F)CH, C(HC=C)CHC(OCH2)), 6.91 (d, J = 8.3 Hz, 1 H, 
C(HC=C)CHCH), 5.17 (s, 2 H, CH2Ar(BPin)), 4.84 (s, 2 H, NCH2Ar(F)), 4.14 - 4.11 (m, 4 H, 
ArOCH2CH2, CH2CH2OTs), 3.84 - 3.78 (m, 2 H, CH2CH2OTs), 3.77 - 3.74 (m, 2 H, 
ArOCH2CH2), 2.38 (s, 3 H, CH3Ar), 1.34 (s, 12 H, BO2(CH3)4); 13C NMR (100 MHz, CDCl3) 
δ =167.90, 166.24, 162.68 (d, 1JC-F =250.84 Hz), 151.04, 149.11, 144.83, 139.47, 135.15, 
134.23, 133.06, 131.19 (d, 4JC-F =2.31 Hz), 130.96 (d, 3JC-F =9.25 Hz), 129.87, 128.06, 126.49, 
126.40, 125.28, 118.83, 115.70 (d, 2JC-F =20.81 Hz), 115.56, 114.21, 83.99, 70.85, 69.80, 
69.36, 69.22, 69.16, 44.52, 24.98, 21.72, C-BPin not visible; IR (solid): 3671, 2974, 1917, 
1734, 1677, 1592, 1508, 1454, 1355 cm-1; HRMS (ESI+) (m/z) calcd for C41H43 11BFNO10S2 
[M + H]+ 821.2744, found 821.2756.  
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Method 2: 
B2Pin2 (0.22 g, 0.90 mmol, 1.1 eq.), KOAc (0.23 g, 2.40 mmol, 3.0 eq.) and PdCl2dppf (33 
mg, 0.04 mmol, 0.05 eq.) was added to  a solution of (Z)-2-(2-(2-((4-bromobenzyl)oxy)-5-((3-
(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)phenoxy)ethoxy)ethyl 4-methyl 
benzenesulfonate (0.60 g, 0.79 mmol, 1.0 eq.), in anhydrous dioxane  (25 mL). The resulting 
mixture was heated to 80°C for 24 h, then cooled to room temperature. The resulting slurry 
was filtered through a plug of silica, eluting with DCM (100 mL) and the filtrate filtered 
through a second silica plug. The filtrate was then evaporated to a brown oil which was 
purified by flash column chromatography (50% EtOAc / 50% light petroleum ether) to afford 
tosylate 50 as a yellow oil (0.63 g, 64 %).  
 
The material was analysed via 1H NMR spectroscopy, (CDCl3) and was found to be in 
agreement with that of method 1. 
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7.1.37 (Z)-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2- 
(tosyloxy)ethoxy)ethoxy)phenoxy)methyl)phenyl)boronic acid, (51) 
 
 
Method 1: 
NaIO4 (70 mg, 3.3 mmol, 6 eq.) was added to a solution of (Z)-2-(2-(5-((3-(4-fluorobenzyl)-
2,4-dioxothiazolidin-5-ylidene)methyl)-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (43 mg, 0.5 mmol, 1eq.) in 
THF/ H2O 1:4 (1 mL) and the resulting mixture stirred for 30 min at room temperature. 1 M 
HCl aq. (0.2 mL) was then added and stirred for 2 h. A second portion of NaIO4 (47 mg, 2.2 
mmol, 4 eq.) was added and this was stirred for 14 h. The reaction mixture was diluted with 
H2O (20 mL) and extracted with EtOAc (3 x 15 mL). The organic extracts were combined, 
dried over anhydrous MgSO4, filtered and evaporated to obtain a grainy yellow oil. MeCN (3 
mL) was added, which effected the precipitation of boronic acid 51 as a yellow crystalline 
solid, that was then decanted and the solid dried (10 mg, 25 %). 
 
1H NMR (400 MHz ,ACETONE-d6) δ = 7.87 (d, J = 7.8 Hz, 2 H, C(B(OH)2)CH), 7.83 (s, 1 
H, C=CH), 7.75 (d, J = 8.2 Hz, 2 H, C(SO3)CH), 7.46 - 7.41 (m, 4 H, C(CH2N)CH, 
C(CH2O)CH), 7.37 (d, J = 8.2 Hz, 2 H, C(CH3)CH), 7.22 - 7.19 (m, 3 H, C(HC=C)CHCH, 
C(HC=C)CHCH, C(HC=C)CHC(OCH2)), 7.13 - 7.06 (m, 2 H, C(F)CH), 5.22 (s, 2 H, 
CH2ArB(OH)2), 4.86 (s, 2 H, NCH2), 4.19 - 4.10 (m, 4 H, ArOCH2CH2, CH2CH2OTs), 3.82 - 
3.72 (m, 4 H, ArOCH2CH2, CH2CH2OTs), 2.35 (s, 3H, ArCH3); 13C NMR (100 MHz, 
ACETONE-d6) δ =167.37, 165.80, 162.43 (d, J=245.37 Hz), 151.08, 149.36, 144.89, 139.07, 
134.37, 133.59, 133.43, 132.20 (d, J=2.88 Hz), 130.54 (d, J=7.67 Hz), 129.95, 127.89, 126.61, 
126.57, 124.59, 118.87, 115.57, 115.36 (d, J=21.09 Hz), 114.45, 70.53, 69.91, 69.39, 69.03, 
68.82, 44.11, 20.69, C-B(OH)2 Not visible; ; IR (solid): 3334, 2932, 1733, 1672, 1590, 1513, 
1345, 1270 cm-1; HRMS (ESI+) (m/z) calcd for C35H33 11BFNO10S2 [M + H]+ 722.1702, found 
722.1701; Mp = 139 – 142 ℃.  
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7.1.38 Potassium (Z)-trifluoro(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene) 
methyl)-2-(2-(2-(tosyloxy)ethoxy)ethoxy)phenoxy)methyl)phenyl)borate 
 
 
 
KHF2 4.5M aq. (1.42 mL, 6.4 mmol, 10 eq.) was added in one potion to a solution of (Z)-2-
(2-(5-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-((4-(4,4,5,5-tetramethyl 
-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenoxy)ethoxy)ethyl4-methylbenzenesulfonate (0.50  
g, 0.6 mmol, 1.0 eq.) in MeOH (10 mL), then stirred for 1 h at room temperature. Acetone (15 
mL) was then added. The solution was filtered under gravity, and the filtrate was then 
evaporated under reduced pressure to give an oily yellow residue. The residue was subjected 
to MeOH / H2O 1:1 evaporation cycles (as previously described). The entire reaction was 
repeated with the yellow solid obtained and then worked-up as described, to obtain a yellow 
crystalline solid (quantitative).  
 
The material was then carried through to the next reaction without any further purification as 
an intermediate. 
 
Trimethylsilyl chloride (0.40 mL, 3.1 mmol, 5.0 eq.) and H2O (60 µL, 3.1 mmol, 5.0 eq.) were 
added to as solution of potassium (Z)-trifluoro(4-((4-((3-(4-fluorobenzyl)-2,4-
dioxothiazolidin-5-ylidene)methyl)-2-(2(2(tosyloxy)ethoxy)ethoxy)phenoxy)methyl)phenyl) 
borate (0.49 g, 0.6 mmol, 1 eq.) in MeCN (10 mL) and stirred for 1 h at room temperature. A 
solution of sodium bicarbonate sat. aq. (1 mL) was added. The mixture was then dried using 
anhydrous sodium sulfate, filtered and evaporated to give a yellow solid. 
This was purified via flash column chromatography (90% Acetone / 10% light petroleum 
ether) to give boronic acid 51 as a yellow solid (0.34 g, 71%).  
 
The material was analysed via 1H NMR spectroscopy (Acetone-D6) and in agreement with 
that of method 1, (boronic acid 51). 
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7.1.39 Methyl 4-((4-formyl-2-hydroxyphenoxy)methyl)benzoate, (39) 
 
3,4-Dihydroxybenzaldehyde (1.51 g, 10.9 mmol, 1.0 eq.) was stirred in DMF (40 mL), sodium 
bicarbonate (1.29 g, 15.3 mmol, 1.5 eq.), methyl-4-(bromomethyl)-benzoate (5.00 g, 21.8 
mmol, 2.0 eq.) and sodium iodide (0.49 g, 3.3 mmol, 0.3 eq.) was added. The reaction mixture 
stirred for 2 days at 40 °C. The reaction was quenched using 1M HCl aq. (100 mL) and then 
diluted with H2O (100 mL). The organic portion was extracted with EtOAc (3 x 200 mL), 
combined, washed with a solution of 5% LiCl aq. (3 x 250 mL), then brine (1 x 400 mL), dried 
over anhydrous MgSO4, filtered and evaporated under reduced pressure to obtain a light brown 
solid. This was then recrystallized using a mixture of EtOAc / hexanes to obtain ester  39 as a 
tan crystalline solid (1.00 g, 32 %).   
1H NMR (400 MHz, CDCl3) δ = 9.85 (s, 1H, CHO), 8.09 (d, J = 8.3 Hz, 2H, C(CO2Me)CH), 
7.62 - 7.46 (m, 3H, C(CO2Me)CHCH, C(CHO)CHC(OH)), 7.41 (dd, J = 8.5, 1.9 Hz, 1H, 
C(CHO)CHCH), 7.00 (d, J = 8.2 Hz, 1H, C(CHO)CHCH), 5.81 (s, 1H, C(OH)), 5.28 (s, 2H, 
O(CH2)), 3.94 (s, 3H, CO2CH3); 13C NMR (100 MHz, CDCl3) δ = 191.08, 166.67, 150.68, 
146.36, 140.30, 131.13, 130.54, 130.26, 127.50, 124.40, 114.76, 111.65, 70.61, 52.41; IR 
(neat) cm-1; 3270, 2952, 2361, 1710, 1673, 1608, 1582, 1505, 1436, 1278, 1110; HRMS (ESI) 
[M + H]+ calcd for C16H14O5, 287.0914 found 287.0916, Mp = 138 – 140 °C. 
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7.1.40 Methyl 4-((4-formyl-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (40) 
 
Potassium carbonate (0.92 g, 6.6 mmol, 2.0 eq.), potassium iodide (0.55 g, 3.3 mmol, 1.0 eq.) 
and 2-(2-chloro-ethoxy)-ethanol (1.05 mL, 10.0 mmol, 3.0 eq.) was added to a solution of 
methyl 4-((4-formyl-2-hydroxyphenoxy)methyl)benzoate (0.95 g, 3.32 mmol, 1.0 eq.) in 
DMF (20 mL). The resulting mixture was heated to 70 °C for 40 h. The solution was diluted 
with H2O (70 mL) and extracted with EtOAc (3 x 100 mL), the organic extracts were 
combined,  washed with a solution of 5% LiCl aq. (3 × 200 mL) and brine (2 x 300 mL), dried 
over anhydrous MgSO4, filtered and evaporated to brown oil. The crude material was purified 
via flash column chromatography (70% EtOAc / light petroleum ether →100% EtOAc) to 
give alcohol 40 as a white solid (1.12 g, 95 %). 
 
1H NMR (400 MHz, CDCl3) δ = 9.83 (s, 1H, CHO), 8.06 (d,  J = 8.3, 2H, C(CO2Me)CH), 
7.60 - 7.45 (m, 3H, C(CO2Me)CHCH, C(CHO)CHC(OCH2CH2)), 7.41 (dd, J = 8.2, 2.1, 1H, 
C(CHO)CHCH), 6.97 (d, J = 8.5, 1H, C(CHO)CHCH), 5.28 (s, 2H, OCH2ArCO2Me), 4.33 - 
4.19 (m, 2H, ArOCH2CH2O), 4.02 - 3.86 (m, 5H, ArOCH2CH2O, CO2Me), 3.79 - 3.56 (m, 
4H, CH2CH2OH); 13C NMR (100 MHz, CDCl3) δ = 195.14, 171.00, 157.84, 153.53, 145.50, 
134.80, 134.24, 134.17, 131.25, 131.09, 117.08, 115.67, 76.96, 74.46, 73.70, 73.01, 66.08, 
56.48. IR (solid): 3671, 3504, 3442, 3407, 2908, 1722, 1685, 1584 cm-1; HRMS (ESI+) calcd 
for C20H22O7 [M + H]+ 375.1438, found 375.1441. Mp = 56-59 °C.   
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7.1.41 4-((4-Formyl-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoic acid, (41) 
 
 
 
Methyl 4-((4-formyl-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate  (1.09 g, 3.1 
mmol, 1.0 eq.) was dissolved in DMSO (18 mL). H2O (12 mL) was added followed by NaOH 
aq. (1M, 3.07 mL, 3.1 mmol, 1.0 eq.), the mixture was then heated to 70 °C for 1 h, and then 
cooled to room temperature. The pH was adjusted to pH 2 via the careful addition of 1 M HCl 
aq. effecting the precipitation of a white solid, which was collected through vacuum filtration. 
The filter cake was then dried under reduced pressure to obtain carboxylic acid 41 as a white 
powder, (quantitative). 
 
1H NMR (400 MHz, CDCl3) δ = 9.84 (s, 1H, ArCHO), 8.09 (d,  J = 8.3 Hz, 2H, C(COOH)CH), 
7.54 (d, J = 8.3 Hz, 2H, C(COOH)CHCH), 7.50 (d, J = 1.8 Hz, 1H, C(OCH2CH2)CHC(CHO)), 
7.42 (dd, J = 8.1, 1.8 Hz, 1H, C(CHO)CHCH), 6.98 (d, J = 8.2 Hz, 1H, C(CHO)CHCH), 5.30 
(s, 2H, CH2ArCOOH), 4.29 (dd, J = 5.3, 3.8 Hz, 2H, ArOCH2CH2), 3.97 (dd, J = 5.3, 3.7 Hz, 
2H, ArOCH2CH2), 3.81 - 3.64 (m, 4H, CH2CH2OH); 13C NMR (100 MHz, CDCl3) δ = 191.01, 
170.55, 153.60, 149.31, 142.05, 130.63, 130.07, 129.27, 127.09, 126.94, 112.85, 111.42, 
72.75, 70.24, 69.50, 68.74, 61.85. IR (solid): 3347,2861, 1678, 1584, 1508 cm-1; HRMS (ESI+) 
calcd for C19H20O7  [M + H]+ 361.1282, found 361.1286. Mp = 116-119 °C.   
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7.1.42 (Z)-4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-
hydroxyethoxy)ethoxy)phenoxy)methyl)benzoic acid, (43) 
 
 
 
Piperidine (0.26 mL, 2.6 mmol, 1.0 eq.) and 4-((4-formyl-2-(2-(2-hydroxyethoxy)ethoxy) 
phenoxy)methyl)benzoic acid (0.94 g, 2.6 mmol, 1.0 eq.) was added to a solution of 3-(4-
fluorobenzyl)-1,3-thiazolane-2,4-dione (0.59 g, 2.6 mmol, 1.0 eq.) in EtOH (10 mL). The 
solution was heated to 78 °C for 24 h. The mixture was cooled to room temperature and the 
resulting in precipitate was collected via vacuum filtration to yield heterocycle 43 as a pale-
yellow powder (0.72 g, 50%). 
  
1H NMR (400 MHz, DMSO-d6) δ = 8.01 (d, J = 8.2, 2H, C(CH2OAr)CH), 7.90 (s, 1H, C=CH), 
7.60 (d, J = 8.2, 2H, C(COOH)CH), 7.39 (dd, J = 8.6, 5.5, 2H, C(CH2N)CH), 7.31 - 7.05 (m, 
5H, C(HC=C)CHCH, C(HC=C)CHCH, C(HC=C)CHC(OCH2CH2), C(F)CH), 5.30 (s, 2H, 
CH2Ar(COOH)), 4.83 (s, 2H, CH2Ar(F)), 4.30 - 4.08 (m, 2H, ArOCH2CH2), 3.88 - 3.74 (m, 
2H, ArOCH2CH2), 3.57 (s, 4H, OHCH2CH2, OHCH2CH2). 13C NMR (100 MHz, DMSO-d6) 
δ = 167.88, 167.63, 166.03, 162.20 (d, 1JC-F = 243.5 Hz), 150.54, 149.08, 142.23, 134.23, 
132.28 (d, 4JC-F = 2.9 Hz), 130.78, 130.49 (d, 3JC-F = 7.7 Hz), 130.03, 127.75, 126.63, 124.51, 
118.78, 115.97 (d, 2JC-F = 22.0 Hz), 114.72, 73.14, 69.87, 69.31, 68.91, 60.82, 44.38, 22.68. 
IR (solid): 3672, 3448, 2972, 2902, 1729, 1678, 1509 cm-1; HRMS (ESI+) (m/z) calcd for 
C29H26FNO8S [M + H]+ 568.1436, found 568.1430; (Found: C, 61.15; H, 4.73; N, 2.61. 
C29H26FNO8S requires C, 61.37; H, 4.62; N, 2.47%); Mp = 188-191 °C.   
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7.1.43 Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-
ylidene)methyl)-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (44) 
 
 
 
Triisopropylsilyl chloride (0.38 mL, 1.8 mmol, 1.40 eq.) was added to a solution of  (Z)-4-((4-
((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxyethoxy) 
ethoxy)phenoxy)methyl)benzoic acid (0.72 g, 1.3 mmol, 1.0 eq.) in anhydrous THF (30 mL). 
Triethylamine (0.16 mL, 1.4 mmol, 1.1 eq.) was then added and the reaction mixture was 
stirred for 1 h at room temperature. The resulting mixture was then diluted with Et2O (20 mL) 
and then evaporated to give an oily yellow solid. The crude material was purified by flash 
column chromatography (60% EtOAc / light petroleum ether) to yield TIPS ester 44 as a bright 
yellow powder (0.92 g, 81 %).  
 
1H NMR (400 MHz, CDCl3) δ = 8.07 (d, J = 8.3, 2H, C(COOTIPS)CH), 7.80 (s, 1H, C=CH), 
7.51 (d, J = 8.3, 2H, C(CH2O)CH), 7.46 - 7.39 (m, 2H, C(CH2N)CH), 7.09 - 6.89 (m, 5H, 
C(HC=C)CHCH, C(HC=C)CHC(OCH2), C(HC=C)CHCH,), 5.26 (s, 2H, 
CH2Ar(COOTIPS)), 4.85 (s, 2H, CH2ArF), 4.30 - 4.11 (dd, J = 5.2, 4.0, 2H, ArOCH2CH2), 
3.95 (dd, J = 5.3, 4.0, 2H, ArOCH2CH2), 3.75 - 3.42 (m, 4H, OHCH2CH2, OHCH2CH2), 1.52 
- 1.31 (m, 3H, Si(CH(CH3)2)3), 1.12 (d, J = 7.4, 18H, Si(CH(CH3)2)3). 13C NMR (100 MHz, 
CDCl3) δ = 167.84, 166.22, 165.99, 162.70 (d, 1JC-F = 246.3 Hz, 1C), 150.61, 149.14, 141.47, 
134.10, 131.34, 131.15 (d, 4JC-F = 2.9 Hz, 1C), 130.98 (d, 3JC-F = 7.7 Hz, 1C), 130.63, 126.85, 
126.75, 125.20, 119.06, 115.72 (d, 2JC-F = 21.1 Hz, 1C), 115.23, 114.10, 72.75, 70.32, 69.52, 
69.01, 61.88, 44.55, 17.96, 12.14; IR (solid): 3536,2944, 2868, 1728, 1669, 1510 cm-1; HRMS 
(ESI+) (m/z) calcd for C38H46FNO8SSi+ [M + H]+ 724.2770, found 724.2774. (Found: C, 62.96; 
H, 6.53; N, 2.04. C38H46FNO8SSi requires C, 63.05; H, 6.41; N, 1.93%). Mp = 107-109 °C.   
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7.1.44 Triisopropylsilyl(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-
ylidene)methyl)-2-(2-(2-(tosyloxy)ethoxy)ethoxy)phenoxy)methyl)benzoate, (45) 
 
 
 
Tosyl chloride (0.21 g, 1.1 mmol, 2.0 eq.) and triethylamine (0.15 mL, 1.1 mmol, 2.0 eq.) 
were added to a solution of triisopropylsilyl (Z)-4-((4-((3-(4-fluorobenzyl)-2,4-
dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl) 
benzoate (0.40 g, 0.6 mmol, 1.0 eq.) in DCM (12 mL). The reaction mixture was stirred at 
room temperature for 36 h, then evaporated to a yellow residue which was purified by flash 
column chromatography (50% EtOAc / 50 % light petroleum ether) to afford tosylate 45 as a 
yellow crystalline solid (0.30 g, 61 %).  
 
1H NMR (400 MHz, ACETONE-d6) δ = 8.08 (d, J = 8.2, 2H, C(COOTIPS)CH), 7.84 (s, 1H, 
C=CH), 7.76 (d, J = 8.2, 2H, C(SO3)CH,), 7.64 (d, J = 8.2, 2H, C(CH2O)CH), 7.48 - 7.41 (m, 
2H, C(CH2N)CH), 7.37 (d, J = 8.2, 2H, C(CH3)CH), 7.25 - 7.18 (m, 3H, C(HC=C)CHCH,  
C(HC=C)CHCH, C(HC=C)CHC(OCH2)), 7.15 - 7.07 (m, 2H, C(F)CH), 5.33 (s, 1H, 
CH2ArCOOH), 4.87 (s, 2H, CH2ArF), 4.23 - 4.14 (m, 4H, ArOCH2CH2, TsOCH2CH2), 3.86 - 
3.75 (m, 4H, ArOCH2CH2, TsOCH2CH2), 2.36 (s, 3H, CH3), 1.49 - 1.36 (m, 3H, 
Si(CH(CH3)2)3), 1.14 (d, J = 7.3, 18H, Si(CH(CH3)2)3). 13C NMR (100 MHz, ACETONE-d6) 
δ = 168.10, 166.55, 166.34, 163.21 (d, 1JC-F = 245.4 Hz), 151.48, 150.17, 145.61, 143.39, 
134.27, 134.24, 132.94 (d, 4JC-F = 3.8 Hz), 131.69, 131.32 (d, 3JC-F = 8.6 Hz), 130.99, 130.68, 
128.65, 128.16, 127.62, 125.24, 119.83, 116.28, 116.13 (d, 2JC-F = 21.1 Hz), IR (solid) 115.36, 
70.69, 70.64, 70.17, 69.69, 69.55, 44.88, 21.46, 18.16, 12.72 cm-1 (solid): 2926, 2867, 2667, 
1731, 1681, 1592. HRMS (ESI+) (m/z) calcd for C45H52FNO10S2SiNH4+  [M + NH4]+ 
896.3124, found 896.3123. (Found: C, 61.44 ; H, 5.79 ; N, 1.71 . C38H46FNO8SSi requires C, 
61.55; H, 5.97; N, 1.60%). Mp = 72-75 °C.   
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7.1.45 Potassium (Z)-trifluoro(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene) 
methyl)-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)phenyl)borate (51) 
 
 
 
A solution of KHF2 aq. (4.5 M, 5.1 mL, 23.1 mmol, 10.0 eq.) was added to a solution of (Z)-
3-(4-fluorobenzyl)-5-(3-(2-(2-hydroxyethoxy)ethoxy)-4-((4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)oxy)benzylidene)thiophene-2,4(3H,5H)-dione (1.50 g, 2.3 mmol, 
1.0 eq.) in MeOH (25 mL). The solution was stirred at room temperature for 1 h, after which 
acetone (100 mL) was added resulting in the precipitation of a white solid, which was then 
filtered. The filtrate was evaporated under reduced pressure to a give a yellow residue that was 
then co-evaporated with MeOH / H2O 1:1, 3 times (as previously described). The entire 
process was repeated once more with the crude product, to yield trifluoroborate 51 as a yellow 
solid (0.76 g, 52 %), which was used immediately.  
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7.1.46 (Z)-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-
hydroxyethoxy)ethoxy)phenoxy)methyl)phenyl)boronic acid, (52) 
 
 
 
H2O (0.10 mL, 5.7 mmol, 5 eq.) and trimethylsilyl chloride (0.73 mL, 5.7 mmol, 5 eq.) was 
added to a solution of potassium (Z)-trifluoro(4-((4-((3-(4-fluorobenzyl)-2,4-
dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)phenyl) 
borate  (0.72 g, 1.1 mmol, 1.0 eq.)  in MeCN (12 mL). The resulting mixture was stirred at 
room temperature for 30 min, then H2O (0.5 mL) was added followed by MeCN (20 mL), 
effecting the precipitation of a light-yellow solid. The liquid was carefully decanted and the 
solid re-suspended in MeCN (10 mL), the liquid was then decanted. This process was repeated 
three additional times. The solid was thoroughly dried under high vacuum, then finally washed 
in hexanes and dried, to obtain boronic acid 51 as a light-yellow powder (0.43 g, 67 %). 
 
1H NMR (400 MHz, DMSO-d6) δ = 7.90 (s, 1H, C=CH), 7.81 (d, J = 8.10 Hz, 2H, 
C(B(OH)2CH), 7.36 (d, J = 7.90 Hz, 2H, C(B(OH)2CHCH), 7.34 - 7.30 (m, 2H, (NCH2)CCH), 
7.25 (br. s, 1H, (HC=C)CCHC(OCH2CH2)), 7.18 – 7.12 (m, 4H, C(HC=C)CHCH, C(F)CH), 
5.23 (s, 2H, CH2ArB(OH)2), 4.86 - 4.75 (m, 1H, CH2CH2OH), 4.18 - 4.08 (m, 2H, 
ArOCH2CH2), 3.84 - 3.70 (m, 2H, ArOCH2CH2), 3.61 - 3.44 (m, 4H, CH2CH2OH); 13C NMR 
(100 MHz, DMSO-d6) δ = 167.42, 165.57, 161.67 (d, 1JC-F = 244.4 Hz, 1C), 150.27, 148.53, 
138.41, 134.29, 133.79, 131.82 (d, 4JC-F = 2.9 Hz), 129.94 (d, 3JC-F = 8.6 Hz), 126.50, 125.89, 
124.04, 118.20, 115.50 (d, 2JC-F = 22.0 Hz,), 114.22, 72.57, 69.89, 68.77, 68.35, 60.24, 43.89, 
C-B(OH)2 not visible; IR (neat) 3374, 2937, 1730, 1677, 1590, 1509, 1380, 1334, 1276, 1143 
cm-1; HRMS (ESI) (Sample + ethylene glycol) [M + H]+ calcd for C31H31 11BFNO8S, 594.1774 
found 594.1774*; Mp = 115 - 118 ℃ 
 
*Sample analysed reacted with diethylene glycol by the National Mass Spectrometry Facility 
at Swansea, to obtain the accurate mass for the boronate ester adduct.258  
  
244 
 
7.1.47 (Z)-2-(4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-
hydroxyethoxy)ethoxy)phenoxy)methyl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-
dione, (53) 
 
 
(Z)-(4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxy 
ethoxy)ethoxy)phenoxy)methyl)phenyl)boronic acid (0.34 g, 0.6 mmol, 1.0 eq.) and N-methyl 
imonodicacetic acid (109 mg, 0.7 mmol, 1.2 eq.) were heated under Dean-Stark conditions, in 
a 15:1 mixture of toluene and DMSO (32 mL), for 16 h. The crude mixture was stripped of 
solvent as far as possible by evaporation under reduced pressure, to obtain a yellow residue. 
Following the addition of MeCN (10 mL) a white precipitate formed which was filtered and 
washed with additional MeCN. The filtrate was evaporated under reduced pressure to obtain 
a yellow solid, which was triturated in hexanes (2 x 5 mL) and the remaining solid dried.  
The crude material was purified by flash column chromatography (50 % EtOAc / 50 % 
acetone) to obtain MIDA boronate 53 as a bright yellow solid (97 mg, 24 %). 
 
1H NMR (400 MHz, ACETONE-d6) δ = 7.82 (s, 1 H, C=CH), 7.55 (d, J = 8.7 Hz, 2 H, 
C(BO2)CH), 7.50 (d, J = 8.7 Hz, 2 H, C(CH2O)CH), 7.46 - 7.40 (m, 2 H, C(CH2N)CH), 7.26 
- 7.17 (m, 3 H, C(OCH2)CHCH, C(OCH2)CHCH, C(HC=C)CHC(O)), 7.13 - 7.06 (m, 2 H, 
C(F)CH, 2 H), 5.23 (s, CH2ArMIDA), 4.85 (s, 2 H, CH2ArF), 4.33 (d, J = 16.9 Hz, 2 H, 
CH2NMe), 4.26 - 4.20 (m, 2 H, ArOCH2CH2), 4.13 (d, J = 16.9 Hz, 2 H, CH2NMe), 3.88 - 
3.82 (m, 2 H, ArOCH2CH2), 3.60 (s, 4 H, OHCH2CH2, OHCH2CH2), 2.72 (s, 3 H, NCH3); 13C 
NMR (100 MHz, ACETONE-d6) δ =168.50, 167.40, 165.79, 162.35 (d, 1JC-F =243.45 Hz), 
151.11, 149.48, 137.85, 133.64, 132.77, 132.20 (d, 4JC-F =2.88 Hz), 130.55 (d, 3JC-F =8.63 Hz), 
127.03, 126.56, 124.57, 118.80, 115.51, 115.36 (d, 2JC-F =22.04 Hz), 114.43, 102.91, 72.95, 
70.54, 69.32, 68.98, 61.91, 61.21, 47.44, 44.1; IR (solid) 3455, 2952, 1731, 1678, 1590, 1509, 
1494, 1423,1380 cm-1; HRMS (ESI) [M + NH4]+ calcd for C33H32 11BFN2O10SNH4, 696.2199 
found 696.2195; HRMS (ESI) [M + Na]+ calcd for C33H32 11BFN2O10SNa, 701.1753 found 
701.1745; Mp = 186 – 186 ℃. 
 
 
245 
 
7.1.48 (Z)-2-(2-(5-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-((4-(6-
methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzyl)oxy)phenoxy)ethoxy)ethyl 
4methylbenzenesulfonate, (54) 
 
 
 
 
Triethylamine (30 μL, 0.2 mmol, 2.0 eq.) and tosyl chloride (46 mg, 0.2 mmol, 2.0 eq.) was 
added to a solution of (Z)-2-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene) 
methyl)-2-(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)phenyl)-6-methyl-1,3,6,2-
dioxazaborocane-4,8-dione (80 mg, 0.1 mmol, 1.0 eq.) in DCM (5 mL). The resulting mixture 
was stirred at room temperature for 5 days. The solvent was evaporated under reduced pressure 
to obtain a yellow residue, which was purified by flash column chromatography (100 % 
EtOAc) to yield tosylate 54 as a pale-yellow oil (21 mg, 21 %).  
 
1H NMR (400 MHz ,CDCl3) δ = 7.79 (s, 1 H, C=CH), 7.72 (d, J = 8.2 Hz, 2 H, C(SO3)CH), 
7.55 (d, J = 7.8 Hz, 2 H, CHC(BMIDA)), 7.47 - 7.38 (m, 4 H, NCH2CH, C(CH2O)CH), 7.27 
(d, J = 8.2 Hz, 2 H, C(CH3)CH), 7.08 (dd, J = 8.7 2.3 Hz, 1 H, C(HC=C)CHCH), 7.03 - 6.96 
(m, 4 H, C(HC=C)CHCH, C(F)CH, C(HC=C)CHCOCH2), 5.13 (s, 2 H, CH2ArBMIDA), 4.84 
(s, 2 H, CH2ArF), 4.14 - 4.06 (m, 4 H, ArOCH2CH2, CH2CH2OTs), 3.97 (d, J = 16.9 Hz, 2 H, 
N(CH3)CH2), 3.85 (d, J = 16.9 Hz, 2 H, N(CH3)CH2), 3.82 - 3.79 (m, 2 H, ArOCH2CH2), 3.78 
- 3.74 (m, 2 H, CH2CH2OTs), 2.55 (s, 3 H, N(CH3)), 2.37 (s, 3 H, CH3ArSO3); 13C NMR (100 
MHz, CDCl3) δ =167.84, 166.22, 164.76 162.69 (d, 1JC-F =247.28 Hz), 150.96, 149.09, 145.10, 
137.92, 134.18, 132.78, 132.62, 131.16 (d, 4JC-F =2.88 Hz), 130.97 (d, 3JC-F =8.63 Hz), 129.99, 
128.05, 127.18, 126.57, 125.30, 118.89, 115.72 (d, 2JC-F =22.04 Hz), 115.04, 113.99, 102.87 
70.70, 69.69, 69.54, 69.23, 69.18, 62.02, 47.73, 44.55, 21.74; IR (neat) 2897, 1719, 1643, 
1564, 1504, 1473, 1455, 1398, 1350, 1301 cm-1; HRMS (ESI) [M + H]+ calcd for C40H38 
11BFN2O12S2H, 833.2023 found 833.2023; HRMS (ESI) [M + 2H]+ calcd for C40H38 
11BFN2O12S2H2, 834.2050 found 834.2047 
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7.1.49 4-((4-bromobenzyl)oxy)-3-(2-(2-hydroxyethoxy)ethoxy)benzaldehyde, (55) 
 
 
 
A solution of 2-chloro-2-ethoxy ethanol (1.49 mL, 14.1 mmol, 3.0 eq.) in DMF (1 mL) was 
added dropwise (over 1 min) to a solution of 4-((4-bromobenzyl)oxy)-3-
hydroxybenzaldehyde (1.44 g, 4.7 mmol, 1.0 eq.) in DMF (20 mL). K2CO3 (0.98 g, 7.1 mmol, 
1.5 eq.) and KI (0.75 g, 4.7 mmol, 1.0 eq.) were added, and the resulting mixture was then 
stirred at 75 °C for two days. The solution was cooled to room temperature, diluted with H2O 
(200 mL) and extracted with EtOAc (3 x 150 mL). The combined organic extracts were 
washed with a solution of 5% LiCl aq. (2 x 250) and brine (2 x 400 mL). The organic portion 
was dried over anhydrous MgSO4, filtered and evaporated to obtain a dark brown oil. The 
crude material was purified by flash column chromatography (80% EtOAc / 20% light 
petroleum ether), to afford ether 55 as a yellow oil (1.84 g, 99%).  
 
1H NMR (400 MHz ,CDCl3) δ = 9.82 (s, 1 H, CHO), 7.51 (d, J = 8.2 Hz, 2 H, CHCBr), 7.47 
(d, J = 1.8 Hz, 1 H, CHCOH), 7.40 (dd, J = 8.2 1.8 Hz, 1 H, C(CHO)CH), 7.31 (d, C(CH2)CH, 
J = 8.2 Hz, 2 H), 6.96 (d, C(O)CH, J = 7.8 Hz, 1 H), 5.16 (s, ArCH2, 2 H), 4.27 - 4.23 (m, 
ArOCH2CH2,  2 H), 3.95 - 3.91 (m, ArOCH2CH2, 2 H), 3.74 - 3.65 (m,CH2CH2OH, 4 H), 2.33 
(t, OH, J = 5.7 Hz, 1 H); 13C NMR (100 MHz ,CDCl3) δ = 191.01, 153.72, 149.34, 135.22, 
131.91, 130.56, 129.06, 127.03, 122.23, 112.82, 111.47, 72.77, 70.26, 69.55, 68.83, 61.91; IR 
(neat) 3425, 2872, 1681, 1584, 1507, 1434, 1263, 1123 cm-1; HRMS (ESI) [M + H]+ calcd for 
C18H19 79BrO5, 395.0489 found 395.0491. 
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7.1.50 (Z)-5-(4-((4-Bromobenzyl)oxy)-3-(2-(2-hydroxyethoxy)ethoxy)benzylidene)-3-(4-
fluorobenzyl)thiazolidine-2,4-dione, (56) 
 
 
 
3-(4-Fluorobenzyl)thiazolidine-2,4-dione (1.08 g, 4.7 mmol, 1.0 eq.) and piperadine (0.47 mL, 
4.7 mmol, 1.0 eq.) were added to a solution of 4-((4-bromobenzyl)oxy)-3-(2-(2-
hydroxyethoxy)ethoxy)benzaldehyde (1.46 g, 4.7 mmol, 1.0 eq.) dissolved in ethanol (50 mL). 
The mixture was then stirred at 78 °C for 16 h. The solution was cooled to room temperature 
and left to stand for 1 h, which effected the precipitation of a yellow solid. This was collected 
by vacuum filtration and thoroughly dried to obtain bromide 56 as a yellow powder (1.62 g, 
57 %).  
  
1H NMR (400 MHz, CDCl3) δ = 7.79 (s, 1 H, C=CH), 7.49 (d, J = 8.2 Hz, 2 H, CBrCH), 7.45 
- 7.39 (m, 2 H, CHC(CH2N)), 7.30 (d, J = 8.2 Hz, 2 H, C(CH2)CH), 7.08 - 6.96 (m, 4 H, 
C(O)CHCH, C(CH=C)CH, C(F)CH), 6.91 (d, J = 8.2 Hz, 1 H, C(O)CH), 5.12 (s, 2 H, ArCH2), 
4.84 (s, 2 H, NCH2), 4.26 - 4.14 (m, 2 H, ArOCH2CH2), 3.97 - 3.84 (m, 2 H, ArOCH2CH2), 
3.77 - 3.62 (m, 4 H, CH2CH2OH), 2.28 (br. s., 1 H, OH); 13C NMR (100 MHz, CDCl3) δ = 
167.85, 166.22, 162.69 (d, ,1JC-F =248.24 Hz), 150.60, 149.12, 135.35, 134.12, 131.88, 131.15 
(d, 4JC-F  =2.90 Hz), 130.99 (d, 3JC-F =7.67 Hz), 128.99, 126.70, 125.19, 122.20, 119.02, 115.72 
(d, 2JC-F =21.09 Hz), 115.12, 114.08, 102.88, 72.74, 70.22, 69.48, 68.97, 61.88, 44.55; IR 
(neat) 3394, 2930, 2876, 1731, 1678, 1591, 1508, 1425, 1378 cm-1; HRMS (ESI) [M + H]+ 
calcd for C28H25 79BrFNO6S, 602.0648 found 602.0651; Mp = 143 – 144 ℃. 
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7.1.51 (Z)-2-(2-(2-((4-Bromobenzyl)oxy)-5-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-
ylidene)methyl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate, (57) 
 
 
 
Tosyl chloride (0.98 g, 5.1 mmol, 2.0 eq.) and triethylamine (0.72 mL, 5.1 mmol, 2.0 eq.) 
were added to a solution of (Z)-5-(4-((4-bromobenzyl)oxy)-3-(2-(2-
hydroxyethoxy)ethoxy)benzylidene)-3-(4-fluorobenzyl)thiazolidine-2,4-dione (1.55 g, 2.5 
mmol, 1.0 eq.) in DCM, (25 mL) and stirred at room temperature for 2.5 days. The mixture 
was then evaporated to a yellow residue, which was purified via flash column chromatography 
(50% EtOAc / 50% light petroleum ether) to afford tosylate 57 as a pale-yellow oil (1.55 g, 
80 %). 
 
1H NMR (400 MHz ,CDCl3) δ = 7.79 (s, 1 H, C=CH), 7.75 (d, J = 8.2 Hz, 2 H, C(SO3)CH), 
7.47 (d, J = 10.1 Hz, 2 H, C(Br)CH), 7.44 - 7.39 (m, 2 H, C(CH2N)CH), 7.30 - 7.24 (m, 4 H, 
C(CH3)CH, C(CH2O)CH), 7.05 (dd, J = 8.1, 2.1 Hz, 1 H, C(HC=C)CHCH), 7.02 - 6.97 (m, 3 
H, C(HC=C)CHC(O), C(F)CH), 6.92 (d, J = 8.7 Hz, 1 H, C(OCH2ArBr)CH), 5.09 (s, 2 H, 
CH2ArBr), 4.84 (s, 2 H, CH2ArF), 4.15 - 4.10 (m, 4 H, ArOCH2CH2, CH2CH2OTs), 3.85 - 
3.80 (m, 2 H, ArOCH2CH2), 3.78 - 3.73 (m, 2 H, CH2CH2OTs), 2.38 (s, 3 H, CH3); 13C NMR 
(100 MHz, CDCl3) δ = 167.84, 166.20, 162.68 (d, 1JC-F  =246.33 Hz), 150.71 , 149.17, 144.90, 
135.44, 134.12, 133.02, 131.85, 131.18 (d, 4JC-F  =2.87 Hz), 130.98 (d, 3JC-F  =8.63 Hz) 129.91, 
129.04, 128.04, 126.74, 125.16, 122.16, 119.02, 115.71 (d, 2JC-F  =21.09 Hz), 115.33, 114.30, 
70.27, 69.79, 69.34, 69.17, 69.09, 44.55, 21.74; IR (neat) 3665, 2988, 1731, 1682, 1589, 1509, 
1489, 1424, 1378, cm-1; HRMS (ESI) [M + H]+ calcd for C35H31 79BrFNO8S2, 756.0737 found 
756.0736; Mp = 61 – 63 ℃. 
 
 
 
 
 
 
 
 
 
 
 
249 
 
7.1.52 (Z)-3-(4-Fluorobenzyl)-5-(3-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2dioxa 
borolan-2-yl)benzyl)oxy)benzylidene)thiazolidine-2,4-dione, (58) 
 
 
 
3-(4-Fluorobenzyl)thiazolidine-2,4-dione (0.47 g, 2.1 mmol, 1 eq.) and piperidine (0.21 mL, 
2.08 mmol, 1 eq.) were added to a solution of 3-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)oxy)benzaldehyde (0.77 g, 2.1 mmol, 1.0 eq.) in ethanol (20 mL) 
and stirred at 78 ℃ and for 22 h. The reaction mixture was then slowly cooled to 0 ℃ which 
effected the precipitation of a tan solid, that was collected by vacuum filtration to give 
boronate ester 58 as a tan crystalline solid (0.56 g, 48 %). 
 
1H NMR (400 MHz ,CDCl3) δ = 7.84 (d, J = 7.8 Hz, 2 H, C(BPin)CH), 7.78 (s, 1 H, C=CH), 
7.45 - 7.38 (m, 4 H, C(BPin)CHCH, C(CH2N)CH), 7.08 (d, J = 2.3 Hz, 1 H, 
C(HC=C)CHC(OH)), 7.03 - 6.92 (m, 4 H, C(F)CH, C(OCH2)CHCH), 5.75 (br s, 1 H, OH), 
5.18 (s, 2 H, OCH2), 4.84 (s, 2 H, NCH2), 1.34 (s, 12 H, BO2C2(CH3)4); 13C NMR (100 MHz 
,CDCl3) δ = 168.09, 166.33, 162.68 (d, 1JC-F,   J=247.28 Hz), 147.82, 146.29, 138.43, 135.37, 
134.30, 134.28, 131.19 (d, 4JC-F, J=2.88 Hz), 131.00 (d, 3JC-F, J=8.63 Hz), 127.02, 124.04, 
119.18, 115.99, 115.71 (d, 3JC-F,    J=22.04 Hz), 112.34, 84.08, 71.18, 44.50, 24.95, C-BPin 
not visible; IR (neat) 3475, 2981, 2936, 2114, 1911, 1728, 1596, 1505, 1450, 1355, 1269, 
1208, 1133, 1082 cm-1; HRMS (ESI) [M + H]+ calcd for C30H29 11BFNO6S, 562.1871 found 
562.1862; Mp = 168 - 169 ℃. 
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7.1.53 (Z)-3-(4-Fluorobenzyl)-5-(3-hydroxy-4-((4-(trifluoro-l4-boraneyl)benzyl) 
oxy)benzylidene)thiazolidine-2,4-dione, potassium salt, (59) 
 
 
 
A solution of KHF2 aq. (4.5M, 1.2 mL, 5.3 mmol, 10.0 eq.) was added in one portion to a 
solution of (Z)-3-(4-fluorobenzyl)-5-(3-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2dioxaboro 
lan-2-yl)benzyl)oxy)benzylidene)thiazolidine-2,4-dione (0.30 g, 0.5 mmol, 1 eq.) in a 5:1 
mixture of MeOH / DCM (20 mL), the solution was then stirred for 1 h at room temperature. 
The mixture was diluted in acetone (150 mL), filtered, the filtrate was then evaporated under 
reduced pressure. Four MeOH / H2O evaporation cycles were then applied to the residue (as 
described previously). The reaction / work-up procedure was repeated in its entirety, to obtain  
trifluoroborate 59 as a fine yellow powder (0.29 g, 76 %).  
 
1H NMR (400 MHz ,DMSO-d6) δ = 7.71 (s, 1 H, C=CH), 7.36 - 7.26 (m, 4 H, CHCHC(CH2N), 
C(BF3K)CHCH), 7.17 - 7.08 (m, 4 H, C(BF3K)CHCH, C(F)CH), 7.04 - 6.97 (m, 2 H, 
C(OCH2)CHCH, C(HC=C)CHC(OH)), 6.91 (d, J = 7.3 Hz, 1 H, C(OCH2)CHCH), 5.02 (s, 2 
H, OCH2), 4.75 (s, 2 H, NCH2); 13C NMR (100 MHz, DMSO-d6) δ = 168.13, 166.14, 162.26 
(d, 1JC-F, J=240.57 Hz), 135.02, 134.98, 134.95, 133.58, 132.43 (d, 4JC-F, J=2.88 Hz), 132.08, 
131.83, 130.43 (d, 3JC-F, J=8.63 Hz), 126.59, 126.42, 126.08, 116.68, 115.98 (d, 2JC-F, J=21.09 
Hz), 114.40, 70.94, 44.28, C-BF3K not visible; IR  (neat) 3445, 2115, 1724, 1669, 1592, 1508, 
1437, 1329, 1283, 1224, 1129, 975 cm-1; HRMS (ESI) [M - K]- calcd for C24H17 11BF4KNO4S, 
502.0917 found 502.0919; Mp = 211 – 213 ℃ (decomposed). 
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7.1.54 (Z)-(4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-
hydroxyphenoxy)methyl)phenyl)boronic acid, (60) 
 
 
 
Trimethylsilyl chloride (0.23 mL, 1.8 mmol, 5.0 eq.) and H2O (30 μL, 1.8 mmol, 5 eq.) were 
added to a solution of (Z)-3-(4-fluorobenzyl)-5-(3-hydroxy-4-((4-(trifluoro-l4-
boraneyl)benzyl)oxy)benzylidene)thiazolidine-2,4-dione, potassium salt (0.20 g, 0.4 mmol, 
1.0 eq.) in MeCN (3 mL), the resulting solution was stirred at room temperature for three h. 
H2O (0.3 mL) was added to the reaction mixture, followed by MeCN (30 mL), precipitating 
an off-white solid, which was filtered, the filtrate was then evaporated to obtain boronic acid 
60 as a yellow powder (84 mg, 48 %).  
 
1H NMR (400 MHz, ACETONE-d6) δ = 7.89 (d, J = 8.2 Hz, 2H, C(B(OH)2)CHCH), 7.79 (s, 
1H, C=CH), 7.51 - 7.40 (m, 4H, C(B(OH)2)CHCH, NCH2CCH), 7.21 - 7.01 (m, 5H, C(F)CH, 
C(OCH2)CHCH, C(OCH2)CHCH, C(OH)CH), 5.26 (s, 2H, COCH2), 4.86 (s, 2H, NCH2); 13C 
NMR (100 MHz, ACETONE-d6) δ = 167.43, 165.84, 162.44 (d, 1JC-F, J = 244.4 Hz), 149.13, 
147.42, 138.65, 134.37, 133.70, 132.22 (d, 4JC-F, J = 2.9 Hz), 130.56 (d, 3JC-F, J = 7.7 Hz), 
127.05, 126.65, 123.66, 118.60, 116.59, 115.36 (d, 2JC-F, J = 22.0 Hz), 113.43, 70.47, 44.08, 
C-B(OH)2 not visible; IR  (neat) 3315, 3215, 2114, 1730, 1661, 1595, 1512, 1438, 1333, 1286, 
1215 cm-1; HRMS (ESI) [M + H]+ calcd for C24H19 11BFNO6S, 480.1087 found 480.1080; Mp 
= 176 – 179 ℃.  
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7.1.55 Procedure for the isolation of solid Icodextrin from Adept® adhesion reduction 
solution: 
  
Adept® solution (150 mL approx.) was dialysed against H2O (1 L, 20 kDa). The water was 
changed 9 times over a period of 3 days. The contents of the dialysis membranes were 
transferred to a beaker, acetone (200 mL) was then added, which caused the solution to turn 
cloudy, the beaker was then left to stand for 1 h at room temperature. The liquid portion was 
then decanted, leaving a thick tacky residue on the bottom of the beaker. A further portion of 
acetone (50 mL) was added which precipitated a white solid. The solid was collected via 
vacuum filtration and dried under high vacuum, to afford a white powder, 10.4 g. 
 
Anhydrous Icodextrin was prepared by heating a flask of stirring finely powdered IDX at           
50 °C, under high vacuum (0.1 mbar minimum) for two days.   
 
Dialysis procedure: 
 
(As shown in photos on the next page) 
 
1.) The dialysis membrane pre-soaked in distilled water for one h and then “opened-
out”, distilled water was run through the inside of the membrane. 
2.) 1 closure secured approx. 5 cm from one end of the membrane 
3.) Thin parcel string (wet) was used to tie the end securely, then excess membrane and 
string was trimmed. 
4.) A second closure was placed over the knot. 
5.) Using a funnel or syringe, the material (dissolved in water) was added to the 
membrane, excess material was washed with distilled water. 
6.) The free-end was secured with a closure, approx. 0.5 cm above the top of the 
material. 
7.) The membrane was then tied using wet string, excess membrane was trimmed away. 
8.) A second closure was placed above the knot. 
9.) The membrane was placed in a beaker containing a suitable dialysis solvent, (and a 
stirrer bar) and was suspended approx. 4 cm above the stirrer bar and secured to the 
beaker using excess string (attached to the membrane) and masking tape. Solvent 
changed as specified.  
 
Note: Care should be taken to ensure the membrane is not punctured or damaged, such as 
keeping the membrane wet throughout the procedure and away from abrasive surfaces. 
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7.1.56 Photos to demonstrate dialysis procedure: 
 
1.)    2.)  
3.)     4.)  
 
5.)  6.)  7.)   
 
8.)   9.)   
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7.1.57 Benzyl Icodextrin conjugate, (Conjugate 16)   
 
 
 
A solution of anhydrous Icodextrin (0.50 g, 3.1 mmol, 1.0 eq.) in anhydrous DMAc (3 mL) 
was heated to 160 °C, under a flow of N2, for 90 min, until IDX completely dissolved. The 
mixture was cooled to 100 °C, where upon anhydrous LiCl (0.50 g (w / w IDX) was added. 
The resulting mixture was then stirred overnight. The solution was cooled to room 
temperature, then a mineral oil dispersion of NaH (60 %, 0.19 g, 4.7 mmol, 1.75 eq.) was 
added and the solution was stirred for 4 h. Benzyl bromide (1.63 mL, 13.4 mmol, 5 eq.) was 
then added dropwise and the reaction mixture stirred for 2 days.  
The material was dialysed against MeOH (1 L, 8 kDa MWCO), the methanol was changed 
twice over a period of 4 h. The contents of the dialysis membrane were transferred to a beaker, 
a solid was precipitated following the addition of cold acetone (20 mL). The material was then 
collected via vacuum filtration and washed with additional cold acetone. The solid was dried 
over a high vacuum for 4 h to afford Conjugate 16 as an off-white solid (0.36 g). 
 
1H NMR (400 MHz ,DMSO-d6) δ = 7.42 - 7.16 (m, Ph-H), 5.71 - 5.39 (m, IDX-H), 5.16 - 4.87 
(m, IDX-H), 4.79 - 4.70 (m, CH2Ph), 4.56 (br. s., IDX-H), 3.87 - 3.33 (m, IDX-H) 
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7.1.58 Icodextrin-44 conjugate, (Conjugate 17) 
 
 
 
Anhydrous Icodextrin (0.12 g, 0.2 mmol, 1.00 eq.) was suspended in anhydrous DMAc (5 
mL) with anhydrous LiCl (0.12 g, w / w IDX) under a flow of nitrogen and the mixture was 
heated to 132 °C until all of the IDX had dissolved. The solution was then cooled to room 
temperature and sodium hydride (60% mineral oil dispersion, (40 mg, 1.0 mmol, 0.67 eq.) was 
added and the reaction mixture and stirred for 4 h. A solution of triisopropylsilyl-(Z)-4-((4-
((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-(tosyloxy)ethoxy) 
ethoxy)phenoxy)methyl)benzoate (0.45 g, 0.5 mmol, 0.33 eq.) in anhydrous DMAc (1 mL) 
was added dropwise (over 2 minutes) to the reaction mixture and then stirred for 16 h. The 
reaction mixture was then dialysed against MeOH (1 L, 8 kDa MWCO), the methanol was 
changed 9 times over a period of 3 days. The contents of the dialysis membrane were then 
evaporated to yield an off-white solid which was precipitated from methanol (3 mL). The 
liquid was then carefully decanted and the retained solid washed twice with methanol (3 mL) 
and once with DCM (3 mL). The remaining solid was then dried under high vacuum to yield 
Conjugate 17 as an off-white solid (81 mg). 
 
1H NMR (400 MHz ,DMSO-d6) δ = 7.87 (s, Ar-H), 7.43 - 7.29 (m, Ar-H), 7.29 - 7.20 (m, Ar-
H), 7.19 - 7.06 (m, Ar-H), 5.68 - 5.28 (m, IDX-H), 5.20 (s, CH2ArCOOH), 5.14 - 4.84 (m, 
IDX-H), 4.80 (m, IDX-H), 4.63 - 4.41 (s, IDX-H), 4.19 - 4.07 (m, ArCH2CH2O), 3.83 - 3.39 
(m, IDX-H)  
 
*1H NMR data in agreement our previous findings 147 
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7.1.59 Inulin-(44) conjugate, (Conjugate 26) 
 
 
 
Anhydrous Inulin (0.13 g, 0.8 mmol, 1.0 eq.) was suspended in anhydrous DMAc (5 mL) with 
anhydrous LiCl (0.13 g, w / w INU) under a flow of nitrogen and heated to 116 °C until 
completely dissolved. The solution was then cooled to room temperature and sodium hydride 
(60% mineral oil dispersion, (24 mg, 0.6 mmol, 0.8 eq.) was added. The reaction mixture was 
stirred for 4 h. A solution of triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-
dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-(tosyloxy)ethoxy)ethoxy)phenoxy)methyl) 
benzoate (0.24 g, 0.3 mmol, 0.4 eq.) in anhydrous DMAc (1 mL) was added dropwise (over 2 
min) to the reaction mixture and then stirred for 16 h. The reaction mixture was then dialysed 
against MeOH (1 L, 1 kDa MWCO), the methanol was changed 7 times over a period of 2 
days. The contents of the dialysis membrane were then evaporated to yield a pale-yellow solid 
which was precipitated from methanol (3 mL), the liquid was then carefully decanted, and the 
retained solid washed twice with methanol (3 mL) and twice with DCM (3 mL). The 
remaining solid was then dried under high vacuum to yield Conjugate 26 as a pale-yellow 
solid (93 mg). 
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7.1.60 Inulin-(44) conjugate, (Conjugate 35) 
 
Inulin, (5000 Da, 39 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 2 
mL), and (±)-epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added. The resulting mixture 
was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 M) was 
added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-INU). 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (0.21 g, 0.3 mmol, 1.2 eq.) was 
dissolved in acetone (6 mL) and added dropwise to the mixture. K2CO3 (66 mg, 0.5 mmol, 2.0 
eq.), was then added and the reaction was heated to 50 °C (to aid solubility of both 
components) for 48 h. The reaction mixture was then evaporated under reduced pressure to 
obtain a yellow oily residue. A light-yellow solid was precipitated by trituration with 1:1 
acetone / DMF (5 mL). The liquid portion was decanted and the remaining solid re-suspended 
in 1:1 acetone / DMF (5 mL), then the liquid decanted again; this process was repeated 10 
times in total (until liquid became clear), followed by acetone (5 x 5 mL). The solid was then 
dissolved in H2O (5 mL) and dialysed against H2O (dist.) (1L, 1 kDa MWCO). The water was 
changed 10 times over a period of 2 days, followed by IMS (0.6 L), which was changed 6 
times in total over a period of 24 h at room temperature throughout. The contents of the dialysis 
membrane were then evaporated under reduced pressure and dried under vacuum to obtain 
Conjugate 35 as a light-yellow solid, (42 mg).  
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.71 - 7.65 (m, Ar-H (Drug)), 7.39 - 7.25 
(m, Ar-H (Drug)), 7.13 (s, Ar-H (Drug)), 7.10 - 7.05 (m, Ar-H (Drug)),  6.95 - 6.85 (m, Ar-H 
(Drug)), 5.06 (s, CH2OAr(COOH) (Drug)), 4.17 - 3.84 (m, (Drug / INU)), 3.81 - 3.35 (m, 
(Drug / INU)); IR (neat) 3348, 2992, 2090, 1730, 1680, 1592, 1560, 1509, 1377, 1340, 1270, 
1218, 1018 cm-1; (Found: C, 36.63; H, 2.37; N, 1.74; Ds (degree of substitution) = 0.68).  
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7.1.61 Inulin-(44) conjugate, (Conjugate 36) 
 
Inulin, (5000 Da, 39 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 2 
mL), and (±)-epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added. The resulting mixture 
was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 M) was 
added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-
INU).Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene) 
methyl)-2-(2-(2hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (0.14 g, 0.2 mmol, 0.8 eq.)  
was dissolved in acetone, (6 mL) and added dropwise to the reaction mixture. K2CO3 (66 mg, 
0.5 mmol, 2.0 eq.), was added and the reaction was heated to 50 °C for 2 days. The reaction 
mixture was then evaporated under reduced pressure to obtain a light-yellow residue. An off-
white solid was precipitated by trituration in 1:1 acetone / DMF (5 mL). The liquid portion 
was decanted and the remaining solid re-suspended in 1:1 acetone / DMF, (5 mL). The  liquid 
was then decanted, this process was repeated 10 times (until liquid became clear), followed 
by acetone (5 x 5 mL). The solid was then dissolved in H2O (5 mL) and dialysed against H2O 
(dist.) (1L, 1 kDa MWCO). The water was changed 9 times over a period of 2 days, followed 
by IMS, 0.6 L, which was changed 5 times in total, over a period of 24 h (at room temperature 
throughout). The contents of the dialysis membrane were evaporated under reduced pressure 
and then dried under vacuum to obtain Conjugate 36 as a white solid (11 mg). 
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.75 - 7.69 (m, Ar-H (Drug)), 7.41 - 7.35 
(m, Ar-H (Drug)), 7.19 - 7.16 (m, Ar-H (Drug)), 7.13 - 7.07 (m, Ar-H (Drug)), 6.98 - 6.93 (m, 
Ar-H (Drug)), 5.12 - 5.10 (br. s, CH2OAr(COOH) (Drug)), 4.71 (br, s,  NCH2Ar(F) (Drug)), 
4.13 - 4.03 (m, (Drug / INU)), 3.96 – 3.88 (m, (Drug / INU)), 3.80 - 3.44 (m, (Drug / INU)); 
IR (neat) 3293, 3929, 2106, 1776, 1595, 1508, 1450, 1375, 1266, 1112, 1020, 933 cm-1; 
Elemental analysis (Found: C, 48.67; H, 6.18; N, 1.35, Ds = 0.35). 
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7.1.62 Inulin-(44) conjugate, (Conjugate 37) 
 
Inulin, (5000 Da, 39 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 2 
mL), and (±)-epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added. The resulting mixture 
was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 M) was 
added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-INU). 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (87 mg, 0.1 mmol, 0.5 eq.) was 
dissolved in acetone (6 mL) and added dropwise to the reaction mixture. K2CO3 (66 mg, 0.50 
mmol, 2.0 eq.), was added and the reaction was heated to 50°C for 48 h. The reaction mixture 
was then evaporated under reduced pressure to obtain a light-yellow residue, an off-white 
solid was precipitated by trituration in 1:1 acetone / DMF (5 mL). The liquid portion was 
decanted and the remaining solid re-suspended in 1:1 acetone / DMF (5 mL), then the liquid 
decanted, this process was repeated 10 times in total (until liquid became clear), followed by 
acetone (5 x 5 mL). The solid was then dissolved in H2O (dist.) (5 mL) and dialysed against 
H2O (dist.) (1L, 1 kDa MWCO). The water was changed 9 times over a period of 2 days, 
followed by IMS (0.6 L) which was changed 5 times in total, over a period of 24 h (at room 
temperature throughout). The contents of the dialysis membrane were evaporated under 
reduced pressure and then dried under vacuum to obtain Conjugate 37 as a white crystalline 
solid (13 mg). 
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.72 - 7.64 (m, Ar-H (Drug)), 7.41 - 7.32 
(m, Ar-H (Drug)), 7.17 - 7.06 (m, Ar-H (Drug)), 6.99 - 6.93 (m, Ar-H (Drug)), 5.10 (br.s, 
CH2OAr(COOH) (Drug)), 4.71 (br. s, NCH2Ar(F) (Drug)), 4.11 - 4.03 (m, (Drug / INU)),  
3.96 - 3.86 (m, (Drug / INU)), 3.80 - 3.44 (m, (Drug / INU)); IR (neat) 3309, 2925, 2473, 
2118, 1596, 1550, 1508, 1377, 1268, 1112, 1017, 931 cm-1; Elemental analysis (Found: C, 
48.79; H, 6.11; N, 1.30, Ds = 0.32). 
 
 
 
 
 
 
 
 
  
260 
 
7.1.63 Inulin-(44) conjugate, (Conjugate 38) 
 
Inulin, (5000 Da, 39 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 2 
mL), and (±)-epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added. The resulting mixture 
was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 M) was 
added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-INU). 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-
(2-(2hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (52 mg, 0.07 mmol, 0.3 mmol) was 
dissolved in acetone (6 mL) and added dropwise to the reaction mixture. K2CO3 (66 mg, 0.5 
mmol, 2.0 eq.), was added and the reaction heated to 50 °C for 48 h. The reaction mixture was 
then evaporated under reduced pressure to obtain a cream coloured residue. An off-white solid 
was precipitated by trituration in 1:1 acetone / DMF (5 mL). The liquid portion was decanted 
and the remaining solid re-suspended in 1:1 acetone / DMF (5 mL), then the liquid decanted, 
this process was repeated 10 times in total (until liquid became clear), followed by acetone (5 
x 5 mL). The solid was then dissolved in  H2O (5 mL) and dialysed against H2O (1L, 1 kDa 
MWCO). The water was changed 9 times over a period of 2 days, followed by IMS (0.6 L) 
which was changed 5 times in total, over a period of 24 h (at room temperature throughout). 
The contents of the dialysis membrane were evaporated under reduced pressure, washed / 
decanted in acetone (5 x 3 mL) and then dried under vacuum to obtain Conjugate 38 as a white 
crystalline solid (25 mg). 
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.75 - 7.66 (m, Ar-H (Drug)), 7.43 - 7.31 
(m, Ar-H (Drug)), 7.18 - 7.08 (m, Ar-H (Drug)), 7.00 - 6.89 (m, Ar-H (Drug)), 5.10 (br.s, 
CH2OAr(COOH) (Drug)), 4.61 (br. s, NCH2Ar(F) (Drug)), 4.13 - 4.05 (m, (Drug / INU)), 4.00 
- 3.85 (m, (Drug / INU)), 3.84 - 3.45 (m, (Drug / INU)); IR (neat) 3302, 2925, 2107, 1715, 
1636, 1595, 1508, 1412, 1376, 1266, 1221, 1108, 1016, 931 cm-1; Elemental analysis (Found: 
C, 48.57; H, 4.90; N, 1.16, Ds = 0.25). 
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7.1.64 Inulin-(44) conjugate, (Conjugate 39) 
 
Inulin, (5000 Da, 39 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 2 
mL), and (±)-epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added. The resulting mixture 
was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 M) was 
added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-INU). 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate (0.30 g, 0.40 mmol, 1.7 eq.) was 
dissolved in acetone (8 mL) and added dropwise to stirring the mixture. K2CO3 (66 mg, 0.5 
mmol, 2.0 eq.), was added and the reaction heated to 50 °C for 2 days. The mixture was then 
evaporated under reduced pressure to obtain a cream coloured residue, a cream solid was 
precipitated by trituration in 1:1 acetone / DMF (5 mL). The liquid portion was decanted and 
the remaining solid re-suspended in 1:1 acetone / DMF (5 mL). The liquid was then decanted, 
this process was repeated 10 times in total (until liquid became clear), followed by acetone (5 
x 5 mL). The solid was then dissolved in H2O (5 mL) and dialysed against H2O (1L, 1 kDa 
MWCO). The water was changed 8 times over a period of 2 days, followed by IMS, (0.6 L) 
which was changed 6 times in total, over a period of 24 h (at room temperature throughout). 
The contents of the dialysis membrane were evaporated under reduced pressure, the resulting 
solid was further washed with acetone (5 x 3 mL) and then dried under vacuum to obtain 
Conjugate 39 as an off-white solid (31 mg). 
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.72 - 7.67 (m, Ar-H (Drug)), 7.40 - 7.33 
(m, Ar-H (Drug)), 7.16 - 7.13 (m, Ar-H (Drug)), 7.12 - 7.07 (m, Ar-H (Drug)), 6.98 - 6.93 (m, 
Ar-H (Drug)), 5.11 (br.s, CH2OAr(COOH) (Drug)), 4.13 - 4.03 (m, (Drug / INU)), 3.96 - 3.86 
(m, (Drug / INU)), 3.81 - 3.45 (m, (Drug / INU)) 
 
N.B. Inspection of the H1 NMR spectrum of Conjugate 39 compared to Conjugate 35, showed 
a negligible increase in drug loading.  
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7.1.65 Inulin-(52) conjugate, (Conjugate 44) 
 
 
 
Inulin, (5000 Da, 27 mg, 0.2 mmol, 1 eq.), was dissolved in a solution of NaOH aq. (0.5 M, 
1.5 mL), and (±)-epichlorohydrin (0.026 mL, 0.5 mmol, 2 eq.) was added. The resulting 
mixture was then stirred at room temperature for 80 min. To quench the reaction, HCl aq. (0.1 
M) was added to adjust the pH to pH 7, to give epichlorohydrin-activated Inulin (EPI-INU). 
(Z)-(4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxy 
ethoxy)ethoxy)phenoxy)methyl)phenyl)boronic acid, (0.11 g, 0.2 mmol, 1.2 eq.), was added 
dropwise, as a solution in acetone (4.5 mL). K2CO3 (45 mg, 0.3 mmol, 2.0 eq.) was then added 
and the resulting mixture was heated to 50 °C and stirred for 1.5 days. The reaction mixture 
was then cooled to room temperature and evaporated under reduced pressure, to expose a 
yellow residue. A light cream solid was obtained by precipitating the residue in 1:1 acetone / 
DMF (5 mL). The liquid was discarded and the solid re-suspended in acetone / DMF (5 mL), 
then the liquid decanted, this process was repeated 10 times in total. Then with 5 additional 
times with acetone (5 mL). The resulting solid was dissolved in H2O (10 mL) and dialysed 
against H2O (1L, 1 kDa MWCO). The water was changed 9 times over a period of 2 days, 
then IMS, (0.6 L) which was changed 5 times. The contents of the dialysis membrane were 
then evaporated under reduced pressure and dried under high vacuum, to obtain Conjugate 44 
as an off-white solid (11 mg). 
 
1H NMR (400 MHz ,DEUTERIUM OXIDE) δ = 7.66 - 7.56 (m, Ar-H (Drug)), 7.42 - 7.31 
(m, Ar-H (Drug)), 7.19 - 7.11 (m, Ar-H (Drug)), 7.09 - 7.03 (m, Ar-H (Drug)), 6.95 - 6.88 (m, 
Ar-H (Drug)), 5.09 (br.s, CH2OAr(B(OH)2) (Drug)), 4.14 - 4.04 (m, (Drug / INU)), 3.98 - 3.38 
(m, (Drug / INU)); IR (neat) 3299, 2932, 2882, 1650, 1503, 1460, 1270, 1190, 1107, 1015, 
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925   cm-1; Elemental analysis (Found: C, 43.16; H, 6.90; N, 1.03, Ds (degree of substitution) 
= 0.20). 
 
7.1.66 Icodextrin-(44) conjugate, (Conjugate 34) 
 
 
(±)-Epichlorohydrin (0.04 mL, 0.5 mmol, 2 eq.) was added to Icodextrin (39 mg, 0.2 mmol, 1 
eq.) in a solution of NaOH aq. (0.5 M, 2 mL) and stirred for 80 min, at room temperature. The 
pH was carefully adjusted to pH 7, using a solution of HCl aq. (0.1 M). The  solvent was 
removed under reduced pressure, to obtain a grainy white residue. The residue was triturated 
in acetone (5 mL), which precipitated a white solid, the liquid was then carefully decanted. 
The solid was re-suspended in acetone and the process repeated 5 additional times, then the 
resulting white powder dried under reduced pressure, to obtain epichlorohydrin activated 
Icodextrin (EPI-IDX), which was used without further purification in the next reaction. 
 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2- 
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (0.21 g, 0.3 mmol, 1.2 eq.) in a 
solution of acetone, (6 mL), was added to EPI-IDX in H2O (2 mL), (3:1 acetone / H2O). K2CO3 
(66 mg, 0.5 mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2.5 
days. The mixture was evaporated under reduced pressure to give a residue, which was then 
suspended in a mixture of acetone / DMF (1:1) and the liquid decanted, this process was 
repeated 10 times, then acetone (5 x 5 mL). The yellow solid was dissolved in H2O (10 mL) 
and then dialysed against H2O (1 L, 3.5 kDa MWCO). The water was changed 9 times in total, 
over a period of 2 days, then IMS (0.6 L), which was changed 5 times, over 1.5 days. The 
contents of the dialysis membrane were then evaporated under reduced pressure and dried 
under high vacuum to obtain as Conjugate 34 as a yellow solid (56 mg). 
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1H NMR (400 MHz, DMSO-d6) δ = 8.14 - 7.74 (m, Ar-H (Drug)), 7.49 - 7.29 (m, Ar-H 
(Drug)), 7.27 - 6.75 (m, Ar-H (Drug)), 5.25 - 4.96 (m, CH2OAr(COOH), IDX), 4.90 - 4.42 
(m, NCH2Ar(F), IDX), 4.27 - 3.93 (m, (Drug / IDX)), 3.87 - 3.41 (m, (Drug / IDX)); IR (neat) 
3334, 2928, 2871, 1676, 1594, 1550, 1507, 1375, 1262, 1220, 1135, 1015 cm-1; Elemental 
analysis (Found: C, 52.57; H, 4.24; N, 1.0, Ds (degree of substitution) = 0.76). 
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7.1.67 Icodextrin-(44) conjugate, (Conjugate 40) 
 
 
EPI-IDX was prepared in the same manner as Conjugate 34, using the exact same quantities 
of reagents. 
 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2- 
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (0.14 g, 0.18 mmol, 0.8 eq.) in a 
solution of acetone (6 mL) was added to EPI-IDX in H2O (2 mL), (3:1 acetone / H2O). K2CO3 
(66 mg, 0.5 mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2.5 
days. The mixture was evaporated under reduced pressure to give an orange residue, which 
was then suspended in a mixture of acetone / DMF (1:1) and the liquid decanted, this process 
was repeated 10 times, followed by acetone (5 x 5 mL). The yellow solid was dissolved in 
H2O (10 mL) and then dialysed against H2O (1 L, 3.5 kDa MWCO). The water was changed 
8 times over a period of 2 days, then IMS (0.6 L), which was changed 5 times, over 1.5 days. 
The contents of the dialysis membrane were evaporated under reduced pressure, and dried 
under high vacuum to obtain Conjugate 40 as a light yellow solid (34 mg).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.89 (br s, Ar-H (Drug)), 7.49 - 7.23 (m, Ar-H (Drug)), 
7.20 - 6.74 (m, Ar-H (Drug)), 5.45 - 4.54 (m, Drug / IDX), 4.49 - 4.16 (m, Drug / IDX), 4.15 
- 3.39 (m, Drug / IDX); IR (neat) 3348, 2924, 2875, 1596, 1551, 1507, 1375, 1260, 1220, 
1118, 1014, 769 cm-1; Elemental analysis (Found: C, 47.77; H, 4.57; N, 1.50, Ds (degree of 
substitution) = 0.44). 
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7.1.68 Icodextrin-(44) conjugate, (Conjugate 41) 
 
 
EPI-IDX was prepared in the same manner as Conjugate 34, using the exact same quantities 
of reagents. 
 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2- 
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (87 mg, 0.12 mmol, 0.5 eq.) in a 
solution of acetone (6 mL) was added to EPI-IDX in H2O (2 mL) (3:1 acetone / H2O). K2CO3 
(66 mg, 0.5 mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2 
days. The mixture was evaporated under reduced pressure to give a yellow residue, which was 
then suspended in a mixture of acetone / DMF (1:1) and the liquid decanted; this process was 
repeated 10 times, followed by acetone (5 x 5 mL). The yellow solid was dissolved in H2O 
(10 mL) and then dialysed against H2O (1 L, 3.5 kDa MWCO). The water was changed 8 
times, over a period of 2 days, then IMS (0.6 L), which was changed 5 times, over 1.5 days. 
The contents of the dialysis membrane were then evaporated under reduced pressure, and dried 
under high vacuum to obtain Conjugate 41 as a golden solid (28 mg).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.95 - 7.74 (m, Ar-H (Drug)), 7.47 - 7.23 (m, Ar-H 
(Drug)), 7.21 - 6.88 (m, Ar-H (Drug)), 5.89 - 5.35 (m, IDX), 5.26 - 4.86 (m, CH2OAr(COOH), 
IDX), 4.78 - 4.47 (m, Drug / IDX), 4.43 - 4.25 (m, Drug / IDX), 4.19 - 4.01 (m, Drug / IDX), 
3.86 - 3.41 (m, Drug / IDX); IR (neat) 3334, 2927, 2458, 2106, 1594, 1551, 1507, 1364, 1262, 
1121, 1013 cm-1; Elemental analysis (Found: C, 48.15; H, 4.25; N, 1.38, Ds (degree of 
substitution) = 0.36). 
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7.1.69 Icodextrin-(44) conjugate, (Conjugate 42) 
 
EPI-IDX was prepared in the same manner as Conjugate 34, using the exact same quantities 
of reagents. 
 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2- 
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (52 mg, 0.07 mmol, 0.3 eq.) in a 
solution of acetone (6 mL) was added to EPI-IDX in H2O (2 mL) (3:1 acetone / H2O). K2CO3 
(66 mg, 0.5 mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2 
days. The mixture was evaporated under reduced pressure to give a yellow residue, which was 
then suspended in a mixture of acetone / DMF (1:1), and the liquid decanted; this process was 
repeated 10 times, then acetone (5 x 5 mL). The white solid was dissolved in H2O (10 mL) 
and then dialysed against H2O (1 L, 3.5 kDa MWCO). The water was changed 9 times over a 
period of 2 days, then IMS (0.6 L), which was changed 6 times over 1.5 days. The contents of 
the dialysis membrane were then evaporated under reduced pressure and dried further under 
high vacuum to obtain Conjugate 42 as an off-white solid (25 mg).  
 
1H NMR (400 MHz, DMSO-d6) δ = 7.89 - 7.73 (m, Ar-H (Drug)), 7.49 - 7.24 (m, Ar-H 
(Drug)), 7.22 - 6.84 (m, Ar-H (Drug)), 5.84 - 5.34 (m, IDX), 5.20 - 4.80 (m, Drug / IDX), 4.78 
- 4.01 (m, Drug / IDX), 3.79 - 3.33 (m, Drug / IDX); IR (neat) 3307, 2925, 2086, 1596, 1551, 
1507, 1364, 1261, 1121, 1013 cm-1; Elemental analysis (Found: C, 44.66; H, 5.72; N, 1.13, 
Ds (degree of substitution) = 0.24). 
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7.1.70 Icodextrin-(44) highly cross-linked conjugate, (Conjugate 43) 
 
 
EPI-IDX was prepared in the same manner as Conjugate 34, using the following quantities of 
reagents: IDX (56 mg, 0.3 mmol, 1.0 eq.), (±)-epichlorohydrin (0.03 mL, 0.40 mmol, 1.1 eq.), 
in NaOH aq. (0.5 M, 3 mL). 
 
Triisopropylsilyl-(Z)-4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2- 
(2-(2-hydroxyethoxy)ethoxy)phenoxy)methyl)benzoate, (0.30 g, 0.4 mmol, 1.2 eq.) in a 
solution of acetone (9 mL) was added to EPI-IDX in H2O (3 mL) (3:1 acetone / H2O). K2CO3 
(95 mg, 0.7 mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2 
days. The mixture was evaporated under reduced pressure to give a yellow residue, which was 
then suspended in a mixture of acetone / DMF (1:1), and the liquid decanted; this process was 
repeated 15 times, then acetone (5 x 5 mL). The material was dried under vacuum, to obtain a 
light-yellow solid. The solid was re-dissolved in a solution of NaOH aq. (0.5 M, 2 mL), then 
(±)-epichlorohydrin (0.08 mL, 1.0 mmol, 3 eq.) was added and the resulting mixture stirred 
for 18 h at room temperature, the solvent was then evaporated under reduced pressure. The 
resulting yellow residue was washed / decanted in acetone (5 x 5 mL) to give a yellow powder. 
This was then dissolved in H2O (10 mL) and then dialysed against H2O (1 L, 8 kDa MWCO). 
The water was changed 9 times in total, over a period of 2 days, then IMS (0.6 L) which was 
changed 6 times, over 1.5 days. The contents of the dialysis membrane were then evaporated 
under reduced pressure and dried under high vacuum to obtain Conjugate 43 as a yellow solid 
(42 mg).  
 
1H NMR (400 MHz, DMSO-d6) δ = 8.01 - 7.67 (m, Ar-H (Drug)), 7.52 - 7.16 (m, Ar-H 
(Drug)), 7.22 - 6.47 (m, Ar-H (Drug)), 5.77 - 5.41 (m, IDX), 5.38 - 4.42 (m, Drug / IDX), 4.24 
- 3.12 (m, Drug / IDX); IR (neat) 2322, 2873, 2115, 1701, 1597, 1507, 1375, 1261, 1120, 1013 
cm-1; Elemental analysis (Found: C, 47.07; H, 5.94; N, 1.03, Ds (degree of substitution) = 
0.20). 
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7.1.71 Icodextrin-(52) conjugate, (Conjugate 45) 
 
 
(±)-Epichlorohydrin (0.035 mL, 0.44 mmol, 2 eq.) was added to Icodextrin (35 mg, 0.22 
mmol, 1 eq.) in a solution of NaOH aq. (0.5 M, 2 mL) and stirred for 80 min, at room 
temperature. The pH was carefully adjusted to pH 7, using a solution of HCl aq. (0.1 M). The  
solvent was removed under reduced pressure, to obtain a grainy white residue. The residue 
was triturated in acetone (5 mL), which precipitated a white solid. The liquid was then 
carefully decanted. The solid was then re-suspended in acetone and the process repeated five 
additional times. The resulting white powder was dried under reduced pressure, to obtain 
epichlorohydrin activated Icodextrin (EPI-IDX), which was used without further purification 
in the next reaction. 
(Z)-(4-((4-((3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-ylidene)methyl)-2-(2-(2-hydroxy 
ethoxy)ethoxy)phenoxy)methyl)phenyl)boronic acid (0.15 g, 0.3 mmol, 1.2 eq.) in acetone (6 
mL) was added to EPI-IDX dissolved in H2O (2 mL) (3:1 acetone / H2O). K2CO3 (61 mg, 0.4 
mmol, 2.0 eq.) was then added and the resulting mixture heated to 50 °C for 2.5 days. The 
mixture was evaporated under reduced pressure to give a brown residue, which was then 
suspended in a mixture of acetone / DMF (1:1), and the liquid decanted. This process was 
repeated 10 times, then acetone (5 mL) x 5. The brown solid was dissolved in H2O (10 mL) 
and then dialysed against H2O (1 L, 3.5 kDa MWCO). The water was changed 12 times, over 
a period of 2.5 days, then IMS (0.6 L), which was changed 5 times, over 1.5 days. The contents 
of the dialysis membrane were then evaporated under reduced pressure and dried further under 
high vacuum to obtain Conjugate 45 as a light brown solid (27 mg).  
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1H NMR (400 MHz, DMSO-d6) δ = 7.64 - 7.26 (m, Ar-H (Drug)), 7.16 - 7.05 (m, Ar-H 
(Drug)), 5.65 - 5.25 (m, CH2OAr(B(OH)2), 5.20 - 4.43 (m, (Drug / IDX)), 4.03 - 3.42 (m, 
(Drug / INU)); IR (neat) 3312, 2925, 2103, 1699, 1596, 1510, 1363, 1148, 1016 cm-1; 
Elemental analysis (Found: C, 54.79; H, 5.33; N, 0.5, Ds (degree of substitution) = 0.07).  
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7.1.72 2-Amino-4-(4-fluorophenyl)thiazole-5-carbontirile, (61) 
 
 
 
 
 
 
Pyridine (1.23 mL, 15.3 mmol, 1 eq.) was added to a solution of 4-flourobenzoylacetonitrile 
(2.50 g, 15.3 mmol, 1 eq.) in ethanol (30 mL) and stirred at 70 ℃ for 15 min. The  solution 
was then cooled to room temperature, where upon a slurry of thiourea (2.33 g, 30.6 mmol, 2 
eq.) and I2 (3.88 g, 15.3 mmol, 1 eq.) in ethanol (15 mL) was added to the reaction mixture. 
This was then stirred for 1.5 h at room temperature. A solution of Na2S3O3 aq. (1 M, 20 mL) 
was added, effecting the precipitation of a heterocycle 61 as a cream solid, which was collected 
by vacuum filtration and thoroughly dried (2.61 g, 77 %).  
 
1H NMR (400 MHz, DMSO-d6) δ = 8.25 (s, 2H), 8.06 - 7.90 (m, 2H), 7.35 (t, J = 8.1 Hz, 2H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
 
 
7.1.73 2-Chloro-4-(4-fluorophenyl)thiazole-5-carbonitrile, (62) 
 
 
 
tert-Butyl nitrite (1.53 mL, 12.9 mmol, 1.5 eq.) was added dropwise (over 2 minutes) to CuCl2 
(1.38 g, 10.3 mmol, 1.2 eq.) in MeCN (20 mL) and stirred for 30 min at room temperature, to 
obtain a dark green precipitate. 2-Amino-4-(4-fluorophenyl)thiazole-5-carbonitrile (1.91 g, 
8.6 mmol, 1.0 eq.) was then added portion wise (over 5 min) and stirred for 1 h at room 
temperature. The reaction was quenched following the addition of a solution of HCl aq. (1 M, 
25 mL) and stirred for an additional 15 min. The reaction mixture was then diluted with H2O 
(20 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed 
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with brine (100 mL), dried over anhydrous MgSO4, filtered and evaporated to obtain an orange 
residue. 
 
The residue was dissolved in DCM (5 mL) and the mixture filtered through a plug of silica 
gel (prepared with DCM), the filtrate was evaporated under reduced pressure to obtain a 
golden-brown residue. The residue was then triturated in heptane to obtain chloride 62 as an 
orange powder, which was collected by decanting the liquid and drying the solid under high 
vacuum, (1.10 g, 53 %). 
 
1H NMR (400 MHz, DMSO-d6) δ = 8.13 - 7.96 (m, 2H), 7.44 (t, J = 8.1 Hz, 2H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
 
7.1.74 6-Bromo-3-(chloro-l5-azaneyl)-2-ethyl-8-methylimidazo[1,2-a]pyridine, (63) 
 
 
 
 
Benzotriazole (2.67 g, 2.2 mmol, 1.05 eq.) and propanal (2.29 mL, 3.2 mmol, 1.50 eq.) were 
added to 5-bromo-3-methylpyridine (4.00 g, 2.1 mmol, 1.00 eq.) in a solution of anhydrous 
toluene (15 mL), under a flow of nitrogen and stirred for 4 h at room temperature. Then, EtOH 
(30 mL) was added, followed by KCN (1.66 g, 2.6 mmol, 1.20 eq.) and the resulting mixture 
stirred for 16 h, at room temperature, then for 2 h at 75 ℃. The reaction mixture was cooled 
to room temperature and quenched using a solution of NaOH aq. (2.5 M, 20 mL). The solution 
was diluted with H2O (30 mL) and extracted with EtOAc (4 x 50 mL). The organic extracts 
were combined, washed with NaOH aq. (2M, 2 x 50 mL), dried over anhydrous Na2SO4, 
filtered and evaporated to give the free amine product: 6-bromo-2-ethyl-8-methylimidazo[1,2-
a]pyridin-3-amine, as an orange oil, used immediately.  
 
Acetyl chloride (2.43 mL, 3.41 mmol, 1.60 eq.) was added to 6-bromo-2-ethyl-8-
methylimidazo[1,2-a]pyridin-3-amine as solution in ethanol (20 mL) and stirred at room 
temperature for 16 h, then evaporated. The oil was triturated in Et2O (15 mL), effecting the 
precipitation of a solid, which was washed / decanted in DCM (5 x 15 mL), then thoroughly 
dried to obtain hydrochloride salt (63) as a light brown solid (2.31 g, 37 %).     
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1H NMR (400 MHz, DMSO-d6) δ = 8.67 - 8.54 (m, 1H), 7.74 - 7.55 (m, 1H), 2.75 (q, J = 7.5 
Hz, 2H), 2.49 (s, 3H), 1.18 (t, J = 7.5 Hz, 3H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers67  
  
 
 
7.1.75 N-(6-Bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)formamide, (64) 
 
 
 
6-Bromo-3-(chloro-l5-azaneyl)-2-ethyl-8-methylimidazo[1,2-a]pyridine (2.3 g, 7.91 mmol, 
1.0 eq.) was stirred in formic acid (2.1 mL, 55.3 mmol, 7.0 eq.) at 80 ℃, for 4 h then cooled 
to room temperature. A solution of NaOH aq. (3 M, 6 mL) was added, then the pH adjusted 
to 8-9 using a solution of NaHCO3 sat. aq. (approx. 50 mL), which resulted in the precipitation 
of a brown solid. The solid was collected by vacuum filtration, then slurried in toluene (3 mL), 
then MTBE (20 mL) (1:7) which gave a light brown precipitate. The liquid portion was 
decanted and the solid then re-suspended in MTBE (10 mL), then decanted once more, this 
process was repeated 3 times. The resulting cream solid (amide 64) was thoroughly dried 
under vacuum (1.41 g, 69 %).  
 
1H NMR (400 MHz, DMSO-d6), presence of two rotomers δ = 9.91 (br s, 1H), 8.23 (br s, 
1H), 8.10  (br s, 1H), 7.95 (br s, 1H), 7.13 (br s, 1H), 7.09 (br s, 1H), 2.57 - 2.41 (m, 2H), 
2.38 (br s, 3H), 2.34 (br s, 3H), 1.21 - 0.89 (m, 3H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers67  
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7.1.76 N-(6-Bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)-N-methylformamide, (65) 
 
 
 
Methyl iodide (0.46 mL, 7.4 mmol, 1.5 eq.) and K2CO3 (2.06 g, 14.9 mmol, 3.0 eq.) was added 
to N-(6-bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)formamide (1.40 g, 4.9 mmol, 1.0 
eq.) in DMF (9 mL). The resulting mixture was heated at 80 ℃, for 10 min. The reaction 
mixture was diluted with H2O (100 mL), then extracted with DCM (4 x 50 mL). The combined 
organic extracts were then washed with a solution of 5% LiCl aq. (3 x 50 mL), dried over 
anhydrous MgSO4, filtered and evaporated to obtain methyl amide 65 as a crystalline solid 
(0.82 g, 56 %).  
 
1H NMR (400 MHz, CDCl3), presence of two rotomers δ = 8.49 (s, 1H), 8.19 (s, 1H), 7.84 - 
7.73 (m, 1H), 7.67 - 7.63 (m, 1H), 7.31 - 7.23 (m, 1H), 7.18 - 7.12 (m, 1H), 7.10 - 7.06 (m, 
1H), 3.36 (s, 3H), 3.24 (s, 3H), 2.80 - 2.66 (m, 2H), 2.64 - 2.59 (m, 3H), 1.31 (t, J = 7.8 Hz, 
3H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
 
 
7.1.77 6-Bromo-2-ethyl-N,8-dimethylimidazo[1,2-a]pyridin-3-amine, (66) 
 
 
 
N-(6-bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)-N-methylformamide was added to 
a solution of HCl in methanol (1.25 M, 5.6 mL, 2.50 eq.) and stirred at 80 ℃ for 4 h. A second 
portion of HCl in methanol (1.25 M, 2.3 mL, 1.25 eq.) was added and stirred for 2 h. The 
reaction mixture was then evaporated under reduced pressure to obtain a brown oil which was 
diluted with H2O (50 mL). Powdered NaHCO3 was added to bring the pH to 9. The organic 
layer was extracted using DCM (4 x 50 mL), then combined, washed with NaHCO3 sat. aq. 
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(70 mL), brine (70 mL), dried over anhydrous MgSO4, filtered and evaporated to obtain amine 
66 as a light brown crystalline solid (0.55 g, 73%).  
 
1H NMR (400 MHz, CDCl3) δ = 8.03 - 7.84 (m, 1H), 7.03 - 6.84 (m, 1H), 2.92 - 2.74 (m, 5H), 
2.66 (s, 3H), 1.31 (t, J = 7.7 Hz, 3H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
 
 
7.1.78 2-((6-Bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-
fluorophenyl)thiazole-5-carbonitrile, (67) 
 
 
NaH as a dispersion in mineral oil, 60 %, (0.86 g, 4.6 mmol, 3.0 eq.) was added to 6-bromo-
2-ethyl-N,8-dimethylimidazo[1,2-a]pyridin-3-amine (0.42 g, 1.5 mmol, 1.0 eq.) dissolved in 
anhydrous THF (7 mL), under a flow of N2. The resulting mixture was heated to 90 ℃ for 30 
min and then cooled to 40 ℃. This was followed by the addition of 2-Chloro-4-(4-
fluorophenyl)thiazole-5-carbonitrile (0.44 g, 1.9 mmol, 1.2 eq.). The temperature was 
increased to 90 ℃, and the mixture stirred for 1.5 h. The reaction was quenched following the 
addition of H2O (70 mL). The organic portion was extracted with EtOAc (6 x 30 mL), 
combined, dried over anhydrous MgSO4, filtered and evaporated to obtain heterocycle 67 as 
a brown solid, which was used without any further purification as an intermediate. 
 
1H NMR (400 MHz, CDCl3) δ = 8.20 - 8.09 (m, 2H), 7.77 (s, 1H), 7.24 - 7.12 (m, 3H), 3.62 
(s, 3H), 2.81 - 2.71 (m, 2H), 2.61 (s, 3H), 1.35 (t, J = 7.7 Hz, 3H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers67  
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7.1.79 tert-Butyl 4-(3-((5-cyano-4-(4-fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl-8-
methylimidazo[1,2-a]pyridin-6-yl)piperazine-1-carboxylate, (68) 
 
 
N-Boc piperazine (0.60 g, 3.0 mmol, 1.50 eq.), sodium tert butoxide (0.38 g, 4.0 mmol, 2.00 
eq.), John phos (60 mg, 0.02 mmol, 0.10 eq.) and Pd2(dba)3 (92 mg, 0.01 mmol, 0.05 eq.) was 
added to 2-((6-bromo-2-ethyl-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-
fluorophenyl)thiazole-5-carbonitrile (0.94 g, 2 mmol, 1.00 eq.) in a solution of toluene (15 
mL), under a flow of N2. The reaction mixture was the heated to 115 ℃, for 1 h, then cooled 
to room temperature. The crude mixture was filtered through a plug of silica (EtOAc), and the 
filtrate evaporated under reduced pressure to obtain piperazine 68 as a brown oil (0.18 g) 
which was used without further purification in the next reaction.  
 
7.1.80 2-((2-Ethyl-8-methyl-6-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-
(4-fluorophenyl)thiazole-5-carbonitrile, (69) 
 
 
 
HCl in Et2O (2 M, 0.96 mL, 6.0 eq.) was added to tert-butyl 4-(3-((5-cyano-4-(4-
fluorophenyl)thiazol-2-yl)(methyl)amino)-2-ethyl-8-methylimidazo[1,2-a]pyridin-6-
yl)piperazine-1-carboxylate (0.18 g, 0.3 mmol, 1.0 eq.) dissolved in methanol (1 mL) and 
stirred for 3 h at room temperature. The reaction mixture was then evaporated under reduced 
pressure to obtain an oily residue. The oil was layered under EtOAc (20 mL) and then basified 
with NaOH aq. (1 M) (pH 8-9). The organic layer was extracted with EtOAc (3 x 20 mL), 
combined, washed with brine (30 mL), dried over anhydrous MgSO4, filtered and evaporated 
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under reduced pressure, to give piperazine 69 as a brown oil (0.11 g). The crude material was 
carried through to the next reaction, without further purification.  
 
7.1.81 2-Chloro-1-(3-hydroxyazetidin-1-yl)ethan-1-one, (70) 
 
 
 
To a solution of 3-hydroxyazetidine hydrochloride (1.00 g, 9.1 mmol, 1 eq.) in H2O (20 mL), 
K2CO3 (1.39 g, 10.0 mmol, 1.1 eq.) was added, this was stirred for 30 min at room temperature. 
DCM (4 mL) was added and the reaction mixture cooled to 0 ℃. 2-Chloroacetyl chloride 
(1.46 mL, 18.3 mmol, 2.0 eq.) dissolved in DCM (3 mL) was added dropwise. The solution 
was then warmed to room temperature and stirred overnight. The organic portion was 
extracted with EtOAc / Butanol 1:1 (4 x 10 mL), the extracts were combined, dried over 
anhydrous MgSO4, filtered and evaporated to obtain a light green oil. The oil was dissolved 
in acetone (10 ml) and stirred vigorously for 10 min, then filtered under gravity. The filtrate 
was then evaporated under reduced pressure to give azetidine 70 as a pale orange oil (0.86 g, 
63 %).  
1H NMR (400 MHz, CDCl3) δ = 4.82 - 4.66 (m, 1H), 4.58 - 4.46 (m, 1H), 4.34 (dd, J = 10.7, 
6.7 Hz, 1H), 4.25 - 4.17 (m, 1H), 3.99 (br dd, J = 11.0, 3.9 Hz, 1H), 3.94 (s, 2H) 
 
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
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7.1.82 2-((2-Ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-
methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile, 
(71) 
 
 
 
2-Chloro-1-(3-hydroxyazetidin-1-yl)ethan-1-one (45 mg, 0.3 mmol, 1.3 eq.) and K2CO3  
(64 mg, 0.5 mmol, 2.0 eq.) was added to 2-((2-ethyl-8-methyl-6-(piperazin-1-yl)imidazo[1,2-
a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (0.11 g, 0.2 mmol, 
1.0 eq.) dissolved in MeCN (2 mL) and the resulting mixture stirred at 80 ℃ for one day.  
The solution was cooled to room temperature, diluted with MeCN (10 mL), then filtered. The 
filtrate was evaporated under reduced pressure to give a brown oil. The crude material was 
purified via flash column chromatography (100 % acetone), to give heterocycle 71 (GLPG 
1690) as a white solid (12 mg, 1.3 %, over 4 steps)  
 
1H NMR (400 MHz, CDCl3) δ = 8.12 - 8.08 (m, 2H), 7.17 - 7.02 (m, 2H), 6.97 - 6.80 (m, 2H), 
4.75 - 4.56 (m, 1H), 4.43 - 4.29 (m, 1H), 4.27 - 4.14 (m, 1H), 4.07 - 3.95 (m, 1H), 3.91 - 3.79 
(m, 1H), 3.61 - 3.48 (m, 3H), 3.05 (br d, J = 3.7 Hz, 4H), 2.78 - 2.59 (m, 6H), 2.54 (s, 3H), 
1.26 (t, J = 7.7 Hz, 3H) 
  
The 1H NMR spectrum was found to be in agreement with that of Heckman and co-workers.67  
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7.1.83 (3R,9bS)-3-Phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, (73) 
 
 
 
(R)-Phenyl glycinol, (5.00 g, 36.0 mmol, 1 eq.) was heated for 48 h with 2-carboxy 
benzaldehyde (6.02 g, 40.0 mmol, 1.1 eq.) in toluene (300 mL) under Dean-Stark conditions. 
The crude mixture was then evaporated to an oil and purified via flash column 
chromatography, (50 % Et2O / 50 % light petroleum ether), to afford lactam 73 as a white 
crystalline solid (6.45 g, 88 %).  
 
1H NMR (400 MHz, CDCl3) δ = 7.97 - 7.78 (m, 1H), 7.71 - 7.55 (m, 3H), 7.51 - 7.29 (m, 
5H), 6.06 (s, 1H), 5.23 (t, J = 7.4 , 1H), 4.85 (dd, J = 8.7, 7.7, 1H), 4.17 (dd, J = 8.8, 7.4,  
1H) 
 
1HNMR Spectrum identical to that reported by Allin and co-workers.234 
 
7.1.84 (R)-2-((R)-2-Hydroxy-1-phenylethyl)-3-methylisoindolin-1-one, (74a) 
 
 
 
To a stirring solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one,  
(1.00 g, 3.9 mmol, 1.0 eq.) in  anhydrous THF (15 mL), under N2, cooled to -78 °C, was added 
LiHMDS as a solution in THF (1M, 4.36 mL, 4.4 mmol, 1.1 eq.) dropwise (over 5 min) and 
the resulting mixture stirred for 30 min. Methyl iodide (0.30 mL, 4.8 mmol, 1.2 eq.) was then 
added dropwise (over 2 min). The solution was warmed to room temperature overnight. NH4Cl 
sat. aq. (20 mL) was added to quench the reaction, then diluted with H2O (20 mL). The organic 
portion was extracted with Et2O (5 x 30 mL) and washed with brine (30 mL), dried with 
anhydrous MgSO4, filtered and evaporated to a light brown oil, to yield crude intermediate 
(3R)-9b-methyl-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, used immediately 
without purification. 
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TiCl4 as a solution in DCM (1 M, 5.94 mL, 5.9 mmol, 1.5 eq.) was added dropwise (over 2 
min) to (3R)-9b-methyl-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (1.059 g, 
3.9 mmol, 1.0 eq.) in anhydrous DCM (15 mL), under N2, at -78 °C and stirred for 30 min. 
Triethylsilane (0.95 mL, 5.9 mmol, 1.5 eq.) was added dropwise (over 1 min) to the mixture, 
then after 10 min warmed to room temperature overnight. The reaction was quenched using 
NH4Cl sat. aq. (20 mL) and then diluted with H2O (20 mL). The organic portion was extracted 
with DCM (3 x 40 mL) washed with brine (30 mL), dried over anhydrous MgSO4, filtered and 
evaporated to a light brown residue. This was then purified by flash column chromatography 
(100% light petroleum ether), to afford isoindolinone 74a as a yellow oil (0.34 g, 32 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 7.4, Ar-H, 1H), 7.62 - 7.44 (m, 2H, Ar-H), 7.39 - 
7.26 (m, 6H, Ar-H), 5.00 - 4.89 (m, 1H, CH2OH), 4.77 (dd, J = 8.0, 3.4, 1H, NCHAr), 4.53 - 
4.43 (m, 1H, CHHOH), 4.34 (q, J = 6.7, 1H, CH(CH3)), 4.18 - 4.05 (m, 1H, CHHOH), 1.46 
(d, J = 6.7, 3H, CH3); 13C NMR (100 MHz, CDCl3) δ 169.75, 147.14, 137.96, 132.13, 128.93, 
128.42, 128.13, 127.32, 123.96, 122.03, 64.73, 62.57, 57.14, 18.45; IR (solid): 3333, 1658, 
1469, 1404, 1353 cm-1; HRMS (ESI, m/z): calcd. for C17H17NO2 [M + H]+ 268.1332, found: 
268.1334; [α]D = + 244 (c 0.5, CH2Cl2). 
 
 
7.1.85  (R)-3-Ethyl-2-((R)-2-hydroxy-1-phenylethyl)isoindolin-1-one, (74b) 
 
 
 
A stirring solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one,  
(0.50 g, 1.98 mmol, 1.0 eq.) in anhydrous THF (15 mL), under N2, was cooled to -78 °C. 
LiHMDS as a solution in THF (1 M, 2.18 mL, 2.2 mmol, 1.1 eq.) was added dropwise (over 
5 min) and the resulting mixture stirred for 30 min. Ethyl iodide (0.19 mL, 2.4 mmol, 1.2 eq.) 
was then added dropwise and the warmed to room temperature overnight. NH4Cl sat. aq. (15 
mL) was added to quench the reaction, which was then diluted with H2O (20 mL). The organic 
portion was extracted with Et2O (5 x 30 mL), washed with brine (30 mL), dried with anhydrous 
MgSO4, filtered and evaporated to an orange oil, to yield crude intermediate ((3R)-9b-ethyl-
3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, used in the next step without further 
purification. 
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TiCl4, as a solution in DCM (1 M, 2.97 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 2 
mins) to (3R)-9b-ethyl-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (0.55 g, 1.9 
mmol, 1.0 eq.) in anhydrous DCM (10 mL), under N2 at -78 °C and stirred for 30 min. 
Triethylsilane (0.47 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 1 min) to the mixture, 
which after 10 min was warmed to room temperature overnight. The reaction was quenched 
with NH4Cl sat. aq. (20 mL) and then diluted with H2O (20 mL). The organic portion was 
extracted with DCM (3 x 30 mL), washed with brine (30 mL), dried over anhydrous MgSO4, 
filtered and evaporated to a light brown residue. This was then purified by flash column 
chromatography (80 % EtOAc / 20 % light petroleum ether), to afford isoindolinone 74b as a 
yellow crystalline solid (0.26 g, 47 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 7.5, 1H, Ar-H), 7.62 - 7.40 (m, 2H, Ar-H), 7.38 - 
7.26 (m, 6H, Ar-H), 7.38 - 7.21 (m, 1H, Ar-H), 5.07 - 4.99 (m, 1H, CH2OH), 4.62 (dd, J = 
8.0, 3.3 1H, NCHPh), 4.48 (dt, J = 12.5, 7.9, 1H, CHHOH), 4.40 (dd, J = 5.1, 2.7, 1H, 
CHCH2CH3), 4.11 (ddd, J = 12.5, 7.0, 3.3, 1H, CHHOH), 2.13 - 1.90 (m, 2H, CHCH2CH3), 
0.55 (t, J = 7.4, 3H, CH2CH3); 13C NMR (100 MHz, CDCl3) δ 170.47, 144.95, 138.02, 132.94, 
132.06, 128.92, 128.47, 128.13, 127.36, 123.84, 122.07, 64.83, 62.86, 61.18, 22.94, 5.97; IR 
(solid): 3345, 2995, 2876, 1659, 1469, 1407, 1214 cm-1; HRMS (ESI, m/z): calcd. for 
C18H19NO2 [M + H]+ 282.1489, found 282.1489; [α]D = + 180 (c 0.5, CH2Cl2); Mp: 101-104 
⁰C 
  
A suitable crystal was obtained by slow evaporation in Et2O / light petroleum ether). 
Diffraction data (3135 total reflections with Rint = 0.0254) were collected on a Rigaku Oxford 
Diffraction Excalibur diffractometer at T = 150 K using graphite-monochromated Mo-Kα 
radiation. The structure was solved and refined using the SHELXS-2016 and SHELXL-2016 
programs.256 Crystal data: C18H19NO2, M = 293.35, colourless plate, 0.454  0.384  0.277 
mm3, orthorhombic, space group P 21 21 21 (No. 18), V = 1504.58(14) Å3, Z = 4, Dc = 1.2419 
g/cm3, F000 = 600, Xcalibur, Sapphire3, Gemini, Mo K radiation,  = 0.71073 Å, T = 
150.00(10)K, 2max = 58.6º, 4837 reflections collected, 3135 unique (Rint = 0.0543). Final 
GooF = 0.877, R1 = 0.0476, wR2 = 0.1309, R indices based on 2711 reflections with I I > 2(I) 
(refinement on F2), 192 parameters, 0 restraints. Lp and absorption corrections applied,  = 
0.082 mm-1. Absolute structure parameter = -0.4(15) (Flack, H. D. Acta Cryst. 1983, A39, 876-
881). 
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7.1.86 (R)-2-((R)-2-Hydroxy-1-phenylethyl)-3-propylisoindolin-1-one, (74c) 
 
 
 
A stirring solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one  
(0.50 g, 1.9 mmol, 1.0 eq.) in THF (15 mL), under N2, was cooled to -78 °C. LiHMDS as a 
solution in THF (1 M, 2.18 mL, 2.1 mmol, 1.1 eq.) was then added dropwise (over 5 min) and 
the resulting mixture stirred for 30 min. 1-Iodopropane (0.23 mL, 2.4 mmol, 1.2 eq.) was 
added dropwise (over 2 min), then warmed to room temperature overnight. NH4Cl sat. aq. 
(20mL) was added to quench the reaction, then diluted with H2O (20 mL). The organic portion 
was extracted with Et2O (5 x 30 mL), washed with brine (30 mL), dried with anhydrous 
MgSO4, filtered and evaporated to a light brown oil, to yield crude intermediate (3R)-3-
phenyl-9b-propyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, used in the next step 
without any further purification. 
 
TiCl4 as a solution in DCM (2.97 mL, 2.9 mmol, 1.5 eq.) was added dropwise to (3R)-3-
phenyl-9b-propyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (0.58 g, 1.9 mmol, 1.0 eq.) 
in anhydrous DCM (10 mL), under N2, at -78 °C and stirred for 30 min. Triethylsilane (0.47 
mL, 2.9 mmol, 1.5 eq.) was added dropwise to the mixture, which after 10 min was warmed 
to room temperature overnight. The reaction was quenched with NH4Cl sat. aq. (20 mL) and 
then diluted with H2O (20 mL). The organic portion was extracted with DCM (3 x 30 mL) 
washed with brine (30 mL), dried over anhydrous MgSO4, filtered and evaporated to a light 
brown residue. This was then purified by flash column chromatography (80 % EtOAc /  
20 % light petroleum ether), to afford isoindolinone 74c as a white crystalline solid (0.19 g, 
32 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 7.5, 1H, Ar-H), 7.61 - 7.42 (m, 2H, Ar-H), 7.38 - 
7.15 (m, 6H, Ar-H), 5.08 - 4.94 (m, 1H, CH2OH), 4.66 (dd, J = 8.0, 3.4, 1H, NCHPh), 4.47 
(dt, J = 12.5, 7.9, 1H, CHHOH), 4.42 - 4.31 (m, 1H, CHCH2CH2CH3), 4.09 (ddd, J = 12.4, 
7.3, 3.4, 1H, CHHOH), 2.02 - 1.79 (m, 2H, CHCH2CH2CH3), 0.88 - 0.68 (m, 5H, 
CHCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 170.26, 145.44, 137.92, 132.58, 131.82, 
128.84, 128.25, 127.93, 127.18, 123.75, 121.95, 64.74, 62.63, 60.57, 32.35, 15.17, 13.98; IR 
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(solid): 3300, 2998, 2875, 1660, 1413, 1305, 1216 cm-1 HRMS (ESI, m/z): calcd. for 
C19H21NO2 [M + H]+ 296.1645, found 296.1644; [α]D = + 132 [c 0.5, CH2Cl2]; Mp: 149-151 
⁰C. 
 
7.1.87 (R)-3-Allyl-2-((R)-2-hydroxy-1-phenylethyl)isoindolin-1-one, (74d) 
 
 
 
A solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, (1.00 g, 3.96 
mmol, 1.0 eq.) in anhydrous THF (15 mL), under N2, was cooled to -78 °C. LiHMDS as a 
solution in THF (1 M, 4.4 mL, 4.36 mmol, 1.1 eq.) was added dropwise (over 5 min) and the 
resulting mixture stirred for 30 min. Allyl bromide (0.41 mL, 4.8 mmol, 1.2 eq.) was added 
dropwise (over 2 min), then the solution was warmed to room temperature overnight. NH4Cl 
sat. aq. (15 mL) was added to quench the reaction, then further diluted with H2O (20 mL). The 
organic portion was extracted with Et2O (5 x 30 mL), combined, washed with brine (30 mL),  
dried over anhydrous MgSO4, filtered and evaporated to an orange oil, to yield crude 
intermediate (3R)-9b-allyl-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, which 
was used without further purification. 
 
TiCl4, as a solution in DCM (5.94 mL, 5.9 mmol, 1.5 eq.) was added to (3R)-3-phenyl-9b-
propyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (1.15 g, 3.9 mmol, 1.0 eq.) in 
anhydrous DCM (10 mL) was added dropwise (over 2 min), under N2 and at -78 °C and stirred 
for 30 min. Triethylsilane (0.95 mL, 5.9 mmol, 1.5 eq.) was added dropwise (over 1 min) to 
the mixture, which after 10 min was warmed to room temperature overnight. The reaction was 
quenched by the addition of  NH4Cl sat. aq. (20 mL) and then diluted with H2O (20 mL). The 
organic portion was extracted with DCM (3 x 30 mL), washed with brine (30 mL), dried over 
anhydrous MgSO4, filtered and evaporated to a light brown oil. This was then purified by flash 
column chromatography, (70 % Et2O / 30 % light petroleum ether) to afford isoindolinone 
74d as a yellow solid (0.57 g, 49 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 7.4, 1H, Ar-H), 7.60 - 7.44 (m, 2H, Ar-H), 7.41 - 
7.21 (m, 6H, Ar-H), 5.56 - 5.15 (m, 1H, HC=CH2), 5.12 - 4.96 (m, 3H, CH2OH, C=CH2), 4.74 
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(dd, J = 7.7, 3.2, 1H, NCHPh), 4.49 - 4.36 (m, 2H, CHCH2CH=CH2, CHHOH), 4.13 (m,  1H, 
CHHOH), 2.80 - 2.48 (m, 2H, CH2CH=CH, 2H); 13C NMR (100 MHz, CDCl3) δ 170.11, 
144.88, 137.83, 132.35, 131.83, 130.47, 128.82, 128.31, 127.92, 127.15, 123.73, 122.26, 
119.77, 64.53, 62.64, 59.93, 34.92; IR (solid): 3381, 2924, 1725, 1646, 1406 cm-1; HRMS 
(ESI, m/z): calcd. for C19H19NO2 [M + H]+ 294.1489, found 294.1490. [α]D = + 104 (c 0.5, 
CH2Cl2); Mp = 108-112 ℃. 
 
A suitable crystal was obtained by slow evaporation in Et2O / light petroleum ether. 
Diffraction data (5424 total reflections with Rint = 0.022) were collected on a Rigaku Oxford 
Diffraction Excalibur diffractometer at T = 150 K using graphite-monochromated Mo-Kα 
radiation. The structure was solved and refined using the SHELXS-2016 and SHELXL-2016 
programs.256 Crystal data: C19H19NO2, M = 293.35, colourless needle, 0.454 x 0.384 x 0.277 
mm3,  space group  P212121, V = 1545.30(10) Å3, Z = 4, Dc = 1.261 g/cm3, F000 = 624, 
Xcalibur, Sapphire3, Gemini, MoKα radiation, λ = 0.71073 Å,  T = 150(2)K, 2θmax = 58.7º, 
5427 reflections collected, 3364 unique (Rint = 0.0222).  Final GooF = 1.078, R1 = 0.0423, 
wR2 = 0.0874, R indices based on 3072 reflections with I I > 2(I) (refinement on F2), 205 
parameters, 0 restraints.  Lp and absorption corrections applied, m = 0.082 mm-1.  Absolute 
structure parameter = -0.1(7) (Flack, H. D. Acta Cryst. 1983, A39, 876-881). 
 
 
 
7.1.88 (R)-3-Benzyl-2-((R)-2-hydroxy-1-phenylethyl)isoindolin-1-one, (74e) 
 
 
 
A solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, (0.50 g, 1.9 
mmol, 1.0 eq.) in anhydrous THF (15 mL), under N2, was cooled to -78 °C. LiHMDS as a 
solution in THF (1 M, 2.2 mL, 2.18 mmol, 1.1 eq.) was then added dropwise and the resulting 
mixture stirred for 30 min. Benzyl bromide (0.31 mL, 2.4 mmol, 1.2 eq.) was added dropwise 
(over 2 min), then warmed to room temperature overnight. NH4Cl sat. aq. (20mL) was added 
to quench the reaction, then diluted with H2O (20 mL). The organic portion was extracted with 
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Et2O (5 x 30 mL), washed with brine (30 mL), combined, dried with anhydrous MgSO4, 
filtered and evaporated to a light orange solid, to yield crude intermediate (3R)-9b-benzyl-3-
phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, used in the next step without further 
purification. 
 
TiCl4, as a solution in DCM (1 M, 2.97 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 2 
min) to (3R)-9b-benzyl-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (0.676 g, 
1.98 mmol, 1.0 eq.) in anhydrous DCM (10 mL), under N2 at -78 °C. The solution was then 
stirred for 30 min. Triethylsilane (0.47 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 1 
min) to the mixture, which after 10 min was warmed to room temperature overnight. The 
reaction was quenched by the addition of NH4Cl sat. aq. (20 mL) and then diluted with H2O 
(20 mL). The organic portion was extracted with DCM (3 x 30 mL), washed with brine (30 
mL), dried over anhydrous MgSO4, filtered and evaporated to a light brown oil. This was then 
purified by flash column chromatography (90 % Et2O / 10 % light petroleum ether) to afford 
isoindolinone 74e as a white crystalline solid (0.24 g, 35 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.84 - 7.74 (m, 1H, Ar-H), 7.51 - 7.14 (m, 10H, Ar-H), 6.98 - 
6.91 (m, 2H, Ar-H), 6.88 - 6.78 (m, 1H, Ar-H), 5.10 - 4.95 (m, 1H, CH2OH), 4.87 (dd, J = 
7.8, 3.4, 1H, NCHPh), 4.54 (dd, J = 7.8, 4.5, 1H, HC(Bn)), 4.46 (dt, J = 12.5, 7.7, 1H, 
CHHOH), 4.09 (ddd, CHHOH, J = 12.4, 6.9, 3.3, 1H), 3.37 (dd, CHCHHPh, J = 13.9, 4.4, 
1H), 2.88 (dd, J = 13.8, 7.8, 1H, CHCHHPh); 13C NMR (100 MHz, CDCl3) δ 169.94, 144.93, 
137.97, 135.44, 132.08, 131.49, 129.41, 128.95, 128.42, 128.35, 128.02, 127.14, 127.12, 
123.74, 122.82, 64.65, 63.13, 61.75, 38.12; IR (solid): 3380, 2924, 2885, 1649, 1408 cm-1; 
HRMS (ESI, m/z): calcd. for C23H21NO2 [M + H]+ 344.1645, found 344.1643. [α]D = + 124 (c 
0.5, CH2Cl2); Mp: 174-177 ℃. 
 
A suitable crystal was obtained by slow evaporation in diethyl ether / light petroleum ether. 
Diffraction data (3860 total reflections with Rint = 0.024) were collected on a Rigaku Oxford 
Diffraction Excalibur diffractometer at T = 150 K using graphite-monochromated Mo-Kα 
radiation. The structure was solved and refined using the SHELXS-2016 and SHELXL-2016 
programs.256 Crystal data: C23H21NO2, Mr = 343.41 g mol–1, orthorhombic, P212121, a = 
8.6454(3), b =10.5715(3), c = 20.1931(6) Å, V = 1845.55(10) Å3, Z = 4, R[F2 > 2σ(F2)] = 
0.053 for 3401 reflections with I > 2σ(I), wR(F2) = 0.097 for all 3860 independent data, GOF 
= 1.104, 239 refined parameters. The crystallographic data is deposited as CCDC 1583682. 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif.  
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7.1.89  (R)-3-(2-Fluorobenzyl)-2-((R)-2-hydroxy-1-phenylethyl)isoindolin-1-one, (74f) 
 
 
 
A stirring solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one,  
(0.50 g, 1.98 mmol, 1.0 eq.) in anhydrous THF (15 mL), under N2, was cooled to -78 ℃. 
LiHMDS as a solution in THF (1 M, 2.18 mL, 2.2 mmol, 1.1 eq.) was then added dropwise 
(over 5 min) and the resulting mixture stirred for 30 min. 2-Fluoro benzyl bromide (0.29 mL, 
2.4 mmol, 1.2 eq.) was added dropwise (over 2 min), the solution was then allowed to warm 
to room temperature overnight. NH4Cl sat. aq.  (10 mL) was added to quench the reaction, 
then diluted with H2O (20 mL). The organic portion was then extracted with EtOAc (3 x 40 
mL), washed with brine, dried with anhydrous MgSO4, filtered and evaporated to a light 
orange oil, to yield crude intermediate (3R)-9b-(2-fluorobenzyl)-3-phenyl-2,3-
dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, used in the next step without any further 
purification. 
 
TiCl4, as a solution in DCM (1 M, 2.97 mL, 2.9 mmol, 1.5 eq.) was added dropwise to (3R)-
9b-(2-fluorobenzyl)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (0.71 g, 1.9 
mmol, 1.0 eq.) in anhydrous DCM (10 mL), under N2 at -78 ℃. The solution was stirred for 
30 min. Triethylsilane (0.47 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 2 min) to the 
mixture, which after 10 min, was warmed to room temperature overnight. The reaction was 
quenched by the addition of NH4Cl sat. aq. (10 mL) and then diluted with H2O (20 mL). The 
organic portion was extracted with DCM (3 x 30 mL), washed with brine (30 mL), dried over 
anhydrous MgSO4, filtered and evaporated to a light brown oil. This was then purified by flash 
column chromatography (70 % EtOAc / 30 % light petroleum ether), to afford isoindolinone 
74f as an off-white crystalline solid (0.46 g, 65 %). 
 
1H NMR (400 MHz, CDCl3) δ 7.85 - 7.77 (m, 1H, Ar-H), 7.50 - 6.88 (m, 12H, Ar-H), 4.96 - 
4.82 (m, 2H, CH2OH, NCHPh), 4.59 (dd, J = 7.7, 4.3, 1H, CHCH2Ar(F)), 4.48 (dt, J = 12.5, 
7.8, 1H, CHHOH), 4.13 (ddd, J = 12.5, 7.0, 3.4, 1H, CHHOH), 3.43 (dd, J = 14.0, 4.2, 1H, 
CHCHHAr(F)), 2.93 (dd, J = 14.0, 7.7, 1H, CHCHHAr(F)); 13C NMR (100 MHz, CDCl3) δ 
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170.01, 161.23 (d, 1JC-F = 245.4 Hz), 144.93, 137.97, 132.14, 131.75 (d, 3JC-F = 4.8 Hz), 
131.58, 129.16 (d, 2JC-F = 7.7 Hz), 128.95, 128.47, 128.08, 127.22, 124.03 (d, 3JC-F = 3.8 Hz), 
123.84, 122.82, 122.71 (d, 4JC-F = 15.3 Hz), 115.43 (d, 2JC-F = 22.0 Hz), 64.64, 63.08, 60.58, 
31.65; IR (solid): 3313, 2871, 1657, 1491, 1230 cm-1; HRMS (ESI, m/z): calcd. for 
C23H20FNO2 [M + H]+ 362.1551 found, 362.1550; [α]D = + 152 (c 0.5, CH2Cl2); Mp = 140-
143 ℃. 
 
7.1.90 (R)-2-((R)-2-Hydroxy-1-phenylethyl)-3-(3-methoxybenzyl)isoindolin-1-one, (74g) 
 
 
 
A stirring solution of (3R,9bS)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one,  
(0.50 g, 1.9 mmol, 1.0 eq.) in anhydrous THF (15 mL) under N2, was cooled to -78 ℃. 
LiHMDS as a solution in THF (1 M, 2.18 mL, 2.2 mmol, 1.1 eq.) was then added dropwise 
(over 5 min) and the resulting mixture stirred for 30 min. 3-Methoxy benzyl bromide (0.33 
mL, 2.4 mmol, 1.2 eq.) was then added dropwise (over 2 min). The solution was allowed to 
warm to room temperature A solution of sat. NH4Cl aq. (10 mL) was added and then diluted 
with H2O (20 mL). The organic portion was extracted with EtOAc (3 x 40 mL) and washed 
with brine (1 x 30 mL). The combined extracts were then dried with anhydrous MgSO4, 
filtered and evaporated to a light orange oil, to yield crude intermediate (3R)-9b-(3-
methoxybenzyl)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one, this was used in 
the next step without any further purification. 
 
Crude (3R)-9b-(3-methoxybenzyl)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one 
(0.74 g, 1.9 mmol, 1.0 eq.) was stirred in anhydrous DCM (10 mL), under N2 and cooled to -
78 °C. A solution of TiCl4 (1 M, 2.9 mL, 2.97 mmol, 1.5 eq.) in DCM was added dropwise 
(over 2 mins) to the reaction mixture and left to stir for 30 minutes at -78 °C. Triethylsilane 
(0.47 mL, 2.9 mmol, 1.5 eq.) was added dropwise (over 1 min) to the reaction mixture, which 
was then warmed to room temperature overnight. The reaction was quenched following the 
addition of a solution of sat. NH4Cl aq. (10 mL) and then diluted with H2O (20 mL). The 
organic portion was extracted with DCM (3 x 20 mL), washed with brine (1 x 30 mL), dried 
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over anhydrous MgSO4, filtered and evaporated to a light brown oil. This was then purified 
by flash column chromatography (70 % EtOAc / 30 % light petroleum ether), to afford 
isoindolinone 74g as an off-white solid, (0.45 g, 61 %). 
1H NMR (400 MHz, CDCl3) δ = 7.84 - 7.76 (m, 1H, Ar-H), 7.49 - 7.40 (m, 2H, Ar-H), 7.38 - 
7.28 (m, 3H, Ar-H), 7.27 - 7.20 (m, 2H, Ar-H), 7.14 (t, J = 7.9, 1H, Ar-H), 6.96 - 6.88 (m, 1H, 
Ar-H), 6.76 (dd, J = 8.2, 2.0, 1H, Ar-H), 6.56 (d, J = 7.5, 1H, Ar-H), 6.45 - 6.39 (m, 1H, Ar-
H), 5.07 - 5.00 (m, 1H, OH), 4.85 (dd, J = 7.8, 3.1, 1H, CHCH2Ar(OMe)), 4.54 (dd, J = 7.7, 
4.4, 1H, CHPh), 4.50 - 4.39 (m, 1H, CHCHHAr(OMe)), 4.19 - 4.00 (m, 1H, 
CHCHHAr(OMe)), 3.68 (s, 3H, OCH3), 3.34 (dd, J = 13.8, 4.3, 1H, CHHOH), 2.86 (dd, J = 
14.0, 7.8, 1H, CHHOH). 13C NMR (100 MHz, CDCl3) δ = 169.96, 159.47, 145.02, 137.87, 
136.93, 132.05, 131.47, 129.41, 128.91, 128.33, 128.03, 127.15, 123.72, 122.80, 121.80, 
114.76, 112.65, 64.62, 63.14, 61.64, 55.07, 38.05; IR (neat) 2868, 1715, 1616, 1361, 1311 cm-
1; HRMS (ESI+) (m/z) calcd for C24H23NO3+ [M + H]+, 374.1751 found, 374.1749, [α]D = + 
40 [c=0.5, CH2Cl], Mp = 94-96 °C.  
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7.1.91 Preparation of C-3 racemic compound for chiral HPLC investigation 
2-((R)-2-Hydroxy-1-phenylethyl)-3-methylisoindolin-1-one 
 
 
To a stirring solution of (R)-2-((R)-2-hydroxy-1-phenylethyl)-3-methylisoindolin-1-one,  
(71 mg, 0.3 mmol, 1 eq.) in acetone / H2O 3:1 (4 mL), powdered sodium hydroxide (20 mg, 
0.5 mmol, 2 eq.) was added and the resulting mixture was stirred at 50 ℃ for 3 h (until the 
formation of a second diastereomer was indicated by TLC). The mixture was diluted with H2O 
(10 mL) and carefully acidified to pH 7 using a 1 M solution of HCl aq. The organic portion 
was extracted using EtOAc (3 x 20 mL), combined, washed with brine (40 mL), dried over 
anhydrous MgSO4 , filtered and evaporated to obtain isoindolinone 74a (racemic) as a pale-
yellow oil (71 mg, quantitative).  
 
Inspection of the 1HNMR (400 MHz, CDCl3) spectrum indicated formation of a new 
diastereomer, 6:4 in favour of the starting material. The chiral auxiliary was then removed in 
the same manner as (R)-3-methylisoindolin-1-one, 75. 
 
7.1.92 (R)-3-Methylisoindolin-1-one, (75) 
 
To a test tube, (R)-2-((R)-2-hydroxy-1-phenylethyl)-3-methylisoindolin-1-one, (53 mg, 0.2 
mmol, 1.0 eq.) was dissolved in conc. H2SO4 (96%, 2 mL). This was then immediately heated 
for two min in a steam bath, then cooled to room temperature. Cold H2O (20 mL, 5 °C) was 
added. The organic portion extracted using DCM (3 x 20 mL), the extracts were pooled, dried 
over anhydrous MgSO4, filtered and evaporated to obtain a pale-yellow oil.   
The material was then purified using preparative chromatography (80 % EtOAc / 20 % light 
petroleum ether) to obtain isoindolinone 75 as colourless oil (11 mg, 38 %).  
 
1H NMR (400 MHz, CDCl3) δ = 7.89 - 7.77 (m, 1H), 7.63 - 7.52 (m, 1H), 7.52 - 7.39 (m, 2H), 
4.70 (q, J = 6.5, 1H), 1.51 (d, J = 6.7, 3H), e.e 98% (determined by chiral HPLC) 
 
1HNMR Spectrum identical to that reported by Allin and co-workers.234 
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7.1.93 (3S)-9b-((1,3-Dioxolan-2-yl)methyl)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-
5(9bH)-one, (76) 
 
 
A solution of (3S,9bR)-3-phenyl-2,3-dihydrooxazolo[2,3-a]isoindol-5(9bH)-one (1.20 g, 4.7 
mmol, 1.0 eq.) in anhydrous THF (20 mL), under a flow of N2 was cooled to -78 °C. A solution 
of LiHMDS (1 M, 5.25 mL, 5.2 mmol, 1.1 eq.) in THF, was then added dropwise (over 5 min) 
to the reaction mixture. After 30 min, a solution of bromomethyl-1,3-dioxolane (0.60 mL, 5.7 
mmol, 1.2 eq.) in anhydrous THF (10 mL) was added dropwise. The reaction mixture was 
then allowed to warm to room temperature overnight. The reaction was quenched using a 
solution of saturated NH4Cl aq. (20 mL), diluted with H2O (20 mL), and then extracted with 
Et2O (3 x 50 mL). The combined organic extracts were then washed with brine (1 x 50 mL), 
dried over anhydrous MgSO4, filtered and evaporated under reduced pressure to give 
dioxolane 76 as a yellow oil, (1.86 g). 
 
Analysis by 1H NMR spectroscopy indicated the formation of the desired product, as a 1:1 
mixture of diastereomers, with an approximate conversion of 50 %. The material was used 
without further purification.  
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7.2 Biological evaluation 
 
7.2.1 Bis-pNPP assay  
 
Recombinant ATX was obtained from 3E3 cells, that were genetically engineered to 
overexpress ATX, 3E3 cells were seeded in a T150 x 3 and incubated until 50% confluent. 
The medium was replaced with serum-free medium (approx. 15 mL) and incubated overnight 
(37 °C). The supernatant was collected and combined, which was then centrifuged at 16 G for 
5 min. The supernatant was then collected, the pellet was discarded. A Sepharose column 
(HiTrap Con A, 1 mL) was prepared by eluting with Tris buffered saline (TBS, 20 mM, 0.5 
M NaCl, pH 7.4, 20 mL), at a flow rate of approximately 1.0 mL / min, 4 °C. The collected 
supernatant was loaded on to the column at a rate of 0.1 mL / min, and then eluted with TBS 
(25 mL) at a flow rate of 1 mL / min. A solution of methyl α-D-mannopyranoside in TBS (0.5 
M, 2 mL) was passed through the column. The eluent was collected, both the column and the 
eluent were held at 4 °C overnight. The eluent was then passed through the column and the 
resulting eluent then dialysed (8 kDa MWCO) against TBS (20 mM, 0.05 M NaCl, pH 7.4, 1 
L), at 4 °C, for 2 h. The TBS solution was then changed once. Dialysed ATX was then used 
without further purification.  
The drug conjugates were diluted to a concentration appropriate to their predicted activity in 
distilled water, a 3-fold dilution series was then prepared (final concentration = 0 μg / mL), 
which were additionally diluted 5-fold when added to the assay plate. 
 
In a 96-well plate, reaction buffer (Tris HCl aq. 250 mM, KCl aq. 25 mM, CaCl2 aq. 5 mM, 
MgCl2.6H2O aq. 5 mM, NaCl aq. 700 mM, pH 7.8, 20 µL), bis-pNPP aq. (1 mM, 10 μL), and 
the test compound (20 µL) were added to each well, followed by the addition of autotaxin as 
a solution in TBS (50 μL). The plate was incubated at 37 °C for 4 h. The absorbance of the 
plate was measured at a wavelength of 405 nm, using a Synergy 2 multimode microplate 
reader. The resulting data were analysed using Graph Pad Prism software. Non-linear 
regression was used to fit a 4 parameter (Hill equation) dose-response curve to determine the 
IC50 value for each conjugate.  
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7.2.2 FS3 Assay 
 
The drug conjugates were diluted to a concentration appropriate to their predicted activity in 
distilled water, a 3-fold dilution series was prepared, which was further diluted 10-fold when 
added to the assay plate.  
 
The assay was then performed as per instructed in the assay kit supplied by Echelon 
Biosciences Inc., ATX as a solution in reaction buffer (80 µL) was added to a 96-well plate. 
The test compound (20 µL), at an appropriate dilution was then added. The plate was then 
gently mixed by hand for 1 minute and incubated at room temperature for 10 min. A solution 
of FS-3 substrate (10 µL) was then added to each well and the fluorescence was then read 
immediately (λ Ex = 485 nm, λ Em = 528 nm) using a Synergy 2 multimode microplate reader, 
every two min, for 30 min in total, at room temperature. 
 
Fluorescence for each concentration was plotted as a function against time. A linear regression 
was then fitted to the graph. Non-linear regression was then used to fit a 4 parameter (Hill 
equation) dose-response curve to the rate of reaction for each concentration in order to 
determine the IC50 value for each conjugate. 
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7.2.3 Peritoneal retention 
 
A solution of Conjugate 35 in PBS (0.2 mg / mL) was sterilised by filtering the solution 
through a syringe filter. This was repeated with a 0.2 mg / mL solution of Inulin. 
 
7-week old nude mice (supplied by Envigo) were allowed to acclimatize for one week, before 
the experiment began. Mice were weighed, then injected (using a 26G syringe) with a solution 
of conjugate 35 (0.4 mL) in their lower left quadrant, at pre-determined timepoints (0 min, 30 
min, 1, 3, 6 and 24 h). The mice were then dispatched by cervical dislocation. The entire 
process was performed in triplicate. Ventral skin was removed and the peritoneal cavity was 
washed with PBS solution (0.4 mL). The washings were collected, then centrifuged at 2300 
rpm, 5 min, 4 °C. The supernatant was collected. As a control, three mice were injected with 
a solution of Inulin and then immediately dispatched and processed, as described previously.  
 
The peritoneal washings were analysed using fluorescence spectroscopy (λEx = 360 nm, λEM = 
485 nm), alongside a calibration curve prepared with Conjugate 35, (2-fold dilution, 0.2 μg / 
mL, top conc.) in order to determine the concentration of the conjugate present in each sample.  
 
 
Mice were monitored through the experiment for any adverse effects.  
Animal experiments were performed at Keele University and were approved by the animal 
welfare commission of Keele University. 
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